

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:55:00 ; Search time 11.2849 Seconds
(without alignment)

5501.769 Million cell updates/sec

Title: US-10-676-079-6

Perfect score: 23
Sequence: 1 ttcgacccaagaagatcaac 23

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

N Geneseq_19Jun03.*
1: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*
25: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT.*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	23	100.0	23	20	AAK35646
2	23	100.0	23	21	AAA75049
3	23	100.0	23	21	AAA75063
4	23	100.0	23	21	AAZ33293
5	23	100.0	1584	24	ABL40753
6	23	100.0	1593	20	AAZ11236
7	23	100.0	1669	25	ABZ22816
8	23	100.0	1713	20	AAK37259

9	23	100.0	1721	20	AAK35648
10	23	100.0	1721	21	AAA75051
11	23	100.0	1721	21	AAZ39195
12	23	100.0	1721	21	AAZ33290
13	23	100.0	1721	21	AAA31112
14	23	100.0	1722	22	AAZ3788
15	23	100.0	1723	20	AAK37260
16	23	100.0	1724	22	AAH20940
17	23	100.0	1899	20	AAK35650
18	23	100.0	1899	21	AAZ75053
19	23	100.0	3726	20	AAK86671
20	23	100.0	4848	21	AAA75080
21	23	95.7	474	22	AAZ3984
22	17.2	74.8	2884	16	AAZ3984
23	17.2	74.8	159400	24	ABO88126
24	17.2	74.8	160271	22	AAZ3984
25	17.2	74.8	160271	22	AAZ3984
26	17.2	74.8	160271	22	AAZ3984
27	17.2	74.8	160271	22	AAZ3984
28	17.2	74.8	160271	22	AAZ3984
29	17.2	74.8	160271	22	AAZ3984
30	17.2	74.8	160271	22	AAZ3984
31	17.2	74.8	160271	22	AAZ3984
32	16.8	73.0	343	21	AAZ3984
33	16.8	73.0	367	24	ABN15848
34	16.8	73.0	577	22	AAZ3984
35	16.8	73.0	577	22	AAZ3984
36	16.8	73.0	577	22	AAZ3984
37	16.8	73.0	577	22	AAZ3984
38	16.8	73.0	577	22	AAZ3984
39	16.8	73.0	577	22	AAZ3984
40	16.8	73.0	577	22	AAZ3984
41	16.8	73.0	577	24	ABN12053
42	16.8	73.0	588	22	AAH08812
43	16.8	73.0	1731	22	AAH13668
44	16.8	73.0	2747	23	AAZ3984
45	16.8	73.0	2747	23	AAZ3984

ALIGNMENTS

RESULT 1	AAK35646	standard; DNA; 23 BP.
ID	AAK35646	
AC	AAK35646	
DT	09-JUL-1999	(first entry)
DE	PCR primer used to amplify human hp3.cDNA.	
XX	Heparinase; hp; modulator; heparin-binding growth factor;	
XX	cellular response; cytokine; cell interaction; plasma lipoprotein;	
XX	cellular susceptibility; infection; disintegration;	
XX	neurodegenerative plaque; wound healing; angiogenesis;	
XX	atherosclerosis; inflammation; neurodegenerative disease; neuritis;	
XX	plasma heparin; micrometastasis; autoimmune lesion; renal failure;	
XX	PCR primer; ss.	
OS	Synthetic.	
PN	WO9911798-A1.	
PD	11-MAR-1999.	
XX	31-AUG-1998; 98WO-US17954.	
XX	02-JUL-1998; 98US-0109386.	
XX	02-SEP-1997; 97US-0922170.	
XX	(FRIE/) FRIEDMAN M M.	
PA	(HADA-) HADASIT MEDICAL RES SERVICES & DEV.	

CDNA encoding a hu
CDNA encoding a hu
Human heparinase e
Human heparinase n
Human heparinase
Human CDNA encodin
Seq ID No: 14 of W
Human heparinase i
CDNA encoding a hu
CDNA encoding a hu
CDNA encoding a hu
CDNA encoding a hu
Nucleotide sequenc
Primer specific fo
Rat AT2 receptor c
Human osteoblast d
Bipolar affective
Human chromosome 1
Human chromosome 1
Human chromosome 1
Human chromosome 1
160kb fragment of
Human chromosome 1
Nucleotide sequenc
Human secreted pro
Human ORFX polynuc
Human foetal liver
Probe #9465 for ge
Human brain expres
Human bone marrow
Probe #8749 for ge
Probe #12624 used
Human liver single
Human genome-deriv
Human CDNA clone (
Human CDNA sequenc
DNA encoding novel
DNA encoding novel

PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX Feinstein E, Pecker I, Vlodayvsky I;
XX
XX MPI; 1999-302255/25.
DR
XX
XX New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
XX
XX Example 1; Page 23; 63pp; English.
XX
XX The specification describes a polypeptide having heparanase (hp)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC PCR primers AAX35646-47 were used to amplify hp3 cDNA, in the course of
CC the invention.
XX
SQ Sequence 23 BP; 9 A; 6 C; 4 G; 4 T; 0 other;
XX
Query Match 100.0%; Score 23; DB 20; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.19; Mismatches 0; Indels 0; Gaps 0;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 TTCGATCCCAAGAGAAATCAAC 23
Db 1 TTCGATCCCAAGAGAAATCAAC 23
XX
RESULT 2
AAAT75049
ID AAA75049 standard; DNA; 23 BP.
XX
XX AAA75049;
AC
XX 15-JAN-2001 (first entry)
DT
XX
XX PCR primer HPU35 used to amplify human cDNA encoding heparanase.
DE
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
KW wound healing; infection; burn; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease;
KW Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200052178-A1.
PN
XX
XX 08-SEP-2000.
PD
XX
XX 14-FEB-2000; 2000WO-US03542.
PF
XX
XX 01-MAR-1999; 99US-0258892.
PR
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodayvsky I, Feinstein E;
PI
XX
XX MPI; 2000-579289/54.
DR
XX
XX New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating

PT tumour, inflammation, autoimmunity, neurodegenerative diseases -
XX
XX Disclosure; Page 44; 152pp; English.
XX
XX The present PCR primer was used to amplify a human cDNA sequence,
CC which encoded a protein with heparanase catalytic activity. The
CC heparanase (hpa) polynucleotide is useful in gene therapy, particularly
CC in treating tumour, inflammation or autoimmunity. Particularly, the
CC polynucleotide is useful in modulating the bioavailability of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8),
CC cell interaction with plasma lipoproteins, cellular susceptibility to
CC certain viral and some bacterial and protozoa infections, or
CC integration of neurodegenerative plaques. The polynucleotide is
CC also useful in wound healing (e.g. thermal, chemical or radiation burns),
CC and in the treatment of angiogenesis, restenosis, atherosclerosis,
CC inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome
CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.
XX
SQ Sequence 23 BP; 9 A; 6 C; 4 G; 4 T; 0 other;
XX
Query Match 100.0%; Score 23; DB 21; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.19; Mismatches 0; Indels 0; Gaps 0;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 TTCGATCCCAAGAGAAATCAAC 23
Db 1 TTCGATCCCAAGAGAAATCAAC 23
XX
RESULT 3
AAAT75063
ID AAA75063 standard; DNA; 23 BP.
XX
XX AAA75063;
AC
XX 15-JAN-2001 (first entry)
DT
XX
XX PCR primer Hpu-335 used to amplify human cDNA encoding heparanase.
DE
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
KW wound healing; infection; burn; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease;
KW Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200052178-A1.
PN
XX
XX 08-SEP-2000.
PD
XX
XX 14-FEB-2000; 2000WO-US03542.
PF
XX
XX 01-MAR-1999; 99US-0258892.
PR
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodayvsky I, Feinstein E;
PI
XX
XX MPI; 2000-579289/54.
DR
XX
XX New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating
PT tumour, inflammation, autoimmunity, neurodegenerative diseases -
XX
XX Disclosure; Page 45; 152pp; English.
XX
XX The present PCR primer was used to amplify a human cDNA sequence,
CC which encoded a protein with heparanase catalytic activity. The

CC heparanase (hpa) polynucleotide is useful in gene therapy, particularly
CC in treating tumor, inflammation or autoimmunity. Particularly, the
CC polynucleotide is useful in modulating the bioavailability of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8),
CC cell interaction with plasma lipoproteins, cellular susceptibility to
CC certain viral and some bacterial and protozoa infections, or
CC disintegration of neurodegenerative plaques. The polynucleotide is
CC also useful in wound healing (e.g. thermal, chemical or radiation burns),
CC and in the treatment of angiogenesis, restenosis, atherosclerosis,
CC inflammation, neurodegenerative diseases (Gerstmann-Sträussler Syndrome
CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.

CC
XX Sequence 23 BP; 9 A; 6 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 23; DB 21; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTGCATCCCAAGAGATCAAC 23
1 TTGCATCCCAAGAGATCAAC 23

Db 1 TTGCATCCCAAGAGATCAAC 23

RESULT 4
AA233293
ID AA233293 standard; DNA; 23 BP.
AC AA233293;
XX 21-FEB-2000 (first entry)
DT
XX Human heparanase PCR primer Hpu-355 SEQ ID NO:6.
DE
XX Human heparanase; hpa; diagnosis; therapy; tumor; cytostatic;
XX Human; heparanase; hpa; diagnosis; therapy; tumor; cytostatic;
KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
KW autoimmune disease; anticancer; kidney disease; PCR primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO957153-A1.
PN 11-NOV-1999.
PD 29-APR-1999; 99WO-US09255.
PF 01-MAY-1998; 98US-0071739.
PR (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADAST MEDICAL RES SERVICES & DEV.
PA (PRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodayvsky I, Friedman Y, Perets T;
XX WPI; 2000-052944/04.
DR
XX Heparanase-specific molecular probes useful for diagnosis and
PT treatment, e.g. of tumors, and for targeted drug delivery -
XX
XX Example; Page 30; 90pp; English.
XX
XX The present invention describes heparanase-specific molecular probes,
XX useful for methods of detecting heparanase in situ. The probes and
XX anti-heparanase antibodies are used to detect or quantify the expression
XX of heparanase, for diagnosis and monitoring of diseases (especially
XX metastasis), for treatment of heparanase-associated diseases (e.g.
XX tumour, adenocarcinoma, squamous cell carcinoma, teratocarcinoma,
XX mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its

CC metastases) derived from liver, prostate, bladder, breast, ovary,
CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted
CC drug delivery (e.g. of anticancer agents) and as research reagents.
CC The present sequence represents a PCR primer for human heparanase, which
CC is used in an example from the present invention.

CC
XX Sequence 23 BP; 9 A; 6 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 23; DB 21; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTGCATCCCAAGAGATCAAC 23
1 TTGCATCCCAAGAGATCAAC 23

Db 1 TTGCATCCCAAGAGATCAAC 23

RESULT 5
ABL40753
ID ABL40753 standard; cDNA; 1584 BP.
AC ABL40753;
XX 03-JUL-2002 (first entry)
DT
XX Chicken signal peptide/human heparanase chimeric cDNA.
DE
XX Heparanase; catalytic; cytostatic; antiviral; antibacterial; enzyme;
XX anti-protozoan; neuroprotective; heparin; chicken; human; chimeric; ss.
XX
XX Synthetic.
OS Gallus gallus.
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH 1..1584
FT CDS
FT sig_peptide 1..57
FT /tag= b
FT /note= "chimeric chicken-human heparanase"
FT mat_peptide 58..1581
FT /tag= c
FT /note= "human mature heparanase"

XX
XX US2002034810-A1.
XX
XX 21-MAR-2002.
XX
XX 16-AUG-2001; 2001US-0930218.
XX
XX 20-SEP-2000; 2000US-0666390.
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX Goldsmidt O, Pecker I, Vlodayvsky I, Michal I, Zcharia E;
XX WPI; 2002-338926/37.
XX P-PSDB; ABB07815.
XX
XX Nucleic acid encoding avian and reptile heparanase polypeptide is
XX useful to treat various heparin-related disorders and the signal
XX peptide is useful in production of membrane-targeted or secreted
XX recombinant proteins -
XX
XX Disclosure; Page 24-25; 39pp; English.
XX
XX The invention relates to an isolated avian and reptile nucleic acid,
XX encoding a polypeptide with heparanase catalytic activity. The signal
XX peptide of the nucleic acid can be used to express membrane-associated or
XX secreted proteins in heterologous expression systems. The encoded

CC polypeptides can be used to prevent tumour angiogenesis, metastasis and
CC invasion, and to intervene with pathologies associated with impaired
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoa and bacterial infections or
CC deintegration of neurodegenerative plaques. The present sequence
CC represents a chicken signal peptide/human heparanase chimeric CDNA
CC sequence.
XX
SQ Sequence 1584 BP; 424 A; 361 C; 373 G; 426 T; 0 other;
Query Match 100.0%; Score 23; DB 24; Length 1584;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TTGATCCCAAGAGATCAAC 23
DB 262 TTGATCCCAAGAGATCAAC 284
RESULT 6
AAZ11236
ID AAZ11236 standard; CDNA; 1593 BP.
AC AAZ11236;
XX
DT 15-NOV-1999 (first entry)
XX
DE Human pre-proheparanase coding sequence.
XX
KW Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;
KW inflammation; psoriasis; diabetic retinopathy; solid tumour; arthritis;
KW heparin degradation; anticoagulant neutralisation; ashenia; CNS disease;
KW inflammatory disease; vascular restenosis; atherosclerosis; diagnosis;
KW tumour growth; fibroproliferative disorder; neurodegenerative disease;
KW therapy; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..1593
FT /*tag= a
FT /product= pre-proheparanase
XX
PN MO9943830-A2.
XX
PD 02-SEP-1999.
XX
PF 18-FEB-1999; 99WO-US01489.
XX
PR 26-MAR-1998; 98US-0079401.
PR 24-FEB-1998; 98US-0075706.
XX
PA (PHAA) PHARMACIA & UPJOHN CO.
XX
PI Fairbanks MB, Heinrikson RL, Mildner AM;
XX
DR WPI; 1999-540598/45.
DR P-PSDB; AAY34173.
XX
PT New isolated platelet heparanase polypeptides, used to develop
PT products for, e.g. wound healing and blocking angiogenesis
XX
PS Claim 2; Fig 7; 57pp; English.
XX
CC This sequence encodes the human pre-proheparanase of the invention. This
CC sequence was isolated from human platelets. The heparanase can be used
CC for identifying agents which alter heparanase activity. The heparanase
CC can be used for wound healing or for blocking angiogenesis or
CC inflammation. It can be used for treating e.g. psoriasis, diabetic
CC retinopathy or solid tumours, or for the degradation of heparin and the
CC neutralisation of heparin's anticoagulant properties during surgery.
CC Inhibitors of heparanase activity can be used in the treatment of

CC arthritis, asthma, and other inflammatory diseases, vascular restenosis,
CC atherosclerosis, tumour growth and progression, fibroproliferative
CC diseases, and central nervous system (CNS) and neurodegenerative
CC diseases. The products can also be used for detection and diagnosis. The
CC purified heparanase, both recombinantly produced human heparanase and
CC heparanase isolated from human platelet activity, allows for the
CC convenient selection of compounds having anti-heparanase activity,
CC i.e. inhibitors of heparanase activity, by measuring inhibition of
CC heparanase activity. Inhibition of heparanase activity can be measured by
CC blocking heparanase-mediated release of radioactive fragments from in
CC vivo radiolabelled (HSG)/heparin.
XX
SQ Sequence 1593 BP; 426 A; 370 C; 369 G; 428 T; 0 other;
Query Match 100.0%; Score 23; DB 20; Length 1593;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TTGATCCCAAGAGATCAAC 23
DB 271 TTGATCCCAAGAGATCAAC 293
RESULT 7
ABZ22816
ID ABZ22816 standard; CDNA; 1669 BP.
AC ABZ22816;
XX
DT 02-APR-2003 (first entry)
XX
DE Human heparanase encoding CDNA SEQ ID NO:17.
XX
KW Human; heparanase; phosphorothioate; antisense oligonucleotide;
KW cytosolic; gene therapy; tumour; enzyme; gene; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..1638
FT /*tag= a
FT /product= "heparanase"
XX
PN MO2003004705-A1.
XX
PD 16-JAN-2003.
XX
PF 01-JUL-2002; 2002WO-US20636.
XX
PR 05-JUL-2001; 2001US-0899440.
XX
PA (UYCO) UNIV COLUMBIA NEW YORK.
XX
PI Stein C;
XX
DR WPI; 2003-201558/19.
DR P-PSDB; ABP56822.
XX
PT New oligonucleotide having a sequence complementary to a sequence of
PT ribonucleic acid encoding a heparanase, useful for preparing a
PT composition for treating tumor -
XX
PS Disclosure; Fig 3; 48pp; English.
XX
CC The present invention describes an oligonucleotide having a sequence
CC complementary to a sequence of ribonucleic acid encoding a heparanase.
CC The oligonucleotide hybridises with the ribonucleic acid under conditions
CC of high stringency and has a sequence comprising 10-40 bp. The
CC internucleoside linkages of the oligonucleotide comprise at least one
CC phosphorothioate linkage. Hybridisation of the oligonucleotide to the
CC ribonucleic acid inhibits expression of the heparanase, where inhibition
CC of heparanase means at least a 50% reduction in the quality of
CC heparanase. Also described: (1) a method of inhibiting expression of a

CC heparanase in a cell; (2) a composition comprising the above
 CC oligonucleotide in an amount effective to inhibit the expression of
 CC heparanase in the cell and a carrier; and (3) a method of treating a
 CC tumour in a subject comprising administering to the subject an amount of
 CC the above oligonucleotide effective to inhibit expression of a heparanase
 CC in the subject. Heparanase antisense oligonucleotides have cytostatic
 CC activity, can be used in gene therapy, and can be used for preparing a
 CC composition for treating tumours. The present sequence encodes human
 CC heparanase, which is given in the exemplification of the present
 CC invention.

XX Sequence 1669 BP; 445 A; 396 C; 388 G; 440 T; 0 other;

SO Query Match 100.0%; Score 23; DB 25; Length 1669;
 Best Local Similarity 100.0%; Pred. No. 0.32;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTCGATCCCAAGAGATCAAC 23
 |||||
 DB 316 TTCGATCCCAAGAGATCAAC 338

RESULT 8
 AAX37259
 ID AAX37259 standard; DNA; 1713 BP.

XX AAX37259;

XX 21-JUL-1999 (first entry)

XX Human heparanase enzyme encoding DNA.

XX Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
 KW metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
 KM arteriosclerosis; atherosclerosis; inflammation; tissue development;
 KW human; HSPG; ss.

XX Homo sapiens.

XX W09921975-A1.

XX 06-MAY-1999.

XX 28-OCT-1998; 98WO-AU00898.

XX 09-DEC-1997; 97AU-0000812.

XX 28-OCT-1997; 97AU-0000062.

XX (AUSU) UNIV AUSTRALIAN NAT.

XX Freeman CG, Handorf BJ, Hulett MD, Parish CR;

XX WPI; 1999-312956/26.

XX P-PSDB; AAY17082.

XX Polynucleotides encoding mammalian endoglucuronidases, especially
 PT heparanases, useful to promote wound healing

XX Claim 3; Page 69-73; 112pp; English.

XX The invention relates to nucleic acid sequences that encode heparanase
 CC enzymes having endoglucuronidase activity. Recombinant heparanases are
 CC capable of removing the HS side chain from heparan sulfate proteoglycan
 CC (HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to
 CC inhibit heparanase, this is useful for treatment of a physiological or
 CC medical condition associated with elevated heparanase activity, such as
 CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
 CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
 CC rat heparanases can be used to enhance wound healing, especially
 CC associated with tissue development and repair. The conditions mentioned
 CC above can be diagnosed using specific antibodies, and also using primers
 CC and probes specific for the heparanase polynucleotides. Other uses of the
 CC heparanases include sequencing sulfated molecules such as HSPG. The

CC present sequence represents a DNA encoding human heparanase.

XX Sequence 1713 BP; 460 A; 404 C; 406 G; 443 T; 0 other;

SO Query Match 100.0%; Score 23; DB 20; Length 1713;
 Best Local Similarity 100.0%; Pred. No. 0.32;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTCGATCCCAAGAGATCAAC 23
 |||||
 DB 355 TTCGATCCCAAGAGATCAAC 377

RESULT 9
 AAX35648
 ID AAX35648 standard; cDNA; 1721 BP.

XX AAX35648;

XX 09-JUL-1999 (first entry)

XX cDNA encoding a human heparanase protein.

XX Heparanase; hpa; modulator; heparin-binding growth factor;
 KW cellular response; cytokine; cell interaction; plasma lipoprotein;
 KW cellular susceptibility; infection; disintegration;
 KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;
 KW atherosclerosis; inflammation; neurodegenerative disease; neuritis;
 KW plasma heparin; microvasculitis; autoimmune lesion; renal failure;
 KW ss.

XX Homo sapiens.

XX W09911798-A1.

XX 11-MAR-1999.

XX 31-AUG-1998; 98WO-US17954.

XX 02-JUL-1998; 98US-0109386.

XX 02-SEP-1997; 97US-0922170.

XX (FRIE/) FRIEDMAN M M.

XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

XX (INST-) INSIGHT STRATEGY & MARKETING LTD.

XX Feinstein E, Pecker I, Vlodaysky I;

XX WPI; 1999-302255/25.

XX P-PSDB; AAY02345.

XX New human polynucleotide useful for treating angiogenesis,
 PT restenosis, and inflammation

XX Claim 4; Fig 1; 63pp; English.

XX The specification describes a polypeptide having heparanase (hpa)
 CC activity. The recombinant protein is used as a modulator of
 CC heparin-binding growth factors, cellular responses to heparin-binding
 CC growth factors and cytokines, cell interaction with plasma lipoproteins,
 CC cellular susceptibility to viral, protozoal and bacterial infections
 CC or disintegration of neurodegenerative plaques. Heparanase may be
 CC useful for conditions such as wound healing, angiogenesis, restenosis,
 CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
 CC infections. Mammalian heparanase can be used to neutralize plasma
 CC heparin, and anti-heparanase antibodies may be used to neutralize
 CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
 CC and renal failure in biopsy specimens, plasma samples, and body fluids.
 CC The present sequence encodes human heparanase.

XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

SO Query Match 100.0%; Score 23; DB 20; Length 1721;

Best Local Similarity 100.0%; Pred. No. 0.32; Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCGATCCCAAGAGGATCAAC 23
Db 372 TTCGATCCCAAGAGGATCAAC 394

RESULT 10

AAAT5051
ID AAAT5051 standard; cDNA; 1721 BP.

AC AAAT5051;

DT 15-JAN-2001 (first entry)

DE cDNA encoding a human heparanase polypeptide.

Human; heparanase; gene therapy; tumour; inflammation; autoimmunity; heparin-binding growth factor; cytokine; neurodegenerative plaque; wound healing; infection; burn; angiogenesis; restenosis; atherosclerosis; inflammation; neurodegenerative disease; Gerstmann-Straussler Syndrome; Creutzfeldt-Jakob disease; de.

OS Homo sapiens.

Key Location/Qualifiers

FT CDS 63..1693

FT /tag= a

FT /product= "heparanase"

FT /tag= b

FT /note= "these nucleotides are likely to be involved in forming stem and loop structures"

XX WO200052178-A1.

XX 08-SEP-2000.

XX 14-FEB-2000; 2000WO-US03542.

XX 01-MAR-1999; 99US-0256892.

XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.

XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

XX (FRIE/) FRIEDMAN M M.

XX Pecker I, Vlodavsky I, Feinstein E;

XX WPI; 2000-579289/54.

XX P-PSDB; AAB08849.

XX New polynucleotides encoding a polypeptide having heparanase activity, useful in wound healing and in gene therapy, particularly in treating tumour, inflammation, autoimmunity, neurodegenerative diseases

XX Claim 9; Fig 1; 152pp; English.

XX The present sequence encodes a human protein with heparanase catalytic activity. The heparanase (hpa) polynucleotide is useful in gene therapy, particularly in treating tumour, inflammation or autoimmunity.

XX Particularly, the polynucleotide is useful in modulating the bioavailability of heparin-binding growth factors, cellular responses to heparin-binding growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins, cellular susceptibility to certain viral and some bacterial and protozoa infections, or disintegration of neurodegenerative plaques. The polynucleotide is also useful in wound healing (e.g. thermal, chemical or radiation burns), and in the treatment of angiogenesis, restenosis, atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-Straussler Syndrome or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa infections.

SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match 100.0%; Score 23; DB 21; Length 1721;

Best Local Similarity 100.0%; Pred. No. 0.32; Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCGATCCCAAGAGGATCAAC 23
Db 372 TTCGATCCCAAGAGGATCAAC 394

RESULT 11

AAZ39195
ID AAZ39195 standard; cDNA; 1721 BP.

AC AAZ39195;

DT 02-MAR-2000 (first entry)

DE Human heparanase encoding cDNA.

Human; heparanase; hpa; genetic modification; expression; anticancer; angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumour; anti-atherosclerotic; anti-inflammatory; antineurodegeneration; heparan sulphate; heparin-binding growth factor; tumour angiogenesis; metastasis; wound healing; restenosis; atherosclerosis; inflammation; neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis; micrometastasis; autoimmune lesion; kidney failure; ss.

OS Homo sapiens.

Key Location/Qualifiers

FT CDS 63..1694

FT /tag= a

FT /product= "heparanase"

XX WO9957244-A1.

XX 11-NOV-1999.

XX 29-APR-1999; 99WO-US09256.

XX 01-MAY-1998; 98US-0071618.

XX 02-MAR-1999; 99US-0260038.

XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.

XX (FRIE/) FRIEDMAN M M.

XX Ben-Artzi H, Ayal-HersHKovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;

XX Shlom Y;

XX WPI; 2000-062144/05.

XX P-PSDB; AAZ57590.

XX Engineered cells that express recombinant heparanase, useful therapeutically, e.g. for treating angiogenesis and to screen for specific inhibitors, potential anticancer agents

XX Claim 2; Page 106-107; 118pp; English.

XX The present invention describes genetically modified cells (A) containing a polynucleotide (I) that encodes a polypeptide with heparanase activity, and express recombinant heparanase (II). Heparanase cleaves heparan sulphate (HS) at specific intrachain sites, resulting in release of heparin-binding growth factors, enzymes and proteins that are sequestered by HS in basement membranes, extracellular matrix or cell surface. It may also be implicated in tumour angiogenesis and metastases. (II) is potentially useful in wound healing and for treating angiogenesis, restenosis, atherosclerosis, inflammation, neurodegeneration, viral infection and cystic fibrosis. It can also be used to neutralise heparin (an alternative to protamine) and to screen for specific inhibitors (potentially useful for treating cancer and metastases). Antibodies raised against (II) are used for immunodetection and diagnosis of

CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
CC in large quantities, in a form that is homogeneously processed and
CC activated/neutralised by a dedicated protease. The present sequence
CC encodes human heparanase.

SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match	100.0%	Score 23	DB 21	Length 1721
Best Local Similarity	100.0%	Pred. Nc.	0.32	
Matches 23	Conservative 0	Mismatches 0	Indels 0	Gaps 0

Oy 1 TTGGATCCCAAGAAGGATCAAC 23
| | | | |
Db 372 TTCGATCCCAGAAGGAATCAAC 394

RESULT 12
AAZ33290
ID AAZ33290 standard; cDNA; 1721 BP.

AC	AAZ33290;
XX	
DT	21-FEB-2000 (first entry)

DE Human heparanase nucleotide sequence

KM Human; heparinase; hpa; diagnosis; therapy; tumour; cytostatic;
KM antiadhesive; immunomodulatory; anti-inflammatory; nephrotropic;
KM metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
KM mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
KM inflammation; haemorrhagic nephritis; nephrotic syndrome;
KM autoimmune disease; anticancer; kidney disease; ds.

OS Homo sapiens

	Key	Location/Qualifiers
FT	CDS	63..1694
FT		/*tag= a
FT		/product= "heparanase"

PN W09957153-A1

PD 11-NOV-1999

PF 29-APR-1999; 99WO-US09255

PR 01-MAY-1998; 98US-0071739

PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

PI Pecker I, Vlodavsky I, Friedman Y, Perets T;

DR WPI; 2000-052944/04
DR P-PSDB; AAY52990.

PT Heparanase-specific molecular probes useful for diagnosis and treatment, e.g. of tumors, and for targeted drug delivery -

PS Example; Page 82-84; 90pp; English.

CC The present invention describes heparanase-specific molecular probes,
CC useful for methods of detecting heparanase in situ. The probes and
CC anti-heparanase antibodies are used to detect or quantify the expression
CC of heparanase, for diagnosis and monitoring of diseases (especially
CC metastasis), for treatment of heparanase-associated diseases (e.g.
CC tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
CC metastases) derived from liver, prostate, bladder, breast, ovary,
CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted

CC drug delivery (e.g. of anticancer agents) and as research reagents.
CC The present sequence encodes human heparanase, which is used in the
CC exemplification of the present invention.

SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match	100.0%	Score 23	DB 21	Length 1721
Best Local Similarity	100.0%	Pred. No. 0.32		
Matches 23	Conservative 0	Mismatches 0	Indels 0	Gaps 0

```

QY      1 TTGATCCCAAGAGAATCAAC 23
          |||||
Db      372 TTGATCCCAAGAGAATCAAC 394

```

RESULT 13
AAA91112
ID AAA91112 standard; DNA; 1721 BP.

AC AAA91112;

DT 20-APR-2001 (first entry)

DB Human heparanase, coding sequence fragment isolated from EST clone.

KM Heparanase, hmbpl; wound healing; angiogenesis; retinosis; Scrape;
KM atherosclerosis, inflammation; pulmonary disease; Alzheimer's disease;
KM neurodegenerative disease; Creutzfeldt-Jakob disease; viral infection;
KM gene therapy; mouse; expressed sequence tag; ds.

Homo sapiens

PN WO200100643-A2.

PD 04-JAN-2001

PF 19-JUN-2000; 2000WO-IL00358.

PR 25-JUN-1999; 99US-0140801.

PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.

PI Pecker I, Michal I, Itzhaki H;

DR WPI; 2001-137930/14

PT New polynucleotides and polypeptides that are distantly homologous to
PT heparanase, useful in wound healing, as well as in gene therapy
PT protocols for angiogenesis, restenosis, atherosclerosis, or
PT inflammation -

PS Example 1; Page 67; 67pp; English

CC This sequence represents a human heparanase coding sequence clone,
CC isolated from an EST clone. The invention relates to heparanase DNA
CC and protein sequences. The heparanase DNA and protein sequences are
CC useful in wound healing, angiogenesis, xeroderma, atherosclerosis,
CC inflammation, pulmonary diseases, neurodegenerative diseases (such as
CC scrapie, Alzheimer's disease, and Creutzfeldt-Jacob disease) or viral
CC infections. The heparanase coding sequence is particularly useful in gene
CC therapy.

Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match	100.0%	Score 23	DB 22	Length 1721
Best Local Similarity	100.0%	Pred. No.	0.32	
Matches 23	Conservative 0	Mismatches 0	Indels 0	Gaps 0

[illegible]

```
RESULT 14
AA3788
ID AAF93788 standard; cDNA, 1722 BP.
XX
AC AAF93788;
XX
DT 23-MAY-2001 (first entry)
XX
DE Human cDNA encoding a membrane or secretory protein clone PSEC0090.
XX
KW Human; secretory protein; membrane protein; vaccine; gene therapy;
KW rheumatoid arthritis; diabetes; ss.
XX
OS Homo sapiens.
XX
EP EPI067182-A2.
XX
PN 10-JAN-2001.
XX
PD 07-JUL-2000; 2000EP-0114090.
XX
PF 08-JUL-1999; 99JP-0194179.
XX
PR 11-JAN-2000; 2000JP-0118775.
XX
PR 02-MAY-2000; 2000JP-0183766.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isegai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
XX
DR WPI; 2001-093989/11.
XX
DR P-PSDB; AAB88361.
XX
PT Nucleic acid encoding secretory proteins/membrane proteins, useful in
XX
PT gene therapy or as candidate target molecules in drug development -
XX
XX
PS Claim 1; SEQ ID 89; 609PP + CD ROM; English.
XX
XX
This invention relates to nucleic acid sequences AAF93744 - AAF93916
CC which encode human secretory or membrane proteins represented by
CC AAB88317 - AAB88419. Included in the invention are primers
CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the
CC cDNA sequences of the invention. The invention also includes methods for
CC the production of antibodies directed against the proteins, and cDNA
CC sequences, which can be used in vaccines. The polynucleotide sequences
CC can be used in gene therapy. The polynucleotide sequences and the
CC proteins they encode may be used in the prevention, treatment and
CC diagnosis of diseases associated with inappropriate secretory
CC protein/membrane protein expression. The nucleic acids and complementary
CC sequences may also be used as DNA probes in diagnostic assays
CC (e.g. polymerase chain reactions (PCR)) to detect and quantitate the
CC presence of similar nucleic acid sequences in samples. They may also be
CC used to study the expression and function of secretory proteins/membrane
CC polypeptides and their role in metabolism. The polypeptides may be used
CC as antigens in the production of antibodies against them and in assays to
CC identify modulators (agonists and antagonists) of expression and
CC activity. The antibodies and antagonists may also be used as therapeutic
CC agents to down regulate expression and activity. The antibodies may also
CC be used as diagnostic agents for detecting the presence of the
CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay
CC (ELISA). Examples of diseases which may be treated include rheumatoid
CC arthritis and diabetes.
XX
SQ Sequence 1722 BP; 449 A; 414 C; 412 G; 447 T; 0 other;
```

```
RESULT 15
AA37260
ID AAX37260 standard; DNA, 1723 BP.
XX
AC AAX37260;
XX
DT 21-JUL-1999 (first entry)
XX
DE Seq ID No: 14 of WO9921975.
XX
KW Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
KW metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KW arteriosclerosis; atherosclerosis; inflammation; tissue development;
KW human; HSPG; ss.
XX
OS Homo sapiens.
XX
PN WO9921975-A1.
XX
PD 06-MAY-1999.
XX
PF 28-OCT-1998; 98WO-AU00898.
XX
PR 09-DEC-1997; 97AU-0000812.
XX
PR 28-OCT-1997; 97AU-0000062.
XX
PA (AUSU ) UNIV AUSTRALIAN NAT.
XX
PI Freeman CG, Hamdorf BJ, Hulet MD, Parish CR;
XX
DR WPI; 1999-312956/26.
XX
DR P-PSDB; AAY17083.
XX
PT Polynucleotides encoding mammalian endoglucuronidases, especially
XX
PT heparanases, useful to promote wound healing
XX
XX
PS Claim 11; Page 76-79; 112PP; English.
XX
XX
The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG.
XX
SQ Sequence 1723 BP; 461 A; 407 C; 412 G; 443 T; 0 other;
```

Search completed: February 16, 2004, 09:18:13
Job time : 13.2849 secs

```
Query Match 100.0%; Score 23; DB 22; Length 1722;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

1 TTCGATCCCAAGAGATCAAC 23
|||||
373 TTCGATCCCAAGAGATCAAC 395

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 109.813 Seconds

(without alignments).
8568.399 Million cell updates/sec

Title: US-10-676-079-6

Perfect score: 23

Sequence: 1 ttctgaccccaagaagaatcaac 23

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 288871 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

Genbm1:*
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vt:*
15: gb_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_ov:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vt:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_pln:*
35: em_htg_rnd:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	23	100.0	23 6 AR080677	AR080677 Sequence
2	23	100.0	23 6 AR125607	AR125607 Sequence
3	23	100.0	23 6 AR287439	AR287439 Sequence
4	23	100.0	23 6 BD074425	BD074425 Polynucle
5	23	100.0	558 6 BD110974	BD110974 EST and e
6	23	100.0	1593 6 AR210040	AR210040 Sequence
7	23	100.0	1593 6 BD136761	BD136761 Human pla
8	23	100.0	1669 9 AF084467	AF084467 Homo sapi
9	23	100.0	1694 9 AF152376	AF152376 Homo sapi
10	23	100.0	1713 6 AR156691	AR156691 Sequence
11	23	100.0	1713 6 AX034643	AX034643 Sequence
12	23	100.0	1721 6 AR080679	AR080679 Sequence
13	23	100.0	1721 6 AR080680	AR080680 Sequence
14	23	100.0	1721 6 AR125603	AR125603 Sequence
15	23	100.0	1721 6 AR125604	AR125604 Sequence
16	23	100.0	1721 6 AR194189	AR194189 Sequence
17	23	100.0	1721 6 AR194190	AR194190 Sequence
18	23	100.0	1721 6 AR221285	AR221285 Sequence
19	23	100.0	1721 6 AR221286	AR221286 Sequence
20	23	100.0	1721 6 AR243203	AR243203 Sequence
21	23	100.0	1721 6 AR243204	AR243204 Sequence
22	23	100.0	1722 6 AR287435	AR287435 Sequence
23	23	100.0	1721 6 AR287436	AR287436 Sequence
24	23	100.0	1721 6 BD074427	BD074427 Polynucle
25	23	100.0	1721 6 BD074428	BD074428 Polynucle
26	23	100.0	1722 6 AX136167	AX136167 Sequence
27	23	100.0	1722 6 BD123536	BD123536 Secretary
28	23	100.0	1722 9 AK075400	AK075400 Homo sapi
29	23	100.0	1723 6 AR156692	AR156692 Sequence
30	23	100.0	1723 6 AX034645	AX034645 Sequence
31	23	100.0	1724 6 AX147946	AX147946 Sequence
32	23	100.0	1724 9 AF165154	AF165154 Homo sapi
33	23	100.0	1758 9 AF144325	AF144325 Homo sapi
34	23	100.0	1810 9 BC051321	BC051321 Homo sapi
35	23	100.0	1899 6 BD074430	BD074430 Polynucle
36	23	100.0	1899 6 BD074431	BD074431 Polynucle
37	23	100.0	3726 6 AR235866	AR235866 Sequence
38	23	100.0	3726 6 AX019348	AX019348 Sequence
39	23	100.0	3726 6 BD131218	BD131218 Human hep
40	23	100.0	3726 9 AF155510	AF155510 Homo sapi
41	23	100.0	149188 9 AC114781	AC114781 Homo sapi
42	22	95.7	474 6 AX136496	AX136496 Sequence
43	22	95.7	474 6 BD123736	BD123736 Secretary
44	18.8	81.7	191721 10 AC101883	AC101883 Mus muscu
45	18.8	81.7	248754 2 AC134101	AC134101 Rattus no

ALIGNMENTS

RESULT 1
AR080677
LOCUS AR080677 23 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 6 from patent US 5968822.
ACCESSION AR080677
VERSION AR080677.1 GI:10007407
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 23)
Pecker, I., Vlodavsky, I. and Feinstein, E.
Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
Patent: US 5968822-A 6 19-OCT-1999;
JOURNAL

FEATURES
source
1. .23
/organism="unknown"
BASE COUNT 9 a 6 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGCATCCCAAGAGGATCAAC 23
Db 1 TTGCATCCCAAGAGGATCAAC 23

RESULT 2
ARI25607
LOCUS
DEFINITION Sequence 6 from patent US 6177545.
ACCESSION ARI25607
VERSION ARI25607.1 GI:14111669
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .23
/organism="unknown"
BASE COUNT 9 a 6 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGCATCCCAAGAGGATCAAC 23
Db 1 TTGCATCCCAAGAGGATCAAC 23

RESULT 3
AR287439
LOCUS
DEFINITION Sequence 6 from patent US 6531129.
ACCESSION AR287439
VERSION AR287439.1 GI:29725133
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .23
/organism="unknown"
BASE COUNT 9 a 6 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGCATCCCAAGAGGATCAAC 23
Db 1 TTGCATCCCAAGAGGATCAAC 23

RESULT 4
BD074425
LOCUS
DEFINITION Polynucleotide encoding polypeptide having heparanase activity and expression of the polypeptide in induced cell.
ACCESSION BD074425
VERSION BD074425.1 GI:22620028
KEYWORDS JP 2001514855-A/6.
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

OS Nucleic acid
PN JP 2001514855-A/6
PD 18-SEP-2001
PR 31-AUG-1998 JP 2000508806
PC 02-SEP-1997 US 08/922170.02-JUL-1998 US 09/109386 P1
IRIS PECKER, ISRAEL VLODAVSKY, FEINSTEIN ELENA
PC C12N15/09, A61K38/00, A61P9/10, A61P17/00, A61P29/00, A61P35/00, PC A61P37/00,
PC A61P43/00, C12N5/10, C12N9/24, C12Q1/68, G01N33/15, G01N33/50// PC A61K39/395
PC A61K39/395, C12N15/00, A61K37/02, C12N5/00
CC Polynucleotide encoding polypeptide having heparanase activity
and
CC expression of the polypeptide in induced cell FH Key
CC Location/Qualifiers
FT source 1. .23
FT /organism="Nucleic acid".
FEATURES
source
1. .23
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 6 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGCATCCCAAGAGGATCAAC 23
Db 1 TTGCATCCCAAGAGGATCAAC 23

RESULT 5
BD110974
LOCUS
DEFINITION EST and encoded human protein.
ACCESSION BD110974
VERSION BD110974.1 GI:23205792
KEYWORDS JP 2002010789-A/3051.
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

OS Homo sapiens (human)
PN JP 2002010789-A/3051
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
EST and encoded human protein.
Patent: JP 2002010789-A 3051 15-JAN-2002;
GENSET CORP
OS Homo sapiens (human)
PN JP 2002010789-A/3051

PD 15-JAN-2002
 PF 07-AUG-2000 JP 2000280989
 PR 05-AUG-1999 US 60/147699
 PI JEAN BABUTIST DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
 GIORANO
 PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
 C12N1/21,
 PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
 C12N15/00
 CC EST and encoded human protein
 FH Key Location/Qualifiers
 FT CDS 140..403.
 Location/Qualifiers
 1..558
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 181 a 111 c 108 g 157 t 1 others
 ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 558;
 Best Local Similarity 100.0%; Pred. No. 2.3;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGGATCAAC 23
 173 TTCGATCCCAAGAGGATCAAC 151

Db

RESULT 6
 LOCUS AR210040 1593 bp DNA linear PAT 20-JUN-2002
 DEFINITION Sequence 1 from patent US 6387643.
 ACCESSION AR210040
 VERSION AR210040.1 GI:21512167
 KEYWORDS
 SOURCE
 ORGANISM Unknown.
 Unclassified.
 1 (bases 1 to 1593)
 Heintz, R., Leroy, J., Fairbanks, M.B. and Milder, A.M.
 Human platelet heparanase polypeptides, polynucleotide molecules
 that encode them, and methods for the identification of compounds
 that alter heparanase activity
 Patent: US 6387643-A 1 14-MAY-2002;
 Location/Qualifiers
 1..1593
 /organism="unknown"
 /db_xref="taxon:9606"

BASE COUNT 426 a 370 c 369 g 428 t
 ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 1593;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGGATCAAC 23
 271 TTCGATCCCAAGAGGATCAAC 293

Db

RESULT 7
 LOCUS BD136761 1593 bp DNA linear PAT 18-SEP-2002
 DEFINITION Human platelet heparanase polypeptide, polynucleotide molecule
 encoding the same and method of identifying compound changing
 heparanase activity.
 accession BD136761
 version BD136761.1 GI:23231706
 keywords JP 2002504376-A/1.
 source unidentified
 organism unidentified
 reference 1 (bases 1 to 1593)

AUTHORS Heintz, R.L., Fairbanks, M.B. and Milder, A.M.
 TITLE Human platelet heparanase polypeptide, polynucleotide molecule
 encoding the same and method of identifying compound changing
 JOURNAL Patent: JP 2002504376-A 1 12-FEB-2002;
 PHARMACIA & UPJOHN CO
 COMMENT
 OS Unidentified
 PN JP 2002504376-A/1
 PD 12-FEB-2002
 PF 18-FEB-1999 JP 2000533569
 PR 24-FEB-1998 US 60/075706 26-MAR-1998 US 60/079401 PI
 ROBERT L. HEINTZ, MICHAEL B. FAIRBANKS, ANA M. MILDNER PC
 C12N15/09, C07K16/40, C12N1/21, C12N5/10, C12N9/24, C12Q1/34, C12N15/00, C12N5/00
 CC Strandedness: Double;
 CC Topology: Linear;
 CC Human platelet heparanase polypeptide, polynucleotide molecule

CC encoding
 CC the same and method of identifying compound changing CC
 FH heparanase activity Location/Qualifiers
 FT source 1..1593
 /organism="Unidentified".
 Location/Qualifiers
 1..1593
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

BASE COUNT 426 a 370 c 369 g 428 t
 ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 1593;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGGATCAAC 23
 271 TTCGATCCCAAGAGGATCAAC 293

Db

RESULT 8
 LOCUS AF084467 1669 bp mRNA linear PRI 18-OCT-2000
 DEFINITION Homo sapiens heparanase mRNA, complete cds.
 ACCESSION AF084467
 VERSION AF084467.1 GI:5870623
 KEYWORDS
 SOURCE
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 1 (bases 1 to 1669)
 Dempsey, L.A., Plummer, T.B., Coombes, S.L. and Platt, J.L.
 Heparanase expression in invasive trophoblasts and acute vascular
 damage
 Glycobiology 10 (5), 467-475 (2000)

JOURNAL
 MEDLINE
 PUBMED
 2 (bases 1 to 1669)
 Dempsey, L.A., Holzkecht, R.A. and Platt, J.L.
 Identification of the cDNA encoding human heparanase
 JOURNAL
 REFERENCE
 3 (bases 1 to 1669)
 Dempsey, L.A., Holzkecht, R.A. and Platt, J.L.
 Direct Submission
 Submitted (14-AUG-1998) Surgery, Duke University, Research Dr., Rm.
 401 MSRB, Durham, NC 27710, USA
 Location/Qualifiers
 1..1669
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /cell_line="mekakaryocyte"

CDS

/cissue_type="placenta"
1..1638
/note="endoglycosidase; expressed in placenta and platelets"
/codon_start=1
/product="heparanase"
/protein_id="AAD54516.1"
/db_xref="GI:5870624"
/translation="MLRSKPALPPPLMLLLGLPLSPGALPRPAQADVDVLD
FTQEPHLVSPFLSVITIDANLATDPRFLILGSPKLTARGLSPAYLRGGTKTD
FLIPDKKSTPEERSYMOVONODICKYGI PPRVEKRLREMPYQDOLLREHYOK
KFNKSTYRSRSDVYITPANGSGDLLIGNALLTATDQNNSSNAOLLIDYCSKGY
NISWELGNEPNSFLKKADI FINGSLGDFIQHLKLRKSTFKNAKLGPVQGRK
TAKMLKSLKAGGEVIDSVTWHYLYNGATREDPLNDVLDIFISSVQKVFQVES
TRPGKRWLGETSAYGGAPLSDTPAAGFMWLDKLGISAMGIEVMROVFGAGN
YHLVDENFDPLPDYMLSLFLKLVGKVLMAVVOGSKRKRLRVYLCNTDPRKXG
DLTYATINHTYKTLRLPYPSNKQVDKYLRLPLGPHGLSKSVQNLGTLTKWDDQ
TLPLMEKPLRPGSSSLGAPAFSYSPFVIRNAKVAACI"

BASE COUNT 445 a 396 c 388 g 440 t

ORIGIN

Query Match 100.0%; Score 23; DB 9; Length 1669;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTGGATCCCAAGAGGATCAAC 23
|||||
316 TTGGATCCCAAGAGGATCAAC 338

Db

RESULT 9
AF152376 1694 bp mRNA linear PRI 28-JUL-1999
LOCUS Homo sapiens heparanase mRNA, complete cds.
DEFINITION AF152376
ACCESSION AF152376.1 GI:5616196
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 1694)
AUTHORS Kuesle,P.H., Hulmes,J.D., Ludwig,D.L., Patel,S., Navarro,E.C.,
Seddon,A.P., Giorgio,N.A. and Bohlen,P.
TITLE Cloning and functional expression of a human heparanase gene
JOURNAL Biochem. Biophys. Res. Commun. 261 (1), 183-187 (1999)
MEDLINE 10405343
PUBMED 2 (bases 1 to 1694)
AUTHORS Kuesle,P.H., Hulmes,J.D., Ludwig,D., Patel,S., Navarro,E.C.,
Seddon,A.P., Giorgio,N.A. and Bohlen,P.
TITLE Direct Submission
JOURNAL Submitted (18-MAY-1999) Protein Chemistry, Imclone Systems Inc.,
180 Varick Street, New York, NY 10014, USA
FEATURES
source
1..1694
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cissue_type="placenta"
15..1646
/codon_start=1
/product="heparanase"
/protein_id="AAD45669.1"
/db_xref="GI:5616197"
/translation="MLRSKPALPPPLMLLLGLPLSPGALPRPAQADVDVLD
FTQEPHLVSPFLSVITIDANLATDPRFLILGSPKLTARGLSPAYLRGGTKTD
FLIPDKKSTPEERSYMOVONODICKYGI PPRVEKRLREMPYQDOLLREHYOK
KFNKSTYRSRSDVYITPANGSGDLLIGNALLTATDQNNSSNAOLLIDYCSKGY
NISWELGNEPNSFLKKADI FINGSLGDFIQHLKLRKSTFKNAKLGPVQGRK
TAKMLKSLKAGGEVIDSVTWHYLYNGATREDPLNDVLDIFISSVQKVFQVES
TRPGKRWLGETSAYGGAPLSDTPAAGFMWLDKLGISAMGIEVMROVFGAGN
YHLVDENFDPLPDYMLSLFLKLVGKVLMAVVOGSKRKRLRVYLCNTDPRKXG
DLTYATINHTYKTLRLPYPSNKQVDKYLRLPLGPHGLSKSVQNLGTLTKWDDQ
TLPLMEKPLRPGSSSLGAPAFSYSPFVIRNAKVAACI"

CDS

BASE COUNT 465 a 398 c 391 g 440 t

ORIGIN

Query Match 100.0%; Score 23; DB 9; Length 1694;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTGGATCCCAAGAGGATCAAC 23
|||||
324 TTGGATCCCAAGAGGATCAAC 346

Db

RESULT 10
AR156691 1713 bp DNA linear PAT 08-AUG-2001
LOCUS Sequence 12 from patent US 6242238.
DEFINITION AR156691
ACCESSION AR156691.1 GI:15125395
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1713)
AUTHORS Freeman,C.GeoFFrey., Hulet,M.Darren., Parish,C.Richard. and
Hamdorf,B.James.
TITLE Isolated nucleic acid molecule encoding mammalian endoglycuronidase
JOURNAL Patent: US 6242238-A 12-05-JUN-2001;
FEATURES
source
1..1713
/organism="unknown"
BASE COUNT 460 a 404 c 406 g 443 t

ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 1713;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTGGATCCCAAGAGGATCAAC 23
|||||
355 TTGGATCCCAAGAGGATCAAC 377

Db

RESULT 11
AX034643 1713 bp DNA linear PAT 22-SEP-2000
LOCUS Sequence 12 from Patent EPI032656.
DEFINITION AX034643
ACCESSION AX034643
VERSION AX034643.1 GI:10303224
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Hamdorf,B.J., Freeman,C.G., Hulet,M.D. and Parish,C.R.
TITLE Isolated nucleic acid molecule encoding mammalian endoglycuronidase
JOURNAL Patent: EP 1032656-A 12-06-SEP-2000;
JOURNAL UNIV AUSTRALIAN (AU)
FEATURES
source
1..1713
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
46..1677
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC10139.1"
/db_xref="GI:10303225"
/translation="MLRSKPALPPPLMLLLGLPLSPGALPRPAQADVDVLD
FTQEPHLVSPFLSVITIDANLATDPRFLILGSPKLTARGLSPAYLRGGTKTD
FLIPDKKSTPEERSYMOVONODICKYGI PPRVEKRLREMPYQDOLLREHYOK
KFNKSTYRSRSDVYITPANGSGDLLIGNALLTATDQNNSSNAOLLIDYCSKGY
NISWELGNEPNSFLKKADI FINGSLGDFIQHLKLRKSTFKNAKLGPVQGRK
TAKMLKSLKAGGEVIDSVTWHYLYNGATREDPLNDVLDIFISSVQKVFQVES
TRPGKRWLGETSAYGGAPLSDTPAAGFMWLDKLGISAMGIEVMROVFGAGN
YHLVDENFDPLPDYMLSLFLKLVGKVLMAVVOGSKRKRLRVYLCNTDPRKXG
DLTYATINHTYKTLRLPYPSNKQVDKYLRLPLGPHGLSKSVQNLGTLTKWDDQ
TLPLMEKPLRPGSSSLGAPAFSYSPFVIRNAKVAACI"

CDS

TOEPHLVPSFSLVTIDANLATPRFLILIGSPKLTATLNGLSPAYLRFSGTKTDFL
 IFDPKKESTPEERSWMOQVONODICKGSIIPDVEBKLEMPYOEOLLEHOKKE
 KNSYRSVVLYTTPANCSGLDILFGINALPTADLOMNSNMLLDYCSSGVNT
 SWEIGNEPNSLKKADIFINSQJGEBDTQJHKLKSTFPKALTYEPDVQCPKRTA
 KMLKSFLEAGGEVIDSVTHHYLYNGRTAREDEFLNPDVLDIPLSSVQKQVVESTR
 PGKRVMLGETSSAVGGAPLSDTFAAFPMWLDKGLSARMGIEVMQVFFGAGNHA
 LVDPNFPDLPDYMLSLFFKLVGTKVLMAVSQSKRRLRLRYLHCTMTDNRYEGL
 TLVAIINHNTKYLRLPYFPENKQVDKYLRLPLGPHGLSLSSVOLNGULTLMVDQTL
 PLMEKPLRPSSSLGIPAFSFFVIRAKTAACI"

mat_peptide

517.1674
 /product="unnamed"

BASE COUNT 460 a 404 c 406 g 443 t

ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 1713;

Best Local Similarity 100.0%; Pred. No. 2.1;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGCATCCCAAGAGGATCAAC 23

Db 355 TTGCATCCCAAGAGGATCAAC 377

RESULT 12

AR080679

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

ORIGIN

Query Match

Best Local Similarity

Matches

OY

Db

RESULT 13

AR080680

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

ORIGIN

Query Match

Best Local Similarity

Matches

OY

Db

RESULT 14

AR125603

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 1721;

Best Local Similarity 100.0%; Pred. No. 2.1;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGCATCCCAAGAGGATCAAC 23

Db 372 TTGCATCCCAAGAGGATCAAC 394

RESULT 14

AR125603

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

ORIGIN

Query Match

Best Local Similarity

Matches

OY

Db

RESULT 15

AR125604

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

ORIGIN

Query Match

Best Local Similarity

Matches

OY

Db

RESULT 16

AR165604

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

ORIGIN

Query Match

Best Local Similarity

Matches

OY

Db

Search completed: February 16, 2004, 11:43:02
 Job time : 109.813 secs

This Page Blank (uspio)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 : Search time 89.3432 Seconds
(without alignment)
6256.802 Million cell updates/sec

Title: US-10-676-079-6

Sequence: 1 ttcgaccccaagaagatcaac 23

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 22781392 seqs, 1215238056 residues

Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

EST: *
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estcov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rtd:*
26: em_gss_phg:*
27: em_gss_vrt1:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	23	100.0	881	14	CB988510 AGNCOURT
2	23	100.0	924	13	B0691142 AGNCOURT
3	23	100.0	1185	9	AL552174 AL552174
4	23	100.0	1201	9	AL545270 AL545270

C 5	18.8	81.7	494	29	CC066085	CSU-K33r.
C 6	18.8	81.7	711	29	B2527295	OGAEU93TC
C 7	18.8	81.7	711	29	B2539243	OGAM622TC
C 8	18.4	80.0	581	9	A1965004	fc85e07.y
C 9	18.4	80.0	592	14	CB091033	gy83f07.g
C 10	18.4	80.0	594	14	CB091179	h899d02.g
C 11	18.2	79.1	401	9	A1624038	ts25h10.x
C 12	18.2	79.1	483	13	B0821234	UB20CPG09
C 13	18.2	79.1	519	13	B0833017	T040G08 P
C 14	18.2	79.1	568	29	CC327702	OC08S65TH
C 15	18.2	79.1	603	28	BH549506	BH549506
C 16	18.2	79.1	623	13	B0835590	T075H04 P
C 17	18.2	79.1	669	13	B0837501	T102E06 P
C 18	18.2	79.1	696	13	B0892096	P059D01 P
C 19	18.2	79.1	717	13	B0831251	T019D07 P
C 20	18.2	79.1	812	28	BH439125	BH439125
C 21	18.2	79.1	853	29	B2409786	OGACR81TC
C 22	18.2	79.1	890	29	B2973851	PUG1W57TB
C 23	18.2	79.1	948	29	CC008795	PUDM49TD
C 24	18.2	79.1	948	29	CA621440	w11n-DK00
C 25	17.8	77.4	393	9	AJ225474	AJ225474
C 26	17.8	77.4	400	29	FR0048882	Fugu rubr
C 27	17.8	77.4	497	28	AQ716252	HS_5452_B
C 28	17.8	77.4	1072	29	CNS054DM	AL320611
C 29	17.8	77.4	1078	10	BE615628	601278645
C 30	17.4	75.7	420	29	CC054600	SALK_0778
C 31	17.4	75.7	572	29	CC414518	PUG542TD
C 32	17.4	75.7	597	28	AQ563293	HS_5334_B
C 33	17.4	75.7	659	14	CB449302	703490_OG1
C 34	17.4	75.7	701	29	AG105115	Pan trogl
C 35	17.4	75.7	716	28	BH095882	RPCI-24-2
C 36	17.4	75.7	720	28	BH427866	BOCMK6OTR
C 37	17.4	75.7	787	28	BH525146	BOH5281TF
C 38	17.4	75.7	800	29	BZ285719	CH230-255
C 39	17.4	75.7	1071	28	BZ165314	CH230-462
C 40	17.2	74.8	140	29	BZ539173	OGAFV20TC
C 41	17.2	74.8	175	29	BZ712362	OGDM29TC
C 42	17.2	74.8	178	29	BZ712351	OGDM29TC
C 43	17.2	74.8	186	29	BZ659850	OGANUG61TC
C 44	17.2	74.8	197	9	AV358527	AV358527
C 45	17.2	74.8	239	13	BQ454119	sac76c06.

ALIGNMENTS

RESULT 1
CB988510
LOCUS
DEFINITION AGNCOURT 13905817 NIH MGC_147 Homo sapiens cDNA clone
IMAGE:30340461 5', mRNA sequence.

ACCESSION
CB988510
VERSION
CB988510.1 GI:30283030

KEYWORDS
SOURCE
ORGANISM

Homo sapiens (human)

REFERENCE
1 (bases 1 to 881)
Nih-MGC http://mgs.nci.nih.gov/
National Institutes of Health, Mammalian Gene Collection (MGC)

UNPUBLISHED
Contact: Robert Strusberg, Ph.D.
Email: cga@bbs-remail.nih.gov
Tissue Procurement: Dr. Stefan Hansson
CDNA Library Preparation: Michael J. Brownstein (NHGRI) with help
and advice from Piero Carninci (RIKEN)

CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LMNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LMNL at:
http://image.llnl.gov

Plate: NDM370 row: 6 column: 22

FEATURES

High quality sequence stop: 664.
Location/Qualifiers

1..881

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="IMAGE:30340461"

/tissue_type="Human Placenta"

/lab_host="DH10B Tona"

/clone_lib="NIH MGC 147"

/note="Organ: placenta; Vector: pBluescript; site: 1: att-xhoI; site 2: BamH; Oligo-dT primed using primer 5'-TTTTTTTTTTTNN-3', size-selected for average insert size 2.3 kb and normalized to R0T 5. This is a primary library enriched for full-length clones and constructed using the Cap-trapper method (Carninci, in preparation). Library constructed by M. Brownstein (NIH/NHGRI, National Institutes of Health). Note: This is a NIH MGC library."

BASE COUNT

200 a 244 c 229 g 208 t

ORIGIN

Query Match 100.0%; Score 23; DB 14; Length 881;

Best Local Similarity 100.0%; Pred. No. 4.3; Mismatches 0; Indels 0; Gaps 0;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TTCGATCCCAAGAGATCAAC 23

431 TTCGATCCCAAGAGATCAAC 453

RESULT 2 B0691142 924 bp mRNA linear EST 15-JUL-2002

LOCUS B0691142 AGENCOURT 8343629 NIH_MGC_110 Homo sapiens CDNA clone IMAGE:6250265

DEFINITION B0691142 5' mRNA sequence.

ACCESSION B0691142.1 GI:21816458

VERSION B0691142.1 GI:21816458

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 924)

NIH-MGC http://mgs.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished

Contact: Robert Strusberg, Ph.D.

Email: gsgabs-remail.nih.gov

Tissue Procurement: ATCC

CDNA Library Preparation: Rubin Laboratory

CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)

DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LNL at:

http://image.llnl.gov

Plate: L1CM2393 row: a column: 18

High quality sequence stop: 710.

Location/Qualifiers

1..924

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="IMAGE:6250265"

/tissue_type="ductal carcinoma, cell line"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH_MGC_110"

/note="Organ: pancreas; Vector: pOTV; site 1: XhoI; site 2: EcoRI; CDNA made by oligo-dT priming.

directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACAGC(G). Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-CDNA synthesis kit

FEATURES

(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH_MGC library."

BASE COUNT

203 a 271 c 227 g 219 t

4 others

Query Match 100.0%; Score 23; DB 13; Length 924;

Best Local Similarity 100.0%; Pred. No. 4.4; Mismatches 0; Indels 0; Gaps 0;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TTCGATCCCAAGAGATCAAC 23

444 TTCGATCCCAAGAGATCAAC 466

RESULT 3 B0691142 1185 bp mRNA linear EST 31-MAY-2003

LOCUS B0691142 AGENCOURT 8343629 NIH_MGC_110 Homo sapiens CDNA clone IMAGE:6250265

DEFINITION B0691142 5' mRNA sequence.

ACCESSION B0691142.1 GI:21816458

VERSION B0691142.1 GI:21816458

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 1185)

NIH-MGC http://mgs.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished

Contact: Robert Strusberg, Ph.D.

Email: gsgabs-remail.nih.gov

Tissue Procurement: ATCC

CDNA Library Preparation: Rubin Laboratory

CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)

DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LNL at:

http://image.llnl.gov

Plate: L1CM2393 row: a column: 18

High quality sequence stop: 710.

Location/Qualifiers

1..1185

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="CS0D1059YN15"

/tissue_type="PLACENTA COT 25-NORMALIZED"

/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"

/note="Five prime end enriched, double-strand cDNA was

digested with Not I and cloned into the Not I and EcoR V

sites of the pCMVSPORT 6 vector. Library was normalized."

BASE COUNT 280 a 293 c 293 g 280 t

39 others

Query Match 100.0%; Score 23; DB 9; Length 1185;

Best Local Similarity 100.0%; Pred. No. 4.7; Mismatches 0; Indels 0; Gaps 0;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TTCGATCCCAAGAGATCAAC 23

438 TTCGATCCCAAGAGATCAAC 460

RESULT 4 B0691142 1201 bp mRNA linear EST 31-MAY-2003

LOCUS B0691142 AGENCOURT 8343629 NIH_MGC_110 Homo sapiens CDNA clone IMAGE:6250265

DEFINITION B0691142 5' mRNA sequence.

ACCESSION B0691142.1 GI:21816458

VERSION B0691142.1 GI:21816458

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 1201)

NIH-MGC http://mgs.nci.nih.gov/.

```

VERSION      AL545270.2  GI:31267106
KEYWORDS     EST.
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
              1 (bases 1 to 1201)
              Li, W.B., Gruber, C., Jessee, J., and Polayes, D.
              Full-length cDNA libraries and normalization
              Unpublished
              On Feb 15, 2001 this sequence version replaced gi:1287751.
COMMENT      Contact: Genoscope
              Genoscope - Centre National de Sequencage
              BP 191 91006 Evry cedex - France
              Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
              Library was constructed by Life Technologies, a division of
              Invitrogen. This sequence belongs to sequence cluster 2469. For
              more information about this cluster, see
              http://www.genoscope.cns.fr/
              cgi-bin/cluster.cgi?seq=CSOD1028DC020PL&cluster=2469.r. Contact :
              Feng Liang Email : fliang@lifetech.com URL : Corporation 1600
              http://fulllength.invitrogen.com/Invitrogen
              Paraday Avenue Genoscope sequence ID : CSOD1028DC020PL.
              Location/Qualifiers
                1..1201
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /clone="CSOD1028YF04"
                /cissue_type="PLACENTA COT 25-NORMALIZED"
                /clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
                /note="First strand cDNA was primed with a NotI-oligo (dT)
                primer. Five prime end enriched, double-strand cDNA was
                digested with Not I and cloned into the Not I and EcoR V
                sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT   292 a      282 c      305 g      279 t
ORIGIN
Query Match 100.0%; Score 23; DB 9; Length 1201;
Best Local Similarity 100.0%; Pred. No. 4.7;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 TTGCATCCCAAGAGGATCAAC 23
    |||||
Db 431 TTGCATCCCAAGAGGATCAAC 453

RESULT 5
CC066085/c 494 bp DNA linear GSS 16-APR-2003
LOCUS      CSU-K33r.41K4.T7 CSU-K33r Aedes aegypti genomic clone CSU-K33r.41K4
DEFINITION , genomic survey sequence.
ACCESSION  CC066085
VERSION    CC066085.1 GI:29904591
KEYWORDS   GSS.
SOURCE     Aedes aegypti (yellow fever mosquito)
ORGANISM   Aedes aegypti
              Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
              Neoptera; Endopterygota; Diptera; Nematocera; Culicoidae; Aedes.
              1 (bases 1 to 494)
              Loftus, B., Shetty, J., Severson, D., Brown, S. and Knudson, D.
              End sequencing of Aedes aegypti BACs
              Unpublished
              Other_GSSs: CSU-K33r.41K4.SP6
              Contact: Brendan Loftus
              Department of Eukaryotic Genomics
              TIGR
              9712 Medical Center Drive, Rockville, MD 20850, USA
              Tel: 301-838-3543
              Fax: 301-838-0208
              Email: enta@tigr.org
              Library was provided by Susan Brown and Dennis Knudson at Colorado
              State University:

```

```

Seq primer: T7
Class: BAC ends.
FEATURES
  source      Location/Qualifiers
    1..494
    /organism="Aedes aegypti"
    /mol_type="genomic DNA"
    /strain="Rexville"
    /db_xref="taxon:7159"
    /clone="CSU-K33r.41K4"
    /note="Vector: pBelBAC11; Site_1: HindIII"
BASE COUNT   177 a      78 c      123 g      116 t
ORIGIN
Query Match 81.7%; Score 18.8; DB 29; Length 494;
Best Local Similarity 90.9%; Pred. No. 3.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1 TTGCATCCCAAGAGGATCAA 22
    |||||
Db 95 TTGCATCCCAAGAGGATCAA 74

RESULT 6
BZ527295/c 711 bp DNA linear GSS 16-DEC-2002
LOCUS      OGAEGJ33TC ZM2_0_7_1.5_KB Zea mays genomic clone ZMMBMA0042018,
DEFINITION genomic survey sequence.
ACCESSION  BZ527295
VERSION    BZ527295.1 GI:27067857
KEYWORDS   GSS.
SOURCE     Zea mays
              Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
              Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
              clade; Panicoideae; Andropogoneae; Zea.
              1 (bases 1 to 711)
              Whitelaw, C.A., Quackenbush, J., Van Aken, S., Uterback, T., Resnick
              , R.W., Nundberg, A., Robbins, M.A., Bedell, J.A., Rohlfing, T., Citek
              , A., Frazer, C.M., Budiman, M.A., and Lakey, N.
              Consortium for Maize Genomics
              Unpublished
              Contact: Cathy Whitelaw
              TIGR
              9712 Medical Center Drive, Rockville, MD 20850, USA
              Tel: 301-838-5843
              Fax: 301-838-0208
              Email: whitelaw@tigr.org
              Seq primer: T7
              Class: shared ends.
FEATURES
  source      Location/Qualifiers
    1..711
    /organism="Zea mays"
    /mol_type="genomic DNA"
    /strain="B73"
    /db_xref="taxon:4577"
    /clone="ZMMBMA0042018"
    /clone_lib="ZM2_0_7_1.5_KB"
    /note="Vector: pBCSK-; Site_1: HincII; 0.7-1.5 kb
    methylation filtered genomic DNA library"
BASE COUNT   161 a      186 c      158 g      206 t
ORIGIN
Query Match 81.7%; Score 18.8; DB 29; Length 711;
Best Local Similarity 90.9%; Pred. No. 3.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1 TTGCATCCCAAGAGGATCAA 22
    |||||
Db 353 TTGCATCCCAAGAGGATCAA 332

RESULT 7

```

BZ539243/c
 LOCUS BZ539243 711 bp DNA linear GSS 16-DEC-2002
 DEFINITION OGAHJ62TC ZM2.0.7.1.5 KB zea mays genomic clone ZMMBMA0061L04,
 genomic survey sequence.
 ACCESSION BZ539243
 VERSION BZ539243.1 GI:27087679
 KEYWORDS GSS.
 SOURCE Zea mays
 ORGANISM Zea mays
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCD
 clade; Panicoideae; Andropogoneae; Zea.
 1 (bases 1 to 711)
 WhiteJaw,C.A., Quackenbush,J., Van Aken,S., Uteerback,T., Resnick
 A., Fraser,C.M., Budiman,M.A., Bedell,J.A., Rohlfing,T., Citek
 R.W., Nurnberg,A., Robbins,D. and Lakey,N.
 Consortium for Maize Genomics
 Unpublished
 TITLE Unpublished
 JOURNAL
 COMMENT TIGR
 Contact: Cathy WhiteJaw
 9712 Medical Center Drive, Rockville, MD 20850, USA
 Tel: 301-838-5843
 Fax: 301-838-0208
 Email: whiteJaw@cigr.org
 Seq primer: TP
 Class: sheared ends.
 Location/Qualifiers
 1..711
 /organism="Zea mays"
 /mol_type="genomic DNA"
 /strain="B73"
 /db_xref="taxon:4577"
 /clone="ZMMBMA0061L04"
 /clone.lib="ZM2.0.7.1.5 KB"
 /note="Vector: pBCSK-; Site 1: HincII; 0.7-1.5 kb
 methylation filtered genomic DNA library"
 BASE COUNT 163 a 183 c 167 g 198 t
 ORIGIN
 Query Match 81.7%; Score 18.8; DB 29; Length 711;
 Best Local Similarity 90.9%; Pred.No.3.7e+02;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 TTCGATCCCAAGAGATCAA 22
 |||||
 396 TTGATGCCAGAGATCAA 375
 RESULT 8
 A1965004 581 bp mRNA linear EST 07-JUN-2001
 LOCUS A1965004
 DEFINITION fc85e07.y1 Zebrafish Washu MPMG EST Dario rerio cDNA clone
 IMAGE3728196 5' similar to gb:X17206.40S RIBOSOMAL PROTEIN S4
 (HUMAN); mRNA sequence.
 ACCESSION A1965004
 VERSION A1965004.1 GI:5759641
 KEYWORDS EST.
 SOURCE Dario rerio (zebrafish)
 ORGANISM Dario rerio
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes
 1 (bases 1 to 581)
 Clark,M., Johnson,S.L., Lehrach,H., Lee,R., Li,F., Marra,M., Eddy
 S., Hillier,L., Kucaba,T., Martin,D., Beck,C., Wylie,T., Underwood
 K., Stepien,M., Theising,B., Allen,M., Bowers,Y., Pearson,B.,
 Swaller,T., Gibbons,M., Page,D., Harvey,N., Schurk,R., Ritter,E.,
 Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R., Waterston,R.
 and Wilson,R.
 Washu zebrafish EST Project 1998
 Unpublished
 JOURNAL
 COMMENT 'Ocher ESTs: fc85e07.x1
 Contact: Stephen L. Johnson

Washington University School of Medicine
 444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: zbrfish@wustl.edu
 cDNA Library Preparation: Matthew Clark. cDNA Library Arrayed by:
 Matthew Clark. DNA Sequencing by: Washington University Genome
 Sequencing Center Clone Distribution: Genome Systems, St. Louis,
 Missouri (web address: www.genomesystems.com) (email contact:
 info@genomesystems.com) and Research Genetics, Huntsville, Alabama
 (web address: www.resgen.com) (email contact: info@resgen.com) and
 ResourcenZentrumPrimaDatenbank, Berlin, Germany (web address:
 www.rzpd.de)
 Trace considered overall poor quality
 zebrafish identity (p-value greater than 1e-99) found to: TIGR:
 TC99 NULL
 Seq primer: T3 ET from Amerham
 High quality sequence stop: 1.
 Location/Qualifiers
 1..581
 /organism="Dario rerio"
 /mol_type="mRNA"
 /db_xref="taxon:7955"
 /clone="IMAGE:3728196"
 /sex="mixed"
 /clone.lib="ZM2.0.7.1.5 KB"
 /stage type="26 somite embryos, adult livers, shield
 stage embryos"
 /lab host="XLI-blue MRF"
 /clone.lib="Zebrafish Washu MPMG EST"
 /note="Vector: pSPORT1; Site 1: NotI; Site 2: SalI; 1st
 strand cDNA was primed with a Not I - oligo(dT)15 primer
 [5'PGACTAGTTCGATCCGAGCGCGCCCTTTTCTTTTCTT3'];
 double-stranded cDNA was ligated to Sal I adaptor (BRL),
 digested with Not I and cloned into the Not I and Sal I
 sites of the pSPORT1 vector (BRL). Library was constructed
 by Matthew Clark (Lehrach lab), ICRF, London and Max Planck
 Institut fuer Molekulare Genetik, Berlin). cDNAs for EST
 analysis were selected following oligonucleotide
 hybridization fingerprinting of arrayed clones from
 zebrafish late somitogenesis (26 ss), adult liver or
 embryonic shield stage (5.6 h) libraries. Fingerprint
 data were used to computationally cluster cDNAs, and a
 single cDNA from each cluster was chosen for sequencing.
 In some cases multiple members of the same cluster were
 sequenced to assess clustering parameters or single clones
 were sequenced additional times to assess quality
 control."
 BASE COUNT 134 a 154 c 166 g 127 t
 ORIGIN
 Query Match 80.0%; Score 18.4; DB 9; Length 581;
 Best Local Similarity 95.0%; Pred.No.5.4e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3 CGATCCCAAGAGATCAA 22
 |||||
 Db 162 CGATCCCAAGAGATCAA 143
 RESULT 9
 CB091033 592 bp mRNA linear EST 27-JAN-2003
 LOCUS CB091033
 DEFINITION gy83f07.g1 Cycad Leaf Library (NYBG) Cycas rumphii cDNA clone
 gy83f07, mRNA sequence.
 ACCESSION CB091033
 VERSION CB091033.1 GI:27915225
 KEYWORDS EST.
 SOURCE Cycas rumphii
 ORGANISM Cycas rumphii
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Cycadophyta; Cycadales; Cycadaceae; Cycas.
 1 (bases 1 to 592)
 Brenner,E.D., Katari,M.S., Dedhia,N.N., O'Shaughnessy,A.L., Balija

TITLE
JOURNAL
COMMENT
Unpublished tag sequences from *Cycas ovule* (NYBG)
Contact: W. Richard McCombie
Lita Annenberg Hazen Genome Sequencing Center
Cold Spring Harbor Laboratory
PO Box 100, Cold Spring Harbor, NY 11724, USA
Tel: 516 367 8884
Fax: 516 367 8874
Email: mcombie@cshl.org
Plate: gy83 row: f column: 07
Seq primer: -21M3UnivRev
High quality sequence stop: 592.
Location/Qualifiers
1..592
/organism="Cycas rumphii"
/mol_type="mRNA"
/db_xref="taxon:58031"
/clone="gy83f07"
/sex="Female"
/clone_lib="Cycad Leaf Library (NYBG)"
/note="Organ: Young leaf; Vector: pBK-CMV; Site_1: Xho I; Site_2: Eco RI; Date: Completed 09/01/2001. Submitted to CSHL 09/05/2001. Sample: Young emergent leaves. From New York Botanical Garden Conservatory accession number 808/59 A (collected 03/2001). Library: Made using Stratagene's ZAP Express Vector Kit. Library was size fractionated for large inserts."

BASE COUNT
ORIGIN
148 a 129 c 149 g 166 t

Query Match 80.0%; Score 18.4; DB 14; Length 592;
Best Local Similarity 95.0%; Pred. No. 5.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 4 GATCCCAAGAGATCAAC 23
Db 302 GCTCCCAAGAGATCAAC 321

RESULT 10
CB091179 594 bp mRNA linear EST 27-JAN-2003
LOCUS he89d02.g1 Cycad Leaf Library (NYBG) Cycas rumphii cDNA clone
DEFINITION he89d02. mRNA sequence.
ACCESSION CB091179
VERSION CB091179.1 GI:27915371
KEYWORDS EST.
SOURCE Cycas rumphii
ORGANISM Cycas rumphii
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Cycadophyta; Cycadales; Cycadaceae; Cycas.
1 (bases 1 to 594)
Bremer, B.D., Katar, M.S., Dedhia, N.N., O'Shaughnessy, A.L., Balija, V., Martienssen, R.A., McCombie, R.W., Benfey, P., Coruzzi, G. and Stevenson, D.
Expressed tag sequences from *Cycas ovule* (NYBG)
Unpublished
Contact: W. Richard McCombie
Lita Annenberg Hazen Genome Sequencing Center
Cold Spring Harbor Laboratory
PO Box 100, Cold Spring Harbor, NY 11724, USA
Tel: 516 367 8884
Fax: 516 367 8874
Email: mcombie@cshl.org
Plate: he89 row: d column: 02
Seq primer: -21M3UnivRev
High quality sequence stop: 594.
Location/Qualifiers
1..594
/organism="Cycas rumphii"
/mol_type="mRNA"

FEATURES
SOURCE

/db_xref="taxon:58031"
/clone="he89d02"
/sex="Female"
/clone_lib="Cycad Leaf Library (NYBG)"
/note="Organ: Young leaf; Vector: pBK-CMV; Site_1: Xho I; Site_2: Eco RI; Date: Completed 09/01/2001. Submitted to CSHL 09/05/2001. Sample: Young emergent leaves. From New York Botanical Garden Conservatory accession number 808/59 A (collected 03/2001). Library: Made using Stratagene's ZAP Express Vector Kit. Library was size fractionated for large inserts."

BASE COUNT
ORIGIN
159 a 127 c 144 g 164 t

Query Match 80.0%; Score 18.4; DB 14; Length 594;
Best Local Similarity 95.0%; Pred. No. 5.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 4 GATCCCAAGAGATCAAC 23
Db 389 GCTCCCAAGAGATCAAC 408

RESULT 11
A1624038/c 401 bp mRNA linear EST 14-DEC-1999
LOCUS he25h10.x1 NCI CGAP Panl Homo sapiens cDNA clone IMAGE:2229667 3'
DEFINITION similar to contains Alu repetitive element; mRNA sequence.
ACCESSION A1624038
VERSION A1624038.1 GI:4648969
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 401)
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
Unpublished
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Life Technologies catalog #: 11548-013
DNA sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/ILMB at: www-bio.lit.nih.gov/bbtp/image/image.html
Insert Length: 835 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 400
POLY(A)-No.
Location/Qualifiers
1..401
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2229667"
/tissue_type="adenocarcinoma"
/lab_host="DH10B"
/clone_lib="NCI CGAP Panl"
/note="Organ: pancreas; Vector: pCMV-SPORT6; Site_1: SalI; Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.72 kb. Life Technologies catalog #: 11548-013"

BASE COUNT
ORIGIN
92 a 86 c 100 g 123 t

Query Match 79.1%; Score 18.2; DB 9; Length 401;
Best Local Similarity 87.0%; Pred. No. 6.1e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCGATCCCAAGAGATCAAC 23
Db 111

FEATURES	source	location/Qualifiers
RESULT 12		
LOCUS	BUB21234/c	483 bp mRNA linear EST 15-OCT-2002
DEFINITION	UB20CPG09 Populus tremula cambium cDNA library Populus tremula cDNA	
ACCESSION	BUB21234	5 prime, mRNA sequence.
VERSION	BUB21234.1	GI:23987320
KEYWORDS	EST.	
SOURCE	Populus tremula	
ORGANISM	Populus tremula	
REFERENCE	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids	
AUTHORS	1 (bases 1 to 483)	
TITLE	Uneberg, P., Bhalerao, R.R., Jansson, S. and Sterky, F.	
JOURNAL	The poplar tree transcriptome: Analysis of expressed sequence tags from multiple libraries	
COMMENT	Unpublished	
CONTACT	BHALERAO RUPALI R.	
UMEA PLANT SCIENCE CENTER		
DEPARTMENT OF PLANT PHYSIOLOGY		
UNIVERSITY OF UMEA, 901 87 UMEA, SWEDEN		
TEL: +46 90 786 5279		
FAX: +46 90 786 6676		
EMAIL: rupali.bhalerao@plantphys.umu.se.		
BASE COUNT	118 a 165 c 84 g 116 t	
ORIGIN		
Query Match	79.1%; Score 18.2; DB 13; Length 483;	
Best Local Similarity	87.0%; Pred. No. 6.4e+02;	
Matches	20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
OR	1 TTGATCCCAAGAGATCAAC 23	
DB	479 TTGCTCCCAAGAGATCAAC 457	
RESULT 13		
LOCUS	BUB33017	519 bp mRNA linear EST 15-OCT-2002
DEFINITION	T040G08 Populus apical shoot cDNA library Populus tremula x Populus	
ACCESSION	BUB33017	tremuloides cDNA 5 prime, mRNA sequence.
VERSION	BUB33017.1	GI:24013112
KEYWORDS	EST.	
SOURCE	Populus tremula x Populus tremuloides	
ORGANISM	Populus tremula x Populus tremuloides	
REFERENCE	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids	
AUTHORS	1 (bases 1 to 519)	
TITLE	Uneberg, P., Bhalerao, R.R., Jansson, S. and Sterky, F.	
JOURNAL	The poplar tree transcriptome: Analysis of expressed sequence tags from multiple libraries	
COMMENT	Unpublished	
CONTACT	BHALERAO RUPALI R.	
UMEA PLANT SCIENCE CENTER		
DEPARTMENT OF PLANT PHYSIOLOGY		
UNIVERSITY OF UMEA, 901 87 UMEA, SWEDEN		
TEL: +46 90 786 5279		
FAX: +46 90 786 6676		
EMAIL: rupali.bhalerao@plantphys.umu.se.		
BASE COUNT	118 a 165 c 84 g 116 t	
ORIGIN		
Query Match	79.1%; Score 18.2; DB 13; Length 483;	
Best Local Similarity	87.0%; Pred. No. 6.4e+02;	
Matches	20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
OR	1 TTGATCCCAAGAGATCAAC 23	
DB	479 TTGCTCCCAAGAGATCAAC 457	

```

source
1..519
/organism="Populus tremula x Populus tremuloides"
/mol_type="mRNA"
/db_xref="taxon:47664"
/tissue_type="apical shoot"
/clone_lib="Populus apical shoot cDNA library"
BASE COUNT      123 a      127 c      125 g      144 t
ORIGIN

Query Match      79.1%; Score 18.2; DB 13; Length 519;
Best Local Similarity 87.0%; Pred. No. 6.5e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY
1 TTGCATCCCAAGAGGATCAAC 23
|||||
47 TTGCCTCCCAAGAGGATCAAC 25

RESULT 14
LOCUS      CC327702
DEFINITION OGBS65YHB_ZM_0.7_1.5_KB Zea mays genomic clone ZMMBMA0369K09,
genomic survey sequence.
ACCESSION  CC327702
VERSION    CC327702.1 GI:30796873
KEYWORDS   GSS.
SOURCE     Zea mays
ORGANISM   Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
clade; Panicoideae; Andropogoneae; Zea.
1 (bases 1 to 568)
WhiteLaw,C.A., Quackenbush,J., Van Aken,S., Urtzback,T., Resnick
,A., Frazer,C.M., Buddiman,M.A., Bedell,J.A., Rohlfing,T., Citek
,R.W., Numberg,A., Robbins,D. and Lakey,N.
Consortium for Maize Genomics
Unpublished
TITLE      TIGR
JOURNAL    Contact: Cathy WhiteLaw
COMMENT    9712 Medical Center Drive, Rockville, MD 20850, USA
          Tel: 301-838-5843
          Fax: 301-838-0208
          Email: whiteLaw@igr.org
          Seq primer: TK
          Class: sheared ends.
FEATURES
source     location/Qualifiers
1..568
/organism="Zea mays"
/mol_type="genomic DNA"
/strain="B73"
/db_xref="taxon:4577"
/clone="ZMMBMA0369K09"
/clone_lib="ZM_0.7_1.5_KB"
/note="Vector: pBCKS-; Site 1: HincII; 0.7-1.5 kb
methylation filtered genomic DNA library"
BASE COUNT      212 a      73 c      85 g      198 t
ORIGIN

Query Match      79.1%; Score 18.2; DB 29; Length 568;
Best Local Similarity 87.0%; Pred. No. 6.7e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY
1 TTGCATCCCAAGAGGATCAAC 23
|||||
296 TTAGACACCAAGAGGATCAAC 318

RESULT 15
LOCUS      BH549506
DEFINITION BHSC40TF BOHS Brassica oleracea genomic clone BOHSC40, genomic
survey sequence.
ACCESSION  BH549506

```


VERSION BH549506.1 GI:17801286
 KEYWORDS GSS.
 SOURCE Brassica oleracea
 ORGANISM Brassica oleracea

REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 TITLE Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids
 JOURNAL ; eurosids II; Brassicales; Brassicaceae; Brassica.
 COMMENT 1 (bases 1 to 603)
 Town, C.D., Van Aken, S., Uterback, T., Koo, H. and Fraser, C.M.
 Whole genome shotgun sequencing of Brassica oleracea
 Unpublished
 Other GSSs: BOHSC40TR
 Contact: Chris Town

TIGR
 9712 Medical Center Drive, Rockville, MD 20850, USA.
 Tel: 301-838-3523
 Fax: 301-838-0208
 Email: cdtown@tigr.org
 DNA is from a doubled haploid provided by Tom Osborn.
 Seq primer: TF
 Class: sheared ends.

FEATURES

source

Location/Qualifiers
 1..603

/organism="Brassica oleracea"
 /mol_type="genomic DNA"
 /strain="TO100DH3"
 /db_xref="taxon:3712"
 /clone="BOHSC40"
 /note="Vector: pHOS1, site 1: BstXI; 2-3 kb sheared
 genomic DNA inserted into pHOS1 using BstXI linkers"

BASE COUNT 189 a 147 c 94 g 173 t
 ORIGIN

Query Match 79.1%; Score 18.2; DB 28; Length 603;
 Best Local Similarity 87.0%; Pred.No. 6.8e+02;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCATCCCAAGAGCAATCAAC 23
 |||||
 Db 236 TTAGATTCAGAGCAAC 258

Search completed: February 16, 2004, 13:41:01
 Job time : 92.3432 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 114.587 Seconds

(without alignments)
8568.399 Million cell updates/sec

Title: US-10-676-079-7

Perfect score: 24
Sequence: 1 gtagtgatgcacatgactgaatc 24Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

```
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_vl:*
14: gb_vt:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_ov:*
22: em_ov:*
23: em_ph:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vl:*
30: em_vt:*
31: em_htg_hum:*
32: em_htg_inv:*
33: em_htg_other:*
34: em_htg_mus:*
35: em_htg_pln:*
36: em_htg_rtd:*
37: em_htg_mam:*
38: em_htg_vrc:*
39: em_htg_hum:*
40: em_htg_mus:*
41: em_htgo_other:*
```

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	24	100.0	24	AR080673	AR080673 Sequence
2	24	100.0	24	AR080678	AR080678 Sequence
3	24	100.0	24	AR125608	AR125608 Sequence
4	24	100.0	24	AR287440	AR287440 Sequence
5	24	100.0	24	AR287442	AR287442 Polynucle
6	24	100.0	24	BD074426	BD074426 Polynucle
7	24	100.0	1593	AR210040	AR210040 Sequence
8	24	100.0	1593	BD136761	BD136761 Human pla
9	24	100.0	1662	AF281160	AF281160 Bos tauru
10	24	100.0	1669	AF084467	AF084467 Homo sapi
11	24	100.0	1694	AF152376	AF152376 Homo sapi
12	24	100.0	1713	AR156691	AR156691 Sequence
13	24	100.0	1713	AX034643	AX034643 Sequence
14	24	100.0	1721	AR080679	AR080679 Sequence
15	24	100.0	1721	AR080680	AR080680 Sequence
16	24	100.0	1721	AR125603	AR125603 Sequence
17	24	100.0	1721	AR125604	AR125604 Sequence
18	24	100.0	1721	AR194189	AR194189 Sequence
19	24	100.0	1721	AR194190	AR194190 Sequence
20	24	100.0	1721	AR221285	AR221285 Sequence
21	24	100.0	1721	AR221286	AR221286 Sequence
22	24	100.0	1721	AR243203	AR243203 Sequence
23	24	100.0	1721	AR243204	AR243204 Sequence
24	24	100.0	1721	AR287435	AR287435 Sequence
25	24	100.0	1721	AR287436	AR287436 Sequence
26	24	100.0	1721	BD074427	BD074427 Polynucle
27	24	100.0	1721	BD074428	BD074428 Polynucle
28	24	100.0	1722	AX136167	AX136167 Sequence
29	24	100.0	1722	BD123536	BD123536 Secretory
30	24	100.0	1722	AK075400	AK075400 Homo sapi
31	24	100.0	1723	AR156692	AR156692 Sequence
32	24	100.0	1723	AX034645	AX034645 Sequence
33	24	100.0	1724	AF147946	AF147946 Sequence
34	24	100.0	1724	AF165154	AF165154 Homo sapi
35	24	100.0	1758	AF144325	AF144325 Homo sapi
36	24	100.0	1810	BC051321	BC051321 Homo sapi
37	24	100.0	1899	BD074430	BD074430 Polynucle
38	24	100.0	1899	BD074431	BD074431 Polynucle
39	24	100.0	3726	AR235866	AR235866 Sequence
40	24	100.0	3726	AX019348	AX019348 Sequence
41	24	100.0	3726	BD131218	BD131218 Human hep
42	24	100.0	3726	AF155510	AF155510 Homo sapi
43	21.4	89.2	149188	AC114781	AC114781 Homo sapi
44	19.8	82.5	118890	AC138159	AC138159 Rattus no
45	19.8	82.5	176787	AC138158	AC138158 Rattus no

ALIGNMENTS

RESULT 1
LOCUS AR080673 24 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 2 from patent US 5968822.
ACCESSION AR080673
VERSION AR080673.1 GI:10007403
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Violdavsky,I. and Feinstein,E.
TITLE Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
JOURNAL Patent: US 5968822-A 2 19-OCT-1999;

FEATURES Location/Qualifiers
source 1..24
/organism="unknown"

BASE COUNT 7 a 4 c 6 g 7 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAAGTAATC 24
Db 1 GTAGTATGCCATGTAAGTAATC 24

RESULT 2
LOCUS AR080678 24 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 7 from patent US 5968822.
ACCESSION AR080678
VERSION AR080678.1 GI:10007408
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I. and Feinstein,E.
TITLE Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
JOURNAL Patent: US 5968822-A 7 19-OCT-1999;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"

BASE COUNT 7 a 4 c 6 g 7 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAAGTAATC 24
Db 1 GTAGTATGCCATGTAAGTAATC 24

RESULT 3
LOCUS AR125608 24 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 7 from patent US 6177545.
ACCESSION AR125608
VERSION AR125608.1 GI:14111670
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Perets,T.
TITLE Heparanase specific molecular probes and their use in research and
medical applications
JOURNAL Patent: US 6177545-A 7 23-JAN-2001;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"

BASE COUNT 7 a 4 c 6 g 7 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAAGTAATC 24
Db 1 GTAGTATGCCATGTAAGTAATC 24

RESULT 4
LOCUS AR287440 24 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 7 from patent US 6531129.
ACCESSION AR287440
VERSION AR287440.1 GI:29725134
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Perets,T.
TITLE Heparanase specific molecular probes and their use in research and
medical applications
JOURNAL Patent: US 6531129-A 7 11-MAR-2003;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"

BASE COUNT 7 a 4 c 6 g 7 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAAGTAATC 24
Db 1 GTAGTATGCCATGTAAGTAATC 24

RESULT 5
LOCUS BD074421 24 bp DNA linear PAT 27-AUG-2002
DEFINITION Polynucleotide encoding polypeptide having heparanase activity and
expression of the polypeptide in induced cell.
ACCESSION BD074421
VERSION BD074421.1 GI:22620024
KEYWORDS JP 2001514855-A/2.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I. and Elena,F.
TITLE Polynucleotide encoding polypeptide having heparanase activity and
expression of the polypeptide in induced cell
JOURNAL Patent: JP 2001514855-A 2 18-SEP-2001;
INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES
& DEVELOPMENT LTD
OS Nucleic acid
PN JP 2001514855-A/2
PD 18-SEP-2001
PF 31-AUG-1998 JP 2000508806 09/109386 PI
PR 02-SEP-1997 US 08/922170, 02-JUL-1998 US
IRIS PECKER, ISRAEL VLODAVSKY, FEINSTEIN ELENA
PC C12N15/09,A61K38/00,A61P9/10,A61P17/00,A61P29/00,A61P35/00, PC
A61P37/00,
PC A61P43/00,C12N5/10,C12N6/24,C12Q1/68,G01N33/15,G01N33/50// PC
A61K39/395,
PC A61K39/395,C12N15/00,A61K37/02,C12N5/00
CC Polynucleotide encoding polypeptide having
heparanase activity
and
CC expression of the polypeptide in induced cell FH Key
FT source 1..24
FT Location/Qualifiers
location/Qualifiers
1..24
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 7 a 4 c 6 g 7 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
1 GTAGTATGCCATGTAAGTATC 24

Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 6
BD074426 24 bp DNA linear PAT 27-AUG-2002
LOCUS Polynucleotide encoding polypeptide having heparanase activity and
DEFINITION expression of the polypeptide in induced cell.
ACCESSION BD074426
VERSION BD074426.1 GI:22620029
KEYWORDS JP 2001514855-A/7.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker, I., Vlodavsky, I. and Elena, F.
TITLE Polynucleotide encoding polypeptide having heparanase activity and
expression of the polypeptide in induced cell
JOURNAL Patent: JP 2001514855-A 7 18-SEP-2001;
INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES
& DEVELOPMENT LTD
OS Nucleic acid
PN JP 2001514855-A/7
PD 18-SEP-2001
PP 31-AUG-1998 JP 2000508806
PR 02-SEP-1997 US 08/922170, 02-JUN-1998 US 09/109386 PT
PIS PECKER, ISRAEL, VLODAVSKY, FEINSTEIN ELENA
PC C12N15/09, A61K38/00, A61P9/10, A61P17/00, A61P29/00, A61P35/00, PC
A61P37/00,
PC A61P43/00, C12N5/10, C12N9/24, C12Q1/68, G01N33/15, G01N33/50// PC
A61K39/395,
PC A61K39/395, C12N15/00, A61K37/02, C12N5/00
CC Polynucleotide encoding polypeptide having
heparanase activity
CC and
CC expression of the polypeptide in induced cell FH Key
Location/Qualifiers 1..24
FT source /organism='Nucleic acid'.
FEATURES location/Qualifiers 1..24
source /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

BASE COUNT 7 a 4 c 6 g 7 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
1 GTAGTATGCCATGTAAGTATC 24

Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 7
AR210040 1593 bp DNA linear PAT 20-JUN-2002
LOCUS Sequence 1 from patent US 6387643.
DEFINITION AR210040
ACCESSION AR210040.1 GI:21512167
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1593)
AUTHORS Heinrikson, R. Leroy., Fairbanks, M. B. and Mildner, A. M.
TITLE Human platelet heparanase polypeptides, polynucleotide molecules
that encode them, and methods for the identification of compounds
that alter heparanase activity
JOURNAL Patent: US 6387643-A 1 14-MAY-2002;
FEATURES location/Qualifiers 1..1593
source /organism='unknown'

BASE COUNT 426 a 370 c 369 g 428 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1593;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
855 GTAGTATGCCATGTAAGTATC 832

Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 8
BD136761 1593 bp DNA linear PAT 18-SEP-2002
LOCUS Human platelet heparanase polypeptide, polynucleotide molecule
DEFINITION encoding the same and method of identifying compound changing
heparanase activity.
ACCESSION BD136761
VERSION BD136761.1 GI:23231706
KEYWORDS JP 2002504376-A/1.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 1593)
AUTHORS Heinrikson, R. L., Fairbanks, M. B. and Mildner, A. M.
TITLE Human platelet heparanase polypeptide, polynucleotide molecule
encoding the same and method of identifying compound changing
JOURNAL Patent: JP 2002504376-A 1 12-FEB-2002;
PHARMACIA & UPJOHN CO
OS Unidentified
PN JP 2002504376-A/1
PD 12-FEB-2002
PP 18-FEB-1998 JP 2000533569
PR 24-FEB-1998 US 60/075706, 26-MAR-1998 US 60/079401 PT
PIS ROBERT L. HEINRIKSON, MICHAEL B. FAIRBANKS, ANA M. MILDNER PC
PC C12N15/09, C07K16/40, C12N1/21, C12N5/10, C12N9/24, C12Q1/34, C12N15/00, C12N5/00
CC Strandedness: Double;
CC Topology: Linear;
CC Human platelet heparanase polypeptide, polynucleotide molecule
CC encoding
CC the same and method of identifying compound changing CC
CC heparanase activity
FH key location/Qualifiers 1..1593
FT source /organism='Unidentified'.
FEATURES location/Qualifiers 1..1593
source /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

BASE COUNT 426 a 370 c 369 g 428 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1593;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
1 GTAGTATGCCATGTAAGTATC 24

Db 855 GTAGTGCATGCTACTGAATC 832

RESULT 9
LOCUS AF281160 1662 bp mRNA linear MAM 12-APR-2001
DEFINITION Bos taurus heparanase mRNA, complete cds.
ACCESSION AF281160
VERSION AF281160.2 GI:13606094
KEYWORDS
SOURCE Bos taurus (cow)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Bovinae; Bos.
REFERENCE 1 (bases 1 to 1662)
AUTHORS Kizaki, K., Nakano, H., Takahashi, T., Imai, K. and Hashizume, K.
TITLE Expression of Heparanase mRNA in Bovine Placenta During Gestation
JOURNAL Unpublished
JOURNAL 2 (bases 1 to 1662)
REFERENCE Kizaki, K., Nakano, H., Takahashi, T., Imai, K. and Hashizume, K.
AUTHORS Direct Submission
JOURNAL Submitted (22-JUN-2000) Laboratory of Reproductive Endocrinology, National Institute of Animal Industry, Tsukuba-norindanchi, PO Box 5, Tsukuba, Ibaraki 305-0901, Japan
3 (bases 1 to 1662)
REFERENCE Kizaki, K., Nakano, H., Takahashi, T., Imai, K. and Hashizume, K.
AUTHORS Direct Submission
JOURNAL Submitted (12-APR-2001) Laboratory of Reproductive Endocrinology, National Institute of Animal Industry, Tsukuba-norindanchi, PO Box 5, Tsukuba, Ibaraki 305-0901, Japan
REMARK COMMENT
FEATURES
SOURCE Location/Qualifiers
1. 1662
/organism="Bos taurus"
/mol_type="mRNA"
/db_xref="taxon:9913"
/tissue_type="placenta"
25. 1662
/note="endoglycosidase"
/codon_start=1
/product="heparanase"
/protein_id="AAF87301.2"
/db_xref="GI:13606095"
/translation="MLACRKGRLPPRLILLLPLGLPGCGSPGPAAPAAADAAEELPETERPLHVSPLSTIDANLATDPRFPLGSSKRLTLARLAAYARFGNKGD FLIDPKKEPFEERSTYWSGNDICSGSIPDVEBKLEWPOEQLLREYOK KFNSTYSRSSVDLVYTFANGSGDLIFGNALLRTDMDSSNAOQLLDYCSKYN ISWELGNEPNSFORKAGIFINGROLGEDPIEFKRLGKSNKNAKYGPDIQPRN TVKMLKSPFKAGGEVDSVTHHYNGRIATKEDFLNPDLPFIISVQKTLRVER IRLPKYWLGETSAPFGGAPFLSNTFAAGFMWLDKGLSARMGIEVVMQVFLGAN YHIVDGNPEPLPDYWSLLPKLVGNKYLMASVSGPDRSKRYVLIHCTNTHPRYKGS DLTLYALNHNVTYRLPFLHLEKQVDKYLIRPSGDTGLSKSVQLNGQLTKWVDQ TLPLMEKPRPSSSLGLPAFSYSFVIRNAKVAACI"

BASE COUNT 435 a 404 c 402 g 421 t

ORIGIN

Query Match 100.0%; Score 24; DB 4; Length 1662;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 GTAGTGCATGCTACTGAATC 24
|||||
Db 924 GTAGTGCATGCTACTGAATC 901
|||||

RESULT 10
LOCUS AF084467 1669 bp mRNA linear PRI 18-OCT-2000
DEFINITION Homo sapiens heparanase mRNA, complete cds.
ACCESSION AF084467
VERSION AF084467.1 GI:5870623

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS 1 (bases 1 to 1669)
TITLE Dempsey, L.A., Plummer, T.B., Coombes, S.L. and Platt, J.L.
JOURNAL Heparanase expression in invasive trophoblasts and acute vascular damage
JOURNAL Glycobiology 10 (5), 467-475 (2000)
MEDLINE 20229546
PIRMBD 10764835
REFERENCE 2 (bases 1 to 1669)
AUTHORS Dempsey, L.A., Holzkreutz, R.A. and Platt, J.L.
TITLE Identification of the cDNA encoding human heparanase
JOURNAL Unpublished
JOURNAL 3 (bases 1 to 1669)
REFERENCE Dempsey, L.A., Holzkreutz, R.A. and Platt, J.L.
AUTHORS Direct Submission
JOURNAL Submitted (14-AUG-1998) Surgery, Duke University, Research Dr., Rm. 401 MSRB, Durham, NC 27710, USA
FEATURES
SOURCE Location/Qualifiers
1. 1669
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="mekakaryocyte"
/tissue_type="placenta"
1. 1638
/note="endoglycosidase; expressed in placenta and platelets"
/codon_start=1
/product="heparanase"
/protein_id="AAD54516.1"
/db_xref="GI:5870624"
/translation="MLRSKRALPPRLIMLLILGLPGSPGPAAPAAQDQVVDL FTOEPLHVSPLSTIDANLATDPRFPLIGSPKRLTLARLGLSPAYLRFSGTKTD FLIDPKKESTFEERSYWOQVQNDICKGSIPDVEBKRLWPVOEQLLREYOK KFNSTYSRSSVDLVYTFANGSGDLIFGNALLRTADLQMSNNAOQLLDYCSKYN ISWELGNEPNSFLKADIFINGSOIGEDPTOLHKLRSKLPNAKLYGPDVQPRK TAKMWSFLKAGGEVDSVTHHYNGRIATKEDFLNPDLPFIISVQKTVQVRES TRPKKWLGETSAPFGGAPFLSNTFAAGFMWLDKGLSARMGIEVVMQVFLGAN YHIVDGNPEPLPDYWSLLPKLVGNKYLMASVSGPDRSKRYVLIHCTNTHPRYKGS DLTLYALNHNVTYRLPYPFSNKQVDKYLIRPSGDTGLSKSVQLNGQLTKWVDQ TLPLMEKPRPSSSLGLPAFSYSFVIRNAKVAACI"

BASE COUNT 445 a 396 c 388 g 440 t

ORIGIN

Query Match 100.0%; Score 24; DB 9; Length 1669;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 GTAGTGCATGCTACTGAATC 24
|||||
Db 900 GTAGTGCATGCTACTGAATC 877
|||||

RESULT 11
LOCUS AF152376 1694 bp mRNA linear PRI 28-JUL-1999
DEFINITION Homo sapiens heparanase mRNA, complete cds.
ACCESSION AF152376
VERSION AF152376.1 GI:5616196
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS 1 (bases 1 to 1694)
TITLE Kussie, P.H., Hulmes, J.D., Ludwig, D.L., Patel, S., Navarro, E.C., Seddon, A.P., Giorgio, N.A. and Bohlen, P.
JOURNAL Cloning and functional expression of a human heparanase gene
Biochem. Biophys. Res. Commun. 261 (1), 183-187 (1999)

MEDLINE 9935379
PUBMED 10405343
REFERENCE 2 (bases 1 to 1694)
AUTHORS Kuesle, P.H., Humes, J.D., Ludwig, D., Patel, S., Navarro, E.C.,
Seddon, A.P., Giorgio, N.A. and Bohlen, P.
TITLE Direct Submission
JOURNAL Submitted (18-MAY-1999) Protein Chemistry, Imclone Systems Inc.,
180 Varick Street, New York, NY 10014, USA
FEATURES
SOURCE Location/Qualifiers
1. 1694
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/tissue_type="placenta"
15. 1676
/codon_start=1
/product="heparanase"
/protein_id="A045669.1"
/db_xref="GI:5616197"
/translation="MLRSKRALPPRLMLLGLPLSPGALPPRPAQADVDLDF
TOEPLHVSFSLVTIDANLATDPRLLILGSKRLTLRGSLPATLRGGTDEL
IFPDKKSTFEERSYWOSQVQDICTGSIIPDVEEKLRLWPEQLLREHYOKF
KNSTYSRSVDVLYTFANCSGLDLIFGLNMLRTADLQWSSNAQLLDYCSSGYNI
SWEIGNEPNSFLKKADIFINGSLGDEDFIOHLKRLRSTFNALYGPDYQSPKRTA
KMLKSFLLKAGEVIVDSVTWHYVNGRTATREDPLNDVDLIFISVOKVQVVESTR
PGKRWIGERTSSAAGGAPILSDPRAGFMWLDLGLSARNGIEVWVRPFEGNVH
LVNDENFPLPDYMLSLFLFKLVGKVLMAVSQSKRRKRLRYLHCTTNDPRYREGIL
TLVAINDLHNTKYLRLPYPSNKKQVDYLLRLPLGPHGLSKSVQNLGLTLKMDVDTL
PPLMEKELRPGSSILGLPAFSYSEFVIRNAKVAACI"

CDS
BASE COUNT 465 a 398 c 391 g 440 t
ORIGIN
Query Match 100.0%; Score 24; DB 9; Length 1694;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAACGAATC 24
DB 908 GTAGTATGCCATGTAACGAATC 885

RESULT 12
AR156691/c
LOCUS AR156691 1713 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 12 from patent US 6242238.
ACCESSION AR156691
VERSION AR156691.1 GI:15125395
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1713)
AUTHORS Freeman, C. Geoffrey., Hulett, M. Darren., Parish, C. Richard. and
Hamdorf, B. James.
TITLE Isolated nucleic acid molecule encoding mammalian endoglucuronidase
and uses therefor
JOURNAL Patent: US 6242238-A 12 05-JUN-2001;
FEATURES Location/Qualifiers
1. 1713
/organism="unknown"
BASE COUNT 460 a 404 c 406 g 443 t
ORIGIN
Query Match 100.0%; Score 24; DB 6; Length 1713;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTACTGATGCATGTAACGAATC 24
DB 939 GTAGTATGCCATGTAACGAATC 916

RESULT 13

AX034643/c
LOCUS AX034643 1713 bp DNA linear PAT 22-SEP-2000
DEFINITION Sequence 12 from Patent EP1032656.
ACCESSION AX034643
VERSION AX034643.1 GI:10303224
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Hamdorf, B.J., Freeman, C.G., Hulett, M.D. and Parish, C.R.
TITLE Isolated nucleic acid molecule encoding mammalian endoglucuronidase
and uses therefor
JOURNAL Patent: EP 1032656-A 12 06-SEP-2000;
UNIV AUSTRALIAN (AU)
FEATURES Location/Qualifiers
1. 1713
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
46. 1677
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC10139.1"
/db_xref="GI:10303225"
/translation="MLRSKRALPPRLMLLGLPLSPGALPPRPAQADVDLDF
TOEPLHVSFSLVTIDANLATDPRLLILGSKRLTLRGSLPATLRGGTDEL
IFPDKKSTFEERSYWOSQVQDICTGSIIPDVEEKLRLWPEQLLREHYOKF
KNSTYSRSVDVLYTFANCSGLDLIFGLNMLRTADLQWSSNAQLLDYCSSGYNI
SWEIGNEPNSFLKKADIFINGSLGDEDFIOHLKRLRSTFNALYGPDYQSPKRTA
KMLKSFLLKAGEVIVDSVTWHYVNGRTATREDPLNDVDLIFISVOKVQVVESTR
PGKRWIGERTSSAAGGAPILSDPRAGFMWLDLGLSARNGIEVWVRPFEGNVH
LVNDENFPLPDYMLSLFLFKLVGKVLMAVSQSKRRKRLRYLHCTTNDPRYREGIL
TLVAINDLHNTKYLRLPYPSNKKQVDYLLRLPLGPHGLSKSVQNLGLTLKMDVDTL
PPLMEKELRPGSSILGLPAFSYSEFVIRNAKVAACI"

mat_peptide 517. 1674
/product="unnamed"
BASE COUNT 460 a 404 c 406 g 443 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1713;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAACGAATC 24
DB 939 GTAGTATGCCATGTAACGAATC 916

RESULT 14
AR080679/c
LOCUS AR080679 1721 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 9 from patent US 5968822.
ACCESSION AR080679
VERSION AR080679.1 GI:10007409
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1721)
AUTHORS Pecker, I., Vlodeavsky, I. and Feinstein, E.
TITLE Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
JOURNAL Patent: US 5968822-A 9 19-OCT-1999;
FEATURES Location/Qualifiers
1. 1721
/organism="unknown"
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN
Query Match 100.0%; Score 24; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0.36;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGAATC 24
 |||||
 Db 956 GTAGTATGCCATGTAAGAATC 933

RESULT 15

AR080680/c

LOCUS

AR080680 1721 bp DNA linear PAT 31-AUG-2000

DEFINITION Sequence 11 from patent US 5968822.

ACCESSION AR080680

VERSION AR080680.1 GI:10007410

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE Unclassified.

1 (bases 1 to 1721)

AUTHORS Pecker, I., Viodelavsky, I. and Feinstein, E.

TITLE Polynucleotide encoding a polypeptide having heparanase activity

JOURNAL and expression of same in transduced cells

FEATURES Patent: US 5968822-A 11 19-OCT-1999;

Location/Qualifiers

1..1721

Source /organism="unknown"

BASE COUNT 451 a 413 c 410 g 447 t

ORIGIN

Query Match

Best local similarity 100.0%; Score 24; DB 6; Length 1721;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGAATC 24
 |||||
 Db 956 GTAGTATGCCATGTAAGAATC 933

Search completed: February 16, 2004, 11:43:03
 Job time: 115.587 secs


```

PA      (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
PI      Feinstein E, Pecker I, Vlodavsky I;
XX
DR      WPI; 1999-302255/25.
XX
PT      New human polynucleotide useful for treating angiogenesis,
XX      restenosis, and inflammation
XX
PS      Example 1, Page 22, 63pp; English.
XX
XX      The specification describes a polypeptide having heparanase (hp)
CC      activity. The recombinant protein is used as a modulator of
CC      heparin-binding growth factors, cellular responses to heparin-binding
CC      growth factors and cytokines, cell interaction with plasma lipoproteins,
CC      cellular susceptibility to viral, protozoal and bacterial infections
CC      or disintegration of neurodegenerative plaques. Heparanase may be
CC      useful for conditions such as wound healing, angiogenesis, restenosis,
CC      atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC      infections. Mammalian heparanase can be used to neutralize plasma
CC      heparin, and anti-heparanase antibodies may be applied for
CC      immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC      and renal failure in biopsy specimens, plasma samples, and body fluids.
CC      PCR primers AAX35642-43 were used to amplify hp3 cDNA, in the course of
CC      the invention.
SO      Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;

Query Match          100.0%; Score 24; DB 20; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches   24; Conservative    0; Mismatches    0; Indels    0; Gaps    0,

OY      1 GTAGTGATGCCATGTACTGAATC 24
        |||||||
DB       1 GTAGTGATGCCATGTACTGAATC 24

RESULT 2
AAX35647
ID      AAX35647 standard; DNA; 24 BP.
XX
AC      AAX35647;
XX
DT      09-JUL-1999 (first entry)
DE      PCR primer used to amplify human hp3 cDNA.
XX
KW      Heparanase; hp; modulator; heparin-binding growth factor;
KW      cellular response; cytokine; cell interaction; plasma lipoprotein;
KW      cellular susceptibility; infection; disintegration;
KW      neurodegenerative plaque; wound healing; angiogenesis; restenosis;
KW      atherosclerosis; inflammation; neurodegenerative disease; neutralise;
KW      plasma heparin; micrometastasis; autoimmune lesion; renal failure;
KW      PCR primer; ss.
XX
OS      Synthetic.
XX
XX      WO9911798-A1.
XX
XX      PD 11-MAR-1999.
XX
XX      PF 31-AUG-1998; 98WO-US17954.
XX
XX      02-JUL-1998; 98US-0109386.
XX      PR 02-SEP-1997; 97US-0922170.
XX
XX      (FRIE/) FRIEDMAN M.M.
XX      PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
XX      PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX      Feinstein E, Pecker I, Vlodavsky I;
XX
XX      WPI; 1999-302255/25.

```

XX	PT	New human polynucleotide useful for treating angiogenesis, restenosis, and inflammation
XX	PS	Example 1; Page 23; 63pp; English.
XX	CC	The specification describes a polypeptide having heparanase (hp) activity. The recombinant protein is used as a modulator of heparin-binding growth factors, cellular responses to heparin-binding growth factors and cytokines, cell interaction with plasma lipoproteins, cellular susceptibility to viral, protozoal and bacterial infections or disintegration of neurodegenerative plaques. Heparanase may be useful for conditions such as wound healing, angiogenesis, restenosis, atherosclerosis, inflammation, neurodegenerative diseases, and viral infections. Mammalian heparanase can be used to neutralize plasma heparin, and anti-heparanase antibodies may be applied for immunodetection and diagnosis of micrometastases, autoimmune lesions, CC and renal failure in biopsy specimens, plasma samples, and body fluids. PCR primers AAA35646-47 were used to amplify hp3 cDNA, in the course of the invention.
XX	XX	Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;
XX	XX	Query Match 100.0%; Score 24; DB 20; Length 24;
XX	XX	Best Local Similarity 100.0%; Pred.No. 0.012;
XX	XX	Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0
XX	OY	1 GTAGTGATGCCATGTAACTGAATC 24
XX	DB	1 GTAGTGATGCCATGTAACTGAATC 24
XX	RESULT 3	
XX	ID	AAA75045 standard; DNA; 24 BP.
XX	AC	AAA75045;
XX	DT	15-JAN-2001 (first entry)
XX	DE	PCR primer HPL229 used to amplify human cDNA encoding heparanase.
XX	KW	Human; heparanase; gene therapy; tumour; inflammation; autoimmunity; heparin-binding growth factor; cytokine; neurodegenerative plaque; wound healing; infection; burn; angiogenesis; restenosis; atherosclerosis; inflammation; neurodegenerative disease; Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss
XX	OS	Homo sapiens.
XX	PN	WO200052178-A1.
XX	PD	08-SEP-2000.
XX	PP	14-FEB-2000; 2000MO-US03542.
XX	PR	01-MAR-1999; 99US-0258892.
XX	PA	(INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX	PA	(HADA-) HADASIT MEDICAL RES SERVICES & DEV.
XX	PA	(PRIE/) FRIEDMAN M M.
XX	P1	Pecker I, Vlodavsky I, Feinstein E;
XX	DR	WPI; 2000-579289/54.
XX	PT	New polynucleotide encoding a polypeptide having heparanase activity, useful in wound healing and in gene therapy, particularly in treating tumour, inflammation, autoimmunity, neurodegenerative diseases
XX	PS	Disclosure; Page 44; 152pp; English.
XX	CC	The present PCR primer was used to amplify a human cDNA sequence,

CC which encoded a protein with heparanase catalytic activity. The
CC heparanase (hpa) polynucleotide is useful in gene therapy, particularly
CC in treating tumour, inflammation or autoimmunity. Particularly, the
CC polynucleotide is useful in modulating the bioavailability of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8),
CC cell interaction with plasma lipoproteins, cellular susceptibility to
CC certain viral and some bacterial and protozoa infections, or
CC disintegration of neurodegenerative plaques. The polynucleotide is
CC also useful in wound healing (e.g. thermal, chemical or radiation burns),
CC and in the treatment of angiogenesis, restenosis, atherosclerosis,
CC inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome
CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.

XX
SQ Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;

Query Match 100.0%; Score 24; DB 21; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTGATGCCATGTAACTGAATC 24
|||||
DB 1 GTAGTGATGCCATGTAACTGAATC 24

RESULT 4
AAAT5050 standard; DNA; 24 BP.
XX
AC AAAT5050;
XX
DT 15-JAN-2001 (first entry)
XX
DE PCR primer HPL229 used to amplify human cDNA encoding heparanase.
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KM heparin-binding growth factor; cytokine; neurodegenerative plaque;
KM wound healing; infection; burn; angiogenesis; restenosis;
KM atherosclerosis; inflammation; neurodegenerative disease;
KM Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200052178-A1.
XX
PD 08-SEP-2000.
XX
PF 14-FEB-2000; 2000WO-US03542.
XX
PR 01-MAR-1999; 99US-0258892.
XX
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (PRIE/) FRIEDMAN M M.
XX
PI Pecker I, Vlodavsky I, Feinstein E;
XX
DR WPI; 2000-579289/54.
XX
PT New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating
PT tumour, inflammation, autoimmunity, neurodegenerative diseases
XX
PS Disclosure; Page 44; 152pp; English.
XX
CC The present PCR primer was used to amplify a human cDNA sequence,
CC which encoded a protein with heparanase catalytic activity. The
CC heparanase (hpa) polynucleotide is useful in gene therapy, particularly
CC in treating tumour, inflammation or autoimmunity. Particularly, the
CC polynucleotide is useful in modulating the bioavailability of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8),
CC cell interaction with plasma lipoproteins, cellular susceptibility to
CC certain viral and some bacterial and protozoa infections, or
CC disintegration of neurodegenerative plaques. The polynucleotide is
CC also useful in wound healing (e.g. thermal, chemical or radiation burns),
CC and in the treatment of angiogenesis, restenosis, atherosclerosis,
CC inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome
CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.

CC cell interaction with plasma lipoproteins, cellular susceptibility to
CC certain viral and some bacterial and protozoa infections, or
CC disintegration of neurodegenerative plaques. The polynucleotide is
CC also useful in wound healing (e.g. thermal, chemical or radiation burns),
CC and in the treatment of angiogenesis, restenosis, atherosclerosis,
CC inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome
CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.

XX
SQ Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;

Query Match 100.0%; Score 24; DB 21; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTGATGCCATGTAACTGAATC 24
|||||
DB 1 GTAGTGATGCCATGTAACTGAATC 24

RESULT 5
AAAT5067 standard; DNA; 24 BP.
XX
AC AAAT5067;
XX
DT 15-JAN-2001 (first entry)
XX
DE PCR primer Hpl 229 used to amplify human cDNA encoding heparanase.
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KM heparin-binding growth factor; cytokine; neurodegenerative plaque;
KM wound healing; infection; burn; angiogenesis; restenosis;
KM atherosclerosis; inflammation; neurodegenerative disease;
KM Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200052178-A1.
XX
PD 08-SEP-2000.
XX
PF 14-FEB-2000; 2000WO-US03542.
XX
PR 01-MAR-1999; 99US-0258892.
XX
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (PRIE/) FRIEDMAN M M.
XX
PI Pecker I, Vlodavsky I, Feinstein E;
XX
DR WPI; 2000-579289/54.
XX
PT New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating
PT tumour, inflammation, autoimmunity, neurodegenerative diseases
XX
PS Disclosure; Page 45; 152pp; English.
XX
CC The present PCR primer was used to amplify a human cDNA sequence,
CC which encoded a protein with heparanase catalytic activity. The
CC heparanase (hpa) polynucleotide is useful in gene therapy, particularly
CC in treating tumour, inflammation or autoimmunity. Particularly, the
CC polynucleotide is useful in modulating the bioavailability of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8),
CC cell interaction with plasma lipoproteins, cellular susceptibility to
CC certain viral and some bacterial and protozoa infections, or
CC disintegration of neurodegenerative plaques. The polynucleotide is
CC also useful in wound healing (e.g. thermal, chemical or radiation burns),
CC and in the treatment of angiogenesis, restenosis, atherosclerosis,
CC inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome
CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.

CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.

SO Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;

Query Match 100.0%; Score 24; DB 21; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
DB 1 GTAGTATGCCATGTAAGTATC 24

RESULT 6
AAZ33294
ID AAZ33294 standard; DNA; 24 BP.

AC AAZ33294;
DT 21-FEB-2000 (first entry)

XX Human heparanase PCR primer Hpl-229 SEQ ID NO:7.

XX Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
KM antidiabetic; immunomodulatory; anti-inflammatory; nephrotoxic;
KM metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
KM mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
KM inflammation; haemorrhagic nephritis; nephrotic syndrome;
KM autoimmune disease; anticancer; kidney disease; PCR primer; ss.

XX Synthetic.
OS Homo sapiens.

XX MO9957153-A1.

XX 11-NOV-1999.

XX 29-APR-1999; 99WO-US09255.

XX 01-MAY-1998; 98US-0071739.

XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M M.

XX Pecker I, Vlodavsky I, Friedman Y, Perets T;

XX WPI; 2000-052944/04.

XX Heparanase-specific molecular probes useful for diagnosis and
PT treatment, e.g. of tumors, and for targeted drug delivery -
XX Example; Page 30; 90pp; English.

XX The present invention describes heparanase-specific molecular probes,
CC useful for methods of detecting heparanase in situ. The probes and
CC anti-heparanase antibodies are used to detect or quantify the expression
CC of heparanase, for diagnosis and monitoring of diseases (especially
CC metastasis), for treatment of heparanase-associated diseases (e.g.
CC tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
CC metastases) derived from liver, prostate, bladder, breast, ovary,
CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted
CC drug delivery (e.g. of anticancer agents) and as research reagents.
CC The present sequence represents a PCR primer for human heparanase, which
CC is used in an example from the present invention.

XX Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;

Query Match 100.0%; Score 24; DB 21; Length 24;

Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
DB 1 GTAGTATGCCATGTAAGTATC 24

RESULT 7
ABL40753/C
ID ABL40753 standard; cDNA; 1584 BP.

XX ABL40753;

XX 03-JUL-2002 (first entry)

XX Chicken signal peptide/human heparanase chimeric cDNA.

XX Heparanase; catalytic; cytostatic; antiviral; antibacterial; enzyme;
KM anti-protozoan; neuroprotective; heparin; chicken; human; chimeric; ss.

XX Synthetic.
OS Gallus gallus.
OS Homo sapiens.

XX Key Location/Qualifiers

XX CDS 1..1584

XX /tag= a

XX /product= "chimeric chicken-human heparanase"

XX sig_peptide 1..57

XX /tag= b

XX /note= "chicken heparanase signal peptide"

XX mat_peptide 58..1581

XX /tag= c

XX /note= "human mature heparanase"

XX US2002034810-A1.

XX 21-MAR-2002.

XX 16-AUG-2001; 2001US-0930218.

XX 20-SEP-2000; 2000US-0666390.

XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.

XX Goldsmidt O, Pecker I, Vlodavsky I, Michal I, Zcharia E;

XX WPI; 2002-338926/37.

XX P-PSDB; ABB07815.

XX Nucleic acid encoding avian and reptile heparanase polypeptide is
PT useful to treat various heparin-related disorders and the signal
PT peptide is useful in production of membrane-targeted or secreted
PT recombinant proteins -
XX Example; Page 24-25; 39pp; English.

XX The invention relates to an isolated avian and reptile nucleic acid,
CC encoding a polypeptide with heparanase catalytic activity. The signal
CC peptide of the nucleic acid can be used to express membrane-associated or
CC secreted proteins in heterologous expression systems. The encoded
CC polypeptides can be used to prevent tumour angiogenesis, metastasis and
CC invasion, and to intervene with pathologies associated with impaired
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoa and bacterial infections or
CC disinfection of neurodegenerative plaques. The present sequence
CC represents a chicken signal peptide/human heparanase chimeric cDNA
CC sequence.

XX Sequence 1584 BP; 424 A; 361 C; 373 G; 426 T; 0 other;

Query Match 100.0%; Score 24; DB 24; Length 1584;
Best Local Similarity 100.0%; Pred. No. 0.026;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAACGATC 24
Db 846 GTAGTATGCCATGTAACGATC 823

RESULT 8

AA21236/c
ID AA21236 standard; cDNA; 1593 BP.

AC AA21236;

DT 15-NOV-1999 (first entry)

DE Human pre-proheparanase coding sequence.

Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;
inflammation; psoriasis; diabetic retinopathy; solid tumour; arthritis;
heparin degradation; anticoagulant neutralisation; asthma; CNS disease;
inflammatory disease; vascular restenosis; atherosclerosis; diagnosis;
tumour growth; fibroproliferative disorder; neurodegenerative disease;
therapy; ds.

OS Homo sapiens.

Key Location/Qualifiers

FT CDS 1..1593
FT /tag= a
FT /product= pre-proheparanase

XX MO9943830-A2.

XX 02-SEP-1999.

XX 18-FEB-1999; 99WO-US01489.

XX 26-MAR-1998; 98US-0079401.

XX 24-FEB-1998; 98US-0075706.

XX (PHMA) PHARMACIA & UPJOHN CO.

XX Fairbanks MB, Heinrichson RL, Mildner AM;

XX WPI; 1999-540598/45.

XX P-PSDB; AAY34173.

PT New isolated platelet heparanase polypeptides, used to develop
FT products for, e.g. wound healing and blocking angiogenesis

XX Claim 2; Fig 7; 57pp; English.

This sequence encodes the human pre-proheparanase of the invention. This
sequence was isolated from human platelets. The heparanase can be used
for identifying agents which alter heparanase activity. The heparanase
can be used for wound healing or for blocking angiogenesis or
inflammation. It can be used for treating e.g. psoriasis, diabetic
retinopathy or solid tumours, or for the degradation of heparin and the
neutralisation of heparin's anticoagulant properties during surgery.
Inhibitors of heparanase activity can be used in the treatment of
arthritis, asthma, and other inflammatory diseases, vascular restenosis,
atherosclerosis, tumour growth and progression, fibroproliferative
diseases, and central nervous system (CNS) and neurodegenerative
diseases. The products can also be used for detection and diagnosis. The
purified heparanase, both recombinantly produced human heparanase and
heparanase isolated from human platelet activity, allows for the
convenient selection of compounds having anti-heparanase activity,
i.e. inhibitors of heparanase activity, by measuring inhibition of
heparanase activity. Inhibition of heparanase activity can be measured by
blocking heparanase-mediated release of radioactive fragments from in
vivo radiolabelled (HSPG)/heparin.

XX SQ Sequence 1593 BP; 426 A; 370 C; 369 G; 428 T; 0 other;

Query Match 100.0%; Score 24; DB 20; Length 1593;
Best Local Similarity 100.0%; Pred. No. 0.026;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAACGATC 24
Db 855 GTAGTATGCCATGTAACGATC 832

RESULT 9

AB222816/c
ID AB222816 standard; cDNA; 1669 BP.

AC AB222816;

DT 02-APR-2003 (first entry)

DE Human heparanase encoding cDNA SEQ ID NO:17.

Human; heparanase; phosphorothioate; antisense oligonucleotide;
cytostatic; gene therapy; tumour; enzyme; gene; ss.

OS Homo sapiens.

Key Location/Qualifiers

FT CDS 1..1638
FT /tag= a
FT /product= "heparanase"

XX WO2003004705-A1.

XX 16-JAN-2003.

XX 01-JUL-2002; 2002WO-US20636.

XX 05-JUL-2001; 2001US-0899440.

XX (UYCO) UNIV COLUMBIA NEW YORK.

XX Stein C;

XX WPI; 2003-201558/19.

XX P-PSDB; ABP56822.

PT New oligonucleotide having a sequence complementary to a sequence of
FT ribonucleic acid encoding a heparanase, useful for preparing a
PT composition for treating tumor -

XX Disclosure; Fig 3; 48pp; English.

The present invention describes an oligonucleotide having a sequence
complementary to a sequence of ribonucleic acid encoding a heparanase.
The oligonucleotide hybridises with the ribonucleic acid under conditions
of high stringency and has a sequence comprising 10-40 bp. The
internucleoside linkages of the oligonucleotide comprise at least one
phosphorothioate linkage. Hybridisation of the oligonucleotide to the
ribonucleic acid inhibits expression of the heparanase, where inhibition
of heparanase means at least a 50% reduction in the quality of
heparanase. Also described: (1) a method of inhibiting expression of a
heparanase in a cell; (2) a composition comprising the above
oligonucleotide in an amount effective to inhibit the expression of
heparanase in the cell and a carrier; and (3) a method of treating a
tumour in a subject comprises administering to the subject an amount of
the above oligonucleotide effective to inhibit expression of a heparanase
in the subject. Heparanase antisense oligonucleotides have cytostatic
activity, can be used in gene therapy, and can be used for preparing a
composition for treating tumours. The present sequence encodes human
heparanase, which is given in the exemplification of the present
invention.

SO Sequence 1669 BP; 445 A; 396 C; 388 G; 440 T; 0 other;

Query Match 100.0%; Score 24; DB 25; Length 1669;

Best Local Similarity 100.0%; Pred. No. 0.026;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
|||||
DB 900 GTAGTATGCCATGTAAGTATC 877

RESULT 10

AA37259/C
ID AA37259 standard; DNA; 1713 BP.

AC AA37259;

DT 21-JUL-1999 (first entry)

XX Human heparanase enzyme encoding DNA.

DE Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;

KW metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;

KW arteriosclerosis; atherosclerosis; inflammation; tissue development;

KW human; HSPG; ss.

XX Homo sapiens.

OS

PN MO9921975-A1.

PD 06-MAY-1999.

PF 28-OCT-1998; 98WO-AU00898.

PR 09-DEC-1997; 97AU-0000812.

PR 28-OCT-1997; 97AU-0000062.

XX (AUSU) UNIV AUSTRALIAN NAT.

XX Freiman CG, Hamdorf BJ, Hulett MD, Parish CR;

XX WPI; 1999-312956/26.

XX P-PSDB; AAY17082.

PT Polynucleotides encoding mammalian endoglucuronidases, especially

PT heparanases, useful to promote wound healing

XX Claim 3; Page 69-73; 112pp; English.

XX The invention relates to nucleic acid sequences that encode heparanase

CC enzymes having endoglucuronidase activity. Recombinant heparanases are

CC capable of removing the HS side chain from heparan sulfate proteoglycan

CC (HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to

CC inhibit heparanase, this is useful for treatment of a physiological or

CC medical condition associated with elevated heparanase activity, such as

CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,

CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and

CC rat heparanases can be used to enhance wound healing, especially

CC associated with tissue development and repair. The conditions mentioned

CC above can be diagnosed using specific antibodies, and also using primers

CC and probes specific for the heparanase polynucleotides. Other uses of the

CC heparanases include sequencing sulfated molecules such as HSPG. The

CC present sequence represents a DNA encoding human heparanase.

XX Sequence 1713 BP; 460 A; 404 C; 406 G; 443 T; 0 other;

SO Query Match 100.0%; Score 24; DB 20; Length 1713;

Best Local Similarity 100.0%; Pred. No. 0.026;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
|||||
DB 939 GTAGTATGCCATGTAAGTATC 916

RESULT 11

AA35648/C
ID AA35648 standard; cDNA; 1721 BP.

AC AA35648;

DT 09-JUL-1999 (first entry)

XX cDNA encoding a human heparanase protein.

DE Heparanase; hpa; modulator; heparin-binding growth factor;

KW cellular response; cytokine; cell interaction; plasma lipoprotein;

KW cellular susceptibility; infection; disintegration;

KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;

KW atherosclerosis; inflammation; neurodegenerative disease; neuritis;

KW plasma heparin; micrometastasis; autoimmune lesion; renal failure;

KW ss.

XX Homo sapiens.

OS

PN MO9911798-A1.

PD 11-MAR-1999.

PF 31-AUG-1998; 98WO-US17954.

PR 02-JUL-1998; 98US-0109386.

PR 02-SEP-1997; 97US-0922170.

XX (FRIE/) FRIEDMAN M M.

XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

XX (INST-) INSIGHT STRATEGY & MARKETING LTD.

XX Feinstein E, Becker I, Vlodevsky I;

XX WPI; 1999-302255/25.

XX P-PSDB; AAY02345.

PT New human polynucleotide useful for treating angiogenesis,

PT restenosis, and inflammation

XX Claim 4; Fig 1; 63pp; English.

XX The specification describes a polypeptide having heparanase (hpa)

CC activity. The recombinant protein is used as a modulator of

CC heparin-binding growth factors, cellular responses to heparin-binding

CC growth factors and cytokines, cell interaction with plasma lipoproteins,

CC cellular susceptibility to viral, protozoal and bacterial infections

CC or disintegration of neurodegenerative plaques. Heparanase may be

CC useful for conditions such as wound healing, angiogenesis, restenosis,

CC atherosclerosis, inflammation, neurodegenerative diseases, and viral

CC infections. Mammalian heparanase can be used to neutralize plasma

CC heparin, and anti-heparanase antibodies may be applied for

CC immunodetection and diagnosis of micrometastases, autoimmune lesions,

CC and renal failure in biopsy specimens, plasma samples, and body fluids.

XX The present sequence encodes human heparanase.

XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

SO Query Match 100.0%; Score 24; DB 20; Length 1721;

Best Local Similarity 100.0%; Pred. No. 0.026;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
|||||
DB 956 GTAGTATGCCATGTAAGTATC 933

RESULT 12

AA575051/C
ID AA575051 standard; cDNA; 1721 BP.

AC	AA75051;
XX	15-JAN-2001 (first entry)
XX	cdna encoding a human heparanase polypeptide.
DE	Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KM	heparin-binding growth factor; cytokine; neurodegenerative plaque;
KM	wound healing; infection; burn; angiogenesis; restenosis;
KM	atherosclerosis; inflammation; neurodegenerative disease;
KM	Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; ds.
XX	
OS	Homo sapiens.
XX	
FH	Key
FT	location/Qualifiers
FT	CDS
FT	63..1693
FT	/*tag= a
FT	/product= "heparanase"
FT	698..724
FT	/*tag= b
FT	/note= "these nucleotides are likely to be involved
FT	in forming stem and loop structures"
XX	
XX	WO200052178-A1.
XX	
XX	08-SEP-2000.
XX	
XX	14-FEB-2000; 2000WO-US03542.
XX	
XX	01-MAR-1999; 99US-0258892.
XX	
XX	(INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA	(HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA	(FRIE/) FRIEDMAN M M.
XX	
PI	Pecker I, Vlodavsky I, Feinstein E;
XX	
XX	WPI; 2000-579289/54.
DR	P-PSDB; AAB08849.
XX	
PT	New polynucleotides encoding a polypeptide having heparanase activity,
PT	useful in wound healing and in gene therapy, particularly in treating,
XX	tumour, inflammation, autoimmunity, neurodegenerative diseases
XX	
PS	Claim 9; Fig 1; 152pp; English.
XX	
CC	The present sequence encodes a human protein with heparanase catalytic
CC	activity. The heparanase (hpa) polynucleotide is useful in gene therapy,
CC	particularly in treating tumour, inflammation or autoimmunity.
CC	Particularly, the polynucleotide is useful in modulating the
CC	bioavailability of heparin-binding growth factors, cellular responses
CC	to heparin-binding growth factors (e.g. bFGF) and cytokines
CC	(e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,
CC	cellular susceptibility to certain viral and some bacterial and protozoa
CC	infections, or disintegration of neurodegenerative plaques. The
CC	polynucleotide is also useful in wound healing (e.g. thermal, chemical
CC	or radiation burns), and in the treatment of angiogenesis, restenosis,
CC	atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-
CC	Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,
CC	bacterial or protozoa infections.
XX	
XX	Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
SO	
Query Match	100.0%; Score 24; DB 21; Length 1721;
Best Local Similarity	100.0%; Pred. No. 0.026;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
1 GTAGGATGCATGTAAGTATC 24	
556 GTAGGATGCATGTAAGTATC 933	

RESULT 13
ID AA239195/C
AA239195 standard; cDNA; 1721 BP.
XX AC AA239195;
XX DT 02-MAR-2000 (first entry)
XX DE Human heparanase encoding cDNA.
XX KW Human; heparanase; hpa; genetic modification; expression; anticancer;
KW angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumour;
KW anti-atherosclerotic; anti-inflammatory; antineurodegeneration;
KW heparan sulphate; heparin-binding growth factor; tumour angiogenesis;
KW metastasis; wound healing; restenosis; atherosclerosis; inflammation;
KW neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;
KW micrometastasis; autoimmune lesion; kidney failure; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT CDS 63..1694
FT /tag= a
FT /product= "heparanase"
PX WO957244-A1.
XX PD 11-NOV-1999.
PF 29-APR-1999; 99WO-US09256.
PR 01-MAY-1998; 98US-0071618.
PR 02-MAR-1999; 99US-0260038.
PA (INST-) INSIGHT STRATEGY & MARKETING LTD.
(FRIE/) FRIEDMAN M.M.
PI Ben-Artzi H, Ayal-Hershkovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;
PI Shlomi Y;
DR WPI: 2000-062144/05.
XX P-PsDB: AAY57590.
PT Engineered cells that express recombinant heparanase, useful
PT therapeutically, e.g. for treating angiogenesis and to screen for
PT specific inhibitors, potential anticancer agents -
XX Claim 2; Page 106-107; 11BPP; English.
PS The present invention describes genetically modified cells (A) containing
XX a polynucleotide (I) that encodes a polypeptide with heparanase activity,
CC and express recombinant heparanase (II). Heparanase cleaves heparan
CC sulphate (HS) at specific intrachain sites, resulting in release of
CC heparin-binding growth factors, enzymes and proteins that are sequestered
CC by HS in basement membranes, extracellular matrix or cell surfaces. It
CC may also be implicated in tumour angiogenesis and metastases. (II) is
CC potentially useful in wound healing and for treating angiogenesis,
CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
CC infection and cystic fibrosis. It can also be used to neutralise heparin
CC (an alternative to protamine) and to screen for specific inhibitors
CC (potentially useful for treating cancer and metastases). Antibodies
CC raised against (II) are used for immunodetection and diagnosis of
CC micrometastases, autoimmune lesions and kidney failure. (A) provide
CC in large quantities, in a form that is homogeneously processed and
CC activated/neutralised by a dedicated protease. The present sequence
CC encodes human heparanase.
XX SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
Query Match 100.0%; Score 24; DB 21; Length 1721;
Best Local Similarity 100.0%; Pred. NO. 0.026;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0

[illegible]

RESULT 14
AAZ33290/c
ID AAZ33290 standard; cDNA; 1721 BP.

DT	21-FEB-2000	(first entry)
XX		
DE	Human heparanase nucleotide sequence.	
XX		
KW	Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic; antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic; metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma; mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes; haemorrhagic nephritis; nephrotic syndrome; autoimmune disease; anticancer; kidney disease; ds.	

PN	WO9957153-A1.
XX	
PD	11-NOV-1999.
XX	
PF	29-APR-1999; 99WO-US09255

PA	(INSI-)	INSIGHT STRATEGY & MARKETING LTD.
PA	(HADA-)	HADASIT MEDICAL RES SERVICES & DEV
PA	(FRIE/)	FRIEDMAN M M.

PI	Pecker I, Vlodavsky I, Perets T
XX	
DR	WPI, 2000-052944/04.
DR	P-ESDB; AAY52990.

PT Heparanase-specific molecular probe useful for diagnosis and
PT treatment, e.g. of tumors, and for targeted drug delivery -
XX
PS Example; Page 82-84, 90pp; English.

The present invention describes heparanase-specific molecular probes, useful for methods of detecting heparanase *in situ*. The probes and anti-heparanase antibodies are used to detect or quantify the expression of heparanase, for diagnosis and monitoring of diseases (especially metastasis), for treatment of heparanase-associated diseases (e.g. tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma, mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its metastases) derived from liver, prostate, bladder, breast, ovary, cervix, colon, skin, intestine, stomach, uterus and pancreas), kidney disease, diabetes and inflammation, or autoimmune disease), nephrotic syndrome, sepsis and inflammatory or haemorrhagic disease), for targeted drug delivery (e.g. of anticancer agents) and as research reagents. The present sequence encodes human heparanase, which is used in the exemplification of the present invention.

SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match	100.0%;	Score 24;	DB 21;	Length 1721;
Best Local Similarity	100.0%;	Pred. No. 0.026;		
Matches 24;	Conservative 0;	Mismatches 0;	Indels 0	

QY .1 GTAGTGATGCCATGTACTGATC 24

Db 956 GTAGTGATGCCATGTAAGTGAATC 933

RESULT 15
AAA91112/c
ID AAA91112 standard; DNA; 1721 BP.

DE Human heparanase, coding sequence fragment isolated from EST clone.
XX
KW Heparanase; hnhp1; wound healing; angiogenesis; restenosis; Scrape;
KW atherosclerosis; inflammation; pulmonary disease; Alzheimer's disease
KW neurodegenerative disease; Creutzfeldt-Jakob disease; viral infection;
KW gene therapy; mouse; expressed sequence tag; ds.

PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.

DR WPI; 2001-137930/14

PT New polymycteleicid and polyepicid that are distantly homologous to
PT heparinase, useful in wound healing, as well as in gene therapy
PT protocols for angiogenesis, restenosis, atherosclerosis, or
PT inflammation -
XX
PS Example 1; Page 67, 67pp; English.

CC This sequence represents a human heparanase coding sequence clone,
CC isolated from an EST clone. The invention relates to heparanase DNA
CC and protein sequences. The heparanase DNA and protein sequences are
CC useful in wound healing, angiogenesis, restenosis, atherosclerosis,
CC inflammation, pulmonary diseases, neurodegenerative diseases (such as
CC Scrapie, Alzheimer's disease, and Creutzfeldt-Jakob disease) or viral
CC infections. The heparanase coding sequence is particularly useful in gene
CC therapy.

SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447.T; 0 other;

Query Match	100.0%	Score 24:	DB 22;	Length 1721;
Best Local Similarity	100.0%;	Pred. No. 0.026;		
Matches 24;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

OY		1	GTA	TGATGC	CATGTACTGA	TCA	TTC	24
Dβ		956	GTA	TGATGC	CATGTACTGA	TCA	TTC	933

Search completed: February 16, 2004, 09:18:14
Job time : 12.7756 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 ; Search time 93.2277 Seconds
(without alignments)
.6256.802 Million cell updates/sec

Title: US-10-676-079-7

Perfect score: 24

Sequence: 1 gtatgtatgcacatgaactgaac 24

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 22781392 seqs, 1215238056 residues

Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hrc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hrc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rtd:*
26: em_gss_phg:*
27: em_gss_vrt:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query	Match	Length	ID	Description
C 1	24	100.0	370	14	N41349		N41349 yw70a03.r1
C 2	24	100.0	587	14	N45367		N45367 yw7a02.r1
C 3	24	100.0	907	13	BQ438834		BQ438834 AGENCOURT
C 4	24	100.0	1083	13	BX398409		BX398409 BX398409

5	24	100.0	1156	9	AL552151	AL552151	AL552151
6	24	100.0	1200	9	AL545232	AL545232	AL545232
7	18.8	78.3	824	28	B2114057	B2114057	B2114057
8	18.4	76.7	493	28	AO260481	AO260481	AO260481
9	18.4	76.7	642	10	BE565766	BE565766	BE565766
10	18.4	76.7	686	10	BB181417	BB181417	BB181417
11	18.4	76.7	2733	11	AK039061	AK039061	AK039061
12	18.2	75.8	401	28	AQ775821	AQ775821	AQ775821
13	18.2	75.8	431	28	AQ363749	AQ363749	AQ363749
14	18.2	75.8	473	10	BG238460	BG238460	BG238460
15	18.2	75.8	540	28	B52785	B52785	B52785
16	18.2	75.8	631	13	BU352277	BU352277	BU352277
17	18.2	75.8	716	13	BU005587	BU005587	BU005587
18	18.2	75.8	732	10	BE565192	BE565192	BE565192
19	18.2	75.8	755	29	CC412604	CC412604	CC412604
20	18.2	75.8	757	12	BG777686	BG777686	BG777686
21	18.2	75.8	768	14	CB970530	CB970530	CB970530
22	18.2	75.8	813	29	B2771989	B2771989	B2771989
23	18.2	75.8	1962	11	AK087283	AK087283	AK087283
24	18.2	75.8	2173	11	AK040471	AK040471	AK040471
25	18.2	75.0	114	29	AL937708	AL937708	AL937708
26	17.8	74.2	84	28	AZ939449	AZ939449	AZ939449
27	17.8	74.2	246	10	BF084900	BF084900	BF084900
28	17.8	74.2	262	14	CB062055	CB062055	CB062055
29	17.8	74.2	543	29	BZ280332	BZ280332	BZ280332
30	17.8	74.2	565	13	BQ465842	BQ465842	BQ465842
31	17.8	74.2	649	10	BB218197	BB218197	BB218197
32	17.8	74.2	657	10	BF207911	BF207911	BF207911
33	17.8	74.2	687	10	BF209562	BF209562	BF209562
34	17.8	74.2	692	12	B1250835	B1250835	B1250835
35	17.8	74.2	727	10	BE567253	BE567253	BE567253
36	17.8	74.2	748	10	BG529572	BG529572	BG529572
37	17.8	74.2	789	10	BF211534	BF211534	BF211534
38	17.8	74.2	829	10	BF028342	BF028342	BF028342
39	17.8	74.2	843	10	BF382630	BF382630	BF382630
40	17.8	74.2	851	10	BG615642	BG615642	BG615642
41	17.8	74.2	857	10	BE865600	BE865600	BE865600
42	17.8	74.2	877	10	BE568413	BE568413	BE568413
43	17.8	74.2	878	10	BG532594	BG532594	BG532594
44	17.8	74.2	900	10	BG615175	BG615175	BG615175
45	17.8	74.2	903	10	BG615047	BG615047	BG615047

ALIGNMENTS

RESULT 1
N41349/c
LOCUS
DEFINITION yw70a03.r1 Searce placenta 8209weeks 2NDHP8to9w Homo sapiens cDNA
clone IMAGE:257548 5', mRNA sequence.
N41349
N41349.1 GI:1165380
EST.
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 370)
Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman
'M., Hultman, M., Kucab, T., Le, M., Lennon, G., Marra, M., Parsons, J.,
Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevaastis, E., Waterston
'R., Williamson, A., Wohlmann, P. and Wilson, R.
The Washu-Merck EST Project
Unpublished
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
High quality sequence stops: 279
Source: IMAGE Consortium, LNL

TITLE JOURNAL COMMENT

FEATURES
source
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
Seq primer: T7
High quality sequence stop: 279.
Location/Qualifiers
1..370
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3887158"
/db_xref="taxon:9606"
/clone="IMAGE:257548"
/dev_stage="two placentae: one from 8 weeks and another
from 9 weeks post conception"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares placenta 8to9weeks 2NBP8to9w"
/note="Organ: placenta; Vector: pT7T3 (Pharmacia) with a
modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st
strand cDNA was primed with a Not I - oligo(dT) primer [5'
TGTTACCATCTGAAGTGGAGCGCGCCGATTTTCTTTTCTTTT 3'],
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacia), digested with Not I and cloned into
the Not I and Eco RI sites of a modified pT7T3 vector
(Pharmacia). Library constructed by Bento Soares and
M.Felina Bonaldo."

BASE COUNT 113 a 64 c 83 g 103 t 7 others
ORIGIN

Query Match 100.0%; Score 24; DB 14; Length 370;
Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
|||||
DB 229 GTAGTATGCCATGTAAGTATC 206
|||||

RESULT 2 587 bp mRNA linear EST 13-FEB-1996
LOCUS N45367/c
DEFINITION yv97a02.r1 Soares placenta 8to9weeks 2NBP8to9w Homo sapiens cDNA
clone IMAGE:260138 5', mRNA sequence.
ACCESSION N45367
VERSION N45367.1 GI:1186533
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 587)
AUTHORS Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman
M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J.,
Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevasalis, E., Waterston
R., Williamson, A., Woldmann, P. and Wilson, R.
The Washu-Merck EST Project
Unpublished
JOURNAL
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
Seq primer: T7
High quality sequence stop: 369.
Location/Qualifiers
1..387

FEATURES
source
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3889844"
/db_xref="taxon:9606"
/clone="IMAGE:260138"
/dev_stage="two placentae: one from 8 weeks and another

from 9 weeks post conception"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares placenta 8to9weeks 2NBP8to9w"
/note="Organ: placenta; Vector: pT7T3 (Pharmacia) with a
modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st
strand cDNA was primed with a Not I - oligo(dT) primer [5'
TGTTACCATCTGAAGTGGAGCGCGCCGATTTTCTTTTCTTTT 3'],
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacia), digested with Not I and cloned into
the Not I and Eco RI sites of a modified pT7T3 vector
(Pharmacia). Library constructed by Bento Soares and
M.Felina Bonaldo."

BASE COUNT 158 a 112 c 153 g 156 t 8 others
ORIGIN

Query Match 100.0%; Score 24; DB 14; Length 587;
Best Local Similarity 100.0%; Pred. No. 2.2;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
|||||
DB 173 GTAGTATGCCATGTAAGTATC 150
|||||

RESULT 3 907 bp mRNA linear EST 24-MAY-2002
LOCUS BQ438834/c
DEFINITION AGENCOURT 7761619 NIH_MGC_70 Homo sapiens cDNA clone IMAGE:6017952
5', mRNA sequence.
ACCESSION BQ438834
VERSION BQ438834.1 GI:21177910
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 907)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL
COMMENT Unpublished
Contact: Robert Strauberg, Ph.D.
Email: cgabbs-remail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Agencourt Bioscience Corporation
clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
http://image.lnl.gov
Plate: LHAM3218 row: b column: 01
High quality sequence stop: 616.
Location/Qualifiers
1..907

FEATURES

source

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6017952"
/tissue="pancreas"
/lab_host="DH10B (pnase-resistant)"
/clone_lib="NIH_MGC_70"
/note="Organ: pancreas; Vector: pCMV-SPORT6; Site 1: NotI;
Site 2: SalI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.1 kb. Library constructed by Life
Technologies."

BASE COUNT 260 a 176 c 226 g 242 t 3 others
ORIGIN

Query Match 100.0%; Score 24; DB 13; Length 907;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
|||||

Db	576	GTAGTGATGCCATGTACTGATC	553
RESULT 4			
LOCUS	BX398409		
DEFINITION	BX398409 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone CSODI058Y124 3-PRIME, mRNA sequence.	1083 bp	linear EST 13-MAY-2003
ACCESSION	BX398409		
VERSION	BX398409.1	GI:30617572	
KEYWORDS	EST.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
AUTHORS	Li, W.B., Gruber, C., Jessee, J. and Polayes, D.		
TITLE	Full-length cDNA libraries and normalization		
JOURNAL	Unpublished		
COMMENT	Contact: Genoscope Genoscope - Centre National de Sequencage BP 191 91006 Evry cedex - France Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see http://www.genoscope.cns.fr/ cgi-bin/cluster.cgi?seq=CSODI058BE12NP1&cluster=2469.r. Contact : Feng liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Paradise Avenue Genoscope sequence ID : CSODI058BE12NP1. Location/Qualifiers 1. 1083 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CSODI058Y124" /issue_type="PLACENTA COT 25-NORMALIZED" /clone_11b="Homo sapiens PLACENTA COT 25-NORMALIZED" /note="1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."		
BASE COUNT	273 a 264 c 206 g 258 t	82 others	
ORIGIN			
Query Match	100.0%; Score 24; DB 13; Length 1083;		
Beet Local Similarity	100.0%; Pred. No. 3;		
Matches	24; Conservative 0; Mismatches 0; Indels 0; Gaps 0.		
Qy	1 GTAGTGATGCCATGTACTGATC 24		
Db	762 GTAGTGATGCCATGTACTGATC 785		
RESULT 5			
LOCUS	AL552151	1156 bp	mRNA linear EST 31-MAY-2003
DEFINITION	AL552151 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone CSODI058Y115 3-PRIME, mRNA sequence.		
ACCESSION	AL552151		
VERSION	AL552151.2	GI:31273967	
KEYWORDS	EST.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
AUTHORS	Li, W.B., Gruber, C., Jessee, J. and Polayes, D.		
TITLE	Full-length cDNA libraries and normalization		
JOURNAL	Unpublished		
COMMENT	On Feb 15, 2001 this sequence version replaced gi:12890775. Contact: Genoscope		

```

Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 2469.r For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSDDIO59CG08NP1&cluster=2469.r. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Paradey Avenue Genoscope sequence ID : CSDDIO59CG08NP1.

FEATURES
    source
        1..1156
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /clone="CSDDIO59YNI15"
            /issue_type="PLACENTA COT 25-NORMALIZED"
            /clone_1fb="Homo sapiens PLACENTA COT 25-NORMALIZED"
            /note="1st strand cDNA was primed with a NotI-oligo(dT)
            primer. Five prime end enriched, double-strand cDNA was
            digested with Not I and cloned into the Not I and EcoR V
            sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT
    305 a      251 c      233 g      223 t      44 others
ORIGIN
Query Match      100.0%; Score 24; DB 9; Length 1156;
Best Local Similarity 100.0%; Pred. No. 3,1;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 GTAGTGATGCATGTAATCAATC 24
        |||||||
DB      732 GTAGTGATGCATGTAATCAATC 755

```

LOCUS AL545232 1200 bp mRNA EST 31-MAY-2003
DEFINITION AL545232 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA
clone CSOD1028YF04 3-PRIME, mRNA sequence.
ACCESSION AL545232
VERSION AL545232.2 GI:31267068
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1. (bases 1 to 1200)
li, W.B., Gruber, C., Jesssee, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished
On Feb 15, 2001 this sequence version replaced gi:12877713.
COMMENT
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 Evry cedex - France
Email: seque@genoscope.cns.fr Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 2469.r For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSOD1028DC02NP1&cluster=2469.r. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Paradise Avenue Genoscope sequence ID : CSOD1028DC02NP1.
FEATURES
Source
Location/Qualifiers
1..1200
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSOD1028YF04"
/rname_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT)

primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."

BASE COUNT

300 a 249 c 249 g 332 t 70 others

Query Match 100.0%; Score 24; DB 9; Length 1200;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GTAGTATCCATGTAATC 24
|||||
Db 703 GTAGTATCCATGTAATC 726

RESULT 7 BZ114057 824 bp DNA linear GSS 11-OCT-2002
LOCUS CH230-385118.TVB CHORI-230 Segment 2 Rattus norvegicus genomic
clone CH230-385118, genomic survey sequence.

ACCESSION BZ114057
VERSION BZ114057.1 GI:23755004
KEYWORDS GSS.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.

REFERENCE 1 (bases 1 to 824)
AUTHORS Zhao, S., Shetty, J., Shatsman, S., Tsogayev, G., Geer, K., Shvartsbeyn, A., Gebregregorius, E., Overton, L., Russell, D., Chen, D., Riggs, F., de Jong, P., and Frazer, C.M.
Rat BAC End Sequences from Library CHORI-230 MboI segment

TITLE Unpublished
JOURNAL
COMMENT Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@tigr.org

Clones are derived from the rat BAC library CHORI-230
(http://www.chori.org/bacpac/rat230.htm). For BAC library
availability, please contact Pieter de Jong (pdejong@mail.cho.org).
Clones may be purchased from BACPAC Resources
(http://www.chori.org/bacpac/or ering information.htm). BAC end
page: http://www.tigr.org/cdb/bac_ends/rat/bac_end_intro.html
Plate: 385 row: I column: 18
Seq primer: T7
Class: BAC ends.

FEATURES

Location/Qualifiers
1..824
/organism="Rattus norvegicus"
/mol_type="genomic DNA"
/strain="BN/SNHsd/MCM"
/db_xref="taxon:10116"
/clone="CH230-385118"
/sex="Female"
/cell_type="Brain"
/clone_lib="CHORI-230 Segment 2"
/note="Vector: pTAKBAC1.3; Site_1: MboI, Site_2: MboI;
CHORI-230 Rat (BN/SNHsd/MCM) BAC library produced by
Pieter de Jong"

BASE COUNT 293 a 133 c 163 g 235 t

Query Match 78.3%; Score 18.8; DB 28; Length 824;
Best Local Similarity 90.9%; Pred. No. 6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1 GTAGTATCCATGTAATC 22
|||||
Db 817 GTAGTATCCATGTAATC 796

RESULT 8 AO260481 493 bp DNA linear GSS 24-OCT-1998
LOCUS CITR1-E1-2504G20.TR CITR1-E1 Homo sapiens genomic clone 2504G20,
genomic survey sequence.

ACCESSION AO260481
VERSION AO260481.1 GI:3787005
KEYWORDS GSS.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 493)
AUTHORS Adams, M.D., Rounsley, S.D., Zhao, S., Baas, S., Linher, K., Golden, K.,
Berry, K., Granger, D., Suh, E., Wible, C., Shizuya, H., Simon, M., and
Venter, J.C.

TITLE Use of a random human BAC End Sequence Database for Sequence-Ready
Map Building
JOURNAL
COMMENT Contact: Mark Adams
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: mdamas@tigr.org

Clones are available from Research Genetics (info@resgen.com). BAC
end search page:
http://www.tigr.org/cdb/humgen/bac_end_search/bac_end_search.html.
Seq primer: M13 Reverse
Class: BAC ends.

FEATURES

Location/Qualifiers
1..493
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="2504G20"
/sex="male"
/cell_type="sperm"
/clone_lib="CITR1-E1"
/note="Vector: pBeloBAC11, Site_1: EcoRI, Site_2: EcoRI;
Catrech Human BAC Library D"

BASE COUNT 180 a 80 c 95 g 138 t

Query Match 76.7%; Score 18.4; DB 28; Length 493;
Best Local Similarity 95.0%; Pred. No. 7.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 5 TGATGCCATGTAATC 24
|||||
Db 322 TGATGCCATGTAATC 341

RESULT 9 BE565766 642 bp mRNA linear EST 15-AUG-2000
LOCUS BE565766 60133857.F1 NIH_MGC_53 Homo sapiens cDNA clone IMAGE:3660848 5',
mRNA sequence.
ACCESSION BE565766
VERSION BE565766.1 GI:9809486
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 642)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL
COMMENT Contact: Robert Strausberg, Ph.D.

Unpublished

FEATURES
SOURCE

FEATURES

Location/Qualifiers
1. .686

```

/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="A230091D07"
/sex="male"
/tissue_type="hypothalamus"
/dev_stage="adult"
/lab_host="DH108"

```

[/note=site:1:Sal1; site:2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken](#)

contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5' GAGACGACGAGATCCAGAGCTCTTTTTCCTTTTTTNN 3'], cDNA was prepared by using trehalose thermo-activated reverse

cap-trapper. cDNA went through one round of normalization to Rot = 20.0 and subtraction to Rot = 459.0. Second strand cDNA was prepared with the primer adapter of sequence 5' GAGAGAGAGATTCGAGTTATTTAAATATCCCCCCCCC

Query Match	76.7%	Score 18.4	DB 10	Length 686
Best Local Similarity	95.0%	Pred. No. 8.3e+02		
Matches 19, Conservative	0	Mismatches 1	Indels 0	Gaps 0

OY		2	TAGTGATGCATGTAACTGA	21
Dd		33	TAGTGATGTCATGTAACTGA	14
RESULT 11				
AK039061/c				
JOCUS		AK039061	2733 bp	mRNA linear HTC 05-DEC-2002

TITLE	Direct Submission									
JOURNAL	Submitted (16-JUL-2001) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute; 1-7-22 Suehito-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail: genome-res@gsc.riken.go.jp), URL: http://genome.gsc.riken.go.jp/, Tel: 81-45-503-9222, Fax: 81-45-503-9216									
COMMENT	cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. Please visit our web site for further details. URL: http://genome.gsc.riken.go.jp/ URL: http://fantom.gsc.riken.go.jp/ Location/Qualifiers									
FEATURES	source									
	1..2733									
	/organism="Mus musculus"									
	/mol_type="mRNA"									
	/strain="C57BL/6J"									
	/db_xref="FANTOM_DB:A230091D07"									
	/db_xref="taxon:10090"									
	/clone="A230091D07"									
	/sex="male"									
	/tissue_type="hypothalamus"									
	/clone_id="RIKEN full-length enriched mouse cDNA library"									
	/dev_stage="adult"									
misc_feature	1..2733									
	/note="adenomatosis polyposis coli (MGI:88039, GBLNM_007462, evidence: BLASTN, 100%, match=3169)"									
BASE COUNT	857 a 520 c 513 g 843 t									
ORIGIN										
Query Match	76.7%; Score 18.4; DB 11; Length 2733;									
Best Local Similarity	95.0%; Pred. No. 1.6e+03;									
Matches	19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Qy	2 TAGTGATGCATGTACTGA 21									
Db	2076 TAGTGATGCATGTACTGA 2057									
RESULT 12										
LOCUS	A0775821									
DEFINITION	A0775821									
ACCESSION	A0775821									
VERSION	A0775821.1									
WORDS	GI:5655549									
SOURCE	GSS.									
ORGANISM	Homo sapiens (human)									
	Homo sapiens									
	Homo sapiens (human)									
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.									
REFERENCE	1 (bases 1 to 401)									
AUTHORS	Mahairas G.G., Wallace J.C., Smith K., Swartzell S., Holzman T., Keller A., Shaker R., Furlong J., Young J., Zhao S., Adams M.D. and Hood L.									
TITLE	Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome									
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)									
MEDLINE	99380589									
PUBMED	10449764									
COMMENT	Contact: Mahairas GG, Wallace JC, Hood L									

High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu

Clones may be purchased from Research Genetics (info@resgen.com).
BAC end Web Server: <http://www.htcsc.washington.edu>
Plate: 2006 row: 0 column: 4

Seq primer: M13 Reverse

Class: BAC ends

High quality sequence stop: 401.

Location/Qualifiers

```
1. .401
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="Plate=2006 Col=4 Row=0"
/sex="male"
/clone_lib="CIT Approved Human Genomic Sperm Library D"
/note="Organ: sperm; Vector: pBelobAC11; BAC Clones in
E-Coli DH10B"
```

BASE COUNT 149 a 63 c 50 g 139 t

ORIGIN

Query Match 75.8%; Score 18.2; DB 28; Length 401;

Best Local Similarity 87.0%; Pred. No. 8e+02; Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1 GTAGTGATGCCATGTACTGAAT 23

Db 74 GAAGTGATCCATGTACTGAAT 96

RESULT 13
AO363749 431 bp DNA linear GSS 16-DEC-1999
LOCUS nbxb0059j12f CUGI Rice BAC library Oryza sativa (japonica
DEFINITION cultivar-group) genomic clone nbxb0059j12f, genomic survey
sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AO363749.2 GI:6583615
GSS.
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Erihartoideae; Oryzaceae; Oryza.

1 (bases 1 to 431)
Wang R.A. and Dean R.A.
A BAC End Sequencing Framework to Sequence the Rice Genome
Unpublished
On Dec 15, 1999 this sequence version replaced gi:4213404.
Contact: Wang RA
Clemson University Genomics Institute
100 Jordan Hall, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: rtwing@clemson.edu
Seq primer: TAATCGACTCAGCTATAGG
Class: BAC ends

High quality sequence stop: 231.

Location/Qualifiers

```
1. .431
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="genomic DNA"
/strain="Japonica"
/cultivar="Nipponbare"
/db_xref="taxon:39947"
/clone="nbxb0059j12f"
/tissue_type="leaf"
/lab_host="E. coli DH10B"
```

FEATURES

SOURCE

/clone_lib="CUGI Rice BAC library"
/note="Vector: pBelobAC11; Site 1: HindIII; Site 2:
HindIII; Rice is one of two most popular grains in the
world. Half of the world population especially those
inhabiting highly populated areas of the humid tropics
and subtropics, rely on rice as their primary source of
carbohydrate. Monocotyledonous rice is a diploid plant
(2n=24) with a haploid genome equivalent of 431 Mbp
(Arumuganathan and Earle, 1991). The relatively small
genome of rice, three times larger than that of
Arabidopsis, makes it suitable for genomic studies. In
order to facilitate positional cloning, physical mapping
and genome sequencing of rice, we have constructed a BAC
library from Oryza sativa, Nipponbare variety. The
library contains 36,864 clones with an average insert size
of 128.5 kb providing 10.9 haploid genome equivalents. The
deep coverage allows the isolation a particular sequence
with a probability of 99.9%. Two high density filters,
each containing 18,432 clones (doubly spotted), represent
the whole library for colony screening."

BASE COUNT 134 a 92 c 96 g 108 t 1 others

ORIGIN

Query Match 75.8%; Score 18.2; DB 28; Length 431;

Best Local Similarity 83.3%; Pred. No. 8.2e+02; Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 GTAGTGATGCCATGTACTGAATC 24

Db 396 GTATNGATGCTTGTAGCTGAATC 419

RESULT 14
BG238460 473 bp mRNA linear EST 28-NOV-2001
LOCUS sb51a01.y1 Gm-c1043 glycine max cDNA clone GENOME SYSTEMS CLONE
DEFINITION ID: Gm-c1043-2690 5' similar to TR:064486 064486 F20D22.2 PROTEIN.
; mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

BG238460.1 GI:12773533
EST.
Glycine max (soybean)
Glycine max
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids
; eurosids 1; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
Glycine.

1 (bases 1 to 473)
Shoemaker R., Keim P., Vodkin L., Erpelting J., Coryell V., Khanna
A., Bolla B., Marra M., Hillier L., Kucaba T., Martin J., Beck C.,
Wyle T., Underwood K., Steptoe M., Allen M., Bowers
Y., Peterson B., Swaller T., Gibbons M., Pape D., Harvey N., Schurk
R., Ritter E., Kohn S., Shin T., Jackson Y., Cardenas M., McCann
R., Waterston R. and Wilson R.
Public Soybean EST Project
Unpublished

TITLE
JOURNAL
COMMENT

Contact: Shoemaker R/Public Soybean EST Project
Public Soybean EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available through: ResGen, Invitrogen Corp. 2130
South Memorial Parkway Huntville, AL 35801 For further information
call: (800)-533-4363 or contact via email: cu@resgen.com.

FEATURES

SOURCE

```
1. .473
/organism="Glycine max"
/mol_type="mRNA"
/db_xref="taxon:3847"
/clone="GENOME SYSTEMS CLONE ID: Gm-c1043-2690"
/tissue_type="Hypocotyl and Plumule, germinating seeds"
```

/lab host="DH10B"
 /clone_1ib="Gm-cl043"
 /note="Vector: pT73pac (Pharmacia); Site 1: EcoRI;
 Site 2: NotI; This cDNA library was constructed from mRNA
 isolated from hypocoely and plumule tissues of seeds
 germinated for three days of the cultivar Williams.
 Complementary DNA was synthesized from mRNA using a primer
 consisting of a poly(dt) sequence with a NotI restriction
 site. EcoRI adapters were ligated to the blunt-ended cDNA
 fragments followed by digestion with EcoRI and NotI. The
 cDNA fragments were directionally cloned into the
 EcoRI-NotI restriction site of the pT73-pac vector. The
 ligated cDNA fragments were transformed into DH10B host
 cells (Gibco BRL). This library was constructed by Dr.
 Randy Shoemaker."

BASE COUNT 138 a 73 c 98 g 164 t
 ORIGIN

Query Match 75.8%; Score 18.2; DB 10; Length 473;
 Best Local Similarity 87.0%; Pred. No. 8.6e+02;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 TAGTGATGCCATGTACTGATC 24
 |||||
 Db 442 TATTGATGCCATGTACTGATC 464

RESULT 15

B52785 540 bp DNA linear GSS 20-JUN-1998

LOCUS CIT-HSP-200604.TR CIT-HSP Homo sapiens genomic clone 200604,
 DEFINITION genomic survey sequence.

ACCESSION B52785

VERSION B52785.1 GI:2607119

KEYWORDS GSS.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 540)

AUTHORS Adams,M.D., Rounsley,S.D., Field,C.E., Bass,S., Linher,K., Golden

,K., Berry,K., Granger,D., Suh,E., Wible,C., Shizuya,H., Simon,M.

and Venter,J.C.

Use of a random BAC End Sequence Database for Sequence-Ready Map

Building

Unpublished

Other_GSSs: CIT-HSP-200604.TF

COMMENT

Contact: Mark Adams

Department of Eukaryotic Genomics

The Institute for Genomic Research

9712 Medical Center Dr., Rockville, MD 20850, USA

Tel: 301 838 0200

Fax: 301 838 0208

Email: mdadams@tigr.org

Clones are available from Research Genetics (info@resgen.com). BAC

end search page:

http://www.tigr.org/tdb/humgen/bac_end_search/bac_end_search.html

Seq primer: M13 Reverse

Class: BAC ends.

FEATURES
 source 1..540
 Location/Qualifiers

/organism="Homo sapiens"

/mol_type="genomic DNA"

/db_xref="GDB:7039830"

/db_xref="taxon:9606"

/clone="200604"

/sex="Male"

/cell_type="Sperm"

/clone_1ib="CIT-HSP"

/note="Vector: pBel0BAC11; Site_1: HindIII; Site_2:

HindIII"

BASE COUNT 189 a 103 c 69 g 179 t

ORIGIN

Query Match 75.8%; Score 18.2; DB 28; Length 540;
 Best Local Similarity 87.0%; Pred. No. 9.2e+02;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 GTAGTGATGCCATGTACTGAT 23
 |||||
 Db 81 GAGTGATGCCATGTACTGAT 103

Search completed: February 16, 2004, 13:41:05
 Job time : 97.2277 secs

XX (FRIE//)FRIEDMAN M. M.
PI Ben-Artzi H, Ayal-Hershkovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;
PI Shlomi Y;
XX
XX WPI, 2000-062144/05.
DR
XX
PT Engineered cells that express recombinant heparanase, useful
PT therapeutically, e.g. for treating angiogenesis and to screen for
PT specific inhibitors, potential anticancer agents -
PS
PS Example 1; Page 36; 11pp; English.
XX
XX The present invention describes genetically modified cells (A) containing
CC a polynucleotide (I) that encodes a polypeptide with heparanase activity,
CC and express recombinant heparanase (II). Heparanase cleaves heparan
CC sulphate (HS) at specific intrachain sites, resulting in release of
CC heparin-binding growth factors, enzymes and proteins that are sequestered
CC by HS in basement membranes, extracellular matrix or cell surfaces. It
CC may also be implicated in tumour angiogenesis and metastases. (II) is
CC potentially useful in wound healing and for treating angiogenesis,
CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
CC infection and cystic fibrosis. It can also be used to neutralise heparin
CC (an alternative to protamine) and to screen for specific inhibitors
CC (potentially useful for treating cancer and metastases). Antibodies
CC raised against (II) are used for immunodetection and diagnosis of
CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
CC in large quantities, in a form that is homogeneously processed and
CC activated/neutralised by a dedicated protease. The present sequence
CC represents a PCR primer for human heparanase, which is used in an
CC example from the present invention.
XX
XX Sequence 24 BP; 5 A; 7 C; 3 G; 9 T; 0 other; .

		Query Match	. 100.0%;	Score 24;	DB 21;	Length 24;
		Best Local Similarity	100.0%;	Pred. No. 0.13;		
Matches	24;	Conservative	0;	Mismatches	0;	Indels
					0;	Gaps
OY	1	TATGATCCTTAGTACTTCTTGAC	24			
D6	1	TATGATCCTTAGTACTTCTTGAC	24			

RESULT 2	
AAZ33292	
ID	AAZ33292 standard; DNA, 24 BP.
XX	
AC	AAZ33292;
XX	
DT	21-FEB-2000 (first entry)
DE	Human heparanase PCR antisense primer SEQ ID NO:5.
XX	
KW	Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic; antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic; metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma; mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes mellitus; haemorrhagic nephritis; nephrotic syndrome; autoimmune disease; anticancer; kidney disease; PCR primer; ss.
XX	
OS	Synthetic.
OS	Homo sapiens.
XX	
PN	WO957153-A1.
XX	
PD	11-NOV-1999.
XX	
PF	29-APR-1999; 99WO-US09255.
XX	
PR	01-MAY-1998; 98US-0071739.
XX	
PA	(INST-) INSIGHT STRATEGY & MARKETING LTD.
PA	(HADA-) HADASIT MEDICAL RES SERVICES & DEV.

PA (FRIE/) FRIEDMAN M M.
XX
XX
PI Becker I, Vlodavsky I, Friedman Y, Perets T;
XX
XX WPI; 2000-052944/04.
DR
XX
XX Heparanase-specific molecular probes useful for diagnosis and
PT treatment, e.g. of tumors, and for targeted drug delivery -
XX
XX
XX Example; Page 27; 90pp; English.

CC The present invention describes heparanase-specific molecular probes,
CC useful for methods of detecting heparanase *in situ*. The probes and
CC anti-heparanase antibodies are used to detect or quantify the expression
CC of heparanase, for diagnosis and monitoring of diseases (especially
CC metastasis), for treatment of heparanase-associated diseases (e.g.
CC tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
CC metastases) derived from liver, prostate, bladder, breast, ovary,
CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
CC syndrome, sepsis and inflammatory or autoimmune diseases), for targeted
CC drug delivery (e.g. of anticancer agents) and as research reagents.
CC The present sequence represents a PCR primer for human heparanase, which
CC is used in an example from the present invention for the construction of
CC a heparanase expression vector.

	Query Match	100.0%;	Score 24;	DB 21;	length 24;
	Best Local Similarity	100.0%;	Pred. No. 0.13;		
	Matches 24; Conservative	0;	Mismatches	0;	Indels 0;
	Gaps	0;			
Qy	1 TATGATCTCTAGACTTTCGCAC	24			
Db	1 TATGATCCTTAGACTTTCGCAC	24			

XX	RESULT 3
ABLS7029/c	
ID	ABLS7029 standard; DNA; 230 BP.
AC	ABLS7029;
XX	
DT	23-JUL-2002 (first entry)
XX	
DE	Nuclear-targeted lacZ baculovirus transfection cassette.
XX	
XX	Baculovirus; vector; gene therapy; lacZ; beta-galactosidase;
KW	enzyme; vasodilator; antithrombotic; thrombolytic; cytostatic;
XX	CMV; pFASTback; ss.
XX	
OS	Baculovirus.
XX	
XX	
Key	Location/Qualifiers
FT	misc_feature 6
FT	/*tag= a
FT	/note="transcription start for the polyhedrin
FT	promoter"
XX	
PN	WQ200190390-A1.
XX	
PD	29-NOV-2001.
XX	
PF	29-MAY-2001; 2001WQ-GB02383.
XX	
PR	26-MAY-2000; 2000GB-0012997.
XX	
PA	(ARKT-) ARK THERAPEUTICS LTD.
XX	
PI	Via-Heritua S, Airene KJ;
XX	
WP	WPI; 2002-401582/43.

XX Delivery of gene product, comprises applying the gene in baculovirus
PT vector to blood-free body compartment, useful e.g. for gene therapy of
PT vascular diseases using periaventricular collar -
XX
PS Example 2; Fig 1; 20pp; English.
XX
CC The present sequence is a portion of baculovirus transfer vector
CC pFastBac1 (pFB). A cytomagalovirus nuclear-targeted lacZ
CC expression cassette (see ABL57028) was inserted into the vector at
CC an StuI site (nucleotide 121-126 of the present sequence), in
CC opposite orientation to the vector's polyhedrin promoter, to
CC construct a nuclear-targeted beta-galactosidase-encoding baculovirus
CC vector. The vector was used in examples from the invention to
CC demonstrate baculovirus-mediated gene transfer to the rabbit
CC arterial wall, rat brain and rabbit skeletal muscle. The invention
CC relates to the delivery of a gene product by providing the gene in
CC a baculovirus vector and applying the vector to a body compartment
CC which is free (or usually free) of blood. In a device for the
CC periaventricular delivery of a gene product, the gene is provided in
CC a baculovirus vector from which the gene is expressed. The
CC baculovirus vector is useful for gene therapy, especially of
CC vascular diseases such as post-angioplasty restenosis, post-bypass
CC atherosclerosis, stenosis of vascular prosthesis anastomoses and
CC thrombus formation. It is also useful for administration to the
CC brain (e.g. for cancer treatment) or ex vivo injection into
CC saline-perfused organs or vessels for transplantation.
CC Note: The specification was published without claims.
XX
SQ Sequence 230 BP; 64 A; 56 C; 53 G; 57 T; 0 other;
XX
Query Match 100.0%; Score 24; DB 24; Length 230;
Best Local Similarity 100.0%; Pred. No. 0.16; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TATGATCCTTAGTACTTCTCGAC 24
DB 225 TATGATCCTTAGTACTTCTCGAC 202
XX
RESULT 4
ABV77225/c
ID ABV77225 standard; DNA; 230 BP.
XX
AC ABV77225;
XX
DT 28-MAR-2003 (first entry)
XX
DE Nucleotide sequence of a CMV-nt lacZ expression cassette fragment.
XX
KW Baculovirus; vector; spinal cord; central nervous system; CNS;
KW periaventricular gene transfer; enzyme replacement; gene therapy;
KW subarachnoid haemorrhage; gene delivery; cerebral choroid plexus;
KW brain disorder; cancer; brain cancer; lacZ; ss.
XX
OS Synthetic.
XX
PN WO200296469-A2.
XX
PD 05-DEC-2002.
XX
PP 28-MAY-2002; 2002WO-GB02504.
XX
PR 29-MAY-2001; 2001WO-GB02383.
XX
PR 29-NOV-2001; 2001GB-0028620.
XX
PA (ARKT-) ARK THERAPEUTICS LTD.
XX
PI Yla-herttuala S, Airenne KJ, Lehtolaenen P;
XX
DR WPI; 2003-129500/12.
XX
PT Use of baculovirus vector containing a gene, for the manufacture of a

PT medicament for treating a condition mediated by spinal cord or central
PT nervous system, by the action of a gene or its product -
XX
PS Disclosure; Fig 1; 14pp; English.
XX
CC The specification describes the use of a baculovirus vector containing
CC a gene, for the manufacture of a medicament for the treatment of a
CC condition that can be mediated via the spinal cord or central nervous
CC system (CNS), by the action of a gene or its product. Baculoviruses are
CC capable of mediating periaventricular gene transfer. The vector is useful
CC for treating a condition that requires enzyme replacement such as
CC subarachnoid haemorrhage. It is useful as an efficient tool for gene
CC delivery to cerebral choroid plexus cells and in gene therapy of several
CC types of brain disorder. It is also useful for treating cancer e.g. in
CC brain. To analyse the gene transfer efficiency of baculovirus and
CC adenovirus vectors (both comprising the lacZ cassette), the viruses were
CC injected into corpus callosum of adult rats. Expression of lacZ was
CC analysed by reverse transcriptase (RT)-polymerase chain reaction (PCR).
CC The present sequence represents a CMV-nt lacZ expression cassette
CC fragment, used in adenovirus or baculovirus vectors.
XX
SQ Sequence 230 BP; 64 A; 56 C; 53 G; 57 T; 0 other;
XX
Query Match 100.0%; Score 24; DB 25; Length 230;
Best Local Similarity 100.0%; Pred. No. 0.16;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TATGATCCTTAGTACTTCTCGAC 24
DB 225 TATGATCCTTAGTACTTCTCGAC 202
XX
RESULT 5
ABK49828/c
ID ABK49828 standard; DNA; 432 BP.
XX
AC ABK49828;
XX
DT 15-JUL-2002 (first entry)
XX
DE Plasmid pFastBac1-HT region encoding MycHis tag.
XX
KW ds; ADAMTS; cytostatic; antidiabetic; antirheumatic; MycHis tag;
KW antiarthritic; antitumor; chronic rheumatoid arthritis; gene therapy;
KW refractory skin ulcer; gastric ulcer; post-operative healing failure;
KW recombinant type 2N-metalloproteinase domain; disintegrin-like domain; TSP1;
KW chromosome 5p15.2-15.3; Cri-du-chat syndrome; pFastBac1-HT.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT CDS 255..320
FT FT /*tag= a
FT /product= "MycHis tag"
FT /note= "No start or stop codon"
XX
PN WO200231163-A1.
XX
PD 18-APR-2002.
XX
PP 11-OCT-2001; 2001WO-JP08913.
XX
PR 11-OCT-2000; 2000JP-0311309.
XX
PR 02-APR-2001; 2001JP-0102905.
XX
PA (KAZU-) KAZUSA DNA RES INST FOUND.
XX
PA (MITS-) MITSUBISHI PHARMA CORP.
XX
PI Ohara O, Nagase T, Nomura N, Yano K, Murakami K, Yasuda S;
XX
PI Kanazaki K;

DR WPI; 2002-372277/40.
 DR P-PSDB; AAU80152.
 XX
 PT Human brain-originated ADAMTS family polypeptide and encoded gene,
 PT applicable in diagnosis and screening compounds for drug compositions
 PT in treating diseases due to e.g. neovascularisation
 PS
 XX Example 20; Fig 16; 172pp; Japanese.
 XX
 CC The invention relates to a polypeptide belonging to the ADAMTS family is
 CC selected from sequences appearing as AAU79496, AAU79497 and AAU79499,
 CC a protein that contains the polypeptide, a protein having not less than
 CC 50% homology with the amino acid sequence of the polypeptides or a
 CC polypeptide modified from any of the polypeptides but with some amino
 CC acids deleted, substituted, added or inserted. Also included are the
 CC polynucleotides encoding the polypeptides (or their complementary
 CC strands or variants), a recombinant vector containing any of the
 CC polynucleotides, a transformant which is transformed with the recombinant
 CC vector, producing the polypeptide, protein or peptide by culturing the
 CC transformant, an antibody that can recognize the polypeptide, protein or
 CC peptide and screening compounds to promote or inhibit activity of the
 CC polypeptide or protein, or to promote or inhibit expression of the
 CC polynucleotide, vector, transformant or/and antibody, particularly in
 CC the presence of a test compound for contact before evaluating the
 CC activity by measuring signal changes. The polypeptide and encoded gene
 CC are applicable in diagnosis and screening compounds for drug compositions
 CC in treating diseases due to neovascularisation, diabetic omentopathy,
 CC chronic rheumatoid arthritis, angioma, refractory skin and gastric ulcers
 CC and post-operative healing failure, including gene therapy.
 CC The gene encoding such polypeptide has conserved replication-type 2N-
 CC metalloprotease domain, disintegrin-like domain and TSP1 (thrombospondin
 CC type 1) domain. Its encoded protein is characterized by high expression
 CC in ovaries, changes in expression dose depending on the sexual cycle, a
 CC decrease in tumour cell and location of the gene on the 5p-syndrome
 CC Cri-du-chat syndrome). The present sequence is a region of plasmid
 CC pFastBac1-HT used to make the expression plasmid pFastBac1-HT-P01256
 CC used to express DNA encoding an ADAMTS protein.
 CC
 XX
 SQ Sequence 432 BP; 138 A; 105 C; 82 G; 107 T; 0 other;
 Query Match 100.0%; Score 24; DB 24; Length 432;
 Best Local Similarity 100.0%; Pred. No. 0.17; 0; Indels 0; Gaps 0;
 Matches 24; Conservative 0; Mismatches 0;
 QY 1 TATGATCCTCTAGTACTTCTCGAC 24
 Db 350 TATGATCCTCTAGTACTTCTCGAC 327
 XX
 RESULT 6
 AA88918/C
 ID AAA88918 standard; DNA; 604 BP.
 XX
 AC AAA88918;
 XX
 DT 05-MAR-2001 (first entry)
 XX
 DE Nucleotide sequence of ricin toxin B chain RTB3 in pFASTBAC1.
 XX
 KM Ricin toxin B; RTB3; crystal protein; insecticide; pesticide;
 KM toxin; transgenic plant; insect resistance; crop protection;
 KM lectin; pFASTBAC1; ds.
 XX
 OS Chimeric - Ricinus communis.
 OS Chimeric - Baculovirus.
 XX
 PN WO200066755-A2.
 XX
 PR 09-NOV-2000.
 PD
 XX 27-APR-2000; 2000WO-GB01633.
 PF

XX
 PR 28-APR-1999; 99GB-0009796.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX
 PI Christou P, Mehlo L;
 XX
 DR WPI; 2001-007228/01.
 XX
 PT Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 PT comprising a toxin and a binding domain for producing transgenic plants
 PT resistant to pests
 PS
 XX Claim 10; Fig 3e; 81pp; English.
 XX
 CC The present sequence is that of ricin toxin B chain RTB3 DNA in
 CC baculovirus transfer vector pFASTBAC1, in which the DNA was cloned
 CC under the control of the polyhedrin promoter. The invention
 CC provides nucleic acids (see AA88919-24) encoding pesticidal fusion
 CC proteins comprising a toxin domain and a heterologous binding domain
 CC capable of binding non-specifically to a cell membrane without
 CC disrupting that membrane. The toxin domain is preferably obtained
 CC from Bacillus thuringiensis crystal proteins CryI(b) or CryI(c),
 CC and the binding domain is preferably derived from a lectin, especially
 CC ricin toxin B chain. The use of such fusions may help to inhibit
 CC the acquisition of resistance in a pest population treated with the
 CC protein. Vectors (e.g. baculovirus vectors or vectors suitable for
 CC use in a plant), host cells, and transgenic plants (especially rice
 CC or maize) are also provided. Expression of the fusion protein in a
 CC plant is useful for influencing or affecting the toxicity of a
 CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
 CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
 CC Orthoptera pests.
 CC
 XX
 SQ Sequence 604 BP; 180 A; 121 C; 134 G; 169 T; 0 other;
 Query Match 100.0%; Score 24; DB 22; Length 604;
 Best Local Similarity 100.0%; Pred. No. 0.17; 0; Indels 0; Gaps 0;
 Matches 24; Conservative 0; Mismatches 0;
 QY 1 TATGATCCTCTAGTACTTCTCGAC 24
 Db 599 TATGATCCTCTAGTACTTCTCGAC 576
 XX
 RESULT 7
 AA88917/C
 ID AAA88917 standard; DNA; 860 BP.
 XX
 AC AAA88917;
 XX
 DT 05-MAR-2001 (first entry)
 XX
 DE Nucleotide sequence of ricin toxin B chain RTB2 in pFASTBAC1.
 XX
 KM Ricin toxin B; RTB2; crystal protein; insecticide; pesticide;
 KM toxin; transgenic plant; insect resistance; crop protection;
 KM lectin; pFASTBAC1; ds.
 XX
 OS Chimeric - Ricinus communis.
 OS Chimeric - Baculovirus.
 XX
 PN WO200066755-A2.
 XX
 PD 09-NOV-2000.
 XX
 PR 27-APR-2000; 2000WO-GB01633.
 PD
 XX 28-APR-1999; 99GB-0009796.
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX
 PI Christou P, Mehlo L;
 PF

```

XX DR WPI; 2001-007228/01.
XX
XX PT Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
XX PT comprising a toxin and a binding domain for producing transgenic plants
XX PT resistant to pests
XX
XX PS Claim 10; Fig 3d; 81pp; English.
XX
XX CC The present sequence is that of ricin toxin B chain RTB2 DNA in
XX CC baculovirus transfer vector pFASTBAC1, in which the DNA was cloned
XX CC under the control of the polyhedrin promoter. The invention
XX CC provides nucleic acids (see AAA88919-24) encoding pesticidal fusion
XX CC proteins comprising a toxin domain and a heterologous binding domain
XX CC capable of binding non-specifically to a cell membrane without
XX CC disrupting that membrane. The toxin domain is preferably obtained
XX CC from Bacillus thuringiensis crystal proteins CryIA(b) or CryIA(c),
XX CC and the binding domain is preferably derived from a lectin, especially
XX CC ricin toxin B chain. The use of such fusions may help to inhibit
XX CC the acquisition of resistance in a pest population treated with the
XX CC protein. Vectors (e.g. baculovirus vectors or vectors suitable for
XX CC use in a plant), host cells, and transgenic plants (especially rice
XX CC or maize) are also provided. Expression of the fusion protein in a
XX CC plant is useful for influencing or affecting the toxicity of a
XX CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
XX CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
XX CC Orthoptera pests.
XX
XX SQ Sequence 860 BP; 256 A; 164 C; 199 G; 241 T; 0 other;
XX
XX Query Match 100.0%; Score 24; DB 22; Length 860;
XX Best Local Similarity 100.0%; Pred. No. 0.18; Mismatches 0; Gaps 0;
XX Matches 24; Conservative 0; Indels 0;
XX
QY 1 TATGATCCTCTAGTACTTCTGCAC 24
Db 855 TATGATCCTCTAGTACTTCTGCAC 832

```

```

XX PS Claim 10; Fig 3c; 81pp; English.
XX
XX CC The present sequence is that of ricin toxin B chain RTB1 DNA in
XX CC baculovirus transfer vector pFASTBAC1, in which the DNA was cloned
XX CC under the control of the polyhedrin promoter. The invention
XX CC provides nucleic acids (see AAA88919-24) encoding pesticidal fusion
XX CC proteins comprising a toxin domain and a heterologous binding domain
XX CC capable of binding non-specifically to a cell membrane without
XX CC disrupting that membrane. The toxin domain is preferably obtained
XX CC from Bacillus thuringiensis crystal proteins CryIA(b) or CryIA(c),
XX CC and the binding domain is preferably derived from a lectin, especially
XX CC ricin toxin B chain. The use of such fusions may help to inhibit
XX CC the acquisition of resistance in a pest population treated with the
XX CC protein. Vectors (e.g. baculovirus vectors or vectors suitable for
XX CC use in a plant), host cells, and transgenic plants (especially rice
XX CC or maize) are also provided. Expression of the fusion protein in a
XX CC plant is useful for influencing or affecting the toxicity of a
XX CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
XX CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
XX CC Orthoptera pests.
XX
XX SQ Sequence 956 BP; 286 A; 188 C; 214 G; 268 T; 0 other;
XX
XX Query Match 100.0%; Score 24; DB 22; Length 956;
XX Best Local Similarity 100.0%; Pred. No. 0.18; Mismatches 0; Gaps 0;
XX Matches 24; Conservative 0; Indels 0;
XX
QY 1 TATGATCCTCTAGTACTTCTGCAC 24
Db 951 TATGATCCTCTAGTACTTCTGCAC 928

```

RESULT 9
 ID AAI64290 standard; DNA; 1189 BP.
 AC AAI64290;
 DT 07-MAY-2002 (first entry)
 DE Protease D-G catalytic domain fusion gene construct encoding sequence.
 KW Serine protease; D-G; human; zymogen; enzyme; cytosolic;
 KW antiinflammatory; dermatological; anticoagulation; cancer;
 KW skin disorder; neuropathic pain; inflammatory disorder;
 KW coagulation diathesis; thrombosis; laundry detergent; skin care;
 KW gene therapy; gene; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 13..891
 FT /*tag= a
 FT /product= "protease D-G"
 FT /trns1_except= (pos: 640..642, aa: Gln)
 FT 13..93
 FT /*tag= b
 FT /note= "Prolactin signal sequence"
 FT mat_peptide 94..888
 FT /*tag= C
 FT /note= "Mature protease D-G"
 XX
 PN WO200202011-A1.
 PD 10-JAN-2002.
 XX
 PD 08-JUN-2001; 2001WO-US18568.
 XX
 PR 30-JUN-2000; 2000US-0607745.
 XX
 PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX

PI Darrow AL, Qi J, Andrade-Gordon P,
 XX WPI; 2002-106601/14.
 DR P-PSDB; AAG78578.
 XX
 PT Nucleic acid encoding a serine protease called D-G protein which is
 PT useful for identifying modulators that are useful for treating a
 PT condition which is mediated by protease D-G, e.g. cancer, skin
 PT disorders, or neuropathic pain -
 XX
 PS Claim 4; Fig 4B; 81pp; English.
 XX
 CC The invention relates to an isolated and purified nucleic acid that
 CC encodes a serine protease called D-G protein. The activity of the protein
 CC of the invention may be described as cytostatic, antiinflammatory,
 CC dermatological and anticocagulation. The serine protease of the invention
 CC is a member of the trypsin/chymotrypsin-like (S1) serine protease family,
 CC which play an important role in processes such as digestion and
 CC regulatory amplification cascades through the proteolytic activation of
 CC inactive zymogen precursors. Protease D-G modulating compounds are useful
 CC for treating a condition which is mediated by protease D-G, e.g. cancer,
 CC skin disorders, neuropathic pain, inflammatory disorders, or coagulation
 CC diathesis/thrombosis. The polynucleotide encoding the protease is useful
 CC for identifying, detecting or isolating mutant forms of DNA molecules
 CC encoding the protease. The protease is useful for identifying modulators
 CC of the functional protease. The D-G protein can be used for formulation
 CC of compositions for laundry detergents and skin care products. Protease
 CC D-G gene therapy may be used to introduce protease D-G into the cells of
 CC target organisms. As the D-G protein is derived from a human, it is less
 CC likely to produce an allergic reaction in sensitive individuals when used
 CC in formulations for laundry detergents and skin care products. The
 CC current sequence represents the protease D-G catalytic domain in the
 CC zymogen activation construct encoding sequence.
 XX
 SQ Sequence 1189 BP; 297 A; 305 C; 307 G; 280 T; 0 other;

Query Match 100.0%; Score 24; DB 24; Length 1189;
 Best Local Similarity 100.0%; Pred. No. 0.18;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATCCTCTAGTACTTCTCGAC 24
 ||||||||||||||||||||
 DB 1087 TATGATCCTCTAGTACTTCTCGAC 1064

RESULT 10
 AAH74721/C
 ID AAH74721 standard; DNA; 1430 BP.
 XX
 AC AAH74721;
 XX
 DT 29-OCT-2001 (first entry)
 XX
 DE Nucleotide sequence of a leech active polypeptide fragment.
 XX
 KW Active polypeptide; ectoparasitic leech; Rhynchobelliida; C3Bb complex;
 KW complement activation; complement factor D; haemodialysis; catheter;
 KW cardio-pulmonary bypass; extra-arterial stent; transplant rejection;
 KW autoimmune disease; lupus arthritis; rheumatoid arthritis; sepsis;
 KW glomerulonephritis; nephritis; nephropathy; reperfusion; anaphylaxis;
 KW asthma; skin reaction; infection; sickle cell anemia; haemolytic anemia;
 KW ds.
 XX
 XX Placodella papillifera.
 OS
 PN WO200147963-A2.
 XX
 PD 05-JUL-2001.
 XX
 PF 21-DEC-2000; 2000WO-GB04971.
 XX
 PR 24-DEC-1999; 99GB-0030659.
 XX

PA (BIOD-) BIO-DISCOVERY LTD.
 XX
 PI Finney S, Seale L, Wallis RB;
 XX WPI; 2001-522011/57.
 DR
 XX
 PT Novel polypeptides from the leech Placodella papillifera which inhibit
 PT alternate pathway of complement activation, useful for treating
 PT rheumatoid arthritis, sepsis, asthma involving alternate complement
 PT pathway -
 XX
 PS Claim 18; Page 53-54; 80pp; English.
 XX
 CC The present sequence encodes an active polypeptide fragment. The active
 CC polypeptide has a molecular weight of 7000-17,000 Da (as measured by
 CC mass spectrometry), and is derived from ectoparasitic leeches, of order
 CC Rhynchobelliida, of genus Placodella and especially of species
 CC P. papillifera. The polypeptide inhibits the alternate route of
 CC complement activation but has substantially no effect on complement
 CC activation by the classical route. The polypeptide is an inhibitor of
 CC complement factor D and/or C3Bb complex. The active polypeptide is
 CC useful for manufacturing a medicament and inhibits one or more steps
 CC in the alternate pathway of complement activation. It is useful for
 CC treating or preventing conditions, such as haemodialysis and
 CC cardio-pulmonary bypass, the presence of in-dwelling catheters and
 CC extra-arterial stents, rejection of transplanted organs or tissues,
 CC autoimmune diseases including lupus arthritis, rheumatoid arthritis,
 CC glomerulonephritis, nephritis, nephropathy, sepsis, injury caused to
 CC tissues by reperfusion after an ischaemic period and other conditions
 CC associated with activation of complement, including anaphylaxis,
 CC asthma, skin reactions, infections, sickle cell anemia and haemolytic
 CC anemia involving activation of alternate complement pathway in a
 CC patient.
 XX
 SQ Sequence 1430 BP; 419 A; 296 C; 296 G; 419 T; 0 other;

Query Match 100.0%; Score 24; DB 22; Length 1430;
 Best Local Similarity 100.0%; Pred. No. 0.18;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATCCTCTAGTACTTCTCGAC 24
 ||||||||||||||||||||
 DB 1126 TATGATCCTCTAGTACTTCTCGAC 1103

RESULT 11
 AAA88914/C
 ID AAA88914 standard; DNA; 2062 BP.
 XX
 AC AAA88914;
 XX
 DT 05-MAR-2001 (first entry)
 XX
 DE Nucleotide sequence of CRYIA(b) in PASTBAC1.
 XX
 KW CRYIA(b); crystal protein; insecticide; pesticide; toxin;
 KW transgenic plant; insect resistance; crop protection; PASTBAC1;
 KW ds.
 XX
 OS Chimeric - Bacillus thuringiensis.
 OS Chimeric - Baculovirus.
 OS
 FH Key Location/Qualifiers
 FT CDS 97..1944
 FT /*tag= a
 XX
 PN WO20006755-A2.
 XX
 PD 09-NOV-2000.
 XX
 PF 27-APR-2000; 2000WO-GB01633.
 XX
 PR 28-APR-1999; 99GB-0009796.
 XX

XX (PLAN-) PLANT BIOSCIENCE LTD.
 PA Christou P, Mehlo L;
 PI WPI; 2001-007228/01.
 XX Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 PT comprising a toxin and a binding domain for producing transgenic plants
 PT resistant to pests -
 PS Claim 9; Fig 3a; 81pp; English.
 CC The present sequence is that of *Bacillus thuringiensis* crystal
 CC protein CryIA(b) DNA in baculovirus transfer vector pFASTBAC1, in
 CC which the gene was cloned under the control of the polyhedrin
 CC promoter. The invention provides nucleic acids (see AAA88919-24)
 CC encoding pesticidal fusion proteins comprising a toxin domain and a
 CC heterologous binding domain capable of binding non-specifically to
 CC a cell membrane without disrupting that membrane. The toxin domain
 CC is preferably obtained from CryIA(b) or CryIA(c), and the binding
 CC domain is preferably derived from a lectin, such as ricin toxin B
 CC chain. The use of such fusions may help to inhibit the acquisition
 CC of resistance in a pest population treated with the protein.
 CC Vectors (e.g. baculovirus vectors or vectors suitable for use in a
 CC plant), host cells, and transgenic plants (especially rice or
 CC maize) are also provided. Expression of the fusion protein in a
 CC plant is useful for influencing or affecting the toxicity of a
 CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
 CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
 CC Orthoptera pests.
 SQ Sequence 2062 BP; 538 A; 552 C; 440 G; 532 T; 0 other;
 Query Match 100.0%; Score 24; DB 22; Length 2062;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 TATGATCCTTAGTACTTCTCGAC 24
 ||||||||||||||||||||
 Db 2057 TATGATCCTTAGTACTTCTCGAC 2034
 RESULT 12
 ID AAA88915/C
 AC AAA88915 standard; DNA; 2062 BP.
 XX AAA88915;
 AC
 DT 05-MAR-2001 (first entry)
 DE Nucleotide sequence of CryIA(c) in pFASTBAC1.
 XX
 KW CryIA(c); crystal protein; insecticide; pesticide; toxin;
 KW transgenic plant; insect resistance; crop protection; pFASTBAC1;
 KW ds.
 OS Chimeric - *Bacillus thuringiensis*.
 OS Chimeric - *Baculovirus*.
 OS
 FH Key Location/Qualifiers
 FT CDS 97..1944
 FT /*tag= a
 FT
 XX MO20006755-A2.
 PN
 PD 09-NOV-2000.
 PF 27-APR-2000; 2000WO-GB01633.
 XX
 PR 28-APR-1999; 99GB-0009796.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.

XX Christou P, Mehlo L;
 PI WPI; 2001-007228/01.
 XX Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 PT comprising a toxin and a binding domain for producing transgenic plants
 PT resistant to pests -
 PS Claim 9; Fig 3b; 81pp; English.
 CC The present sequence is that of *Bacillus thuringiensis* crystal
 CC protein CryIA(c) DNA in baculovirus transfer vector pFASTBAC1, in
 CC which the gene was cloned under the control of the polyhedrin
 CC promoter. The invention provides nucleic acids (see AAA88919-24)
 CC encoding pesticidal fusion proteins comprising a toxin domain and a
 CC heterologous binding domain capable of binding non-specifically to
 CC a cell membrane without disrupting that membrane. The toxin domain
 CC is preferably obtained from CryIA(b) or CryIA(c), and the binding
 CC domain is preferably derived from a lectin, such as ricin toxin B
 CC chain. The use of such fusions may help to inhibit the acquisition
 CC of resistance in a pest population treated with the protein.
 CC Vectors (e.g. baculovirus vectors or vectors suitable for use in a
 CC plant), host cells, and transgenic plants (especially rice or
 CC maize) are also provided. Expression of the fusion protein in a
 CC plant is useful for influencing or affecting the toxicity of a
 CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
 CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
 CC Orthoptera pests.
 SQ Sequence 2062 BP; 544 A; 532 C; 446 G; 540 T; 0 other;
 Query Match 100.0%; Score 24; DB 22; Length 2062;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 TATGATCCTTAGTACTTCTCGAC 24
 ||||||||||||||||||||
 Db 2057 TATGATCCTTAGTACTTCTCGAC 2034
 RESULT 13
 ID AAA88921/C
 AC AAA88921 standard; DNA; 2436 BP.
 XX AAA88921;
 AC
 DT 05-MAR-2001 (first entry)
 DE Nucleotide sequence of CryIA(b)-RTB3 fusion in pFASTBAC1.
 XX
 KW CryIA(b); crystal protein; ricin toxin B; RTB3; lectin;
 KW insecticide; pesticide; toxin; transgenic plant; insect resistance;
 KW crop protection; pFASTBAC1; ds.
 OS Chimeric - *Bacillus thuringiensis*.
 OS Chimeric - *Ricinus communis*.
 OS Chimeric - *Baculovirus*.
 OS
 FH Key Location/Qualifiers
 FT CDS 97..1944
 FT /*tag= a
 FT
 XX MO20006755-A2.
 PN
 PD 09-NOV-2000.
 PF 27-APR-2000; 2000WO-GB01633.
 XX
 PR 28-APR-1999; 99GB-0009796.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 PI Christou P, Mehlo L;
 DR WPI; 2001-007228/01.

PT	Novel nucleic acid molecule encoding a pesticidal fusion polypeptide comprising a toxin and a binding domain for producing transgenic plants resistant to pests
XX	
PS	Claim 11, Fig 3h; 81pp; English.
XX	
CC	This nucleotide sequence is that of a fusion between DNA encoding crystal protein CryIA(b) (see AA68914) of <i>Bacillus thuringiensis</i> and DNA encoding ricin toxin B RTB3 (see AA68918) in baculovirus transfer vector pFASTBAC1, in which the fusion was cloned under the control of the polyhedrin promoter. This is an example of claimed nucleic acids encoding pesticidal fusion proteins between a toxin domain and a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting that membrane. The use of such fusions may help to inhibit the acquisition of resistance in a pest population treated with the protein. Vectors (e.g. baculovirus vectors or vectors suitable for use in a plant), host cells, and transgenic plants (especially rice or maize) are also provided. Expression of the fusion protein in a plant is useful for influencing or affecting the toxicity of a plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera, Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and Orthoptera pests.
SQ	Sequence 2436 BP; 654 A; 617 C; 521 G; 644 T; 0 other;
OY	Query Match 100.0%; Score 24; DB 22; Length 2436; Best Local Similarity 100.0%; Pred. No. 0.19; Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DB	2431 TATGATCCTTAGTACTTGCGAC 2408 1 TATGATCCTTAGTACTTGCGAC 24
RESULT 14	
ID	AAA88924/C
XX	AAA88924 standard; DNA; 2436 BP.
XX	AAA88924;
XX	
DT	05-MAR-2001 (first entry)
XX	
DE	Nucleotide sequence of CryIA(c)-RTB3 fusion in pFASTBAC1.
KX	CryIA(c); crystal protein; ricin toxin B; RTB3; lectin;
KW	insecticide; pesticide; toxin; transgenic plant; insect resistance;
KV	crop protection; pFASTBAC1; de.
XX	
OS	Chimeric - <i>Bacillus thuringiensis</i> .
OS	Chimeric - Ricinus communis.
OS	Chimeric - Baculovirus.
XX	
PN	WO20006755-A2.
XX	
DD	09-NOV-2000.
XX	
PF	27-APR-2000; 2000WO-CBO1633.
XX	
PR	28-APR-1999; 99GB-0009796.
XX	
PA	(PLAN-) PLANT BIOSCIENCE LTD.
XX	
PI	Christou P, Mehlo L,
XX	
DR	WI, 2001-007228/O1.
PT	Novel nucleic acid molecule encoding a pesticidal fusion polypeptide comprising a toxin and a binding domain for producing transgenic plants resistant to pests
PT	-
PS	Claim 11, Fig 3k; 81pp; English.
XX	
CC	This nucleotide sequence is that of a fusion between DNA encoding

CC	crystalloprotein CryIA(c) (see AAA8915) of <i>Bacillus thuringiensis</i> and DNA encoding ricin toxin B RMB3 (see AAA8918) in baculovirus transfer vector pFASTBAC1, in which the fusion was cloned under the control of the polyhedrin promoter. This is an example of claimed nucleic acids encoding pesticidal fusion proteins between a toxin domain CC and a heterologous binding domain capable of binding non-specifically CC to a cell membrane without disrupting that membrane. The use of such CC e.g. lepidoptera, coleoptera, culicidae, stimuliidae, hymenoptera, CC Homoptera, Diptera and Orthoptera pests.
XX	
XX	
SQ	Sequence 2436 BP; 660 A; 597 C; 527 G; 652 T; 0 other;
Query March	100.0%; Score 24; DB 22; Length 2436;
Best Local Similarity	100.0%; Pred. NO. 0.19; 0; Indels 0; Gaps 0;
Matches 24; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
Dy	1 TATGATCCTCTAGACTTCTCGAC 24 2431 TATGATCCTCTAGACTTCTCGAC 2408
Db	
RESULT 15	
AAA8920/C	
ID	AAA8920 standard; DNA; 2692 BP.
XX	
AC	AAA8920;
XX	
DT	05-MAR-2001 (first entry)
XX	
DE	Nucleotide sequence of CryIA(b)-RTB2 fusion in pFASTBAC1.
XX	
KW	CryIA(b); crystal protein; ricin toxin B; RTB2; lectin; insecticide; pesticide; toxin; transgenic plant; insect resistance; crop protection; pFASTBAC1; ds.
XX	
OS	Chimeric - <i>Bacillus thuringiensis</i> .
OS	Chimeric - <i>Ricinus communis</i> .
OS	Chimeric - <i>Baculovirus</i> .
PN	M020006755-A2.
PD	09-NOV-2000.
XX	
XX	
FE	27-APR-2000; 2000MO-GB01633.
XX	
PR	28-APR-1999; 99GB-0009796.
XX	
PA	(PLAN-) PLANT BIOSCIENCE LTD.
XX	
P1	Christou P, Mehlo L;
XX	
DR	WPI; 2001-007228/01.
XX	
PT	Novel nucleic acid molecule encoding a pesticidal fusion polypeptide comprising a toxin and a binding domain for producing transgenic plants resistant to pests -
XX	
PS	Claim 11; Fig 3g; 81pp; English.
XX	
CC	This nucleotide sequence is that of a fusion between DNA encoding crystal protein CryIA(b) (see AAA8914) of <i>Bacillus thuringiensis</i> and DNA encoding ricin toxin B RMB2 (see AAA8917) in baculovirus transfer vector pFASTBAC1, in which the fusion was cloned under the control of the polyhedrin promoter. This is an example of claimed nucleic acids encoding pesticidal fusion proteins between a toxin domain CC and a heterologous binding domain capable of binding non-specifically CC to a cell membrane without disrupting that membrane. The use of such

CC fusions may help to inhibit the acquisition of resistance in a pest
 CC population treated with the protein. Vectors (e.g. baculovirus
 CC vectors or vectors suitable for use in a plant), host cells, and
 CC transgenic plants (especially rice or maize) are also provided.
 CC Expression of the fusion protein in a plant is useful for influencing
 CC or affecting the toxicity of a plant to a pest, allowing control of
 CC e.g. Lepidoptera, Coleoptera, Culicidae, Simuliidae, Hymenoptera,
 CC Homoptera, Diptera and Orthoptera pests.

XX
 SO Sequence 2692 BP; 730 A; 660 C; 586 G; 716 T; 0 other;

Query Match 100.0%; Score 24; DB 22; Length 2692;

Best Local Similarity 100.0%; Pred. No. 0.2;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCTCTAGTACTTCTCGAC 24
 |||||
 Db 2687 TATGATCTCTAGTACTTCTCGAC 2664

Search completed: February 16, 2004, 09:18:11
 Job time : 12.7756 secs

mis Page Blank (uspio)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 ; Search time 93.2277 Seconds

(without alignments)
6256.802 Million cell updates/sec

Title: US-10-676-079-5

Sequence: 1 tatgatccctctagctctcgac 24

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 22781392 seqs, 1215238056 residues

Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

EST:*
1: em_estbda:*
2: em_estbhm:*
3: em_estbin:*
4: em_estbvu:*
5: em_estbvw:*
6: em_estbpl:*
7: em_estbro:*
8: em_estbrc:*
9: gb_estcl:*
10: gb_estc2:*
11: gb_estc3:*
12: gb_estc4:*
13: gb_estc5:*
14: gb_estfun:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rtd:*
26: em_gss_phg:*
27: em_gss_vrt:*
28: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	19.2	80.0	820	13	BU371267 603596334
2	18.8	78.3	293	12	BI024729 RCS-MT025
3	18.8	78.3	389	26	AO105178 HS-3000 A
4	18.4	76.7	749	28	AZ805647 2M067G12

Result No.	Score	Query Match	Length	ID	Description
5	18.2	75.8	491	28	AQ502165 VB81 mtn-A
6	18.2	75.8	566	29	AA660276 00145 MCR
7	18.2	75.8	600	29	B2309602 iC09C08.b
8	18.2	75.8	600	29	B2324410 iC09C08.g
9	18.2	75.8	608	28	AQ305217
10	18.2	75.8	608	28	BH022001
11	18.2	75.8	737	14	CA781659 031G1AF
12	18.2	75.8	741	29	B2506781
13	18.2	75.8	799	29	BZ998034
14	18.2	75.8	815	28	AQ862478
15	18.2	75.8	1661	29	B2576392
16	17.8	74.2	484	9	AM573112
17	17.6	73.3	195	9	AM037530
18	17.6	73.3	327	14	CB891487
19	17.6	73.3	493	9	A1083079
20	17.6	73.3	504	9	A1397571
21	17.6	73.3	533	28	AZ750886
22	17.6	73.3	572	28	BH877505
23	17.6	73.3	609	10	BF643933
24	17.6	73.3	621	10	BE460948
25	17.6	73.3	640	10	BG449733
26	17.6	73.3	645	9	AM586847
27	17.6	73.3	655	10	BF646400
28	17.6	73.3	659	13	BQ147235
29	17.6	73.3	695	9	AV403040
30	17.6	73.3	695	12	BP126081
31	17.6	73.3	704	9	AV404024
32	17.6	73.3	740	10	BG581848
33	17.6	73.3	792	14	CB984130
34	17.6	73.3	1213	29	CC225588
35	17.4	72.5	415	28	AQ556970
36	17.4	72.5	521	29	B251578
37	17.4	72.5	728	28	BH995266
38	17.2	71.7	125	12	BG945612
39	17.2	71.7	164	10	BF859022
40	17.2	71.7	188	9	AM064152
41	17.2	71.7	201	13	BH890760
42	17.2	71.7	235	10	BF858704
43	17.2	71.7	252	10	BF954669
44	17.2	71.7	297	10	BF753157
45	17.2	71.7	378	9	AM181442

ALIGNMENTS

RESULT 1
BU371267
LOCUS
DEFINITION
603596334F1 CSEQCHN73 Gallus gallus CDNA clone CHEST564c9 5', mRNA
ACCESSION
BU371267.1 GI:25879268
VERSION
KEYWORDS
SOURCE
ORGANISM
Gallus gallus (chicken)
REFERENCE
AUTHORS
BOARDMAN, P.E., SANZ-EZQUERRO, J., OVERTON, I.M., BURR, D.W., BOSCH, E.,
FONG, W.T., TICKLE, C., BROWN, W.R.A., WILSON, S.A. and HUBBARD, S.J.
TITLE
A Comprehensive Collection of Chicken cDNAs
JOURNAL
CURR. BIOL. 12 (22), 1965-1969 (2002)
MEDLINE
PUBMED
12445392
COMMENT
Contact: Simon Hubbard
Department of Biomolecular Sciences
University of Manchester Institute of Science and Technology (UMIST)
PO Box 88, Manchester, M60 1OD, UK
Tel: 0161208930
Fax: 01612360409

Email: Simon.Hubbard@unist.ac.uk.
Location/Qualifiers

FEATURES

source

```
1..820
/organism="Gallus gallus"
/mol_type="mRNA"
/strain="Compton Line 151"
/db_xref="taxon:9031"
/clone="ChEST564c9"
/sex="Female"
/tissue_type="not cerebrum or cerebellum"
/dev_stage="adult"
/lab_host="DH10B"
/clone.lib="CSECHN73"
/note="Organ: Brain; Vector: pBluescript II KS(+); Site_1:
EcoRI; Site_2: NotI; This normalized library was
constructed from 1 million independent clones. cDNA
synthesis was initiated using an oligo(dT) primer, using
methylated C in the first strand synthesis reaction.
Following this first strand reaction, double-stranded cDNA
was blunt-ended, ligated to NotI adapters, digested with EcoRI
, size-selected, and cloned into the NotI and EcoRI
compatible sites of a custom modified MCS of the
pBluescript (KS+) vector. The library was normalized in 2
rounds using conditions adapted from Soares et al., PNAS
(1996) 91: 9228-9232 and Bonaldo et al., Genome Research 6
(1996): 791, except that a significantly longer
reannealing hybridization was used."
```

BASE COUNT

204 a 246 c 171 g 199 t

ORIGIN

Query Match

Best Local Similarity 87.5%; Score 19.2; DB 13; Length 820;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY

1 TATGATCCTAGTACTTCTCGAC 24

Db 381 TATGCTTCTACTTCTCTCGAC 404

RESULT 2

BI024729

LOCUS RCS-MT0259-300101-012-G04 MT0259 Homo sapiens CDNA, mRNA sequence.

ACCESSION BI024729

VERSION BI024729.1 GI:14431359

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

AUTHORS

Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Briones, M.R.,
Nagai, M.A., da Silva, W.J., Zago, M.A., Bordin, S., Costa, F.F.,
Goldman, G.H., Carvalho, A.F., Matukuma, A., Bala, S., Simpson, D.H.,
Brunstein, A., de Oliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare,
M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.V. and
Simpson, A.J.

Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags

Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)

JOURNAL

MEDLINE

PUBMED

COMMENT

10737800

Contact: Simpson A.J.G.

Laboratory of Cancer Genetics

Ludwig Institute for Cancer Research

Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil

Tel: +55-11-2704922

Fax: +55-11-2707001

Email: asimpson@ludwig.org.br

This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?l=RC5&t2=RC5-MT0259-

300101-012-G04&t3=2001-01-30&t4=1)
Seq primer: puc 18 forward
High quality sequence start: 293.
High quality sequence stop: 293.
Location/Qualifiers

FEATURES

source

```
1..293
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/dev_stage="Adult"
/clone.lib="MT0259"
/note="Organ: marrow; Vector: puc18; Site_1: SmaI; Site_2:
SmaI; A mini-library was made by cloning products derived
from ORESTES PCR (U.S. Letters Patent Application No. 196
,716 - Ludwig Institute for Cancer Research) profiles
into the puc 18 vector. Reverse transcription of tissue
mRNA and cDNA amplification were performed under low
stringency conditions."
```

BASE COUNT

70 a 76 c 73 g 74 t

ORIGIN

Query Match

Best Local Similarity 90.9%; Score 18.8; DB 12; Length 293;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

2 ATGATCCTAGTACTTCTCGA 23

Db 6 ACGTTCCTAGTACTTCTCGA 27

RESULT 3

AQ105178/c

LOCUS HS_3000_A1_H12_MR_CIT Approved Human Genomic Sperm Library D Homo
sapiens genomic clone Plate=3000 Col=23 Row=0, genomic survey
sequence.

ACCESSION AQ105178

VERSION AQ105178.1 GI:3480534

KEYWORDS GSS.

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

AUTHORS

Maniatis, G.G., Wallace, J.C., Smith, K., Swartzell, S., Holzman, T.,
Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and
Hood, L.

Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome

Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)

JOURNAL

MEDLINE

PUBMED

COMMENT

10449764

Contact: Maniatis GG, Wallace JC, Hood L

High Throughput Sequencing Center

University of Washington

401 Queen Anne Avenue North, Seattle, WA 98109, USA

Tel: (206) 616-3618

Fax: (206) 616-3887

Email: jwallace@u.washington.edu

Sequence Tagged Connector

Plate: 3000 Row: 0 Column: 23
Class: BAC ends
High quality sequence stop: 389.
Location/Qualifiers

FEATURES

source

```
1..389
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="Plate=3000 Col=23 Row=0"
/sex="male"
/note="Organ: sperm; Vector: pBeloBAC11; BAC clones in  
E-Coli DH10B"
```

BASE COUNT 122 a 67 c 81 g 108 t 11 others
ORIGIN

Query Match 76.3%; Score 18.8; DB 28; Length 389;
Best Local Similarity 90.9%; Pred. No. 5.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 ATGATCCTCTAGTACTTCTGCA 23
|||||
Db 194 ATGATCTTCTAGTACTTCTCTA 173

RESULT 4
AZ805647/c 749 bp DNA linear GSS 20-FEB-2001
LOCUS 2M067G12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC2M0067G12 F, genomic survey sequence.
ACCESSION AZ805647
VERSION AZ805647.1 GI:12966458
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 749)
REFERENCE Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
'M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausen, A.
and Wright, D., Weis, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
TITLE Unpublished
JOURNAL Contact: Robert B. Weiss
COMMENT University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0067 row: G column: 12
Seq primer: CGTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 749.
Location/Qualifiers
1..749
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="CS7BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0067G12"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus CS7BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells

BASE COUNT 211 a 203 c 144 g 191 t
ORIGIN and selected for ampicillin resistance."

Query Match 76.7%; Score 18.4; DB 28; Length 749;
Best Local Similarity 95.0%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCT 20
|||||
Db 529 TCTGATCCTCTAGTACTTCT 510

RESULT 5
AO502165 491 bp DNA linear GSS 29-APR-1999
LOCUS V881 mtm-3xHA/lacZ insertion library Saccharomyces cerevisiae
DEFINITION genomic 5', genomic survey sequence.
ACCESSION AO502165
VERSION AO502165.1 GI:4707815
KEYWORDS GSS.
SOURCE Saccharomyces cerevisiae (baker's yeast)
ORGANISM Saccharomyces cerevisiae
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetaceae; Saccharomycetaceae; Saccharomycetes.
1 (bases 1 to 491)
REFERENCE Ross-Wadonald, P., Roemer, T., Coelho, P. S. R., Agarwal, S., Kumar, A.,
desRozes, S. A., Cheung, K. H., Sheehan, A., Symoniatas, D., Jansen, R.,
Umansky, L., Heldman, M., Nelson, K., Iwasaki, H., Kanada, D., Lugo, R.,
Hager, K., Miller, P., Roeder, G. S. and Snyder, M.
Large-scale analysis of the Yeast Genome by Transposon Tagging and
Gene Disruption
TITLE Unpublished
JOURNAL Contact: Kumar A
COMMENT Michael Snyder, Dept. of Mol. Cell. and Dev. Biology
Yale University
P.O. Box 208103, New Haven, CT 06520-8103, USA
Tel: 203 432 9949
Fax: 203 432 6161
Email: anuj.kumar@yale.edu
te of mtm-3xHA/lacZ insertion.
Seq primer: GGCTTCTTCTTGTGGAAGTAC
Class: transposon-tagged.
Location/Qualifiers
1..491
/organism="Saccharomyces cerevisiae"
/mol_type="genomic DNA"
/db_xref="taxon:4932"
/lab_host="E. coli"
/clone.lib="mtm-3xHA/lacZ insertion library"
/note="Vector: pHS56-Sal; A yeast genomic DNA library
(lacking mitochondrial DNA) was prepared in pHS56-Sal;
genomic DNA was size-fractionated (DNA of roughly 2-3 kb
in length) prior to cloning. This library was
subsequently mutagenized with a mtm-3xHA/lacZ
minitransposon containing lacZ, URA3, and tect resistance."
BASE COUNT 125 a 127 c 119 g 116 t 4 others
ORIGIN

Query Match 75.8%; Score 18.2; DB 28; Length 491;
Best Local Similarity 87.0%; Pred. No. 1.1e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 ATGATCCTCTAGTACTTCTGAC 24
|||||
Db 107 ATGATCCTCTTGTACTTGTCTAC 129

RESULT 6
AA660276/c 566 bp mRNA linear EST 08-MAR-2000
LOCUS AA660276
DEFINITION 00145 MCRHE Medicago truncatula cDNA 5' similar to retinoblastoma
binding protein p46, mRNA sequence.

ACCESSION AA660276
 VERSION AA660276.1 GI:2604320
 KEYWORDS EST.
 SOURCE Medicago truncatula
 ORGANISM Medicago truncatula (barrel medic)
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicot; rosids; eurosid I; Fabales; Fabaceae; Papilionoideae; Trifoliaceae; Medicago.
 REFERENCE 1 (bases 1 to 566)
 AUTHORS Covitz, P.A., Smith, L.S. and Long, S.R.
 TITLE Expressed sequence tags from a root-hair-enriched medicago truncatula cDNA library
 JOURNAL Plant Physiol. 117 (4), 1325-1332 (1998)
 COMMENT Contact: Long SR
 Department of Biological Sciences and Howard Hughes Medical Institute
 Stanford University
 Gilbert Biology, Stanford, CA 94305-5020, USA
 Tel: 650 723 3232
 Fax: 650 725 8309
 Email: fa.srl@forssythe.stanford.edu
 Seq primer: 73.
 FEATURES
 source
 location/Qualifiers
 1..566
 /organism="Medicago truncatula"
 /mol_type="mRNA"
 /culturvar="Jemalong"
 /db_xref="taxon:3880"
 /tissue_type="Root hairs & tips"
 /dev_stage="2-3 day old seedlings"
 /clone_lib="MERIE"
 /note="Organ: Root; Vector: PBK-CMV; Site 1: EcoRI; Site 2: XhoI; cDNA was synthesized from a pooled mRNA prep from elongating root hairs (30% w/w) and 2-3cm root tips (70% w/w). XhoI-oligo-dT linker-primer and EcoRI adaptors were used. cDNAs were cloned unidirectionally into Lambda ZAP Express (Stratagene), amplified, and mass-excised into PBK-CMV vector plasmids. More information is available at http://bio-sr18.stanford.edu."
 BASE COUNT 178 a 121 c 135 g 127 t 5 others
 ORIGIN
 Query Match 75.8%; Score 18.2; DB 9; Length 566;
 Best Local Similarity 83.3%; Pred. No. 1.2e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Oy 1 TATGATCCTTAGTACTTCTGCAC 24
 Db 496 TATGATAGCTTGACTTCTTGAC 473
 RESULT 7
 LOCUS BZ309602 600 bp DNA linear GSS 06-NOV-2002
 DEFINITION ic09c08.b1 WGS-ZmayrF (JM107 adapted methyl filtered) Zea mays
 ACCESSION BZ309602
 VERSION BZ309602.1 GI:24670634
 KEYWORDS GSS.
 SOURCE Zea mays
 ORGANISM Zea mays
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD clade; Panicoideae; Andropogoneae; Zea.
 REFERENCE 1 (bases 1 to 600)
 AUTHORS Rabinowicz, P.D., O'Shaughnessy, A.L., Balija, V., Dedhia, N., Katzenburger, F., King, L., Miller, B., Muller, S., Nascimento, L., Zuberav, T., McCombie, W.R. and Martienssen, R.A.
 TITLE Genomic shotgun sequences from Zea mays (methyl-filtered)
 JOURNAL Unpublished
 COMMENT Contact: W. Richard McCombie
 Lita Annenberg Hazen Genome Sequencing Center

Cold Spring Harbor Laboratory
 PO Box 100, Cold Spring Harbor, NY 11724, USA
 Tel: 516 367 8884
 Fax: 516 367 8874
 Email: mcombie@cshl.org
 Plate: ic09 row: C column: 08
 Seq primer: -21M13UnivFwd
 Classes: shotgun
 High quality sequence stop: 610.
 FEATURES
 source
 location/Qualifiers
 1..600
 /organism="Zea mays"
 /mol_type="genomic DNA"
 /culturvar="B73"
 /db_xref="taxon:4577"
 /clone="ic09c08"
 /lab_host="JM107 or DH5a"
 /clone_lib="WGS-ZmayrF (JM107 adapted methyl filtered)"
 /note="Organ: Immature ears; Site_1: Xba I; Site_2: Xba I. The vector was digested with XbaI and one nucleotide was added by fill in in the recessive 3' end. The genomic DNA was nebulized, end repaired, adaptor ligated and size fractionated using sephdex. The resulting fragments were between 0.8 and 3 kb and were cloned into the vector (X/Y reads in M13mp19, B/G reads in pUC19). The same ligation was transformed in either JM107 or DH5a."
 BASE COUNT 175 a 102 c 134 g 188 t 1 others
 ORIGIN
 Query Match 75.8%; Score 18.2; DB 29; Length 600;
 Best Local Similarity 87.0%; Pred. No. 1.2e+03;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 1 TATGATCCTTAGTACTTCTGCA 23
 Db 414 TATATCCTTAGTACTTCAACA 436
 RESULT 8
 LOCUS BZ324410/c 600 bp DNA linear GSS 06-NOV-2002
 DEFINITION ic09c08.g1 WGS-ZmayrF (JM107 adapted methyl filtered) Zea mays
 ACCESSION BZ324410
 VERSION BZ324410.1 GI:24703958
 KEYWORDS GSS.
 SOURCE Zea mays
 ORGANISM Zea mays
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD clade; Panicoideae; Andropogoneae; Zea.
 REFERENCE 1 (bases 1 to 600)
 AUTHORS Rabinowicz, P.D., O'Shaughnessy, A.L., Balija, V., Dedhia, N., Katzenburger, F., King, L., Miller, B., Muller, S., Nascimento, L., Zuberav, T., McCombie, W.R. and Martienssen, R.A.
 TITLE Genomic shotgun sequences from Zea mays (methyl-filtered)
 JOURNAL Unpublished
 COMMENT Contact: W. Richard McCombie
 Lita Annenberg Hazen Genome Sequencing Center
 Cold Spring Harbor Laboratory
 PO Box 100, Cold Spring Harbor, NY 11724, USA
 Tel: 516 367 8884
 Fax: 516 367 8874
 Email: mcombie@cshl.org
 Plate: ic09 row: C column: 08
 Seq primer: -21M13UnivRev
 Classes: shotgun
 High quality sequence stop: 613.
 FEATURES
 source
 location/Qualifiers
 1..600
 /organism="Zea mays"
 /mol_type="genomic DNA"
 /culturvar="B73"

```

/db xref="taxon:4577"
/clone="iG09c08"
/lab host="JM107 or DH5a"
/clone_lib="MGS-zmayrF (JM107 adapted methyl filtered)"
/notes="Organ: Immature ears; Site_1: Xba I; Site_2: Xba I;
The vector was digested with XbaI and one nucleotide was
added by fill in in the recessive 3' end. The genomic DNA
was nebulized, end repaired, adaptor ligated and size
fractionated using sephadex. The resulting fragments were
between 0.8 and 3 kb and were cloned into the vector
(.x/y reads in M13mp19, .b/g reads in pUC19). The same
ligation was transformed in either JM107 or DH5a."
BASE COUNT      187 a      135 c      102 g      176 t
ORIGIN
Query Match      75.8%; Score 18.2; DB 29; Length 600;
Best Local Similarity 87.0%; Pred. No. 1.2e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1 TATGATCCTCTAGTACTTCTCGA 23
Db      188 TAAATCTCTTAGTACTTCTCACGA 166

RESULT 9
AQ05217/c      608 bp      DNA      linear      GSS 16-DEC-1998
LOCUS
DEFINITION
H5_2019_A2_D07_T7 CIT Approved Human Genomic Sperm Library D Homo
sapiens genomic clone Plate=2019 Col=14 Row=G, genomic survey
sequence.
ACCESSION
AQ05217.
VERSION
AQ05217.1 GI:4025003
KEYWORDS
GSS.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 608)
Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and
Hood, L.
Title
Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
Proc. Natl. Acad. Sci. U.S.A. 96 (117), 9739-9744 (1999)
JOURNALS
MEDLINE
99380589
PUBMED
10449764
COMMENT
Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Sequence Tagged Connector
Plate: 2019 row: G column: 14
Class: BAC ends
High quality sequence stop: 608.
Location/Qualifiers
1. 608
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="Plate=2019 Col=14 Row=G"
/sex="male"
/clone_lib="CIT Approved Human Genomic Sperm Library D"
/notes="Organ: sperm; Vector: pELOBAC11; BAC Clones in
E-Coli DH108"
BASE COUNT      168 a      150 c      136 g      140 t      14 others
ORIGIN
Query Match      75.8%; Score 18.2; DB 28; Length 608;
Best Local Similarity 87.0%; Pred. No. 1.2e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

Oy      2 ATGATCCTCTAGTACTTCTCGAC 24
Db      236 ATATCTCTCTGAGTACTTCTCACGAC 214

RESULT 10
BH022001
LOCUS
DEFINITION
GH_MBB0001P10F Gossypium hirsutum L. Gossypium hirsutum genomic
clone GH_MBB0001P10F, genomic survey sequence.
ACCESSION
BH022001
VERSION
BH022001.1 GI:14576289
KEYWORDS
GSS.
SOURCE
Gossypium hirsutum (upland cotton)
ORGANISM
Gossypium hirsutum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids
; eurosids II; Malvales; Malvaceae; Malvaceae; Malvaceae; Gossypium.
1 (bases 1 to 609)
Tomkins, J.P., Peterson, D.G., Yang, T.J., Main, D., Wilkins, T.A.,
Paterson, A.H. and Wing, R.A.
Development of Genomic Resources for Cotton (Gossypium hirsutum
L.): BAC Library Construction, Preliminary STC Analysis, and
Identification of Clones Associated with Fiber Development
Unpublished
Contact: Wing RA
Clemson University Genomics Institute
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: rwing@clemson.edu
Seq primer: TATATGATCCTCTAGTACTTCTCGG
Class: BAC ends
High quality sequence start: 4
High quality sequence stop: 230.
Location/Qualifiers
1. 609
/organism="Gossypium hirsutum"
/mol_type="genomic DNA"
/cultivar="Maxxa"
/db_xref="taxon:3635"
/clone="GH_MBB0001P10F"
/tissue_type="Young leaves"
/lab_host="B. coli"
/clone_lib="Gossypium hirsutum L."
/notes="Vector: pCUGIBAC-1; Site_1: HindIII; Site_2: NotI;
For more details on library preparation, ordering clones
and sequence analysis see
http://www.genome.clemson.edu/projects/stc/cotton/GH_Mbb "
BASE COUNT      152 a      156 c      81 g      220 t
ORIGIN
Query Match      75.8%; Score 18.2; DB 28; Length 609;
Best Local Similarity 87.0%; Pred. No. 1.2e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1 TATGATCCTCTAGTACTTCTCGA 23
Db      390 TACGACCTCTAGTACTTCTCTA 412

RESULT 11
CA781659
LOCUS
DEFINITION
03IG11AF Infected Arabidopsis Leaf Arabidopsis thaliana cDNA, mRNA
sequence.
ACCESSION
CA781659
VERSION
CA781659.1 GI:26019692
KEYWORDS
EST.
SOURCE
Arabidopsis thaliana (thale cress)
ORGANISM
Arabidopsis thaliana

```

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; euroside II; Brassicales; Brassicaceae; Arabidopsids.

1 (bases 1 to 737)
Lundsgaard, M., Emmersen, J., Nielsen, K.L., Wilson, I., Somerville, S. and Weidner, K.G.

EST sequencing of Erysiphe cichoracearum infected Arabidopsis plants

JOURNAL
COMMENT
Contact: Karen G. Weidner
Institute for biotechnology
Aalborg University
Søhngårdsallévej 49, 9000 Aalborg, Denmark
Tel: +45 96358467
Fax: +45 98141808
Email: kgw@bio.auc.dk.

FEATURES
source
1..737
/organism="Arabidopsis thaliana"
/mol_type="rRNA"
/strain="Columbia"
/db_xref="taxon:3702"
/dev_stage="plant 3 weeks old, three days post infection"
/clone_lib="infected Arabidopsis leaf"
/note="Organ: Leaf; Vector: pBluescript; Mixed cDNA library of Arabidopsis and E. cichoracearum infected leaf from three weeks old Arabidopsis plants. Plants were harvested 3 days after infection and mRNA oligo dt selected."

BASE COUNT
204 a 137 c 156 g 240 t
ORIGIN

Query Match
Best Local Similarity 87.0%; Score 18.2; DB 14; Length 737;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGACTTCTCGA 23
Db 668 TATGATCATCAAGTACTTCTTGA 690

RESULT 12
B2506781 741 bp DNA linear GSS 16-DEC-2002
LOCUS BONFA77TF BO.1.6.2 KB tot Brassica oleracea genomic clone BONFA77,
DEFINITION genomic survey sequence.
ACCESSION B2506781 GI:27028149
VERSION B2506781.1 GI:27028149
KEYWORDS GSS.
SOURCE Brassica oleracea
ORGANISM Brassica oleracea
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; euroside II; Brassicales; Brassicaceae; Brassica.

1 (bases 1 to 741)
Town, C.D., Van Aken, S., Utterback, T., Koo, H. and Fraser, C.M.

Whole genome shotgun sequencing of Brassica oleracea
Unpublished
Other GSSs: BONFA77TR
Contact: Chris Town
TIGR
9712 Medical Center Drive, Rockville, MD 20850, USA.
Tel: 301-838-3523
Fax: 301-838-0208
Email: cdtown@tigr.org
DNA is from a doubled haploid provided by Tom Osborn.
Seq primer: TP
Class: sheared ends.

FEATURES
source
1..741
/organism="Brassica oleracea"
/mol_type="genomic DNA"
/strain="TO1000DH3"

/db_xref="taxon:3712"
/clone="BONFA77"
/clone_lib="BO.1.6.2 KB tot"
/note="Vector: pHD51; Site 1: BstXI; 1.6-2 kb sheared total DNA inserted into pHD51 using BstXI linkers"

BASE COUNT
273 a 122 c 115 g 231 t
ORIGIN

Query Match
Best Local Similarity 87.0%; Score 18.2; DB 29; Length 741;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGACTTCTCGA 23
Db 276 TATGATCATCTAGACTTCTTGA 298

RESULT 13
B2998034 799 bp DNA linear GSS 25-MAR-2003
LOCUS PUGFY17TD ZM.0.6.1.0 KB zea mays genomic clone ZMMB7A375D09,
DEFINITION genomic survey sequence.
ACCESSION B2998034 GI:29241451
VERSION B2998034.1 GI:29241451
KEYWORDS GSS.
SOURCE Zea mays
ORGANISM Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; liliopsida; Poales; Poaceae; PACCAD clade; Panicoideae; Andropogoneae; Zea.

1 (bases 1 to 799)
White, C.A., Quackenbush, J., Van Aken, S., Utterback, T., Resnick

A., Fraser, C.M., Yuan, Y., San Miguel, P., Ma, J. and Bennett, J.
Maize Genomics Consortium
Unpublished
Other GSSs: PUGFY17B
Contact: Cathy White
TIGR
9712 Medical Center Drive, Rockville, MD 20850, USA
Tel: 301-838-5843
Fax: 301-838-0208
Email: whitec@tigr.org
Seq primer: TP
Class: sheared ends.

FEATURES
source
1..799
/organism="Zea mays"
/mol_type="genomic DNA"
/strain="B73"
/db_xref="taxon:4577"
/clone="ZMMB7A375D09"
/clone_lib="ZM.0.6.1.0 KB"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; 0.6-1.0 kb high COT selected genomic DNA library"

BASE COUNT
215 a 142 c 181 g 261 t
ORIGIN

Query Match
Best Local Similarity 87.0%; Score 18.2; DB 29; Length 799;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGACTTCTCGA 23
Db 528 TAATATCCTCTAGACTTCTTGA 550

RESULT 14
AO862478 815 bp DNA linear GSS 03-NOV-1999
LOCUS nbeb0019A21f CUGI Rice BAC Library (ECORI) Oryza sativa (japonica
DEFINITION cultivar-group) genomic clone nbeb0019A21f, genomic survey
sequence.
ACCESSION AO862478

VERSION	AOB62478.1	GI:6212935
KEYWORDS	GSS.	
SOURCE	Oryza sativa (japonica cultivar-group)	
ORGANISM	Oryza sativa (japonica cultivar-group)	
	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;	
	Spermatophytes; Magnoliophyta; Liliopsida; Poales; Poaceae;	
	Ehretidoideae; Oryzoae; Oryza.	
REFERENCE	1 (bases 1 to 815)	
AUTHORS	Wing,R.A. and Dean,R.A.	
TITLE	A BAC End Sequencing Framework to Sequence the Rice Genome	
JOURNAL	Unpublished	
COMMENT	Contact: Wing RA Clemson University Genomics Institute Clemson University 100 Jordan Hall, Clemson, SC 29634, USA Tel: 864 656 7288 Fax: 864 656 4293 Email: rtwing@clemson.edu Seq primer: TATATCGACTCATATAGG Class: BAC ends High quality sequence start: 46 High quality sequence stop: 279. Location/Qualifiers	
FEATURES	1..815	
source	/organism="Oryza sativa (japonica cultivar-group)" /mol_type="genomic DNA" /strain="japonica" /cultivar="Nipponbare" /db_xref="taxon:39947" /clone="nbeb0019A21f" /issue_type="leaf" /lab_host="E. coli DH10B" /clone_id="CUGI Rice BAC library (ECORI)" /note="Vector: pBACindigo; Site 1: EcoRI; Site 2: EcoRI; Rice is the most important food crop in the world. Half of the world population, especially those inhabiting highly populated areas of the humid tropics and subtropics, rely on rice as their primary source of carbohydrate. Monocotyledonous rice is a diploid plant (2n=24) with a haploid genome equivalent of 431 Mbp (Arumuganathan and Earle, 1991). The relatively small genome of rice, three times larger than that of Arabidopsis, makes it suitable for genomic studies. In order to facilitate positional cloning, physical mapping and genome sequencing of rice, we have constructed a BAC library from Oryza sativa, Nipponbare variety using EcoRI as the cloning enzyme. The library contains 55,296 clones with an average insert size of 121 kb providing approximately 15 haploid genome equivalents. The deep coverage allows the isolation a particular sequence with a probability of 99.9%. Three high density filters, each containing 18,432 clones (doubly spotted), represent the whole library for colony screening and can be requested from the Clemson University BAC/EST Resource Center (www.genome.clemson.edu)."	
BASE COUNT	215 a 213 c 84 g 298 t	5 others
ORIGIN	Query Match 75.8%; Score 18.2; DB 28; Length 815; Best Local Similarity 87.0%; Pred. No. 1.4e-03; Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0; 1 TATGATCTCTAGTACTTTCGA 23 Db 789 TATATCTCTTAATFACTTCTCTA 811	
RESULT 15	BZ576392	1661 bp DNA linear GSS 17-DEC-2002
LOCUS	BZ576392	
DEFINITION	mh2_4912.Y2 msh Pseudomonas aeruginosa genomic clone mh2_4912, genomic survey sequence.	
ACCESSION	BZ576392	GI:27211453
VERSION	BZ576392.1	GI:27211453

```

KEYWORDS      GSS.
SOURCE        Pseudomonas aeruginosa
ORGANISM      Pseudomonas aeruginosa
REFERENCE     1 (bases 1 to 1661)
AUTHORS       Spencer,D.H., Raymond,C.K., Smith,E.E., Sims,E.E., Hastings,M.,
              Burns,J.L., Kaul,R. and Olsen,M.V.
TITLE         Whole-Genome-Sequence variation among multiple isolates of
              Pseudomonas aeruginosa library
JOURNAL       J. Bacteriol., (2002) In press
COMMENT       Contact: Chris K. Raymond
              Genome Center
              University of Washington
              Box 352145, Seattle, WA 98105-2145, USA
              Tel: 2062216954
              Fax: 2066857244
              Email: craymond@u.washington.edu
              Class: shotgun.
FEATURES
  source      1..1661
              location/Qualifiers
              /organism="Pseudomonas aeruginosa"
              /mol_type="genomic DNA"
              /strain="M5H"
              /db_xref="taxon:287"
              /clone="msh2_4912"
              /clone_1id="msh"
              /note="Environmental isolate. Whole genomic shotgun
              library."
BASE COUNT    340 a      434 c      265 g      618 t      4 others
ORIGIN
Query Match   75.8%, Score 18.2; DB 29; Length 1661;
Best Local Similarity 87.0%; Pred. No. 1.9e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0,
OY            2 ATGATCTCTAGACTTCTCGAC 24
              ||||||| |||||||
Db            656 ATCATCTCTCTACTTCTCGAC 678

```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 114.587 Seconds

(without alignments)
8568.399 Million cell updates/sec

Title: US-10-676-079-5

Perfect score: 24

Sequence: 1 tatgacctctagctactctcgac 24

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

```
Database :
1: GenEmbl:*
2: gb_ba:*
3: gb_bhg:*
4: gb_in:*
5: gb_om:*
6: gb_ov:*
7: gb_pat:*
8: gb_ph:*
9: gb_pl:*
10: gb_pr:*
11: gb_ro:*
12: gb_sts:*
13: gb_sy:*
14: gb_un:*
15: gb_vi:*
16: em_ba:*
17: em_fun:*
18: em_hum:*
19: em_in:*
20: em_mu:*
21: em_om:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_hcg_hum:*
31: em_hcg_inv:*
32: em_hcg_other:*
33: em_hcg_mus:*
34: em_hcg_pln:*
35: em_hcg_rdd:*
36: em_hcg_mam:*
37: em_hcg_vrt:*
38: em_ey:*
39: em_hcgo_hum:*
40: em_hcgo_mus:*
41: em_hcgo_other:*
```

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	24	100.0	24	6	AR125606
2	24	100.0	24	6	AR194192
3	24	100.0	24	6	AR221288
4	24	100.0	24	6	AR243206
5	24	100.0	24	6	AR287438
6	24	100.0	604	6	AX044389
7	24	100.0	604	6	AX044388
8	24	100.0	956	6	AX044387
9	24	100.0	1430	6	AX188665
10	24	100.0	2062	6	AX044385
11	24	100.0	2062	6	AX044386
12	24	100.0	2436	6	AX044392
13	24	100.0	2436	6	AX044395
14	24	100.0	2692	6	AX044391
15	24	100.0	2692	6	AX044394
16	24	100.0	2788	6	AX044390
17	24	100.0	2788	6	AX044393
18	24	100.0	7668	6	BD170085
19	24	100.0	8435	6	BD170083
20	24	100.0	8505	6	BD170084
21	23	95.8	934	6	AX077879
22	18.8	78.3	164000	9	AL591682
23	18.4	76.7	110000	2	LMFLCHR36_22
24	18.4	76.7	169529	2	AC131586
25	18.2	75.8	404	8	ATH529465
26	18.2	75.8	1342	8	AT142502
27	18.2	75.8	2000	6	AX461217
28	18.2	75.8	2338	8	BT005733
29	18.2	75.8	3006	2	AC018026
30	18.2	75.8	24942	8	YSCD9819
31	18.2	75.8	45980	8	ATT24818
32	18.2	75.8	83513	8	ATT20823
33	18.2	75.8	105549	10	AL844906
34	18.2	75.8	108409	14	AF083424
35	18.2	75.8	153125	9	AC104456
36	18.2	75.8	165617	5	AL929502
37	18.2	75.8	171949	9	AC008652
38	18.2	75.8	173810	10	AC083815
39	18.2	75.8	198372	8	ATCHRIV66
40	18.2	75.8	207639	10	AL844581
41	18.2	75.8	209114	9	AC008383
42	18.2	75.8	230128	10	AC098707
43	18.2	75.8	235996	2	AC096147
44	18.2	75.8	242679	2	AC117867
45	18.2	75.8	279353	2	AC120587

ALIGNMENTS

```
RESULT 1
LOCUS      AR125606
DEFINITION Sequence 5 from patent US 6177545.
ACCESSION  AR125606
VERSION    AR125606.1 GI:14111668
KEYWORDS
SOURCE
ORGANISM   Unknown.
            Unclassified.
REFERENCE  1 (bases 1 to 24)
AUTHORS   Pecker,I., Vlodavsky,I., Friedman,Y. and Peretz,T.
TITLE     Heparanase specific molecular probes and their use in research and
          medical applications
JOURNAL   Patent: US 6177545-A 5 23-JAN-2001;
```

FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

RESULT 2
LOCUS AR194192 24 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5 from patent US 6348344.
ACCESSION AR194192
VERSION AR194192.1 GI:20240784
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Ayal-Hershenkovitz,M., Moskowitz,H., Miron,D., Gilboa,A., Mimon,M., Ben-Atzai,H., Yacoby-Zeevi,O., Pecker,I., Peleg,Y. and Schloni,Y.
TITLE Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
JOURNAL Patent: US 6348344-A 5 19-FEB-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

RESULT 3
LOCUS AR221288 24 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 5 from patent US 6426209.
ACCESSION AR221288
VERSION AR221288.1 GI:23328259
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Ayal-Hershenkovitz,M., Pecker,I. and Yacoby-Zeevi,O.
TITLE Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
JOURNAL Patent: US 6426209-A 5 30-JUL-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

Db 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

RESULT 4
LOCUS AR243206 24 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 5 from patent US 6475763.
ACCESSION AR243206
VERSION AR243206.1 GI:27290321
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Ayal-Hershenkovitz,M., Moskowitz,H., Miron,D., Gilboa,A., Mimon,M., Ben-Atzai,H., Yacoby-Zeevi,O., Pecker,I., Peleg,Y. and Schloni,Y.
TITLE Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
JOURNAL Patent: US 6475763-A 5 05-NOV-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

RESULT 5
LOCUS AR287438 24 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 5 from patent US 6531129.
ACCESSION AR287438
VERSION AR287438.1 GI:29725132
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Perets,T.
TITLE Heparanase specific molecular probes and their use in research and medical applications
JOURNAL Patent: US 6531129-A 5 11-MAR-2003;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

RESULT 6
LOCUS AX044389 604 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 5 from Patent WO0066755.
ACCESSION AX044389
VERSION AX044389.1 GI:11343267
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

artificial sequences.

REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 006755-A 5 09-NOV-2000;
Plant Bioscience Limited (GB)
FEATURES
SOURCE Location/Qualifiers
1. .604
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of RTB3 in pFASTBAC1"

BASE COUNT 180 a 121 c 134 g 169 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 604;
Best Local Similarity 100.0%; Pred. No. 0.55; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
Db 599 TATGATCCTCTAGTACTTCTCGAC 576
|||||

RESULT 7
AX044386/c
LOCUS AX044388 860 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 4 from Patent WO0066755.
ACCESSION AX044388
VERSION AX044388.1 GI:11343266
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 006755-A 4 09-NOV-2000;
Plant Bioscience Limited (GB)
FEATURES
SOURCE Location/Qualifiers
1. .860
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of RTB2 in pFASTBAC1"

BASE COUNT 255 a 165 c 200 g 240 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 860;
Best Local Similarity 100.0%; Pred. No. 0.55; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
Db 855 TATGATCCTCTAGTACTTCTCGAC 832
|||||

RESULT 8
AX044387/c
LOCUS AX044387 956 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 3 from Patent WO0066755.
ACCESSION AX044387
VERSION AX044387.1 GI:11343265
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 006755-A 3 09-NOV-2000;
Plant Bioscience Limited (GB)
FEATURES
SOURCE Location/Qualifiers

source 1. .956
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of RTB1 in pFASTBAC1"

BASE COUNT 285 a 189 c 215 g 267 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 956;
Best Local Similarity 100.0%; Pred. No. 0.55; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
Db 951 TATGATCCTCTAGTACTTCTCGAC 928
|||||

RESULT 9
AX188665/c
LOCUS AX188665 1430 bp DNA linear PAT 10-AUG-2001
DEFINITION Sequence 13 from Patent WO0147963.
ACCESSION AX188665
VERSION AX188665.1 GI:15142264
KEYWORDS
SOURCE Placobdella papillifera
ORGANISM Placobdella papillifera
REFERENCE 1
AUTHORS Finney, S., Seale, L. and Wallis, R.B.
TITLE Inhibitors of complement activation, their preparation and use
JOURNAL Patent: WO 0147963-A 13 05-JUL-2001;
Bio-Discovery Limited (GB)
FEATURES
SOURCE Location/Qualifiers
1. .1430
/organism="Placobdella papillifera"
/mol_type="genomic DNA"
/db_xref="taxon:168682"

BASE COUNT 419 a 296 c 296 g 419 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1430;
Best Local Similarity 100.0%; Pred. No. 0.55; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
Db 1126 TATGATCCTCTAGTACTTCTCGAC 1103
|||||

RESULT 10
AX044385/c
LOCUS AX044385 2062 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 1 from Patent WO0066755.
ACCESSION AX044385
VERSION AX044385.1 GI:11343263
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 006755-A 1 09-NOV-2000;
Plant Bioscience Limited (GB)
FEATURES
SOURCE Location/Qualifiers
1. .2062
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(b) in pFASTBAC1"

BASE COUNT 538 a 552 c 440 g 532 t

ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2062;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2057 TATGATCCTCTAGTACTTCTCGAC 2034

RESULT 11
AX044386/c 2062 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 2 from Patent WO0066755.
ACCESSION AX044386
VERSION AX044386.1 GI:11343264
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 2 09-NOV-2000;
Plant Bioscience Limited (GB)
LOCATION/Qualifiers

FEATURES
source 1..2062
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(c) in pFASTBAC1"
BASE COUNT 544 a 532 c 446 g 540 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2062;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2057 TATGATCCTCTAGTACTTCTCGAC 2034

RESULT 12
AX044392/c 2436 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 8 from Patent WO0066755.
ACCESSION AX044392
VERSION AX044392.1 GI:11343270
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 8 09-NOV-2000;
Plant Bioscience Limited (GB)
LOCATION/Qualifiers

FEATURES
source 1..2436
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(b)-RTB3 in pFASTBAC1"
BASE COUNT 654 a 617 c 521 g 644 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2436;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2057 TATGATCCTCTAGTACTTCTCGAC 2034

DB 2431 TATGATCCTCTAGTACTTCTCGAC 2408

RESULT 13
AX044395/c 2436 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 11 from Patent WO0066755.
ACCESSION AX044395
VERSION AX044395.1 GI:11343273
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 11 09-NOV-2000;
Plant Bioscience Limited (GB)
LOCATION/Qualifiers

FEATURES
source 1..2436
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(c)-RTB3 in pFASTBAC1"
BASE COUNT 660 a 597 c 527 g 652 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2436;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2431 TATGATCCTCTAGTACTTCTCGAC 2408

RESULT 14
AX044391/c 2692 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 7 from Patent WO0066755.
ACCESSION AX044391
VERSION AX044391.1 GI:11343269
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 7 09-NOV-2000;
Plant Bioscience Limited (GB)
LOCATION/Qualifiers

FEATURES
source 1..2692
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(b)-RTB2 in pFASTBAC1"
BASE COUNT 730 a 660 c 586 g 716 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2692;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2687 TATGATCCTCTAGTACTTCTCGAC 2664

RESULT 15
AX044394/c 2692 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 10 from Patent WO0066755.

ACCESSION AX044394
 VERSION AX044394.1 GI:11343272
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 artificial sequences.
 REFERENCE 1
 AUTHORS Christou, P. and Mehlo, L.
 TITLE Pesticidal fusions
 JOURNAL Patent: WO 0066755-A 10 09-NOV-2000;
 Plant Bioscience Limited (GB)
 FEATURES
 source
 1. 2692
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 /note="Nucleotide sequence of CryIA(c)-RTB2 in pFASTBAC1"
 BASE COUNT 736 a 640 c 592 g 724 t
 ORIGIN
 Query Match 100.0%; Score 24; DB 6; Length 2692;
 Best Local Similarity 100.0%; Pred. No. 0.55;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TATGATCCTCTAGTACTTCTCGAC 24
 ||||||||||||||||||
 Db 2687 TATGATCCTCTAGTACTTCTCGAC 2664
 ||||||||||||||||||

Search completed: February 16, 2004, 11:43:02
 Job time : 117.587 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OW nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:55:00 ; Search time 12.7569 Seconds
(without alignments)
5501.769 Million cell updates/sec

Title: US-10-676-079-4

Perfect score: 26
Sequence: 1 gcgcatacgcagcagctcgtgcactg 26

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: N_GeneSeq_19Jun03:*

1: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1980.DAT:*
2: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1981.DAT:*
3: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1982.DAT:*
4: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1983.DAT:*
5: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1984.DAT:*
6: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1985.DAT:*
7: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1986.DAT:*
8: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1987.DAT:*
9: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1988.DAT:*
10: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1989.DAT:*
11: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1990.DAT:*
12: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1991.DAT:*
13: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1992.DAT:*
14: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1993.DAT:*
15: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1994.DAT:*
16: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1995.DAT:*
17: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1997.DAT:*
18: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1998.DAT:*
19: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA1999.DAT:*
20: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2000.DAT:*
21: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2001A.DAT:*
22: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2001B.DAT:*
23: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2002.DAT:*
24: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2003.DAT:*
25: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/NA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	26	100.0	26	21	AAZ39196 Human heparanase p
2	26	100.0	26	21	AAZ33291 Human heparanase p
3	20	76.9	30	24	ABN86005 Human heparanase g
4	19.6	75.4	474	22	AAF93984 Primer specific fo
5	19.6	75.4	605	24	ABN86000 Human heparanase g
6	19.6	75.4	1419	24	ABN86003 Human heparanase u
7	19.6	75.4	1593	20	AAZ11236 Human pre-prohepar
8	19.6	75.4	1713	20	AAZ37259 Human heparanase e

9	19.6	75.4	1721	20	AAZ35648
10	19.6	75.4	1721	21	AAZ75051
11	19.6	75.4	1721	21	AAZ39195
12	19.6	75.4	1721	21	AAZ33290
13	19.6	75.4	1721	22	AAZ31112
14	19.6	75.4	1722	22	AAF93788
15	19.6	75.4	1723	22	AAZ37260
16	19.6	75.4	1724	22	AAH0940
17	19.6	75.4	1899	22	AAZ35650
18	19.6	75.4	1899	21	AAZ75053
19	19.6	75.4	3726	20	AAZ86671
20	19.6	75.4	4448	21	AAZ75080
21	19.2	73.8	444	24	ABN90554
22	19.2	73.8	1669	24	ABN90553
23	19	73.1	1369	25	ABZ22816
24	18.6	71.5	35	21	AAZ39200
25	18.6	71.5	2588	25	ABT16043
26	18.6	71.5	4345	22	AAF61716
27	18.6	71.5	11854	20	AAZ33243
28	18.6	71.5	11854	24	ABZ99038
29	18.4	70.8	5770	23	AAZ84301
30	18.2	70.0	1298	24	AAZ42627
31	18.2	70.0	1302	24	AAZ9760
32	18.2	70.0	1302	24	AAZ9773
33	18.2	70.0	1304	24	AAZ42629
34	18.2	70.0	1360	24	AAZ42628
35	18	69.2	33	19	AAZ71120
36	18	69.2	33	20	AAZ30938
37	18	69.2	60	24	ABN40291
38	18	69.2	177	21	AAZ36803
39	18	69.2	177	21	AAZ82894
40	18	69.2	262	25	ABX31423
41	18	69.2	1584	24	ABL40753
42	18	69.2	2032	24	ABL92126
43	18	69.2	2032	25	ABX72051
44	18	69.2	2312	25	ABZ09890
45	18	69.2	2668	24	ABQ70896

ALIGNMENTS

RESULT 1	AAZ39196	AAZ39196 standard; DNA; 26 BP.
ID	AAZ39196	
XX	AAZ39196;	
AC	02-MAR-2000	(first entry)
XX		
DT		
XX		
DE	Human heparanase PCR sense primer SEQ ID NO:4.	
XX		
KW	Human; heparanase; hpa; genetic modification; expression; anticancer;	
KW	angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumor;	
KW	anti-atherosclerotic; anti-inflammatory; antineurodegeneration;	
KW	heparan sulphate; heparin-binding growth factor; tumour angiogenesis;	
KW	metastasis; wound healing; restenosis; atherosclerosis; inflammation;	
KW	neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;	
KW	micrometastasis; autoimmune lesion; kidney failure; PCR primer; ss.	
OS	Synthetic.	
OS	Homo sapiens.	
XX		
PN	W09957244-A1.	
XX		
PD	11-NOV-1999.	
XX		
PF	29-APR-1999;	99WO-US09256.
XX		
PR	01-MAY-1996;	98US-0071618.
XX		
PR	02-MAR-1999;	99US-0260038.
XX		
PA	(INSI-) INSIGHT STRATEGY & MARKETING LTD.	

CDNA encoding a hu
CDNA encoding a hu
Human heparanase e
Human heparanase n
Human heparanase,
Human CDNA encodin
Seq ID No: 14 of W
Human heparanase i
CDNA encoding a hu
CDNA encoding a hu
CDNA encoding a hu
Nucleotide sequenc
Staphylococcus epi
Staphylococcus epi
Human heparanase e
Human heparanase p
NOVX related polym
Human CTAB-2-enco
Enterococcus faeca
Enterococcus faeca
DNA encoding novel
Coffee theobromine
1302nt DNA encodin
1302nt RNA encodin
Coffee theobromine
Coffee theobromine
PCR primer used to
Thermus thermophil
Human spliced tran
Human dyferlin re
Human dyferlin DN
Human GDP-mannose
Chicken signal pep
Human Tumour Endoc
DNA encoding human
Human 5' and/or re
Listeria monocytog

PA (FRIE/) FRIEDMAN M M.
 XX
 PI Ben-Artzi H, Ayal-Hershkovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;
 PI Shlomi Y;
 XX WPI; 2000-062144/05.
 DR
 XX Engineered cells that express recombinant heparanase, useful
 PT therapeutically, e.g. for treating angiogenesis and to screen for
 PT specific inhibitors, potential anticancer agents -
 XX
 PS Example 1; Page 36; 118pp; English.
 XX
 CC The present invention describes genetically modified cells (A) containing
 CC a polynucleotide (I) that encodes a polypeptide with heparanase activity,
 CC and express recombinant heparanase (II). Heparanase cleaves heparan
 CC sulphate (HS) at specific intrachain sites, resulting in release of
 CC heparin-binding growth factors, enzymes and proteins that are sequestered
 CC by HS in basement membranes, extracellular matrix or cell surfaces. It
 CC may also be implicated in tumour angiogenesis and metastases. (II) is
 CC potentially useful in wound healing and for treating angiogenesis,
 CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
 CC infection and cystic fibrosis. It can also be used to neutralise heparin
 CC (an alternative to protamine) and to screen for specific inhibitors
 CC (potentially useful for treating cancer and metastases). Antibodies
 CC raised against (II) are used for immunodetection and diagnosis of
 CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
 CC in large quantities, in a form that is homogeneously processed and
 CC activated/neutralised by a dedicated protease. The present sequence
 CC represents a PCR primer for human heparanase, which is used in an
 CC example from the present invention.
 CC
 SQ Sequence 26 BP; 5 A; 7 C; 9 G; 5 T; 0 other;

Query Match 100.0%; Score 26; DB 21; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.045;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGCATATGACGAGCGTGTGACCTG 26
 DB 1 CGCATATGACGAGCGTGTGACCTG 26

RESULT 2
 AA233291
 ID AA233291 standard; DNA; 26 BP.
 XX
 AC AA233291;
 XX
 DT 21-FEB-2000 (first entry)
 XX
 DE Human heparanase PCR sense primer SEQ ID NO:4.
 XX
 KW Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
 KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
 KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
 KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
 KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
 KW autoimmune disease; anticancer; kidney disease; PCR primer; ss.
 KW
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9957153-A1.
 XX
 PD 11-NOV-1999.
 XX
 PF 29-APR-1999; 99WO-US09255.
 XX
 PR 01-MAY-1998; 98US-0071739.
 XX
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

PA (FRIE/) FRIEDMAN M M.
 XX
 PI Pecker I, Vlodavsky I, Friedman Y, Perets T;
 XX
 DR WPI; 2000-052944/04.
 XX
 PT Heparanase-specific molecular probes useful for diagnosis and
 PT treatment, e.g. of tumors, and for targeted drug delivery -
 XX
 PS Example; Page 27; 90pp; English.

CC The present invention describes heparanase-specific molecular probes,
 CC useful for methods of detecting heparanase in situ. The probes and
 CC anti-heparanase antibodies are used to detect or quantify the expression
 CC of heparanase, for diagnosis and monitoring of diseases (especially
 CC metastasis), for treatment of heparanase-associated diseases (e.g.
 CC tumour, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
 CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
 CC metastases) derived from liver, prostate, bladder, breast, ovary,
 CC cervix; colon, skin, intestine, stomach, uterus and pancreas, kidney
 CC disease, diabetes and inflammatory, haemorrhagic nephritis, nephrotic
 CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted
 CC drug delivery (e.g. of anticancer agents) and as research reagents.
 CC The present sequence represents a PCR primer for human heparanase, which
 CC is used in an example from the present invention for the construction of
 CC a heparanase expression vector.

SQ Sequence 26 BP; 5 A; 7 C; 9 G; 5 T; 0 other;
 Query Match 100.0%; Score 26; DB 21; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.045;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGCATATGACGAGCGTGTGACCTG 26
 DB 1 CGCATATGACGAGCGTGTGACCTG 26

RESULT 3
 ABN86005
 ID ABN86005 standard; DNA; 30 BP.
 XX
 AC ABN86005;
 XX
 DT 06-SEP-2002 (first entry)
 XX
 DE Human heparanase gene specific primer HP-6.
 XX
 KW Human; heparanase; cytostatic; vasotropic; antidiabetic; anti-HIV;
 KW ophthalmological; antirheumatic; antiarthritic; antiporiatic;
 KW antianemic; neutroprotective; nootropic; cerebroprotective;
 KW antibacterial; virucide; protozoicide; fungicide; antinflammatory;
 KW cardiant; immunosuppressive; tumour metastasis; inflammatory disease;
 KW allograft rejection; cell migration; angiogenesis; basement membrane;
 KW extracellular matrix; cancer; ischaemia; diabetic retinopathy;
 KW macular degeneration; rheumatoid arthritis; psoriasis; HIV infection;
 KW sickle cell anaemia; Alzheimer's disease; muscular dystrophy;
 KW neurodegenerative disease; vascular disease; cardiovascular disease;
 KW cystic fibrosis; stroke; gene therapy; PCR; primer; ss.
 KW
 OS Homo sapiens.
 OS
 PN WO200244353-A2.
 XX
 PD 06-JUN-2002.
 XX
 PF 30-NOV-2001; 2001WO-US44798.
 XX
 PR 30-NOV-2000; 2000US-250690P.
 XX
 PA (SANG-) SANGAMO BIOSCIENCES INC.
 XX
 PI Wolffe AP, Qi H;

XX WPI: 2002-527708/56.
 DR Nucleic acid encoding secretory proteins/membrane proteins, useful in
 XX gene therapy or as candidate target molecules in drug development -
 PT New heparanase polynucleotide, useful for controlling disease states
 PT as tumour metastasis, inflammatory diseases and allograft rejection
 PT
 PS Claim 4, SEQ ID 418; 609pp + CD ROM; English.
 XX
 XX Example 1, Page 44; 72pp; English.
 CC The invention relates to novel heparanase sequences, particularly novel
 CC sequences from the regulatory regions upstream and downstream of the
 CC coding region. The activity of polynucleotides of the invention may be
 CC described as, cytostatic, vasotropic, antidiabetic, anti-HIV,
 CC immunomodulatory, antineoplastic, antirheumatic, antiparasitic,
 CC antianemic, neuroprotective, nootropic, cerebroprotective,
 CC antibacterial, virucide, protozoacide, fungicide, antiinflammatory,
 CC cardiatic and immunosuppressive. Modulating expression of heparanase gene
 CC using constructs of the invention is useful for facilitating targeted
 CC control of disease states such as tumour metastasis, inflammatory
 CC diseases, allograft rejection, and for inhibiting processes such as cell
 CC migration, angiogenesis, and degradation of the basement membrane and/or
 CC extracellular matrix. Heparanase-targeted DNA binding domains modulates
 CC gene expression, and are useful for therapeutic or prophylactic
 CC applications, for e.g. cancer, ischaemia, diabetic retinopathy, macular
 CC degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell
 CC anaemia, Alzheimer's disease, muscular dystrophy, neurodegenerative
 CC diseases, vascular disease, cardiovascular disease, cystic fibrosis,
 CC stroke, and bacterial, protozoal, fungal and viral infection. Constructs
 CC of the invention may also be useful in gene therapy. The current sequence
 CC represents a human heparanase gene specific primer designated HP-6. This
 CC was used in the determination of nucleotide sequences in the human
 CC heparanase gene and flanking regions.
 XX
 XX Sequence 30 BP; 4 A; 9 C; 9 G; 8 T; 0 other;
 SQ
 Query Match 76.9%; Score 20; DB 24; Length 30;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 7 TGCAGAGAGCTGCTGACCTG 26
 Db 2 TGCAGAGAGCTGCTGACCTG 21
 RESULT 4
 AAF93984
 ID AAF93984 standard; DNA; 474 BP.
 XX
 XX AAF93984;
 AC
 XX
 XX 23-MAY-2001 (first entry)
 DT
 XX
 XX Primer specific for DNA encoding secretory/membrane protein SEQ ID 418.
 DE
 XX Human; secretory protein; membrane protein; vaccine; gene therapy;
 KW rheumatoid arthritis; diabetes; PCR primer; ss.
 KW
 XX Synthetic.
 OS
 XX EP1067182-A2.
 PN
 XX 10-JAN-2001.
 PD
 XX 07-JUL-2000; 2000EP-0114090.
 PF
 XX 08-JUL-1999; 99JP-0194179.
 PR 11-JAN-2000; 2000JP-0118775.
 PR 02-MAY-2000; 2000JP-0183766.
 XX
 XX (HELI-) HELIX RES INST.
 PA
 XX Ota T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
 PI
 XX

DR WPI: 2001-093989/11.
 XX Nucleic acid encoding secretory proteins/membrane proteins, useful in
 PT gene therapy or as candidate target molecules in drug development -
 PT
 PS Claim 4, SEQ ID 418; 609pp + CD ROM; English.
 XX
 XX This invention relates to nucleic acid sequences AAF93744 - AAF93916
 CC which encode human secretory or membrane proteins represented by
 CC AAB88317 - AAB88419. Included in the invention are primers
 CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the
 CC cDNA sequences of the invention. The invention also includes methods for
 CC the production of antibodies directed against the proteins, and cDNA
 CC sequences, which can be used in vaccines. The polynucleotide sequences
 CC can be used in gene therapy. The polynucleotide sequences and the
 CC proteins they encode may be used in the prevention, treatment and
 CC diagnosis of diseases associated with inappropriate secretory
 CC protein/membrane protein expression. The nucleic acids and complementary
 CC sequences may also be used as DNA probes in diagnostic assays
 CC (e.g. polymerase chain reactions (PCR)) to detect and quantitate the
 CC presence of similar nucleic acid sequences in samples. They may also be
 CC used to study the expression and function of secretory proteins/membrane
 CC polypeptides and their role in metabolism. The polypeptides may be used
 CC as antigens in the production of antibodies against them and in assays to
 CC identify modulators (agonists and antagonists) of expression and
 CC activity. The antibodies and antagonists may also be used as therapeutic
 CC agents to down regulate expression and activity. The antibodies may also
 CC be used as diagnostic agents for detecting the presence of the
 CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay
 CC (ELISA). Examples of diseases which may be treated include rheumatoid
 CC arthritis and diabetes.
 XX
 XX Sequence 474 BP; 86 A; 154 C; 127 G; 101 T; 6 other;
 SQ
 Query Match 75.4%; Score 19.6; DB 22; Length 474;
 Best Local Similarity 84.6%; Pred. No. 38;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Oy 1 CGCATATGCAGAGCTGCTGACCTG 26
 Db 161 CGCATATGCAGAGCTGCTGACCTG 186
 RESULT 5
 AAB86000
 ID AAB86000 standard; DNA; 605 BP.
 XX
 XX AAB86000;
 AC
 XX
 XX 06-SEP-2002 (first entry)
 DT
 XX
 XX Human heparanase gene fragment.
 DE
 XX Human; heparanase; cytostatic; vasotropic; antidiabetic; anti-HIV;
 KW opthalmological; antirheumatic; antirheumatic; antiparasitic;
 KW antianemic; neuroprotective; nootropic; cerebroprotective;
 KW antibacterial; virucide; protozoacide; fungicide; antiinflammatory;
 KW cardiatic; immunosuppressive; tumour metastasis; inflammatory disease;
 KW allograft rejection; cell migration; angiogenesis; basement membrane;
 KW extracellular matrix; cancer; ischaemia; diabetic retinopathy;
 KW macular degeneration; rheumatoid arthritis; psoriasis; HIV infection;
 KW sickle cell anaemia; Alzheimer's disease; muscular dystrophy;
 KW neurodegenerative disease; vascular disease; cardiovascular disease;
 KW cystic fibrosis; stroke; gene therapy; chromosome 4; gene; ds.
 KW
 XX Homo sapiens.
 OS
 XX
 XX Key
 FH location/Qualifiers
 FT 1..605
 FT /tag= a
 FT /product= "heparanase protein fragment"
 FT /note= "contains 2 introns, one full intron and 1 intron
 FT fragment"

FT	exon	1..105
FT	/tag= b	
FT	/number= 1	
FT	106..339	
FT	/tag= c	
FT	/number= 1	
FT	340..602	
FT	/tag= d	
FT	/number= 2	
FT	371..373	
FT	/tag= e	
FT	/note= "start codon"	
FT	603..605	
FT	/tag= f	
FT	/number= 2	
FT	/note= "a small fragment only of this intron is given"	
XX		
PN	WO200244353-A2.	
XX		
PD	06-JUN-2002.	
XX		
PF	30-NOV-2001; 2001WO-US44798.	
XX		
PR	30-NOV-2000; 2000US-250690P.	
XX		
PA	(SANG-) SANGAMO BIOSCIENCES INC.	
XX		
P1	Wolffe AP, Qi H;	
XX		
DR	WPI, 2002-527708/56.	
XX		
PT	New heparanase polynucleotide, useful for controlling disease states such as tumour metastasis, inflammatory diseases and allograft rejection	
PT	-	
XX		
PS	Example 1; Fig 1; 72pp; English.	
XX		
CC	The invention relates to novel heparanase sequences, particularly novel	
CC	sequences from the regulatory regions upstream and downstream of the	
CC	coding region. The activity of polynucleotides of the invention may be	
CC	described as, cytostatic, vasotropic, antidiabetic, anti-HIV,	
CC	ophthalmological, antineumatic, antiarthritic, antipsoriatic,	
CC	antianaemic, neuroprotective, nootropic, cerebroprotective,	
CC	antibacterial, virucide, protozoacide, fungicide, antiinflammatory,	
CC	cardiant and immunosuppressive. Modulating expression of heparanase gene	
CC	using constructs of the invention is useful for facilitating targeted	
CC	control of disease states such as tumour metastasis, inflammatory	
CC	diseases, allograft rejection, and for inhibiting processes such as cell	
CC	miration, angiogenesis, and degradation of the basement membrane and/or	
CC	extracellular matrix. Heparanase-targeted DNA binding domains modulates	
CC	gene expression, and are useful for therapeutic or prophylactic	
CC	applications, for e.g. cancer, ischaemia, diabetic retinopathy, macular	
CC	degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell	
CC	anaemia, Alzheimer's disease, muscular dystrophy, neurodegenerative	
CC	diseases, vascular disease, cardiovascular disease, cystic fibrosis,	
CC	stroke, and bacterial, protozoal, fungal and viral infection. Constructs	
CC	of the invention may also be useful in gene therapy. The current sequence	
CC	.represents a human heparanase gene fragment which is located on	
CC	chromosome 4.	
XX		
SO	Sequence 605 BP; 96 A; 187 C; 230 G; 92 T; 0 other:	
	Query Match: 75.4%; Score 19.6; DB 24; Length 605;	
	Best Local Similarity 84.6%; Pred. No.38;	
	Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0	
OY	1 CGCATATGCAGGACCTCGTGACCTG 26	
Ddb	468 CGCAAGCACAGGACCTCGTGACCTG 493	

ID		ABN86003 standard; DNA; 1419 BP.
AC		
XX		ABN86003;
DT		06-SEP-2002 (first entry)
DE		Human heparanase upstream sequence containing exons 1 and 2.
XX		
KM		Human, heparanase; cytosolic; vasotropic; antidiabetic; anti-HIV;
KM		ophthalmological; antirheumatic; antiarthritis; antiparasitic;
KM		antihistaminic; neuroprotective; nootropic; cerebroprotective;
KW		antibacterial; virucide; protozoicide; fungicide; antiinflammatory;
KV		cardiant; immunosuppressive; tumour metastasis; inflammatory disease;
KW		allograft rejection; cell migration; angiogenesis; basement membrane;
KM		extracellular matrix; cancer; ischaemia; diabetic retinopathy;
KM		macular degeneration; rheumatoid arthritis; psoriasis; HIV infection;
KW		sickle cell anaemia; Alzheimer's disease; muscular dystrophy;
KM		neurodegenerative disease; vascular disease; cardiovascular disease;
KW		cystic fibrosis; stroke; gene therapy; ds.
XX		
OS		Homo sapiens.
PN		WO200244353-A2.
XX		
PD		06-JUN-2002.
XX		
PF		30-NOV-2001; 2001WO-US44798.
XX		
PR		30-NOV-2000; 2000US-250690P.
PA		(SANG-) SANGAMO BIOSCIENCES INC.
XX		
P1		Wolffe AP, Qi H;
PT		
DR		WPI; 2002-527708/56.
XX		
PT		New heparanase polynucleotide, useful for controlling disease states
PT		such as tumour metastasis, inflammatory diseases and allograft rejection
PS		-
XX		
PS		Example 1, Fig 4; 72pp; English.
XX		
CC		The invention relates to novel heparanase sequences, particularly novel
CC		sequences from the regulatory regions upstream and downstream of the
CC		coding region. The activity of polynucleotides of the invention may be
CC		described as, cytostatic, vasotropic, antidiabetic, anti-HIV,
CC		ophthalmological, antirheumatic, antiarthritic, antipsoriatic,
CC		antilaemic, neuroprotective, nootropic, cerebroprotective,
CC		antibacterial, virucide, protozoicide, fungicide, antiinflammatory,
CC		cardiant and immunosuppressive. Modulating expression of heparanase gene
CC		using constructs of the invention is useful for facilitating targeted
CC		control of disease states such as tumour metastasis, inflammatory
CC		diseases, allograft rejection, and for inhibiting processes such as cell
CC		migration, angiogenesis, and degradation of the basement membrane and/or
CC		extracellular matrix. Heparanase-targeted DNA binding domains modulates
CC		gene expression, and are useful for therapeutic or prophylactic
CC		applications, for e.g. cancer, ischaemia, diabetic retinopathy, macular
CC		degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell
CC		anaemia, Alzheimer's disease, muscular dystrophy, neurodegenerative
CC		diseases, bacterial disease, cardiovascular disease, cystic fibrosis,
CC		stroke, and vacerual, protozoal, fungal and viral infection. Constructs
CC		of the invention may also be useful in gene therapy. The current sequence
CC		represents the human heparanase upstream sequence containing exons 1 and
XX		2.
SQ		Sequence 1419 BP; 329 A; 352 C; 452 G; 286 T; 0 other;
Query Match	75.4%	Score 19.6; DB 24; Length 1419;
Best Local Similarity	84.6%; Pred. No. 41;	
Matches	22; Conservative 0; Mismatches	4; Indels 0; Gaps 0;
G	CGCATATGCAGGACTCTGTGCACTG	26
T		

Db 1282 CGCAGCACGAGCGTCGTGACCTG 1307

RESULT 7

ID AA211236 standard; cDNA; 1593 BP.

AC AA211236;

DT 15-NOV-1999 (first entry)

DE Human pre-heparanase coding sequence.

KM Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;
KM inflammation; psoriasis; diabetic retinopathy; solid tumor; arthritis;
KM heparin degradation; anticoagulant neutralisation; asthma; CNS disease;
KM inflammatory disease; vascular restenosis; atherosclerosis; diagnosis;
KM tumour growth; fibroproliferative disorder; neurodegenerative disease;
KM therapy; ds.

OS Homo sapiens.

FH Key Location/Qualifiers

FT CDS 1..1593

FT /tag=a

FT /product= pre-proheparanase

XX MO9943830-A2.

XX 02-SEP-1999.

XX 18-FEB-1999; 99WO-US01489.

XX 26-MAR-1998; 98US-0079401.

XX 24-FEB-1998; 98US-0075706.

XX (PHNA) PHARMACIA & UPJOHN CO.

XX Fairbanks MB, Heinrikson RL, Mildner AM;

XX WPI; 1999-540598/45.

XX P-PSDB; AAY34173.

XX Claim 2; Fig 7; 57pp; English.

CC This sequence encodes the human pre-proheparanase of the invention. This
CC sequence was isolated from human platelets. The heparanase can be used
CC for identifying agents which alter heparanase activity. The heparanase
CC can be used for wound healing or for blocking angiogenesis or
CC inflammation. It can be used for treating e.g. psoriasis, diabetic
CC retinopathy or solid tumours, or for the degradation of heparin and the
CC neutralisation of heparin's anticoagulant properties during surgery.
CC Inhibitors of heparanase activity can be used in the treatment of
CC arthritis, asthma, and other inflammatory diseases; vascular restenosis,
CC atherosclerosis, tumour growth and progression, fibroproliferative
CC disorders, and central nervous system (CNS) and neurodegenerative
CC diseases. The products can also be used for detection and diagnosis. The
CC purified heparanase, both recombinantly produced human heparanase and
CC heparanase isolated from human platelet activity, allows for the
CC convenient selection of compounds having anti-heparanase activity,
CC i.e. inhibitors of heparanase activity, by measuring inhibition of
CC heparanase activity. Inhibition of heparanase activity can be measured by
CC blocking heparanase-mediated release of radioactive fragments from in
CC vivo radiolabelled (HSPG)/heparin.

XX Sequence 1593 BP; 426 A; 370 C; 369 G; 428 T; 0 other;

Query Match 75.4%; Score 19.6; DB 20; Length 1593;

Best Local Similarity 84.6%; Pred. No. 42;

Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 CGCATATGCAGGACGTCGTGACCTG 26
Db 59 CGCAGCACGAGCGTCGTGACCTG 84

RESULT 8

ID AAX37259 standard; DNA; 1713 BP.

AC AAX37259;

DT 21-JUL-1999 (first entry)

DE Human heparanase enzyme encoding DNA.

KM Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
KM metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KM atherosclerosis; atherosclerosis; inflammation; tissue development;
KM human; HSPG; ss.

OS Homo sapiens.

XX MO9921975-A1.

XX 06-MAY-1999.

XX 28-OCT-1998; 98WO-AU00898.

XX 09-DEC-1997; 97AU-0000812.

XX 28-OCT-1997; 97AU-0000062.

XX (AUSU) UNIV AUSTRALIAN NAT.

XX Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;

XX WPI; 1999-312956/26.

XX P-PSDB; AAY17082.

XX Claim 3; Page 69-73; 112pp; English.

CC The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulphates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC atherosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG. The
CC present sequence represents a DNA encoding human heparanase.

XX Sequence 1713 BP; 460 A; 404 C; 406 G; 443 T; 0 other;

Query Match 75.4%; Score 19.6; DB 20; Length 1713;

Best Local Similarity 84.6%; Pred. No. 42;

Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 CGCATATGCAGGACGTCGTGACCTG 26
Db 143 CGCAGCACGAGCGTCGTGACCTG 168

RESULT 9

ID AAX35648 standard; cDNA; 1721 BP.

```

XX AAX35648;
AC
XX
XX 09-JUL-1999 (first entry)
DT
XX
XX cDNA encoding a human heparanase protein.
DE
XX
XX Heparanase; hpa; modulator; heparin-binding growth factor;
KW cellular response; cytokine; cell interaction; plasma lipoprotein;
KW cellular susceptibility; infection; disintegration;
KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease; neurallise;
KW plasma heparin; micrometastasis; autoimmune lesion; renal failure;
KW ss.
XX
XX Homo sapiens.
OS
XX
XX WO9911798-A1.
PN
XX
XX 11-MAR-1999.
PD
XX
XX 31-AUG-1998; 96WO-US17954.
PF
XX
XX 02-JUL-1998; 98US-0109386.
PR
XX
XX 02-SEP-1997; 97US-0922170.
PR
XX
XX (FRIE/) FRIEDMAN M M.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (INST-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX Feinstein E, Pecker I, Vlodaysky I;
PI
XX
XX MPI: 1999-302255/25.
DR
XX
XX P-PSDB; AAV02345.
DR
XX
XX New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
PT
XX
XX Claim 4; Fig 1; 63pp; English.
PS
XX
XX The specification describes a polypeptide having heparanase (hpa)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC The present sequence encodes human heparanase.
XX
XX
XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
SQ
XX
XX
XX Query Match 75.4%; Score 19.6; DB 20; Length 1721;
XX Best Local Similarity 84.6%; Pred. No. 42;
XX Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX
XX 1 CGCATATGCAGAGCGTGTGACCTG 26
QY |||||
XX |||||
Db 160 CGCAAGCACAGACGCTGTGACCTG 185
XX
XX
XX RESULT 10
XX ID AAA75051 standard; cDNA; 1721 BP.
XX
XX AAA75051;
XX
XX 15-JAN-2001 (first entry)
XX

```

```

DE cDNA encoding a human heparanase polypeptide.
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
XX heparin-binding growth factor; cytokine; neurodegenerative plaque;
XX wound healing; infection; burn; angiogenesis; restenosis;
XX atherosclerosis; inflammation; neurodegenerative disease;
XX Gerstmann-Straussler Syndrome; Creutzfeldt-Jakob disease; ds.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
XX CDS 63..1693
XX FT /tag= a
XX FT /product= "heparanase"
XX FT 698..724
XX FT /tag= b
XX FT /note= "these nucleotides are likely to be involved
XX in forming stem and loop structures"
XX
XX WO200052178-A1.
XX
XX 08-SEP-2000.
XX
XX 14-FEB-2000; 2000WO-US03542.
XX
XX 01-MAR-1999; 99US-0258892.
XX
XX (INST-) INSIGHT STRATEGY & MARKETING LTD.
XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
XX (FRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodaysky I, Feinstein E;
PI
XX
XX MPI: 2000-579289/54.
DR
XX
XX P-PSDB; AAB08849.
DR
XX
XX New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating
PT tumour, inflammation, autoimmunity, neurodegenerative diseases -
PT
XX
XX Claim 9; Fig 1; 152pp; English.
PS
XX
XX The present sequence encodes a human protein with heparanase catalytic
CC activity. The heparanase (hpa) polynucleotide is useful in gene therapy,
CC particularly in treating tumour, inflammation or autoimmunity.
CC Particularly, the polynucleotide is useful in modulating the
CC bioavailability of heparin-binding growth factors, cellular responses
CC to heparin-binding growth factors (e.g. bFGF) and cytokines
CC (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,
CC cellular susceptibility to certain viral and some bacterial and protozoa
CC infections, or disintegration of neurodegenerative plaques. The
CC polynucleotide is also useful in wound healing (e.g. thermal, chemical
CC or radiation burns) and in the treatment of angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-
CC Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,
CC bacterial or protozoa infections.
XX
XX
XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
SQ
XX
XX
XX Query Match 75.4%; Score 19.6; DB 21; Length 1721;
XX Best Local Similarity 84.6%; Pred. No. 42;
XX Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX
XX 1 CGCATATGCAGAGCGTGTGACCTG 26
QY |||||
XX |||||
Db 160 CGCAAGCACAGACGCTGTGACCTG 185
XX
XX
XX RESULT 11
XX ID AAZ39195 standard; cDNA; 1721 BP.
XX
XX AAZ39195;
XX

```

XX 02-MAR-2000 (first entry)
 XX Human heparanase encoding cDNA.
 DE
 XX Human; heparanase; hpa; genetic modification; expression; anticancer;
 KW angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumour;
 KW anti-atherosclerotic; anti-inflammatory; antineurodegeneration;
 KW heparan sulphate; heparin-binding growth factor; tumour angiogenesis;
 KW metastasis; wound healing; restenosis; atherosclerosis; inflammation;
 KW neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;
 KW microvessel; autolysosomal lesion; kidney failure; ss.
 KW
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FT CDS 63..1694
 FT /*tag= a
 FT /product= "heparanase"
 XX
 XX MO9957244-A1.
 XX 11-NOV-1999.
 XX
 XX 29-APR-1999; 99WO-US09256.
 XX
 XX 01-MAY-1998; 98US-0071618.
 XX 02-MAR-1999; 99US-0260038.
 XX
 XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 XX (FRIE/) FRIEDMAN M M.
 XX
 XX Ben-Artzi H, Ayal-Hershkovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;
 PI Shlom Y;
 DR MPI; 2000-062144/05.
 DR P-PSDB; AAY57590.
 XX
 XX Engineered cells that express recombinant heparanase, useful
 PT therapeutically, e.g. for treating angiogenesis and to screen for
 PT specific inhibitors, potential anticancer agents -
 XX
 XX Claim 2; Page 106-107; 118pp; English.
 XX
 XX The present invention describes genetically modified cells (A) containing
 CC a polynucleotide (I) that encodes a polypeptide with heparanase activity,
 CC and expresses recombinant heparanase (II). Heparanase cleaves heparan
 CC sulphate (HS) at specific intrachain sites, resulting in release of
 CC heparin-binding growth factors, enzymes and proteins that are sequestered
 CC by HS in basement membranes, extracellular matrix or cell surfaces. It
 CC may also be implicated in tumour angiogenesis and metastases. (II) is
 CC potentially useful in wound healing and for treating angiogenesis,
 CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
 CC infection and cystic fibrosis. It can also be used to neutralise heparin
 CC (an alternative to protamine) and to screen for specific inhibitors
 CC (potentially useful for treating cancer and metastases). Antibodies
 CC raised against (II) are used for immunodetection and diagnosis of
 CC microvessel diseases, autoimmune lesions and kidney failure. (A) provide (II)
 CC in large quantities, in a form that is homogeneously processed and
 CC activated/neutralised by a dedicated protease. The present sequence
 CC encodes human heparanase.
 XX
 XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
 SO
 Query Match 75.4%; Score 19.6; DB 21; Length 1721;
 Best Local Similarity 84.6%; Pred. No. 42;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 CGCATATGAGAGAGCTGTCGACCTG 26
 DB 160 CGCAAGCACAGAGAGCTGTCGACCTG 185

RESULT 12
 AA233290
 ID AA233290 standard; cDNA; 1721 BP.
 XX
 XX AA233290;
 AC
 XX 21-FEB-2000 (first entry)
 DT
 XX Human heparanase nucleotide sequence.
 DE
 XX Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
 KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotoxic;
 KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
 KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
 KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
 KW autoimmune disease; anticancer; kidney disease; ds.
 KW
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FT CDS 63..1694
 FT /*tag= a
 FT /product= "heparanase"
 XX
 XX MO9957153-A1.
 XX 11-NOV-1999.
 XX
 XX 29-APR-1999; 99WO-US09255.
 XX
 XX 01-MAY-1998; 98US-0071739.
 XX
 XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 XX (HADA-) HADAST MEDICAL RES SERVICES & DEV.
 XX (FRIE/) FRIEDMAN M M.
 XX
 XX Pecker I, Vlodayky I, Friedman Y, Perets T;
 PI MPI; 2000-052944/04.
 DR P-PSDB; AAY52990.
 XX
 XX Heparanase-specific molecular probes useful for diagnosis and
 PT treatment, e.g. of tumors, and for targeted drug delivery -
 XX
 XX Example; Page 82-84; 90pp; English.
 XX
 XX The present invention describes heparanase-specific molecular probes,
 CC useful for methods of detecting heparanase in situ. The probes and
 CC anti-heparanase antibodies are used to detect or quantify the expression
 CC of heparanase, for diagnosis and monitoring of diseases (especially
 CC metastasis), for treatment of heparanase-associated diseases (e.g.
 CC tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
 CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
 CC metastases) derived from liver, prostate, bladder, breast, ovary,
 CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
 CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
 CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted
 CC drug delivery (e.g. of anticancer agents) and as research reagents.
 CC The present sequence encodes human heparanase, which is used in the
 CC exemplification of the present invention.
 XX
 XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
 SO
 Query Match 75.4%; Score 19.6; DB 21; Length 1721;
 Best Local Similarity 84.6%; Pred. No. 42;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 CGCATATGAGAGAGCTGTCGACCTG 26
 DB 160 CGCAAGCACAGAGAGCTGTCGACCTG 185

RESULT 13

AAA91112
ID AAA91112 standard; DNA; 1721 BP.
XX
AC AAA91112;
XX
DT 20-APR-2001 (first entry)
XX
DE Human heparanase, coding sequence fragment isolated from EST clone.
XX
XX Heparanase; hnp1; wound healing; angiogenesis; restenosis; Scler;
KM atherosclerosis; inflammation; pulmonary disease; Alzheimer's disease;
KM neurodegenerative disease; Creutzfeldt-Jakob disease; viral infection;
XX gene therapy; mouse; expressed sequence tag; ds.
XX
OS Homo sapiens.
XX
PN WO20010643-A2.
XX
PD 04-JAN-2001.
XX
PE 19-JUN-2000; 2000MO-IL00358.
XX
PR 25-JUN-1999; 99US-0140801.
XX
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
PI Pecker I, Michal I, Itzhaki H;
XX
DR WPI; 2001-137930/14.
XX
PT New polynucleotides and polypeptides that are distantly homologous to
PT heparanase, useful in wound healing, as well as in gene therapy
PT protocols for angiogenesis, restenosis, atherosclerosis, or
PT inflammation -
XX
PS Example 1; Page 67; 67pp; English.
XX
XX This sequence represents a human heparanase coding sequence clone,
CC isolated from an EST clone. The invention relates to heparanase DNA
CC and protein sequences. The heparanase DNA and protein sequences are
CC useful in wound healing, angiogenesis, restenosis, atherosclerosis,
CC inflammation, pulmonary diseases, neurodegenerative diseases (such as
CC Scler, Alzheimer's disease, and Creutzfeldt-Jakob disease) or viral
CC infections. The heparanase coding sequence is particularly useful in gene
CC therapy.
XX
SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
XX
Query Match 75.4%; Score 19.6; DB 22; Length 1721;
Best Local Similarity 84.6%; Pred. No. 42;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
QY 1 CGCATATGACAGACGCTGTGACCTG 26
DB 160 CGCAAGCACAGACGCTGTGACCTG 185
XX
RESULT 14
AAF93788
ID AAF93788 standard; CDNA; 1722 BP.
XX
AC AAF93788;
XX
DT 23-MAY-2001 (first entry)
XX
DE Human cDNA encoding a membrane or secretory protein clone PSEC0090.
XX
XX Human; secretory protein; membrane protein; vaccine; gene therapy;
KM rheumatoid arthritis; diabetes; ss.
XX
OS Homo sapiens.
XX
PN EP1067182-A2.

XX
PD 10-JAN-2001.
XX
PF 07-JUL-2000; 2000EP-0114090.
XX
PR 08-JUL-1999; 99JP-0194179.
XX
PR 11-JAN-2000; 2000JP-0118775.
XX
PR 02-MAY-2000; 2000JP-0183766.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
XX
DR WPI; 2001-093989/11.
XX
DR P-PsDB; AAB88361.
XX
PT Nucleic acids encoding secretory proteins/membrane proteins useful in
PT gene therapy or as candidate target molecules in drug development -
XX
XX Claim 1; SEQ ID 89; 609pp + CD ROM; English.
XX
CC This invention relates to nucleic acid sequences AAF93744 - AAF93916
CC which encode human secretory or membrane proteins represented by
CC AAB88317 - AAB88419. Included in the invention are primers
CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the
CC cDNA sequences of the invention. The invention also includes methods for
CC the production of antibodies directed against the proteins, and cDNA
CC sequences, which can be used in vaccines. The polynucleotide sequences
CC can be used in gene therapy. The polynucleotide sequences and the
CC proteins they encode may be used in the prevention, treatment and
CC diagnosis of diseases associated with inappropriate secretory
CC protein/membrane protein expression. The nucleic acids and complementary
CC sequences may also be used as DNA probes in diagnostic assays
CC (e.g. polymerase chain reactions (PCR)) to detect and quantitate the
CC presence of similar nucleic acid sequences in samples. They may also be
CC used to study the expression and function of secretory proteins/membrane
CC polypeptides and their role in metabolism. The polypeptides may be used
CC as antigens in the production of antibodies against them and in assays to
CC identify modulators (agonists and antagonists) of expression and
CC activity. The antibodies and antigens may also be used as therapeutic
CC agents to down regulate expression and activity. The antibodies may also
CC be used as diagnostic agents for detecting the presence of the
CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay
CC (ELISA). Examples of diseases which may be treated include rheumatoid
CC arthritis and diabetes.
XX
SQ Sequence 1722 BP; 449 A; 414 C; 412 G; 447 T; 0 other;
XX
Query Match 75.4%; Score 19.6; DB 22; Length 1722;
Best Local Similarity 84.6%; Pred. No. 42;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
QY 1 CGCATATGACAGACGCTGTGACCTG 26
DB 161 CGCAAGCACAGACGCTGTGACCTG 186
XX
RESULT 15
AAK37260
ID AAK37260 standard; DNA; 1723 BP.
XX
AC AAK37260;
XX
DT 21-JUL-1999 (first entry)
XX
DE Seq ID No: 14 of WO9921975.
XX
XX Heparanase; endoglyuronidase; heparan sulfate proteoglycan; enzyme;
KM metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KM atherosclerosis; atherosclerosis; inflammation; tissue development;
KM human; HSPG; ss.
XX
OS Homo sapiens.

XX WO9921975-A1.
PN
XX
PD 06-MAY-1999.
XX
PF 28-OCT-1998; 98WO-AU00898.
XX
PR 09-DEC-1997; 97AU-0000812.
PR 28-OCT-1997; 97AU-0000062.
XX
PA (AUSU) UNIV AUSTRALIAN NAT.
XX
PI Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;
XX
XX WPI; 1999-312956/26.
DR P-PSDB; AAY17083.
XX
PT Polynucleotides encoding mammalian endoglucuronidases, especially
PT heparanases, useful to promote wound healing
XX
PS Claim 11; Page 76-79; 112pp; English.
XX
CC The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulphates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG.
XX
SQ Sequence 1723 BP; 461 A; 407 C; 412 G; 443 T; 0 other;

Query Match 75.4%; Score 19.6; DB 20; Length 1723;
Best Local Similarity 84.6%; Pred. No. 42;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CGCATATGACAGAGCTGTGACCTG 26
||| ||||| ||||| ||||| |||||
Db 149 CGCAAGCACAGAGCTGTGACCTG 174

Search completed: February 16, 2004, 09:18:10
Job time : 13.7569 secs

This Page Blank (uspio)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 ; Search time 100.997 Seconds
(without alignments)
6256.802 Million cell updates/sec

Title: US-10-676-079-4
Perfect score: 26
Sequence: 1 cgcatacagcagcagctcgtgacctg 26

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 22781392 seqs, 12152238056 residues
Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
EST:
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hlc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hlc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estcom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rtd:*
26: em_gss_phg:*
27: em_gss_vrt:*
28: gb_gss1:*
29: gb_gss2:*

Prod. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	19.8	76.2	677	14	CD044218 pSHB013XH
2	19.6	75.4	881	14	CB988510 AGENCOURT
3	19.6	75.4	924	13	B0691142 AGENCOURT
4	19.6	75.4	1185	9	AL552174 AL552174

5	19.6	75.4	1201	9	AL545270
6	19.4	74.6	850	29	CNS0448C
7	19.4	74.6	871	12	B1754736
8	19.2	73.8	613	28	BH051472
9	19.2	73.8	613	28	AZ62831
10	19.2	73.8	617	12	BJ008199
11	19.2	73.8	627	12	BJ487056
12	19.2	73.8	711	12	BJ533801
13	19.2	73.8	711	12	BJ533801
14	18.6	71.5	240	9	AA821887
15	18.6	71.5	374	9	AA821887
16	18.6	71.5	434	12	BG60581
17	18.6	71.5	520	9	AL750507
18	18.6	71.5	674	9	AL750507
19	18.6	71.5	1177	11	AK009597
20	18.6	71.5	1396	14	CD387962
21	18.6	71.5	1798	10	BG110194
22	18.6	71.5	2666	11	EC030655
23	18.4	70.8	196	9	AA243145
24	18.4	70.8	226	13	BY000868
25	18.4	70.8	248	13	BY063809
26	18.4	70.8	303	9	AA811576
27	18.4	70.8	358	9	AA769475
28	18.4	70.8	364	9	AA143664
29	18.4	70.8	367	13	BY072622
30	18.4	70.8	410	9	AA732339
31	18.4	70.8	577	10	AW977606
32	18.4	70.8	707	14	BY735903
33	18.4	70.8	730	14	CB031220
34	18.4	70.8	761	12	BI649991
35	18.4	70.8	854	12	BF581403
36	18.4	70.8	884	12	BI104061
37	18.4	70.8	2078	11	BC029952
38	18.2	70.0	285	10	BB181339
39	18.2	70.0	382	9	AA288247
40	18.2	70.0	423	14	CB131946
41	18.2	70.0	530	14	CB136264
42	18.2	70.0	622	28	AZ087080
43	18.2	70.0	622	13	BU110645
44	18.2	70.0	754	10	BE897409
45	18.2	70.0	759	12	BM018081

ALIGNMENTS

RESULT 1
CD044218
LOCUS
DEFINITION
CD044218 677 bp mRNA linear EST 09-MAY-2003
pSHB013XH08f.181768 pSHB: Infected hypocotyl soybean host. 48 hrs
post infection Phytophthora sojae cDNA clone SHB013XH08 5, mRNA
Sequence.

ACCESSION
CD044218 GI:30497811
VERSION
CD044218.1

KEYWORDS
SOURCE
ORGANISM
Phytophthora sojae
Phytophthora sojae
Eukaryota; Ectamniophiles; Oomycetes; Pythiales; Pythiaceae;
Phytophthora.

REFERENCE
AUTHORS
TITLE
USDA-IFAPs: Expression of Phytophthora sojae genes during infection
and propagation
Unpublished

JOURNAL
COMMENT
Tyler lab
Tyler B

VBI
1880 Pratt Dr., Blacksburg, VA 24061, USA
Tel: 540-231-7318
Email: bmtylet@vt.edu
PCR Primers
FORWARD: BK reverse
Plate: 013 row: H column: 08

Seq primer: BK reverse
High quality sequence stop: 677.
Location/Qualifiers

1. 677

/organism="Phytophthora sojae"
/mol_type="mRNA"

/db_xref="taxon:67593"

/clone="SHB013H08"

/tissue_type="infected host tissue"

/dev_stage="48 hour post infection"

/clone_1ib="pshB: Infected hypocotyl soybean host. 48 hrs post infection"

/note="Vector: pBK-CMV; Site 1: EcoRI; Site 2: XhoI; USDA-IPAFS: Expression of Phytophthora sojae genes during infection and propagation."

BASE COUNT 129 a 244 c 198 g 106 t

ORIGIN

Query Match 76.2% Score 19.8; DB 14; Length 677;

Best Local Similarity 91.3%; Pred. No. 6.3e+02; Mismatches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 ATATGACGACGCTGTGACCTG 26

Db 339 AGATCAGACGACGCTGTGACCTG 361

RESULT 2 CB988510 881 bp mRNA linear EST 01-MAY-2003

LOCUS AGENCOURT 13905817 NIH_MGC_147 Homo sapiens cDNA clone

DEFINITION IMAGE:30340461 5', mRNA sequence.

ACCESSION CB988510 GI:30283030

VERSION CB988510.1 GI:30283030

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 881)

NIH-MGC http://mgi.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished

Contact: Robert Strausberg, Ph.D.

Email: cga@bbs-remail.nih.gov

Tissue Procurement: Dr. Stefan Hansson

cDNA Library Preparation: Michael J. Brownstein (NHGRI) with help and advice from Piero Carninci (RIKEN)

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)

DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:

http://image.lnl.gov

Plate: NDA370 row: f column: 22

High quality sequence stop: 664.

Location/Qualifiers

1. 881

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:30340461"

/tissue_type="human placenta"

/lab_host="DH10B TONa"

/clone_1ib="NIH_MGC_147"

/note="Organ: Placenta; Vector: pBluescript, Site 1: all-XhoI; Site 2: BamHI; Oligo-dT primed using primer 5'-TTTTTTTTTTT-3', size-selected for average insert size 2.3 kb and normalized to 10⁶ 5. This is a primary library enriched for full-length clones and constructed using the Cap-trapper method (Carninci, in preparation). Library constructed by M. Brownstein (NIH/NHGRI, National Institutes of Health). Note: This is

BASE COUNT 200 a 244 c 229 g 208 t

ORIGIN

Query Match 75.4% Score 19.6; DB 14; Length 881;

Best Local Similarity 84.6%; Pred. No. 8.2e+02; Mismatches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CGCATATGACGACGCTGTGACCTG 26

Db 219 CGCAGACGACGACGCTGTGACCTG 244

RESULT 3 BO691142 924 bp mRNA linear EST 15-JUL-2002

LOCUS AGENCOURT 8343629 NIH_MGC_110 Homo sapiens cDNA clone IMAGE:6250265

DEFINITION BO691142 5', mRNA sequence.

ACCESSION BO691142 GI:21816458

VERSION BO691142.1 GI:21816458

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 924)

NIH-MGC http://mgi.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished

Contact: Robert Strausberg, Ph.D.

Email: cga@bbs-remail.nih.gov

Tissue Procurement: ATCC

cDNA Library Preparation: Rubin Laboratory

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)

DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:

http://image.lnl.gov

Plate: LCM2393 row: a column: 18

High quality sequence stop: 710.

Location/Qualifiers

1. 924

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:6250265"

/tissue_type="ductal carcinoma, cell line"

/lab_host="DH10B (phage-resistant)"

/clone_1ib="NIH_MGC_110"

/note="Organ: pancreas; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies).

Note: this is a NIH_MGC Library."

BASE COUNT 203 a 271 c 227 g 219 t 4 others

ORIGIN

Query Match 75.4% Score 19.6; DB 13; Length 924;

Best Local Similarity 84.6%; Pred. No. 8.3e+02; Mismatches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CGCATATGACGACGCTGTGACCTG 26

Db 232 CGCAGACGACGACGCTGTGACCTG 257

RESULT 4 AL552174 1185 bp mRNA linear EST 31-MAY-2003

LOCUS AL552174 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA

DEFINITION AL552174 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA

FEATURES	source
http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CS0D1028DC020P1&cluster=2469.r. Contact : Feng Liang Email : fliang@liscach.com URL : http://fulllength.invitrogen.com/Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CS0D1028DC020P1.	Location/Qualifiers 1. 1201 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CS0D1028rF04" /issue_type="PLACENTA COT 25-NORMALIZED" /clone_id="Homo sapiens PLACENTA COT 25-NORMALIZED" /note="1st strand cDNA was primed with a NotI-oligo (dr) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT	292 a 282 c 305 g 279 t 43 others
ORIGIN	
Query Match	75.4%; Score 19.6; DB 9; Length 1201;
Best Local Similarity	84.6%; Pred. No. 8.9e+02;
Matches	22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY	1 CGCATATCGAGGACGTGTCGACCTG 26
Db	219 CGCAGACGACGACGTGTCGACCTG 244
RESULT 6	
CNS0448C	
LOCUS	CNS0448C 850 bp DNA linear GSS 01-SEP-2000
DEFINITION	Tetradon nigroviridis genome survey sequence, PUC-ori end of clone 081G03 of library G from Tetradon nigroviridis, genomic survey sequence.
ACCESSION	AL273765
VERSION	AL273765.1 GI:7996028
KEYWORDS	GSS; genome survey sequence.
SOURCE	Tetradon nigroviridis
ORGANISM	Tetradon nigroviridis Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes; Tetraodontidae; Tetraodontidae; Tetradon.
REFERENCE	1
AUTHORS	Roest Crolius,H., Jalllon,O., Dasilva,C., Bouneau,L., Fisher,C., Bernot,A., Fitzames,C., Winckel,P., Brothier,P., Quetier,F., Saurin,W. and Weissenbach,J.
TITLE	Estimate of human gene number provided by genome-wide analysis using Tetradon nigroviridis DNA sequence
JOURNAL	Nat. Genet. 25 (2), 235-238 (2000)
MEDLINE	20296633
PUBMED	10835645
REFERENCE	2
AUTHORS	Roest Crolius,H., Jalllon,O., Dasilva,C., Ozouf-Costaz,C., Fitzames,C., Fischer,C., Bouneau,L., Billault,A., Quetier,F., Saurin,W., Bernot,A. and Weissenbach,J.
TITLE	Characterization and repeat analysis of the compact genome of the freshwater pufferfish Tetradon nigroviridis
JOURNAL	Genome Res. 10 (7), 939-949 (2000)
MEDLINE	20359837
PUBMED	10899143
REFERENCE	3 (bases 1 to 850)
AUTHORS	Genoscope.
TITLE	Direct Submission
JOURNAL	Submitted (12-APR-2000) Genoscope - Centre National de Sequencage : BP 191 91006 Evry cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
COMMENT	- Web : www.genoscope.cns.fr) This sequence is a single read and was generated as part of a large scale clone-end sequencing project of the Tetradon nigroviridis genome. For more information, please take a look at http://www.genoscope.cns.fr/Tetradon.
FEATURES	Location/Qualifiers

```

source
1. 850
/organism="Tetraodon nigroviridis"
/mol_type="genomic DNA"
/db_xref="taxon:99883"
/clone_11b="G"
/clone_11b="G"
/notes="Genoscope sequence ID : C0B081AD02SP1-end :
PUC-Or1"

BASE COUNT      156 a      251 c      258 g      179 t      6 others
ORIGIN

Query Match      74.6%; Score 19.4; DB 29; Length 850;
Best Local Similarity 95.2%; Pred. No. 9.7e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY
6 ATGCAGACGCTGTCGACCTG 26
|||||
54 ATGCAGACGCTGTCGACCTG 74

RESULT 7
LOCUS      B1754736      871 bp      mRNA      linear      EST 25-SEP-2001
DEFINITION 603025450F1 NIH_MGC_114 Homo sapiens cDNA clone IMAGE:5195845 5',
            mRNA sequence.
ACCESSION  B1754736
VERSION    B1754736.1 GI:15746314
KEYWORDS   EST.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
1 (bases 1 to 871)
NIH-MGC http://mgi.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed By: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
http://image.lnl.gov
Plate: LLM11490 row: c column: 14
High quality sequence stop: 644.
Location/Qualifiers
1. 871
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:5195845"
/lab_host="DH10B"
/clone_11b="NIH_MGC_114"
/notes="Organ: brain; Vector: pCMV-SPORT6; Site 1: NotI;
Site 2: EcoRV (destroyed); RNA source anonymous pool of 6
male brains, age range 23-27 yo. Library is oligo-dT
primed and directionally cloned (EcoRV site is destroyed
upon cloning). Average insert size 1.5 kb, insert size
range 1-3 kb. Library is normalized and enriched for
full-length clones and was constructed by C. Gruber
(invitrogen). Research Genetics tracking code 019. Note:
this is a NIH_MGC Library."

BASE COUNT      174 a      268 c      277 g      152 t
ORIGIN

Query Match      74.6%; Score 19.4; DB 12; Length 871;
Best Local Similarity 95.2%; Pred. No. 9.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY
6 ATGCAGACGCTGTCGACCTG 26
|||||

```

```

Db      558 ATGCAGACGCTGTCGACCTG 578

RESULT 8
LOCUS      BH051472      535 bp      DNA      linear      GSS 17-JUL-2001
DEFINITION RPCI-24-307N24.TV RPCI-24 Mus musculus genomic clone RPCI-24-307N24
            , genomic survey sequence.
ACCESSION  BH051472
VERSION    BH051472.1 GI:14843016
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 535)
Zhao,S., Nierman,W., Malek,J., Shatman,S., Aktinret,B., Levins,M.,
Tsegaye,G., Geer,K., Krol,M., Shavrtbeyn,A., Gebregorgis,E.,
Ruesell,D., de Jong,P. and Fraser,C.M.
Mouse BAC End Sequences from Library RPCI-24
Unpublished
Other_GSSs: RPCI-24-307N24.TV
Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@igr.org
Clones are derived from the mouse BAC library RPCI-24. For BAC
library availability, please contact Pieter de Jong
(pdejong@mail.cho.org). Clones may be purchased from BACPAC
Resources (http://www.choi.org/bacpac/orderingframe.html). BAC end
page: http://www.igr.org/cdb/bac_ends/mouse/bac_end_intro.html
Plate: 307 row: N column: 24
Seq primer: SP6
Class: BAC ends.
Location/Qualifiers
1. 535
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="RPCI-24-307N24"
/sex="Male"
/cell_type="Spleen/Brain"
/clone_11b="RPCI-24"
/notes="Vector: pTARBA1; Site 1: BamHI, Site 2: BamHI,
RPCI-24 Mouse BAC Library produced by Pieter de Jong. The
library was cloned in the pTARBA1 cloning vector at the
BamHI sites using MboI partially digested male C57BL/6J
DNA."

BASE COUNT      114 a      148 c      166 g      107 t
ORIGIN

Query Match      73.8%; Score 19.2; DB 28; Length 535;
Best Local Similarity 87.5%; Pred. No. 1e+03;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY
3 CATATGACGACGCTGTCGACCTG 26
|||||
150 CATGACGACGACGCTGTCGACCTG 173

RESULT 9
LOCUS      A2362831      613 bp      DNA      linear      GSS 02-OCT-2000
DEFINITION IM0108002F Mouse 10kb plasmid UUCG1M library Mus musculus genomic
            clone UUCG1M0108002 F, genomic survey sequence.
ACCESSION  A2362831
VERSION    A2362831.1 GI:10476531
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)

```


Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: east@wustl.wustl.edu
This clone is available royalty-free through LIND ; contact the
IMAGE Consortium (info@image.lind.gov) for further information.
Insert Length: 1694 Std Error: 0.00
Seq primer: -28ml3 rev1 ET from Amersham
High quality sequence stop: 130.

FEATURES

source

Location/Qualifiers
1..240

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:5925988"
/db_xref="taxon:9606"
/clone="IMAGE:729459"
/sex="male"
/lab_host="DH10B"
/clone_lib="Soares testis NHT"
/note="Vector: pT7T3D-Pac (Pharmacia) with a modified
polylinker. Site 1: Not I; Site 2: Eco RI; 1st strand cDNA
was prepared from mRNA obtained from Clontech Laboratories
, Inc., and primed with a Not I - oligo(dT) primer [5'
TGTTACCAATCTGAGTGGAGCGCGCCCAATTTTCTTTTCTT 3']
Double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT7T3 vector. Library
went through one round of normalization to Cot5, and was
constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT

51 a 72 c 50 g 67 t

ORIGIN

Query Match 71.5%; Score 18.6; DB 9; Length 240;
Best Local Similarity 84.0%; Pred. No. 1.4e+03;
Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 2 GCATATGACGAGCGTCGTGACCTG 26

Db 227 GCATATGACGAGCGTCGTGACCTG 203

RESULT 15

AA821887

LOCUS

AA821887 374 bp mRNA linear EST 17-FEB-1998
DEFINITION vp23a05.r1 StrataGene mouse diaphragm (#937303) Mus musculus cDNA
Clone IMAGE:1077488 5', mRNA sequence.

ACCESSION

AA821887

VERSION

AA821887.1 GI:2891755

KEYWORDS

EST.

SOURCE

Mus musculus (house mouse)

ORGANISM

Mus musculus

REFERENCE

1 (bases 1 to 374)
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Marras, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T.,
Geisler, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M.,
Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B.,
Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and
Waterston, R.

AUTHORS

The WashU-HHMI Mouse EST Project

TITLE

Unpublished

JOURNAL

Contact: Marra M/Mouse EST Project

COMMENT

WashU-HHMI Mouse EST Project

COMMENT

Washington University School of Medicine

COMMENT

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

COMMENT

Tel: 314 286 1800

COMMENT

Fax: 314 286 1810

COMMENT

Email: mouseest@wustl.wustl.edu

COMMENT

This clone is available royalty-free through LIND ; contact the

COMMENT

IMAGE Consortium (info@image.lind.gov) for further information.

COMMENT

Seq primer: -28ml3 rev1 ET from Amersham

High quality sequence stop: 371.
Location/Qualifiers
1..374

FEATURES

source

/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="IMAGE:1077488"
/issue_type="diaphragm"
/dev_stage="adult"
/lab_host="SOIR (kanamycin resistant)"
/clone_lib="StrataGene mouse diaphragm (#937303)"
/note="Organ: diaphragm; Vector: pBluescript SK-; Site 1:
EcoRI; Site 2: XhoI; Cloned unidirectionally from mRNA
prepared from diaphragm muscle. Primer: Oligo dT. Average
insert size: 1.5 kb. Uni-ZAP XR Vector; ~5' adaptor
sequence: 5' GAATTCGGCAGAG 3' ~3' adaptor sequence: 5'
CTCGAGTTTCTTTTCTTTTCTTTT 3' "

BASE COUNT

72 a 113 c 130 g 59 t

ORIGIN

Query Match 71.5%; Score 18.6; DB 9; Length 374;
Best Local Similarity 84.0%; Pred. No. 1.6e+03;
Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 2 GCATATGACGAGCGTCGTGACCTG 26

Db 99 GCCTGTGACGAGGCTCGGACCTG 123

Search completed: February 16, 2004, 13:40:54
Job time : 105.997 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 124.136 Seconds

(without alignments)
8568.399 Million cell updates/sec

Title: US-10-676-079-4

Perfect score: 26

Sequence: 1 cgcatacgacgacgtcgtgacctg 26

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

```
1: gb_ba:*
2: gb_hcg:*
3: gb_in:*
4: gb_ov:*
5: gb_ov:*
6: gb_ov:*
7: gb_ov:*
8: gb_ov:*
9: gb_ov:*
10: gb_ov:*
11: gb_ov:*
12: gb_ov:*
13: gb_ov:*
14: gb_ov:*
15: gb_ov:*
16: gb_ov:*
17: gb_ov:*
18: gb_ov:*
19: gb_ov:*
20: gb_ov:*
21: gb_ov:*
22: gb_ov:*
23: gb_ov:*
24: gb_ov:*
25: gb_ov:*
26: gb_ov:*
27: gb_ov:*
28: gb_ov:*
29: gb_ov:*
30: gb_ov:*
31: gb_ov:*
32: gb_ov:*
33: gb_ov:*
34: gb_ov:*
35: gb_ov:*
36: gb_ov:*
37: gb_ov:*
38: gb_ov:*
39: gb_ov:*
40: gb_ov:*
41: gb_ov:*
```

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	26	100.0	26	AR125605	AR125605 Sequence
2	26	100.0	26	AR194191	AR194191 Sequence
3	26	100.0	26	AR221287	AR221287 Sequence
4	26	100.0	26	AR243205	AR243205 Sequence
5	26	100.0	26	AR287437	AR287437 Sequence
6	20	76.9	30	AX557108	AX557108 Sequence
7	19.8	76.2	10328	AE006005	AE006005 Caulobact
8	19.6	75.4	474	AX136496	AX136496 Sequence
9	19.6	75.4	474	BD123736	BD123736 Secretory
10	19.6	75.4	605	AX557103	AX557103 Sequence
11	19.6	75.4	1419	AX557106	AX557106 Sequence
12	19.6	75.4	1593	AR210040	AR210040 Sequence
13	19.6	75.4	1593	BD136761	BD136761 Human pla
14	19.6	75.4	1694	AF152376	AF152376 Homo sapi
15	19.6	75.4	1713	AR156691	AR156691 Sequence
16	19.6	75.4	1713	AX034643	AX034643 Sequence
17	19.6	75.4	1721	AR080679	AR080679 Sequence
18	19.6	75.4	1721	AR080680	AR080680 Sequence
19	19.6	75.4	1721	AR125603	AR125603 Sequence
20	19.6	75.4	1721	AR125604	AR125604 Sequence
21	19.6	75.4	1721	AR194189	AR194189 Sequence
22	19.6	75.4	1721	AR194190	AR194190 Sequence
23	19.6	75.4	1721	AR221285	AR221285 Sequence
24	19.6	75.4	1721	AR221286	AR221286 Sequence
25	19.6	75.4	1721	AR243203	AR243203 Sequence
26	19.6	75.4	1721	AR243204	AR243204 Sequence
27	19.6	75.4	1721	AR287435	AR287435 Sequence
28	19.6	75.4	1721	AR287436	AR287436 Sequence
29	19.6	75.4	1721	BD074427	BD074427 Polynucle
30	19.6	75.4	1721	BD074428	BD074428 Polynucle
31	19.6	75.4	1722	AX136167	AX136167 Sequence
32	19.6	75.4	1722	BD123536	BD123536 Secretory
33	19.6	75.4	1722	AK075400	AK075400 Homo sapi
34	19.6	75.4	1723	AR156692	AR156692 Sequence
35	19.6	75.4	1723	AX034645	AX034645 Sequence
36	19.6	75.4	1724	AX147946	AX147946 Sequence
37	19.6	75.4	1724	AF165154	AF165154 Homo sapi
38	19.6	75.4	1758	AF144325	AF144325 Homo sapi
39	19.6	75.4	1810	BC051321	BC051321 Homo sapi
40	19.6	75.4	1899	BD074430	BD074430 Polynucle
41	19.6	75.4	1899	BD074431	BD074431 Polynucle
42	19.6	75.4	3726	AR235866	AR235866 Sequence
43	19.6	75.4	3726	AX019348	AX019348 Sequence
44	19.6	75.4	3726	BD131218	BD131218 Human hep
45	19.6	75.4	3726	AF155510	AF155510 Homo sapi

ALIGNMENTS

RESULT 1
LOCUS AR125605
DEFINITION Sequence 4 from patent US 6177545.
ACCESSION AR125605
VERSION AR125605.1 GI:14111667
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 26)
Pecker, I., Vlodavsky, I., Friedman, Y. and Peretz, T.
Heparanase specific molecular probes and their use in research and
medical applications
JOURNAL Patent: US 6177545-A 4 23-JAN-2001;

FEATURES
source
location/Qualifiers
1..26
/organism="unknown"

BASE COUNT
5 a 7 c 9 g 5 t

ORIGIN

Query Match
Best Local Similarity 100.0%; Score 26; DB 6; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy
1 CGCATATGCAGAGCGTGTGACCTG 26
|||||
1 CGCATATGCAGAGCGTGTGACCTG 26

RESULT 2
AR194191
LOCUS AR194191 26 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4 from patent US 6348344.
ACCESSION AR194191
VERSION AR194191.1 GI:20240783
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 26)
Ayal-HersHKovitz,M., Moskowicz,H., Miron,D., Gilboa,A., Mimon,M.,
Ben-Artzi,H., Yacoby-Zeevi,O., Pecker,I., Peleg,Y. and Schloni,Y.
TITLE Genetically modified cells and methods for expressing recombinant
heparanase and methods of purifying same
JOURNAL Patent: US 6348344-A 4 19-FEB-2002;
FEATURES location/Qualifiers
source 1..26
/organism="unknown"

BASE COUNT
5 a 7 c 9 g 5 t

ORIGIN

Query Match
Best Local Similarity 100.0%; Score 26; DB 6; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy
1 CGCATATGCAGAGCGTGTGACCTG 26
|||||
1 CGCATATGCAGAGCGTGTGACCTG 26

RESULT 3
AR221287
LOCUS AR221287 26 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 4 from patent US 6426209.
ACCESSION AR221287
VERSION AR221287.1 GI:23328258
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 26)
Ayal-HersHKovitz,M., Pecker,I. and Yacoby-Zeevi,O.
TITLE Genetically modified cells and methods for expressing recombinant
heparanase and methods of purifying same
JOURNAL Patent: US 6426209-A 4 30-JUL-2002;
FEATURES location/Qualifiers
source 1..26
/organism="unknown"

BASE COUNT
5 a 7 c 9 g 5 t

ORIGIN

Query Match
Best Local Similarity 100.0%; Score 26; DB 6; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy
1 CGCATATGCAGAGCGTGTGACCTG 26
|||||
1 CGCATATGCAGAGCGTGTGACCTG 26

Db
1 CGCATATGCAGAGCGTGTGACCTG 26
|||||
1 CGCATATGCAGAGCGTGTGACCTG 26

RESULT 4
AR243205
LOCUS AR243205 26 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 4 from patent US 6475763.
ACCESSION AR243205
VERSION AR243205.1 GI:27290320
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 26)
Ayal-HersHKovitz,M., Moskowicz,H., Miron,D., Gilboa,A., Mimon,M.,
Ben-Artzi,H., Yacoby-Zeevi,O., Pecker,I., Peleg,Y. and Shloni,Y.
TITLE Genetically modified cells and methods for expressing recombinant
heparanase and methods of purifying same
JOURNAL Patent: US 6475763-A 4 05-NOV-2002;
FEATURES location/Qualifiers
source 1..26
/organism="unknown"

BASE COUNT
5 a 7 c 9 g 5 t

ORIGIN

Query Match
Best Local Similarity 100.0%; Score 26; DB 6; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy
1 CGCATATGCAGAGCGTGTGACCTG 26
|||||
1 CGCATATGCAGAGCGTGTGACCTG 26

RESULT 5
AR287437
LOCUS AR287437 26 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 4 from patent US 6531129.
ACCESSION AR287437
VERSION AR287437.1 GI:29725131
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 26)
Pecker,I., Vlodavsky,I., Friedman,Y. and Peters,T.
TITLE Heparanase specific molecular probes and their use in research and
medical applications
JOURNAL Patent: US 6531129-A 4 11-MAR-2003;
FEATURES location/Qualifiers
source 1..26
/organism="unknown"

BASE COUNT
5 a 7 c 9 g 5 t

ORIGIN

Query Match
Best Local Similarity 100.0%; Score 26; DB 6; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy
1 CGCATATGCAGAGCGTGTGACCTG 26
|||||
1 CGCATATGCAGAGCGTGTGACCTG 26

RESULT 6
AX557108
LOCUS AX557108 30 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 6 from Patent W00244353.
ACCESSION AX557108
VERSION AX557108.1 GI:25900161
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

REFERENCE 1 artificial sequences.
AUTHORS Wolffe, A.P.
TITLE Human heparanase gene regulatory sequences
JOURNAL Patent: WO 0244353-A 6 06-JUN-2002;
Sangamo Biosciences Inc. (US)
FEATURES
source Location/Qualifiers
1. 30
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Primer Hp-6"
BASE COUNT 4 a 9 c 9 g 8 t
ORIGIN
Query Match 76.9% Score 20; DB 6; Length 30;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Cy 7 TGCAGAGCTGCTGACCTG 26
2 TGCAGAGCTGCTGACCTG 21
Db
RESULT 7
AE006005/c 10328 bp DNA linear BCT 12-JUN-2002
LOCUS Caulobacter crescentus CB15 section 331 of 359 of the complete
DEFINITION genome.
ACCESSION AE006005 AE005673
VERSION AE006005.1 GI:13425180
KEYWORDS
SOURCE
ORGANISM Caulobacter crescentus CB15
Caulobacter crescentus CB15
Bacteria; Proteobacteria; Alphaproteobacteria; Caulobacterales;
Caulobacteraceae; Caulobacter.
REFERENCE 1 (bases 1 to 10328)
AUTHORS Nierman, W.C., Feldblum, T.V., Laub, M.T., Paulsen, I.T., Nelson, K.E.,
Eisen, J., Heidelberg, J.F., Alley, M.R.K., Ohta, N., Maddock, J.R.,
Potocka, I., Nelson, W.C., Newton, A., Stephens, C., Phadke, N.D., Ely, B.,
DeBoy, R.T., Dodson, R.J., Durkin, A.S., Gwinn, M.L.,
Hart, D.H., Kolonay, J.F., Smit, J., Craven, M., Khouli, H., Shetty, J.,
Berry, K., Uterback, T., Tran, K., Wolf, A., Vamathevan, J.,
Ermolaeva, M., White, O., Salzberg, S.L., Venter, J.C., Shapiro, L. and
Fraser, C.M.
TITLE Complete genome sequence of Caulobacter crescentus
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 98 (7), 4136-4141 (2001)
MEDLINE 11259647
PUBMED
REFERENCE 2 (bases 1 to 10328)
AUTHORS Nierman, W.C., Feldblum, T.V., Paulsen, I.T., Nelson, K.E., Eisen, J.,
Heidelberg, J.F., Alley, M.R.K., Ohta, N., Maddock, J.R., Potocka, I.,
Nelson, W.C., Newton, A., Stephens, C., Phadke, N.D., Ely, B.,
Laub, M.T., DeBoy, R.T., Dodson, R.J., Durkin, A.S., Gwinn, M.L.,
Hart, D.H., Kolonay, J.F., Smit, J., Craven, M., Khouli, H., Shetty, J.,
Berry, K., Uterback, T., Tran, K., Wolf, A., Vamathevan, J.,
Ermolaeva, M., White, O., Salzberg, S.L., Shapiro, L., Venter, J.C. and
Fraser, C.M.
TITLE Direct Submission
JOURNAL Submitted (31-JUN-2001) The Institute for Genomic Research, 9712
Medical Center Dr, Rockville, MD 20850, USA
FEATURES
source Location/Qualifiers
1. 10328
/organism="Caulobacter crescentus CB15"
/mol_type="genomic DNA"
/strain="CB15"
/db_xref="taxon:190650"
/complement (90..2633)
/gene="CC3461"
/complement (90..2633)
/gene="CC3461"
/note="Identified by match to protein family HMM"
/codon_start=1

gene
CDS
/transl_table=11
/product="TonB-dependent receptor"
/protein_id="AAK25423.1"
/db_xref="GI:13425181"
/translation="MTVLSVSNALLIMPSFVDFHDEBGPGRCCVSGNSKAKNTR
EEIMTIVSSGRALPLFGASALSSLLAGVIALPSVATAQADNNAIAETIIVARTRD
ATIQDIPFSINAQTEKDIQRSGAVTLEDSLRNVAAGLTQILNGRQSQVSGVAGV
VRDQPGVEQVGLVLDSEVLSLFTFDDVLPFLNREITRGLPQSTFGSGVGGTR
YINRQPLGSEGFEEFANANLVODDAGGVKGVNPIEDKILAMRAVGLTQYGF
DAREGEGKDVKNVNDGRRGGRRSFYIEPQVONPFRVYVQELRAGFRQETNLF
ANNTRTPRKIQGERQYLLIDERSDNTLLDMTRNLKFDATLTLSVTSFISRDIT
VSRDASLTGSVSVDIGYPAAVLPSNLNDDTDEBTQELRLASTTDDPLOWVIG
FSYKDVAVNQRLPTTGDTYTDVAVLAGSAAVANGFSDSPYNATLPYDIQKALP
GELNATVIGKLTATAGRYDYPSETRQFSGSLFANGDNRTDXTSIDGTFPFLSYFA
SDFTVFAASKGRGLGVNDPLNIPICSAQDRAIPFGYONODELTLMYEGVSRF
GRVTLNAAFTYDIKNLQTLTDAGSGSRVFNVPVAKTHGVEAEELARLANGIDLT
SGSLLEAFSTYKDKGAVIGIRBENRPLSPYKRVSDYVTSKRVAGVGLLA
SLQHVGNRFTQASDQENNPRLFVSNLFGGATGVPAVNLALPSYEVILVLSAGLEWQ
DGVDTLVYNNLPDENALLSPDRERGGARLGYAVGQPRTMGVTVRSF"
2758..3945
/gene="CC3462"
2758..3945
/gene="CC3462"
/note="Identified by match to protein family HMM"
/codon_start=1
/transl_table=11
/product="thiolase family protein"
/protein_id="AAK25424.1"
/db_xref="GI:13425182"
/translation="MREAVIVSYARTGLAKSVRGFNNTGAMAGHAIGHAVSRAQL
EGAEVDVVLVGGCGEGATGMVNAVNAMAGLPVTTSGOTINRFSSGLQALATAAN
YRNEDGVANVAIGGVESISLVNAGHNRPHIIEKMLQHPALMAMIDTADIVAR
YVSRXYODEYALRSQORIAAOAGLFXEIVPMATKMYNNKETEESFVYVVK
DECNRADTTLEGLASLKPWNGEKFITAGNASOLSDPAVVVMAEAKRGITLPG
AFRGPVAGCEPPEWKGIVPFAVPRLLERHGLKXDDIDIELNAPASQCLYSRDRIG
IDPEKYNVNGSGIAIGHPFMTGARCGHLLBGRKAKLGVVTWCTIGGQMGAGLPE
EIP"
complement (3998..4279)
/gene="CC3463"
complement (3998..4279)
/gene="CC3463"
/note="Identified by glimmer2; putative"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="AAK25425.1"
/db_xref="GI:13425183"
/translation="MMELTRMELTVLRQAQDBDFLRTANSRPHPELVEGRGLLRGD
QHFTSKQPKERPETAQAVSGLFQSFSTLSDCAVNRQKISNRPAAPLWIA"
complement (4343..7246)
/gene="CC3464"
complement (4343..7246)
/gene="CC3464"
/note="Identified by match to protein family HMM"
/codon_start=1
/transl_table=11
/product="DNA polymerase I"
/protein_id="AAK25426.1"
/db_xref="GI:13425184"
/translation="MLPAMTDAAAPLPNASELTODGPVAVRLFVDSAVLFRAYNAL
PPLTRKSDGLPVGAVGFCNMLWKLRLADGDPPTHLAVIMSEKFFRPAIDQYVA
HRPPPELDLPPLVREATLFGVPIELRGVADDLIAVACADSDIGEAIIIVS
DKOLMOLVGVGVSMYDMKGVRIERQVPEKRGVYKVDVQALCSDSDVNGVAG
IGIKTAQQLITTEYGDLDTLARAGETIKQPKRRTLINFADQIRLSRLVYLDCTPIR
QPLDALTVREPDKEALAAFLQMFPSRLARVDSAAATPGTLDRPAAPKAAVVS
SYMGAAABAABHVEPVKIDHAAVACVDRDIAKAWAKATDGLVAFDETPALSSA
TAGLCGVSLAIAGEACYIPISHCERKADGAFAPADIEQIPLADVATIKPLIEDPA
LVKVAONAKYDIAVLARHGOVAPIETIMLISVLEKGLGHGDELSLHGLKPP
PKOVASGKQGISFKYVALPEATAYAAEDVDYTLRYNHKKPLARASISTVYETTER
PMFPAVLAMENNGVYDPEALRLSNFSIRMAQFRADELVGRPNLSSQYIGV
LFGBMQKGGKRTATQGWSTDSVLSLAEHLPRVLWDWQLSKLGTGYTEYLIA
IASPTGVHTSVLAATTTORLSSSDPNLQNIIVRTEBGRKIRKAPAAAGHVALISD
YSQIELRLAHIGDIPQLKKAFOEGLDIHAMTASEMDPPIEGMDPMIRRAKAINFG

IVGISAAGLANOIGISGAGAYIKTYFERPGIOAYMDATKAFVREHGVTITFGR
KINI PDIEAKSAHROPERRAIPINAPIOGAADWBRMIPVLAAGISTMILQ
VHDELVEAPAEAEERACAVRAVMEKAEPAVALSTPLTEAALASMDAH"
7355..9202
/gene="CC3465"
7355..9202
/gene="CC3465"
/note="identified by match to protein family HMW"
/codon_start=1
/transl_table=1
/product="ATP-dependent DNA helicase RecQ"
/protein_id="AAK25427.1"
/db_xref="GI:13425185"
/translation="MYVPPESPPELDRAVDLRRTEGHADPRLQAGVITHELTHSNA
AVLPTGGKSLCYQIPSLIRPGLGIVISPLALMADQVQGRQGVAAERDSNSMD
ERSDIWRIDAGEVDLTLSPGLMQLPMLRLSTPLALAVDAHCVSGWGHFRP
EYRMIGRLAEFLPDA PRLAVTADARTRDDIRAEIRLOGAFAVDSFARLALAS
RKRGKGRVVELVLEPRGSGVIYAGSDGTETKLAERLNEGVPALAVHGLDKAVR
ARLEDFLEADAAVAVATIAFGMGVDKDVYVHADPPALIEAVMOEVRAGRDGP
AEGITVGSAMANAARIETREAPDEVKOSRKLQFVAMLEGVTCRAAAVRVYG
EEGVHCGVCDCICSPPTGIDATQAQKALAVHRLGRLGRVITHELMKTDVTP
QEAQPLTFIGERFSQPTWRDLFTLLIFEGLRDPNGRFLIGLGDVEGRQVYRNE
RKVALRQTTDAPDSGGRAGGRRKREGRALTI PAENQLFEALRSWKREQAOLQHV
PYVIFHDATTIAEIAARPAITLALGKAGVCGKLDRYGEAVLKVREN"
9247..9555
/gene="CC3466"
9247..9555
/gene="CC3466"
/note="identified by Glimmer2; putative"
/codon_start=1
/transl_table=1
/product="hypothetical protein"
/protein_id="AAK25428.1"
/db_xref="GI:13425186"
/translation="MTWNSLTPSDITSVVDIVENTKRAQDALDAVKSARDTATEV
AQRTRFAEQARAGAAWTKQAKEAHVADHDHFWGLALGAFGLIGLPLISRLAR
"
gene complement (9792..10250)
/gene="CC3467"
complement (9792..10250)
/gene="CC3467"
/note="identified by Glimmer2; putative"
/codon_start=1
/transl_table=1
/product="conserved hypothetical protein"
/protein_id="AAK25429.1"
/db_xref="GI:13425187"
/translation="MDVIELAPSRPETTLAVTRGAARLVDLVYAPLAEVTLPNGR
ADIMALGPKGVLIYEVKSGLEDPRDKMGDVAPFCDAFYFAVAVSPPDGLPDPG
LLVADGPGGAVVREAPLTPPLAPARKALTALFGRLLAARAAVNAERLS"
BASE COUNT 1665 a 3459 c 3503 g 1701 t
ORIGIN
Query Match 76.2%; Score 19.8; DB 1; Length 10328;
Best Local Similarity 91.3%; Pred. No. 5.7e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4 ATATGCAGACGCTGTCGACCTG 26
DB 247 AGATGCAGACGCGCTGACCTG 225
RESULT 8
AXI36496 474 bp DNA linear PAT 30-MAY-2001
LOCUS AXI36496 418 from Patent EP1067182.
DEFINITION AXI36496
ACCESSION AXI36496
VERSION AXI36496.1 GI:14272900
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Ota, T., Isogai, T., Nishikawa, T., Kawai, Y., Sugiyama, T. and
Hayashi, K.
TITLE Secretory protein or membrane protein
JOURNAL Helix Research Institute (JP)
FEATURES
source 1..474
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 86 a 154 c 127 g 101 t 6 others
ORIGIN
Query Match 75.4%; Score 19.6; DB 6; Length 474;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 CGCATATGCAGACGCTGTCGACCTG 26
DB 161 CGCAGACACGACGCTGTCGACCTG 186
RESULT 9
BD123736 474 bp DNA linear PAT 18-SEP-2002
LOCUS BD123736
DEFINITION Secretory protein or membrane protein.
ACCESSION BD123736
VERSION BD123736.1 GI:23218681
KEYWORDS JP 2002017376-A/245.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 474)
AUTHORS Ota, T., Isogai, T., Nishikawa, T., Kawai, Y., Sugiyama, T. and
Hayashi, K.
TITLE Secretory protein or membrane protein
JOURNAL Patent: JP 2002017376-A 245 22-JUN-2002;
COMMENT HELIX RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002017376-A/245
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253173
PI TOSHIO OTA, TAKAO ISOGAI, TETSUO NISHIKAWA, YURI KAWAI, TOMOYASU
PI SUGIYAMA,
PI KOJI HAYASHI
PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/ PC
10, C12P21/02, C12Q1/68//C12P21/08, C12N15/00, C12N5/00 CC
Secretory protein or membrane protein
FT Key Location/Qualifiers
FT source 1..474
Location/Qualifiers
1..474
/organism="Homo sapiens (human)".
FEATURES
source 1..474
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 86 a 154 c 127 g 101 t 6 others
ORIGIN
Query Match 75.4%; Score 19.6; DB 6; Length 474;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 CGCATATGCAGACGCTGTCGACCTG 26
DB 161 CGCAGACACGACGCTGTCGACCTG 186
RESULT 10

AX557103 605 bp DNA linear PAT 27-NOV-2002
LOCUS AX557103
DEFINITION Sequence 1 from Patent WO0244353.
ACCESSION AX557103
VERSION AX557103.1 GI:25900156
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Wolffe,A.P.
TITLE Human heparanase gene regulatory sequences
JOURNAL Patent: WO 0244353-A 1 06-JUN-2002;
Sangamo Biosciences Inc. (US)
FEATURES
source
1. 605
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="first and second exons of human heparanase gene"
BASE COUNT 96 a 187 c 230 g 92 t
ORIGIN

Query Match 75.4%; Score 19.6; DB 6; Length 605;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 CGCATATGCAGACGTCGTGACCTG 26
Db 468 CGCAGACGACGACGTCGTGACCTG 493

RESULT 11
LOCUS AX557106 1419 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 4 from Patent WO0244353.
ACCESSION AX557106
VERSION AX557106.1 GI:25900159
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Wolffe,A.P.
TITLE Human heparanase gene regulatory sequences
JOURNAL Patent: WO 0244353-A 4 06-JUN-2002;
Sangamo Biosciences Inc. (US)
FEATURES
source
1. 1419
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="human heparanase gene in the vicinity of the
upstream region"

BASE COUNT 329 a 352 c 452 g 286 t
ORIGIN

Query Match 75.4%; Score 19.6; DB 6; Length 1419;
Best Local Similarity 84.6%; Pred. No. 7.2e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 CGCATATGCAGACGTCGTGACCTG 26
Db 1282 CGCAGACGACGACGTCGTGACCTG 1307

RESULT 12
LOCUS AR210040 1593 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 1 from patent US 6387643.
ACCESSION AR210040
VERSION AR210040.1 GI:21512167
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 1593)
AUTHORS Heinrichson,R.Leroy, Fairbanks,M.B. and Mildner,A.M.
TITLE Human platelet heparanase polypeptides, polynucleotide molecules
that encode them, and methods for the identification of compounds
that alter heparanase activity
JOURNAL Patent: US 6387643-A 1 14-MAY-2002;
FEATURES
source
1. 1593
/organism="unknown"
BASE COUNT 426 a 370 c 369 g 428 t
ORIGIN

Query Match 75.4%; Score 19.6; DB 6; Length 1593;
Best Local Similarity 84.6%; Pred. No. 7.2e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 CGCATATGCAGACGTCGTGACCTG 26
Db 59 CGCAGACGACGACGTCGTGACCTG 84

RESULT 13
LOCUS BD136761 1593 bp DNA linear PAT 18-SEP-2002
DEFINITION Human platelet heparanase polypeptide, polynucleotide molecule
encoding the same and method of identifying compound changing
heparanase activity.
ACCESSION BD136761
VERSION BD136761.1 GI:23231706
KEYWORDS JP 2002504376-A/1.
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 1593)
AUTHORS Heinrichson,R.L., Fairbanks,M.B. and Mildner,A.M.
TITLE Human platelet heparanase polypeptide, polynucleotide molecule
encoding the same and method of identifying compound changing
JOURNAL Patent: JP 2002504376-A 1 12-FEB-2002;
PHARMACIA & UPJOHN CO
COMMENT
OS Unidentified
PN JP 2002504376-A/1
PD 12-FEB-2002
PF 18-FEB-1999 JP 2000533569
PR 24-FEB-1998 US 60/075706,26-MAR-1998 US 60/079401 PI
ROBERT L. HEINRICHSON, MICHAEL B. FAIRBANKS, ANA M. MILDNER PC
C12N15/09,C07K16/40,C12N1/21,C12N5/10,C12N9/24,C12Q1/34,C12N15/00,C12N5/00
CC Strandedness: Double;
CC Topology: linear;
CC Human platelet heparanase polypeptide, polynucleotide molecule

CC encoding
CC the same and method of identifying compound changing CC
CC heparanase activity
FH key Location/Qualifiers
FT source 1. 1593
FT Location/Qualifiers
1. 1593
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 426 a 370 c 369 g 428 t
ORIGIN

Query Match 75.4%; Score 19.6; DB 6; Length 1593;
Best Local Similarity 84.6%; Pred. No. 7.2e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 CGCATATGCAGACGTCGTGACCTG 26

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using SW model

Run on: February 16, 2004, 07:55:00 ; Search time 844.407 Seconds
(without alignments)
5501.769 Million cell updates/sec

Title: US-10-676-079-1

Perfect score: 1721
Sequence: 1 ctgagcttcctgactctccg.....atctactgctcgcactg 1721

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

N Geneseq 19Jun03:*

1: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*

2: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*

3: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*

4: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*

5: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*

6: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*

7: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*

8: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*

9: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*

10: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*

11: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*

12: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*

13: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*

14: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*

15: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*

16: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*

17: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*

18: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*

19: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*

20: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*

21: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*

22: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*

23: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*

24: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

25: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1721	100.0	1721	20	AA35648
2	1721	100.0	1721	21	AA75051
3	1721	100.0	1721	21	AA23195
4	1721	100.0	1721	21	AA233290
5	1721	100.0	1721	22	AA91112
6	1719.4	99.9	1899	20	AA35650
7	1719.4	99.9	1899	21	AA75053
8	1713	99.5	1722	22	AA93788

9	1694.6	98.5	1713	20	AA37259
10	1688.8	98.1	1723	20	AA37260
11	1686.8	98.0	3726	20	AA36671
12	1682.6	97.8	1724	22	AA20940
13	1631.4	94.8	1659	25	AB222816
14	1585	92.1	1593	20	AA211236
15	1535	89.2	1584	24	ABL40753
16	1092	63.5	2396	21	AA475081
17	1092	63.5	2396	22	AA475081
18	802.2	46.6	1380	20	AA37261
19	786.2	45.7	1192	20	AA37262
20	595	34.6	553	24	ABL40748
21	486.8	28.3	1505	24	ABL68772
22	453	26.3	824	20	AA35649
23	453	26.3	824	21	AA35649
24	435.2	25.3	474	22	AA93984
25	433.6	25.2	504	22	AA94131
26	413.8	18.2	428	25	ABX51804
27	287.8	16.7	605	24	ABN86000
28	287.8	16.7	1419	24	ABN86003
29	287.8	16.7	44848	21	AA475080
30	285.2	16.6	2060	22	AA391097
31	284.8	16.5	1847	24	AA29202
32	284.8	16.5	2636	22	AAH2671
33	284.6	16.5	2496	24	AA170849
34	282	16.4	1779	22	AA313848
35	278.8	16.2	1779	22	AA313848
36	270.6	15.7	1685	24	AA28204
37	269.4	15.7	1898	22	AA491098
38	230.6	13.4	385	21	AA475082
39	197.6	11.5	1511	24	AA29205
40	196.4	11.4	1724	22	AA491099
41	196.4	11.4	1724	22	AA313843
42	196.4	11.4	2300	22	AAH2673
43	195.6	11.4	1674	24	AA28203
44	195	11.3	3943	22	AAH28347
45	194.4	11.3	1891	24	AB211527

ALIGNMENTS

RESULT 1
ID AA35648 standard: CDNA; 1721 BP.

AA35648;
09-JUL-1999 (first entry)

CDNA encoding a human heparanase protein.

Heparanase; hpa; modulator; heparin-binding growth factor;
cellular response; cytokine; cell interaction; plasma lipoprotein;
cellular susceptibility; infection; disintegration;

neurodegenerative plaque; wound healing; angiogenesis; restenosis;
atherosclerosis; inflammation; neurodegenerative disease; neutralise;
plasma heparin; micrometastasis; autoimmune lesion; renal failure;
88.

Homo sapiens.

WO9911798-A1.

11-MAR-1999.

31-AUG-1998; 98WO-US17954.

02-JUL-1998; 98US-0109386.
02-SEP-1997; 97US-0922170.

(FRIE/) FRIEDMAN M M.
(HADA-) HADASIT MEDICAL RES SERVICES & DEV.

Human heparanase e
Seq ID No: 14 of W
CDNA encoding a hu
Human heparanase i
Human heparanase e
Human pre-prohepar
CDNA encoding a mu
Mouse heparanase c
Murine heparanase
Rat heparanase enz
Chicken heparanase
Kidney cancer rela
3' untranslated re
Murine EST which i
Primer specific fo
Bovine EST associa
Human heparanase g
Human heparanase u
Nucleotide sequenc
Human heparanase-2
Human heparanase-2
Heparanase-like pr
DNA encoding hepar
Human heparanase-2
Human heparanase-2
Human heparanase-2
Rat EST which is h
Human heparanase-2
Human heparanase
DNA encoding novel
Heparanase-like pr
Human heparanase-2
Nucleotide sequenc
Human polynucleoti

PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX Feinstein E, Pecker I, Vlodavsky I;
XX WPI: 1999-302255/25.
DR P-PSDB; AAY02345.
XX
PT New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
XX
PS Claim 4; Fig 1; 63pp; English.
XX
CC The specification describes a polypeptide having heparanase (hpa)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC The present sequence encodes human heparanase.
XX
SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other:

Query Match 100.0%; Score 1721; DB 20; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTAAGCTTTGACCTCTCCGCGCGGAGCTGGCGGGGAGAGCAGCTGAGCCCA 60
DB 1 CTAGAGCTTTTACACTCTCCGCTGCGCGAGCTGGCGGGGAGAGCAGCTGAGCCCA 60
QY 61 AGATCTGCTGCGCTGCAAGCCTGCGCTGCCCGCGCTGATGCTGCTCTGAGGC 120
DB 61 AGATCTGCTGCGCTGCAAGCCTGCGCTGCCCGCGCTGATGCTGCTCTGAGGC 120
QY 121 CGTGGGTCCTCTCCCTGCGCGCTGCGCGCGAGCTGCGAGCAGACAGAGCTGCG 180
DB 121 CGTGGGTCCTCTCCCTGCGCGCTGCGCGCGAGCTGCGAGCAGACAGAGCTGCG 180
QY 181 ACCTGGAATCTTTCACCCAGAGGCGGCTGCACTGTGAGCCCTCTCTCTCCGTC 240
DB 181 ACCTGGAATCTTTCACCCAGAGGCGGCTGCACTGTGAGCCCTCTCTCTCCGTC 240
QY 241 CCATTGAGCGCAACCTGGCGACGACCGCGGCTCTCATCTCTCTGGGTTCTCCAAAGC 300
DB 241 CCATTGAGCGCAACCTGGCGACGACCGCGGCTCTCATCTCTCTGGGTTCTCCAAAGC 300
QY 301 TTTCGATCTTGGCGCAGAGGCTTGTCTCTGCTGACCTGAGGTTGGTGGCAGCAAGAG 360
DB 301 TTTCGATCTTGGCGCAGAGGCTTGTCTCTGCTGACCTGAGGTTGGTGGCAGCAAGAG 360
QY 361 ACTTCTCAATTTTGCATCCCAAGAGGATCAACTTTGAAGAGGAATTACTGGCAAT 420
DB 361 ACTTCTCAATTTTGCATCCCAAGAGGATCAACTTTGAAGAGGAATTACTGGCAAT 420
QY 421 CTCAGATCAACAGAGATATTGCAATATGATCCATCCCTCTGATGTGGAGGAAAGT 480
DB 421 CTCAGATCAACAGAGATATTGCAATATGATCCATCCCTCTGATGTGGAGGAAAGT 480
QY 481 TACGGTTGAATGGCCCTACAGAGCAATTTGCTACTCGAGAAACACTACAGAAAAGT 540
DB 481 TACGGTTGAATGGCCCTACAGAGCAATTTGCTACTCGAGAAACACTACAGAAAAGT 540
QY 541 TCAGAAACAGCAGCTACTCAAGAGCTGTGATGTGCTATACACTTTTGGCAACTGCT 600
DB 541 TCAGAAACAGCAGCTACTCAAGAGCTGTGATGTGCTATACACTTTTGGCAACTGCT 600
QY 601 CAGGACTGAGCTTATCTTTGGCCTAAATGGCTTATTAAGAACAGAGATTGGAGTGA 660

DB 601 CAGGACTGAGCTTATCTTTGGCCTAAATGGCTTATTAAGAACAGAGATTGGAGTGA 660
QY 661 ACAGTTCTAATGCTCAGTGTCTCTGACCTAATCTCTTCCAAAGGATATAAATTCTT 720
DB 661 ACAGTTCTAATGCTCAGTGTCTCTGACCTAATCTCTTCCAAAGGATATAAATTCTT 720
QY 721 GGGAACTAGGAAAGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCATCATAGGGT 780
DB 721 GGGAACTAGGAAAGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCATCATAGGGT 780
QY 781 CGCAGTTAGAGAAAGATTATATTCATTTGCAATTAACCTTTAAGAAAGTCCACTTCAAAA 840
DB 781 CGCAGTTAGAGAAAGATTATATTCATTTGCAATTAACCTTTAAGAAAGTCCACTTCAAAA 840
QY 841 ATGCAAACTTAATGCTCTAATGTTGTGTCAGCTCCGAGAAAGAAACCGCTAAAGTCTGA 900
DB 841 ATGCAAACTTAATGCTCTAATGTTGTGTCAGCTCCGAGAAAGAAACCGCTAAAGTCTGA 900
QY 901 AGAGCTTCTGAAGGCTGTGAGAGATTTGATTCAGTTACATGAGCATCACTACTATT 960
DB 901 AGAGCTTCTGAAGGCTGTGAGAGATTTGATTCAGTTACATGAGCATCACTACTATT 960
QY 961 TGAATGACGAGACTGCTACACAGAGAGATTTTCTTAAACCTGATGTATTGGACAATTTT 1020
DB 961 TGAATGACGAGACTGCTACACAGAGAGATTTTCTTAAACCTGATGTATTGGACAATTTT 1020
QY 1021 TTTTCATCTGTGCAAAAAGTTTTCAGGTGTGTGAGAGACACAGGCTGGCAAGAGCTCT 1080
DB 1021 TTTTCATCTGTGCAAAAAGTTTTCAGGTGTGTGAGAGACACAGGCTGGCAAGAGCTCT 1080
QY 1081 GGTTAGAGAAACAAGCTCTGATATGAGAGGCGAGGCGCTGTATCCGACACTTTG 1140
DB 1081 GGTTAGAGAAACAAGCTCTGATATGAGAGGCGAGGCGCTGTATCCGACACTTTG 1140
QY 1141 CAGCTGCTTTATGTGTGCTGATTAATTTGGCTGTGACGCGGATGGGAATAGAGTGG 1200
DB 1141 CAGCTGCTTTATGTGTGCTGATTAATTTGGCTGTGACGCGGATGGGAATAGAGTGG 1200
QY 1201 TGATGAGCAAGATATCTTTGAGAGAGAACTACATTTATGATGAGAAACCTTCGATC 1260
DB 1201 TGATGAGCAAGATATCTTTGAGAGAGAACTACATTTATGATGAGAAACCTTCGATC 1260
QY 1261 CTTTACCTGATTTATGCTATCTCTCTGTTCAAGAAATGGTGGGACCAAGGTTTAA 1320
DB 1261 CTTTACCTGATTTATGCTATCTCTCTGTTCAAGAAATGGTGGGACCAAGGTTTAA 1320
QY 1321 TGGCAAGGCTCAAGGTTCAAGAGAGAGAGCTTGCAGTATACCTTCATTGCAAAACA 1380
DB 1321 TGGCAAGGCTCAAGGTTCAAGAGAGAGAGCTTGCAGTATACCTTCATTGCAAAACA 1380
QY 1381 CTGACATCCAAAGGATTAAGAGAGAGATTAACCTGTATGCCATTAACCTCCATTAACG 1440
DB 1381 CTGACATCCAAAGGATTAAGAGAGAGATTAACCTGTATGCCATTAACCTCCATTAACG 1440
QY 1441 TCACCAAGTACTTGGGTTACCTATCTTTTCTTAACAAGCAAGTGGATTAATACCTTC 1500
DB 1441 TCACCAAGTACTTGGGTTACCTATCTTTTCTTAACAAGCAAGTGGATTAATACCTTC 1500
QY 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAATCTGTGCAACTGATGCTTAATCTC 1560
DB 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAATCTGTGCAACTGATGCTTAATCTC 1560
QY 1561 TAAAGATGATGATCAAACTTTGCCACTTTTAATGAGAAACCTCTCGGCGCAGGAA 1620
DB 1561 TAAAGATGATGATCAAACTTTGCCACTTTTAATGAGAAACCTCTCGGCGCAGGAA 1620
QY 1621 GTTCACTGGGCTGCGAGCTTCTCATATATTTTGTGATTAAGAAATGCAAGTTG 1680
DB 1621 GTTCACTGGGCTGCGAGCTTCTCATATATTTTGTGATTAAGAAATGCAAGTTG 1680
QY 1681 CTGCTGATCTGAATAATTAATATACGCTGACACTG 1721

Db 1681 CTGCTGCATCTGAATAAATACTACTGCTGACACTG 1721

RESULT 2

AAA75051 standard; cDNA; 1721 BP.

AAA75051;

15-JAN-2001 (first entry)

cDNA encoding a human heparanase polypeptide.

Human; heparanase; gene therapy; tumour; inflammation; autoimmunity; human-binding growth factor; cytokine; neurodegenerative plaque; wound healing; infection; burn; angiogenesis; restenosis; atherosclerosis; inflammation; neurodegenerative disease; Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; da.

Homo sapiens.

Key Location/Qualifiers

CDS 63..1693

/*cag= a

/product= "heparanase"

stem_loop 698..724

/*cag= b

/note= "these nucleotides are likely to be involved in forming stem and loop structures"

MO20052178-A1.

08-SEP-2000.

14-FEB-2000; 2000WO-US03542.

01-MAR-1999; 99US-0258892.

(INSI-) INSIGHT STRATEGY & MARKETING LTD.

(HADA-) HADASIT MEDICAL RES SERVICES & DEV.

(FRIE/) FRIEDMAN M M.

Pecker I, Vlodaysky I, Feinstein E;

WPI: 2000-579289/54.

P-PSDB; AAB08849.

New polynucleotides encoding a polypeptide having heparanase activity, useful in wound healing and in gene therapy, particularly in treating tumour, inflammation, autoimmunity, neurodegenerative diseases -

Claim 9; Fig 1; 152pp; English.

The present sequence encodes a human protein with heparanase catalytic activity. The heparanase (hpa) polynucleotide is useful in gene therapy, particularly in treating tumour, inflammation or autoimmunity. Particularly, the polynucleotide is useful in modulating the bioavailability of heparin-binding growth factors, cellular responses to heparin-binding growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins, cellular susceptibility to certain viral and some bacterial and protozoa infections, or disintegration of neurodegenerative plaques. The polynucleotide is also useful in wound healing (e.g. thermal, chemical or radiation burns), and in the treatment of angiogenesis, restenosis, atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa infections.

Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match 100.0%; Score 1721; DB 21; Length 1721;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CTAGAGCTTTGCACTCTCCGCTGCGCGAGCTGGCGGAGGAGCAGCCAGGTAGGCCA 60

Db 1 CTAGAGCTTTGCACTCTCCGCTGCGCGAGCTGGCGGAGGAGCAGCCAGGTAGGCCA 60

Qy 61 AGATGCTGCTGCGCTCGAAGCTGCGCTGCCGCCGCTGATGCTGCTCTGCGGAGC 120

Db 61 AGATGCTGCTGCGCTCGAAGCTGCGCTGCCGCCGCTGATGCTGCTCTGCGGAGC 120

Qy 121 CGCTGGGTGCCCTCTCCCTGCGGAGCCTGGCCCGAGCTGGCGAAGCAGGACGTCGTG 180

Db 121 CGCTGGGTGCCCTCTCCCTGCGGAGCCTGGCCCGAGCTGGCGAAGCAGGACGTCGTG 180

Qy 181 ACTGGAATCTTTCACCCAGAGAGCGGTGCACTGTGAGGCCCTGCTCTGTCGTCA 240

Db 181 ACTGGAATCTTTCACCCAGAGAGCGGTGCACTGTGAGGCCCTGCTCTGTCGTCA 240

Qy 241 CCATTGACGCCAACCTGGCCACGAGACCGCGGTTCTTCATCTCTGCGTTCTCAAGC 300

Db 241 CCATTGACGCCAACCTGGCCACGAGACCGCGGTTCTTCATCTCTGCGTTCTCAAGC 300

Qy 301 TTGCTACCTTGGCCAGAGGCTTGTCTCTGCTACCTGAGGTTTGTGGACCAAGACAG 360

Db 301 TTGCTACCTTGGCCAGAGGCTTGTCTCTGCTACCTGAGGTTTGTGGACCAAGACAG 360

Qy 361 ACTTCTTAATTTTGCATCCCAAGAGAAATCACTTTGAAGAGAAATTCTGGCAAT 420

Db 361 ACTTCTTAATTTTGCATCCCAAGAGAAATCACTTTGAAGAGAAATTCTGGCAAT 420

Qy 421 CTCAAGTCAACAGAGATATTTGCAATATGAGATCCATCCCTCTGATGTGGAGAAAGT 480

Db 421 CTCAAGTCAACAGAGATATTTGCAATATGAGATCCATCCCTCTGATGTGGAGAAAGT 480

Qy 481 TACGCTTGAATGGCCCTTACAGAGCAATGCTTCACTCCAGAACACTACCAAGAAAGT 540

Db 481 TACGCTTGAATGGCCCTTACAGAGCAATGCTTCACTCCAGAACACTACCAAGAAAGT 540

Qy 541 TCAAGAACAGCACTTCAAGAGCTCTGAGATGCTTCACTTTTCAAACTGCT 600

Db 541 TCAAGAACAGCACTTCAAGAGCTCTGAGATGCTTCACTTTTCAAACTGCT 600

Qy 601 CAGGACTGAGCTTATGCTTGGCTTAAATGCGTTATTAGAACAGCAATTTGAGTGA 660

Db 601 CAGGACTGAGCTTATGCTTGGCTTAAATGCGTTATTAGAACAGCAATTTGAGTGA 660

Qy 661 ACAATTCTAATGCTCAGTTGCTCTGAGACTACTGCTCTTCCAAAGGGTATTAACATTTCTT 720

Db 661 ACAATTCTAATGCTCAGTTGCTCTGAGACTACTGCTCTTCCAAAGGGTATTAACATTTCTT 720

Qy 721 GGAAGCTAGGCAATGAACCTTACAGTTTCTTAAAGAGGCTGATATTTTCAATGAGGT 780

Db 721 GGAAGCTAGGCAATGAACCTTACAGTTTCTTAAAGAGGCTGATATTTTCAATGAGGT 780

Qy 781 CGCAGTTAGAGAGATTAATTAATGCAATTAACCTTAAAGAGTCCACTTCAAAA 840

Db 781 CGCAGTTAGAGAGATTAATTAATGCAATTAACCTTAAAGAGTCCACTTCAAAA 840

Qy 841 ATGCAAACTTATGCTGCTGATGTTGCTGAGCTCGAAGAAACGGCTTAAGTGTGCA 900

Db 841 ATGCAAACTTATGCTGCTGATGTTGCTGAGCTCGAAGAAACGGCTTAAGTGTGCA 900

Qy 901 AGAGCTTCTGGAAGGCTGGTGGAGAGATGATGATGATGATGATGATGATGATGATGAT 960

Db 901 AGAGCTTCTGGAAGGCTGGTGGAGAGATGATGATGATGATGATGATGATGATGATGAT 960

Qy 961 TGAATGACGAGCTGCTACCAAGAGATTTTCTAAACCTGATGATGATGATGATGATGAT 1020

Db 961 TGAATGACGAGCTGCTACCAAGAGATTTTCTAAACCTGATGATGATGATGATGATGAT 1020

Qy 1021 TTTGATCTGTGCAAAAAGTTTTCAGAGTGTGTTGAGAGACCAAGGCTGGCAAGAGTCT 1080

Db 1021 TTTGATCTGTGCAAAAAGTTTTCAGAGTGTGTTGAGAGACCAAGGCTGGCAAGAGTCT 1080

```

QY 1081 GATTAGAGAAAACAGCTCTGCATATGAGAGCGAGCCCGCTTGCTATCCGACACTTTG 1140
DB 1081 GATTAGAGAAAACAGCTCTGCATATGAGAGCGAGCCCGCTTGCTATCCGACACTTTG 1140
QY 1141 CAGCTGCTTTATGCTGCTGATTAATTTGGGCTCTGACCCGAAATGGGAATAGAAATGG 1200
DB 1141 CAGCTGCTTTATGCTGCTGATTAATTTGGGCTCTGACCCGAAATGGGAATAGAAATGG 1200
QY 1201 TGAAGAGGCAAGTATCTTTGGAGAGAGAAATACATTTAGTGAATGAAAATCTCGATC 1260
DB 1201 TGAAGAGGCAAGTATCTTTGGAGAGAGAAATACATTTAGTGAATGAAAATCTCGATC 1260
QY 1261 CTTTACCTGATATTTGCTATCTCTTCTTCAAGAAATGGTGGGCAACAAAGTGTAA 1320
DB 1261 CTTTACCTGATATTTGCTATCTCTTCTTCAAGAAATGGTGGGCAACAAAGTGTAA 1320
QY 1321 TGGCAAGCTGCAAGCTTCAAGAGAGAAAGCTTCAAGTATACCTTCAATTCGACAAACA 1380
DB 1321 TGGCAAGCTGCAAGCTTCAAGAGAGAAAGCTTCAAGTATACCTTCAATTCGACAAACA 1380
QY 1381 CTGCAATCCAAAGGATTAAGAGAGATTTAACTCTGATGCGCAATAAACCTCCATAAG 1440
DB 1381 CTGCAATCCAAAGGATTAAGAGAGATTTAACTCTGATGCGCAATAAACCTCCATAAG 1440
QY 1441 TCACCAAGTATCTGGCGTTACCTTCTTCTTCAAGAGAGTGAATTAATCTTC 1500
DB 1441 TCACCAAGTATCTGGCGTTACCTTCTTCTTCAAGAGAGTGAATTAATCTTC 1500
QY 1501 TAAAGACTTTGGGACCTTCATGATTAATCTTCCAAATCTGTCCACTCAATGCTTAATC 1560
DB 1501 TAAAGACTTTGGGACCTTCATGATTAATCTTCCAAATCTGTCCACTCAATGCTTAATC 1560
QY 1561 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1620
DB 1561 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1620
QY 1621 GTTCACTGGGCTGCGACCTTCTCATATAGTTTTTTTGTATAGAAATGCCAAAGTTG 1680
DB 1621 GTTCACTGGGCTGCGACCTTCTCATATAGTTTTTTTGTATAGAAATGCCAAAGTTG 1680
QY 1681 CTGCTTGATCTGAAATTAATATATAGTCTGACACTG 1721
DB 1681 CTGCTTGATCTGAAATTAATATATAGTCTGACACTG 1721

```

```

XX 29-APR-1999; 99WO-US09256.
PF 01-MAY-1998; 98US-0071618.
PR 02-MAR-1999; 99US-0260038.
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PI (FRIE/) FRIEDMAN M M.
PI Ben-Artzi H, Ayal-Herzhovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;
PI Shlom Y;
DR WPI; 2000-062144/05.
DR P-PSDB; AAY57590.
XX
PT Engineered cells that express recombinant heparanase, useful
PT therapeutically, e.g. for treating angiogenesis and to screen for
PT specific inhibitors, potential anticancer agents
PS Claim 2; Page 106-107; 118pp; English.
CC The present invention describes genetically modified cells (A) containing
CC a polynucleotide (I) that encodes a polypeptide with heparanase activity,
CC and express recombinant heparanase (II). Heparanase cleaves heparan
CC sulphate (HS) at specific intrachain sites, resulting in release of
CC heparin-binding growth factors, enzymes and proteins that are sequestered
CC by HS in basement membranes, extracellular matrix or cell surfaces. It
CC may also be implicated in tumour angiogenesis and metastases. (II) is
CC potentially useful in wound healing and for treating angiogenesis,
CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
CC infection and cystic fibrosis. It can also be used to neutralise heparin
CC (an alternative to procaine) and to screen for specific inhibitors
CC (potentially useful for treating cancer and metastases). Antibodies
CC raised against (II) are used for immunodetection and diagnosis of
CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
CC in large quantities, in a form that is homogeneously processed and
CC activated/neutralised by a dedicated protease. The present sequence
CC encodes human heparanase.
SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
Query Match 100.0%; Score 1721; DB 21; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CTAGAGCTTTGACTCTCCGCTGCGGACCTGCGGGGGAGACAGCAAGTACGCCA 60
DB 1 CTAGAGCTTTGACTCTCCGCTGCGGACCTGCGGGGGAGACAGCAAGTACGCCA 60
QY 61 AGATGCTGCTGCGCTGCAAGGCTGCGGCGCGCGCTGATGCTGCTGCGGGC 120
DB 61 AGATGCTGCTGCGCTGCAAGGCTGCGGCGCGCGCTGATGCTGCTGCGGGC 120
QY 121 CGTGGGCTCCCTCTCTCCCTGCGGCGCGCGCGCTGCGGCGCGCGCTGCGG 180
DB 121 CGTGGGCTCCCTCTCTCCCTGCGGCGCGCGCGCTGCGGCGCGCGCTGCGG 180
QY 181 ACCTGACTTTTCAACCAAGAGCGCTGCGACCTGCGGAGCGCGCTTCTCTG 240
DB 181 ACCTGACTTTTCAACCAAGAGCGCTGCGACCTGCGGAGCGCGCTTCTCTG 240
QY 241 CCATTGAGCCCACTGCGACCGAGCCGCGGCTTCTCATCTCTGCGTTCTCCAA 300
DB 241 CCATTGAGCCCACTGCGACCGAGCCGCGGCTTCTCATCTCTGCGTTCTCCAA 300
QY 301 TTGCTACTTGGCCAGAGGCTTGTCTCTGCTACTGAGGTTGTTGCGACCAAG 360
DB 301 TTGCTACTTGGCCAGAGGCTTGTCTCTGCTACTGAGGTTGTTGCGACCAAG 360
QY 361 ACTTCTAATTTTGGATCCCAAGAGATACCTTTGAAAGAGAAATTAAGGCAAT 420
DB 361 ACTTCTAATTTTGGATCCCAAGAGATACCTTTGAAAGAGAAATTAAGGCAAT 420

```

QY 421 CTCAAGTCAACAGGATATTTGGCAATATATGATCCTCTCTGATGTGAGGAAAGT 480
 Db 421 CTCAAGTCAACAGGATATTTGGCAATATATGATCCTCTCTGATGTGAGGAAAGT 480
 QY 481 TACGGTTGGAAATGGCCCTTACCAAGAGCAATGCTACTCCGAGAAACACTACCAAGAAAGT 540
 Db 481 TACGGTTGGAAATGGCCCTTACCAAGAGCAATGCTACTCCGAGAAACACTACCAAGAAAGT 540
 QY 541 TCAAGAACAGCACTCAAGAAAGCTGTAGATGTGCTATACACTTTTCCAAAGTCT 600
 Db 541 TCAAGAACAGCACTCAAGAAAGCTGTAGATGTGCTATACACTTTTCCAAAGTCT 600
 QY 601 CAGGACTGGAATGATCTTTGGCTTAAATGCGTTATTAAGAACAGCAGATTTGCAAGTGA 660
 Db 601 CAGGACTGGAATGATCTTTGGCTTAAATGCGTTATTAAGAACAGCAGATTTGCAAGTGA 660
 QY 661 ACACTTCAATGCTCAGTTGCTCTGCACTCTGCTCTTCCAAAGGGATTAACATTTCTT 720
 Db 661 ACACTTCAATGCTCAGTTGCTCTGCACTCTGCTCTTCCAAAGGGATTAACATTTCTT 720
 QY 721 GGGAACTAGAGCAATGAACCTTAACAGTTTCTTAAGAAAGCTGATATTTTCAATCAATGGGT 780
 Db 721 GGGAACTAGAGCAATGAACCTTAACAGTTTCTTAAGAAAGCTGATATTTTCAATCAATGGGT 780
 QY 781 CGCAGTTAGAGCAATGATATATTCATATTCATTAACCTTCAAGAAAGTCCAACCTTCAAAA 840
 Db 781 CGCAGTTAGAGCAATGATATATTCATATTCATTAACCTTCAAGAAAGTCCAACCTTCAAAA 840
 QY 841 ATGCAGAAATCTGTATGTCTGTATGTGTCAGCTCGAAGAAAGAGCGCTAAGATGCTGA 900
 Db 841 ATGCAGAAATCTGTATGTCTGTATGTGTCAGCTCGAAGAAAGAGCGCTAAGATGCTGA 900
 QY 901 AGAGCTTCCCTAAGCGCTGTGAGAAAGATGATTAAGTCAATGAGATCACTATCTAT 960
 Db 901 AGAGCTTCCCTAAGCGCTGTGAGAAAGATGATTAAGTCAATGAGATCACTATCTAT 960
 QY 961 TGAATGAGAGGAGCTGTACCAAGGAAAGATTTTCTTAACCTTGAATGATTTGAACATTTT 1020
 Db 961 TGAATGAGAGGAGCTGTACCAAGGAAAGATTTTCTTAACCTTGAATGATTTGAACATTTT 1020
 QY 1021 TTTTCATCTGTGCAAAAAGTTTTCAGGTGTGAGAGCAACAGGCTGTGCAAGAGTCT 1080
 Db 1021 TTTTCATCTGTGCAAAAAGTTTTCAGGTGTGAGAGCAACAGGCTGTGCAAGAGTCT 1080
 QY 1081 GGTATGAGAGAAACAAGCTCTGATATGAGAGGCGAGCGCCCTTGTATCCAGCACTTTG 1140
 Db 1081 GGTATGAGAGAAACAAGCTCTGATATGAGAGGCGAGCGCCCTTGTATCCAGCACTTTG 1140
 QY 1141 CAGCTGCTTATATGTGCTGATTAATTTGGGCTGTCAAGCCGAAATGGGAATGAGATGG 1200
 Db 1141 CAGCTGCTTATATGTGCTGATTAATTTGGGCTGTCAAGCCGAAATGGGAATGAGATGG 1200
 QY 1201 TGATGAGGCAAGTATCTTTTGGAGCAGAGAACTACATTTAGTGTATGAAAACTTCGATC 1260
 Db 1201 TGATGAGGCAAGTATCTTTTGGAGCAGAGAACTACATTTAGTGTATGAAAACTTCGATC 1260
 QY 1261 CTTTACCTGATTAATTTGGCTATCTCTTCTGTTCAAGAAATTTGGTGGCAACCAAGGTGTTAA 1320
 Db 1261 CTTTACCTGATTAATTTGGCTATCTCTTCTGTTCAAGAAATTTGGTGGCAACCAAGGTGTTAA 1320
 QY 1321 TGGCAAGGTGCAAGGTTCAAGAGAGAGCTTCGATTAACCTTCAATGTCACAAAACA 1380
 Db 1321 TGGCAAGGTGCAAGGTTCAAGAGAGAGCTTCGATTAACCTTCAATGTCACAAAACA 1380
 QY 1381 CTGCAATCCAAAGTATTAAGAGAGATTTAACTCTGTATGCAATTAACCTTCATAACG 1440
 Db 1381 CTGCAATCCAAAGTATTAAGAGAGATTTAACTCTGTATGCAATTAACCTTCATAACG 1440
 QY 1441 TCACCAAGTACTTGGGTTACCTTAATCTCTTTTCTTAACAGCAAGTGTAAATACCTTC 1500
 Db 1441 TCACCAAGTACTTGGGTTACCTTAATCTCTTTTCTTAACAGCAAGTGTAAATACCTTC 1500
 QY 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAAAATCTGTCCAACATGCTTAACCTC 1560

Db 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAAAATCTGTCCAACATGCTTAATCTC 1560
 QY 1561 TAAAGCTTTGGGACCTCATGATTAATCTTCAAAATCTGTCCAACATGCTTAATCTC 1620
 Db 1561 TAAAGCTTTGGGACCTCATGATTAATCTTCAAAATCTGTCCAACATGCTTAATCTC 1620
 QY 1621 GTTCACTGGGCTTCCAGCTTTCATATAGTTTTTTTGTATTAAGAAATGCCAAAGTTG 1680
 Db 1621 GTTCACTGGGCTTCCAGCTTTCATATAGTTTTTTTGTATTAAGAAATGCCAAAGTTG 1680
 QY 1681 CTGCTTGATCTGAAATTAATATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
 Db 1681 CTGCTTGATCTGAAATTAATATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721

RESULT 4
 AA233290
 ID AA233290 standard; cDNA; 1721 BP.
 AC AA233290;
 XX
 DT 21-FEB-2000 (first entry)
 DE
 XX
 DE Human heparanase nucleotide sequence.
 XX
 KW Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
 KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
 KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
 KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
 KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
 KW autoimmune disease; anticancer; kidney disease; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 63..1694
 FT /tag= a
 FT /product= "heparanase"
 FT
 XX
 PN W09957153-A1.
 XX
 PD 11-NOV-1999.
 XX
 PE 29-APR-1999; 99MO-US09255.
 XX
 PR 01-MAY-1998; 98US-0071739.
 XX
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PA (HADA-) HADAST MEDICAL RES SERVICES & DEV.
 PA (FRIE/) FRIEDMAN M M.
 XX
 PI Pecker I, Violdavsky I, Friedman Y, Perets T;
 XX
 DR MPI: 2000-052944/04.
 DR P-PBDB: AAY52990.
 XX
 PT Heparanase-specific molecular probes useful for diagnosis and
 PT treatment, e.g. of tumors, and for targeted drug delivery -
 XX
 PS Example; Page 82-84; 90pp; English.
 XX
 CC The present invention describes heparanase-specific molecular probes,
 CC useful for methods of detecting heparanase in situ. The probes and
 CC anti-heparanase antibodies are used to detect or quantify the expression
 CC of heparanase, for diagnosis and monitoring of diseases (especially
 CC metastasis), for treatment of heparanase-associated diseases (e.g.
 CC tumours, (aden)carcinoma, squamous cell carcinoma, teratocarcinoma,
 CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
 CC metastases) derived from liver, prostate, bladder, breast, ovary,
 CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
 CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
 CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted

CC drug delivery (e.g. of anticancer agents) and as research reagents.
 CC The present sequence encodes human heparanase, which is used in the
 CC exemplification of the present invention.

XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match 100.0%; Score 1721; DB 21; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 CTAGAGCTTTGACTCTCCGCTGCGGAGCTGCGGGGGAGCAGCCAGGTGAGCCCA 60
DB 1 CTAGAGCTTTGACTCTCCGCTGCGGAGCTGCGGGGGAGCAGCCAGGTGAGCCCA 60
QY 61 AGAGCTGCTGCGCTGCGAGCGCTGCGCGCGCGCCCTGATGCTGCTGCTCCGGGGC 120
DB 61 AGAGCTGCTGCGCTGCGAGCGCTGCGCGCGCGCCCTGATGCTGCTGCTCCGGGGC 120
QY 121 CGCTGGGTCCCTCTCCCTGGCGCCCTGCGCCGACCTGCGCAACAGACAGACGTCGTG 180
DB 121 CGCTGGGTCCCTCTCCCTGGCGCCCTGCGCCGACCTGCGCAACAGACAGACGTCGTG 180
QY 181 ACTGGACTTCTTCACTCCAGAGACCGCTGCACTGTGAGCCCTCTGCTCTGCTCA 240
DB 181 ACTGGACTTCTTCACTCCAGAGACCGCTGCACTGTGAGCCCTCTGCTCTGCTCA 240
QY 241 CCATTGAGCCCACTGCGCAACGACCCGCGGTTCTCATCTCTGGGTTCTCCAAAGC 300
DB 241 CCATTGAGCCCACTGCGCAACGACCCGCGGTTCTCATCTCTGGGTTCTCCAAAGC 300
QY 301 TTGCTACCTTGGCCAGAGGCTTGTCTCTGCGTACCTGAGGTTGTGGCAACAGACG 360
DB 301 TTGCTACCTTGGCCAGAGGCTTGTCTCTGCGTACCTGAGGTTGTGGCAACAGACG 360
QY 361 ACTTCTTAATTTTGGATCCCAAGAGAAATCAACTTTGAAGAGAAATTACTGGCAAT 420
DB 361 ACTTCTTAATTTTGGATCCCAAGAGAAATCAACTTTGAAGAGAAATTACTGGCAAT 420
QY 421 CTCAAGTAACCAAGATATTTGGCAATATGATCCATCCCTCTCTAATGTGGAGGAAAT 480
DB 421 CTCAAGTAACCAAGATATTTGGCAATATGATCCATCCCTCTCTAATGTGGAGGAAAT 480
QY 481 TACGGTGAATGAGCCCTACACAGAGCAATTGCTACTCCAGAACACTACACAGAAAGT 540
DB 481 TACGGTGAATGAGCCCTACACAGAGCAATTGCTACTCCAGAACACTACACAGAAAGT 540
QY 541 TCAAGAACAGCACTACTCAAGAAAGCTGTAGATGTGTATACATTTTGGCAACGCTCT 600
DB 541 TCAAGAACAGCACTACTCAAGAAAGCTGTAGATGTGTATACATTTTGGCAACGCTCT 600
QY 601 CAGGACTGGAATGATCTTTGGCTTAAATGCTTATTAAGAAACAGCAATTTGCACTGA 660
DB 601 CAGGACTGGAATGATCTTTGGCTTAAATGCTTATTAAGAAACAGCAATTTGCACTGA 660
QY 661 ACAGTCTTAATGCTCAGTTGCTCCTGGACTACTGCTCTCAAGGGGTATTAACATTTCTT 720
DB 661 ACAGTCTTAATGCTCAGTTGCTCCTGGACTACTGCTCTCAAGGGGTATTAACATTTCTT 720
QY 721 GGGAACTAGGCAATGAACCTTAACAGTTTCTTAAGAAAGCTGATATTTTCAATGAGGT 780
DB 721 GGGAACTAGGCAATGAACCTTAACAGTTTCTTAAGAAAGCTGATATTTTCAATGAGGT 780
QY 781 CGCAGTTAGAGAGATTAATTCATTTGATTAACCTTCTTAAGAAAGTCCACTTCAAAA 840
DB 781 CGCAGTTAGAGAGATTAATTCATTTGATTAACCTTCTTAAGAAAGTCCACTTCAAAA 840
QY 841 ATGCAAAAATCTATGCTGCTGATGTTGTCAGCCCTGAAAGAAAGCGCTAAAGATCTGA 900
DB 841 ATGCAAAAATCTATGCTGCTGATGTTGTCAGCCCTGAAAGAAAGCGCTAAAGATCTGA 900
QY 901 AGAGCTTCTGAGAGGCTGTGAGAGAGATGATTCATGATTCATGATTCATGATTCAT 960
DB 901 AGAGCTTCTGAGAGGCTGTGAGAGAGATGATTCATGATTCATGATTCATGATTCAT 960

```

```

QY 961 TGAATGACGAGACTGCTTACACAGGAAAGATTTTCTTAAACCTGATGATTTGACATTTT 1020
DB 961 TGAATGACGAGACTGCTTACACAGGAAAGATTTTCTTAAACCTGATGATTTGACATTTT 1020
QY 1021 TTTCACTGTGCAAAAAGTTTTCAGGTGTGAGAGACCAAGCCCTGGCAAGAGGTCT 1080
DB 1021 TTTCACTGTGCAAAAAGTTTTCAGGTGTGAGAGACCAAGCCCTGGCAAGAGGTCT 1080
QY 1081 GGTTAGAGAAACAAGCTCTGCAATATGAGAGCGAGCGCCCTTGTCTATCCGACCTTTG 1140
DB 1081 GGTTAGAGAAACAAGCTCTGCAATATGAGAGCGAGCGCCCTTGTCTATCCGACCTTTG 1140
QY 1141 CAGCTGCTTATATGCTGATTAATTTGGGCTGTGACCCCGAATGGGAATGAGATGG 1200
DB 1141 CAGCTGCTTATATGCTGATTAATTTGGGCTGTGACCCCGAATGGGAATGAGATGG 1200
QY 1201 TGATGAGCAAGTATTTCTTTGAGACAGAAATCAATTTAGTGAATGAAACTTCGATC 1260
DB 1201 TGATGAGCAAGTATTTCTTTGAGACAGAAATCAATTTAGTGAATGAAACTTCGATC 1260
QY 1261 CTTTACCTGATTAATTTGGCTATCTCTTCTGTTCAAGAAATTTGGGGCACCAAGGTGTA 1320
DB 1261 CTTTACCTGATTAATTTGGCTATCTCTTCTGTTCAAGAAATTTGGGGCACCAAGGTGTA 1320
QY 1321 TGGCAAGCGTCAAGGTTCAAGAGAAAGAGCTTCAAGTATACCTTCAATGCACAACA 1380
DB 1321 TGGCAAGCGTCAAGGTTCAAGAGAAAGAGCTTCAAGTATACCTTCAATGCACAACA 1380
QY 1381 CTGACAAATCAAGGTATTAAGAGAGAAATTAATCTGTATGATCAATTAACCTTCATACG 1440
DB 1381 CTGACAAATCAAGGTATTAAGAGAGAAATTAATCTGTATGATCAATTAACCTTCATACG 1440
QY 1441 TCACCAAGTATTTGGGTTACCTTATCTTTTCTTACACAGAGTGAATTAATCTTC 1500
DB 1441 TCACCAAGTATTTGGGTTACCTTATCTTTTCTTACACAGAGTGAATTAATCTTC 1500
QY 1501 TAAAGCTTTGGGACCTGATGATTAATTTCAATCTGTCACCACTCAATGCTTAACTC 1560
DB 1501 TAAAGCTTTGGGACCTGATGATTAATTTCAATCTGTCACCACTCAATGCTTAACTC 1560
QY 1561 TAAAGATGATGATCAATCAACTTGGCACTTTTAATGAAAGAACTTCCGGCAGAGAA 1620
DB 1561 TAAAGATGATGATCAATCAACTTGGCACTTTTAATGAAAGAACTTCCGGCAGAGAA 1620
QY 1621 GTTCACTGGGCTTGCAGCTTTCTCATATAGTTTGTGATTAAGAAATGCCAAAGTTG 1680
DB 1621 GTTCACTGGGCTTGCAGCTTTCTCATATAGTTTGTGATTAAGAAATGCCAAAGTTG 1680
QY 1681 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
DB 1681 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721

```

RESULT 5
 ID AAA91112 standard; DNA; 1721 BP.

XX AAA91112;
 DT 20-APR-2001 (first entry)

DE Human heparanase, coding sequence fragment isolated from EST clone.
 KW Heparanase; hnp1; wound healing; angiogenesis; restenosis; Scrape;
 KW atherosclerosis; inflammation; pulmonary disease; Alzheimer's disease;
 KW neurodegenerative diseases; Creutzfeldt-Jakob disease; viral infection;
 KW gene therapy; mouse; expressed sequence tag; ds.

OS Homo sapiens.
 XX PN MO20010643-A2.

PD 04-JAN-2001.
 XX 19-JUN-2000; 2000MO-IL00358.
 XX 25-JUN-1999; 99US-0140801.
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PI Pecker I, Michael I, Itzhaki H;
 XX WPI: 2001-137930/14.
 DR
 XX New polynucleotides and polypeptides that are distantly homologous to
 PT heparanase, useful in wound healing, as well as in gene therapy
 PT protocols for angiogenesis, restenosis, atherosclerosis, or
 PT inflammation -
 XX
 PS Example 1; Page 67; 67pp; English.
 XX This sequence represents a human heparanase coding sequence clone,
 CC isolated from an EST clone. The invention relates to heparanase DNA
 CC and protein sequences. The heparanase DNA and protein sequences are
 CC useful in wound healing, angiogenesis, restenosis, atherosclerosis,
 CC inflammation, pulmonary diseases, neurodegenerative diseases (such as
 CC Scrapie, Alzheimer's disease, and Creutzfeldt-Jakob disease) or viral
 CC infections. The heparanase coding sequence is particularly useful in gene
 CC therapy.
 XX
 SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
 Query Match 100.0%; Score 1721; DB 22; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 601 CAGACTGAGCTGATCTTTGGCTAAATGGCTATTAGAACAGCAGATTGCGAGTGA 660
 DB 601 CAGAGCTGAGCTGATCTTTGGCTAAATGGCTATTAGAACAGCAGATTGCGAGTGA 660
 QY 661 ACAGTTCTAATGCTCAGTGTCTCTGAGCTACTGCTCTCCAGAGGATTAACATTTCTT 720
 DB 661 ACAGTTCTAATGCTCAGTGTCTCTGAGCTACTGCTCTCCAGAGGATTAACATTTCTT 720
 QY 721 GGGAACTAGGCAATGAACCTAAGTTTCTTAAGAAAGGCTGATATTTCATCATAGGGT 780
 DB 721 GGGAACTAGGCAATGAACCTAAGTTTCTTAAGAAAGGCTGATATTTCATCATAGGGT 780
 QY 781 CGCAGTTAGGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 840
 DB 781 CGCAGTTAGGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 840
 QY 841 ATGCAAACTATATGCTGATGTTGCTGAGCTCGAAGAAAGCGCTAAGATGCTGA 900
 DB 841 ATGCAAACTATATGCTGATGTTGCTGAGCTCGAAGAAAGCGCTAAGATGCTGA 900
 QY 901 AGAGTTCTTGAAGGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960
 DB 901 AGAGTTCTTGAAGGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960
 QY 961 TGAATGAGAGGAGCTGCTACAGGAGAAAGATTTCTAAACCTGATGATTTGACATTTTGA 1020
 DB 961 TGAATGAGAGGAGCTGCTACAGGAGAAAGATTTCTAAACCTGATGATTTGACATTTTGA 1020
 QY 1021 TTTGATCTGTCGCAAAAGATTTTCCAGGTGTTGAGAGCAGGCTGCGAAGAGGCTCT 1080
 DB 1021 TTTGATCTGTCGCAAAAGATTTTCCAGGTGTTGAGAGCAGGCTGCGAAGAGGCTCT 1080
 QY 1081 GGTTRAGAGAAACAAGCTCTGATATGAGAGCGGAGCGCCCTTGATATCCGACACTTTTG 1140
 DB 1081 GGTTRAGAGAAACAAGCTCTGATATGAGAGCGGAGCGCCCTTGATATCCGACACTTTTG 1140
 QY 1141 CAGTGGCTTTATGAGGCTGATTAATTTGGGCTGTGACCCGAGTGGAAATAGAGTGG 1200
 DB 1141 CAGTGGCTTTATGAGGCTGATTAATTTGGGCTGTGACCCGAGTGGAAATAGAGTGG 1200
 QY 1201 TGATGAGGCAATATTTTGGAGAGGAGAACTACATTTATGATGATGATGATGATGATGATG 1260
 DB 1201 TGATGAGGCAATATTTTGGAGAGGAGAACTACATTTATGATGATGATGATGATGATGATG 1260
 QY 1261 CTTTACCTGATTTATGCTATCTCTTCTGTTCAAGAAATTTGATGATGATGATGATGATG 1320
 DB 1261 CTTTACCTGATTTATGCTATCTCTTCTGTTCAAGAAATTTGATGATGATGATGATGATG 1320
 QY 1321 TGGCAAGGTCGACAGGTCGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
 DB 1321 TGGCAAGGTCGACAGGTCGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
 QY 1381 CTGACAACTCAAGGATTAATTAAGAGAGATTAATCTGTATGATGATGATGATGATGATGAT 1440
 DB 1381 CTGACAACTCAAGGATTAATTAAGAGAGATTAATCTGTATGATGATGATGATGATGATGAT 1440
 QY 1441 TCACCAAGTCTTGGCTTACCTTATCTTTTCTAACAGCAAGTGAATTAATCTTTC 1500
 DB 1441 TCACCAAGTCTTGGCTTACCTTATCTTTTCTAACAGCAAGTGAATTAATCTTTC 1500
 QY 1501 TAAAGCTTTGGGACCTCATGATGATTAATTTCCAAATCTGTCAACTCAATGATGATGATG 1560
 DB 1501 TAAAGCTTTGGGACCTCATGATGATTAATTTCCAAATCTGTCAACTCAATGATGATGATG 1560
 QY 1561 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1620
 DB 1561 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1620
 QY 1621 GTTCACTGGGCTTGGCAGCTTTCTCATATATGATTTTGTGATTAAGAAATGCCAAGTTG 1680
 DB 1621 GTTCACTGGGCTTGGCAGCTTTCTCATATATGATTTTGTGATTAAGAAATGCCAAGTTG 1680

Db 1319 CAGCTGCTTATGTCGTGATTAATTTGGCCCTGTGACCCCAATGGGAATAGAACTGG 1378
 Qy 1201 TGATGAGCAGATATTTCTTTGAGCAGAGAACTACATTTATGATGATGAAATCTTCATC 1260
 Db 1379 TGATGAGCAGATATTTCTTTGAGCAGAGAACTACATTTATGATGATGAAATCTTCATC 1438
 Qy 1261 CTTTACCTGATTTATGCTATCTCTTCTTTCAAGAAATTTGGTGGCCCAAGGTGTTAA 1330
 Db 1439 CTTTACCTGATTTATGCTATCTCTTCTTTCAAGAAATTTGGTGGCCCAAGGTGTTAA 1498
 Qy 1321 TGGCAAGCTGCAAGGTTCAAGAGAGAGAACTTCAGATTTACCTTTATGTCACAAACA 1380
 Db 1499 TGGCAAGCTGCAAGGTTCAAGAGAGAGAACTTCAGATTTACCTTTATGTCACAAACA 1558
 Qy 1381 CTGCAATTCGAAGGATTAAGAGAGAGATTTAACTGTATGCACTAAACCTCCATAAG 1440
 Db 1559 CTGCAATTCGAAGGATTAAGAGAGAGATTTAACTGTATGCACTAAACCTCCATAAG 1618
 Qy 1441 TCACCAAGTATCTTCGCTTACCTTATCTTTTCTAACAGCAAGTGTAAATACCTTC 1500
 Db 1619 TCACCAAGTATCTTCGCTTACCTTATCTTTTCTAACAGCAAGTGTAAATACCTTC 1678
 Qy 1501 TAAAGCTTTGGGACCTCATGATTTACTTTCCAAATCTGTCCAACTCAATGCTTAATC 1560
 Db 1679 TAAAGCTTTGGGACCTCATGATTTACTTTCCAAATCTGTCCAACTCAATGCTTAATC 1738
 Qy 1561 TAAAGATGATGATGATCAACCTTGCACTTTAATGGAATAACCTTCGCGCCAGGAA 1620
 Db 1739 TAAAGATGATGATGATCAACCTTGCACTTTAATGGAATAACCTTCGCGCCAGGAA 1798
 Qy 1621 GTTCACTGGGCTTCCAGACTTTCATATAGTTTTTTTGTGATAAGAAATGCCAAAGTTG 1680
 Db 1799 GTTCACTGGGCTTCCAGACTTTCATATAGTTTTTTTGTGATAAGAAATGCCAAAGTTG 1858
 Qy 1681 CTGCTTGATCTGAATAATTAATATATAGTCTGACACTG 1721
 Db 1859 CTGCTTGATCTGAATAATTAATATATAGTCTGACACTG 1899
 RESULT 7
 ID AAA75053 standard; cDNA, 1899 BP.
 AC AAA75053;
 XX 15-JAN-2001 (first entry)
 DE cDNA encoding a human heparanase polypeptide.
 XX
 KW Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
 KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
 KW wound healing; infection; burn; angiogenesis; restenosis;
 KW atherosclerosis; inflammation; neurodegenerative disease;
 KW Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 94..1872
 FT /*tag= a
 FT /product= "heparanase"
 XX
 XX MO200052178-A1.
 XX
 PD 08-SEP-2000.
 XX
 PF 14-FEB-2000; 2000MO-US03542.
 XX
 PR 01-MAR-1999; 99US-0258892.
 XX
 XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
 PA (FRIE/) FRIEDMAN M M.

XX Pecker I, Vlodaysky I, Feinstein E;
 PI MPI: 2000-579289/54.
 DR P-PSDB; AAB08850.
 XX
 PT New polynucleotides encoding a polypeptide having heparanase activity,
 PT useful in wound healing and in gene therapy, particularly in treating
 PT tumour, inflammation, autoimmunity, neurodegenerative diseases
 XX
 PS Claim 9; Page 121-122; 152pp; English.
 XX
 CC The present sequence encodes a human protein with heparanase catalytic
 CC activity. The heparanase (hpa) polynucleotide is useful in gene therapy,
 CC particularly in treating tumour, inflammation or autoimmunity.
 CC Particularly, the polynucleotide is useful in modulating the
 CC bioavailability of heparin-binding growth factors, cellular responses
 CC to heparin-binding growth factors (e.g. bFGF) and cytokines
 CC (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,
 CC cellular susceptibility to certain viral and some bacterial and protozoa
 CC infections, or disintegration of neurodegenerative plaques. The
 CC polynucleotide is also useful in wound healing (e.g. thermal, chemical
 CC or radiation burns), and in the treatment of angiogenesis, restenosis,
 CC atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-
 CC Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,
 CC bacterial or protozoa infections.
 XX
 SQ Sequence 1899 BP; 495 A; 433 C; 510 G; 461 T; 0 other;

Query Match 99.9%; Score 1719.4; DB 21; Length 1899;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 1720; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CTAGAGCTTTGAGACTTCCTGCGCGGAGCTGGCCGGGAGACAGCAGTAGCCCA 60
 Db 179 CTAGAGCTTCGACTTCCTGCGCGGAGCTGGCCGGGAGACAGCAGTAGCCCA 238
 Qy 61 AGATGCTGCTGCGCTGCGAGCCTGCGCGCGCGCGCTGATCTGCTGCGGAGC 120
 Db 239 AGATGCTGCTGCGCTGCGAGCCTGCGCGCGCGCGCGCTGATCTGCTGCGGAGC 298
 Qy 121 CGTGGGCTCCCTCTCCCTGCGCGCTGCGCGCGCGCGCTGATCTGCTGCGGAGC 180
 Db 299 CGTGGGCTCCCTCTCCCTGCGCGCTGCGCGCGCGCGCTGATCTGCTGCGGAGC 358
 Qy 181 ACCTGAGCTTCTTACACCGAGAGCGCGTGCACCTGTGAGGCGCTTCTCTCCGCA 240
 Db 359 ACCTGAGCTTCTTACACCGAGAGCGCGTGCACCTGTGAGGCGCTTCTCTCCGCA 418
 Qy 241 CCATTGACGCCAACCTGCGCGAGACCGCGGCTTCTCATCTCTGAGTTCTCAAAAGC 300
 Db 419 CCATTGACGCCAACCTGCGCGAGACCGCGGTTCTCATCTCTGAGTTCTCAAAAGC 478
 Qy 301 TTCTGACTTGGCCAGAGAGCTTGTCTCTGTGATCTGAGGTTTGTGGCAACAAGCAG 360
 Db 479 TTCTGACTTGGCCAGAGAGCTTGTCTCTGTGATCTGAGGTTTGTGGCAACAAGCAG 538
 Qy 361 ACTTCTAATTTTGGATCCCAAGAGATTAACCTTTGAAGAAGAGATTACTGGCAAT 420
 Db 539 ACTTCTAATTTTGGATCCCAAGAGATTAACCTTTGAAGAAGAGATTACTGGCAAT 598
 Qy 421 CTCAGTCAACAGAGATTTTGAATAATGATCATCCCTCGATGTGGAGAGAGT 480
 Db 599 CTCAGTCAACAGAGATTTTGAATAATGATCATCCCTCGATGTGGAGAGAGT 658
 Qy 481 TACGTTGGAATGCGCTTACAGAGAGCAATTCTTCCAGAACTACCAAGAAAAGT 540
 Db 659 TACGTTGGAATGCGCTTACAGAGAGCAATTCTTCCAGAACTACCAAGAAAAGT 718
 Qy 541 TCAAGAACAGCACTTCAAGAAAGCTGTGATGTGCTATACATTTTGAACATGCT 600
 Db 719 TCAAGAACAGCACTTCAAGAAAGCTGTGATGTGCTATACATTTTGAACATGCT 778

```

Qy 601 CAGAGCTGAGTGTGATCTTTGGCTTAAATGCGTTATTAAGAAACAGACAGATTTGACAGTGA 660
Db 779 CAGAGCTGAGTGTGATCTTTGGCTTAAATGCGTTATTAAGAAACAGACAGATTTGACAGTGA 838
Qy 661 ACAGTCTTAATGCTCAAGTTGCTCTGAGTACTGCTCTTCCAGAGGGGTAAACATTTCTT 720
Db 839 ACAGTCTTAATGCTCAAGTTGCTCTGAGTACTGCTCTTCCAGAGGGGTAAACATTTCTT 898
Qy 721 GGGAACTAGGCAATGACCTTAACAGTTTCCTTAAGAGGGGTATTTTTCATCAATGGGT 780
Db 899 GGGAACTAGGCAATGACCTTAACAGTTTCCTTAAGAGGGGTATTTTTCATCAATGGGT 958
Qy 781 CGCAGTTAGAGAGATTATATTCATATTCATTAATTCCTTAAGAAAGTCCACCTTCAAAA 840
Db 959 CGCAGTTAGAGAGATTATATTCATATTCATTAATTCCTTAAGAAAGTCCACCTTCAAAA 1018
Qy 841 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTTCGAAAGAAAGCGGTAAAGATGCTGA 900
Db 1019 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTTCGAAAGAAAGCGGTAAAGATGCTGA 1078
Qy 901 AGAGCTTCTGTAAGGCTGCTGAGAGAGTATGATTGATTCAGTTACGATCCTACTATT 960
Db 1079 AGAGCTTCTGTAAGGCTGCTGAGAGAGTATGATTGATTCAGTTACGATCCTACTATT 1138
Qy 961 TGAATGACGCACTGCTACACAGGGAAGATTTTCTAAACCTGATGATTTGACATTTTAA 1020
Db 1139 TGAATGACGCACTGCTACACAGGGAAGATTTTCTAAACCTGATGATTTGACATTTTAA 1198
Qy 1021 TTTTATCTGTGCAAAAAGTTTTCAGAGTGTGTTGAAGACACAGGCTTGGCAAGAGTCT 1080
Db 1199 TTTTATCTGTGCAAAAAGTTTTCAGAGTGTGTTGAAGACACAGGCTTGGCAAGAGTCT 1258
Qy 1081 GGTGAGGAAACAAAGCTCTGCAATGAGAGCGAGCGGCGCTTGTATCCGACACTTTG 1140
Db 1259 GGTGAGGAAACAAAGCTCTGCAATGAGAGCGAGCGGCGCTTGTATCCGACACTTTG 1318
Qy 1141 CAGCTGCTTATATGCTGTGATTAATTGGGCTGTCAAGCCGCAATGGGAATGAAAGTGG 1200
Db 1319 CAGCTGCTTATATGCTGTGATTAATTGGGCTGTCAAGCCGCAATGGGAATGAAAGTGG 1378
Qy 1201 TGATGAGCAAGTATCTTTGGAGACAGAACTACCATTTAGTGATGAAAACTTGCATC 1260
Db 1379 TGATGAGCAAGTATCTTTGGAGACAGAACTACCATTTAGTGATGAAAACTTGCATC 1438
Qy 1261 CTTTACCTGATTTATGCGTATCTCTCTGTTCAAGAAATGGTGGGCAACAAAGGTAA 1320
Db 1439 CTTTACCTGATTTATGCGTATCTCTCTGTTCAAGAAATGGTGGGCAACAAAGGTAA 1498
Qy 1321 TGGCAAGCGTGCAGAGTTCAAGAGAGAGAGCTTGAATATACCTTCAATGGCAACAA 1380
Db 1499 TGGCAAGCGTGCAGAGTTCAAGAGAGAGAGCTTGAATATACCTTCAATGGCAACAA 1558
Qy 1381 CTGACATTCGAAGTATTAAGAGAGATTTAATCTGTGATGCCATTAACCTCCATAAG 1440
Db 1559 CTGACATTCGAAGTATTAAGAGAGATTTAATCTGTGATGCCATTAACCTCCATAAG 1618
Qy 1441 TCACCAATACTTGGGTTAACCTTCTTTTCAAGAAGAAATGGATTAATACCTTC 1500
Db 1619 TCACCAATACTTGGGTTAACCTTCTTTTCAAGAAGAAATGGATTAATACCTTC 1678
Qy 1501 TAAGACTTTGGGACCTCATGATGATTTCTTCAAACTGTCCAACTCATAGTCTTAATC 1560
Db 1679 TAAGACTTTGGGACCTCATGATGATTTCTTCAAACTGTCCAACTCATAGTCTTAATC 1738
Qy 1561 TAAAGATGATGATGATCAAACTTGGCCACTTTAATGAAAAACCTCTCGGCGCAGAA 1620
Db 1739 TAAAGATGATGATGATCAAACTTGGCCACTTTAATGAAAAACCTCTCGGCGCAGAA 1798
Qy 1621 GTTACCTGGGCTTGGACGCTTCTCATATAGTTTTTTTGTGATAAGAAATGCCAAGTGG 1680
Db 1799 GTTACCTGGGCTTGGACGCTTCTCATATAGTTTTTTTGTGATAAGAAATGCCAAGTGG 1858
Qy 1681 CTGCTTGATCTGAATAATAATATATAGTCTCTGACACTG 1721

```

```

Db 1859 CTGCTTGATCTGAAAAATAATATATAGTCTGACACTG 1899
RESULT 8
AAFP3788
ID AAFP3788 standard; cDNA; 1722 BP.
XX
AC AAFP3788;
XX
DT 23-MAY-2001 (first entry)
XX
DE Human cDNA encoding a membrane or secretory protein clone PSEC0090.
XX
KW Human; secretory protein; membrane protein; vaccine; gene therapy;
XX rheumatoid arthritis; diabetes; ss.
XX
OS Homo sapiens.
XX
PN EP1067182-A2.
XX
PD 10-JAN-2001.
XX
PF 07-JUL-2000; 2000EP-0114090.
XX
PR 08-JUL-1999; 99JP-0194179.
XX 11-JAN-2000; 2000JP-0118775.
PR 02-MAY-2000; 2000JP-0103766.
XX
PA (HELI-) HELIX RES INST.
PI Oca T, Isegai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
XX WPI: 2001-093989/11.
DR P-P8DB; AAB88361.
XX
PT Nucleic acids encoding secretory proteins/membrane proteins, useful in
XX gene therapy or as candidate target molecules in drug development -
XX
PS Claim 1; SEQ ID 89; 609pp + CD ROM; English.
XX
CC This invention relates to nucleic acid sequences AAFP3744 - AAFP3916
XX CC which encode human secretory or membrane proteins represented by
XX CC AAB88317 - AAB88419. Included in the invention are primers
XX CC AAFP3917 - AAFP4295 and AAFP6232 - AAFP6235 which are used to isolate the
XX CC cDNA sequences of the invention. The invention also includes methods for
XX CC the production of antibodies directed against the proteins, and cDNA
XX CC sequences, which can be used in vaccines. The polynucleotide sequences
XX CC can be used in gene therapy. The polynucleotide sequences and the
XX CC proteins they encode may be used in the prevention, treatment and
XX CC diagnosis of diseases associated with inappropriate secretory
XX CC protein/membrane protein expression. The nucleic acids and complementary
XX CC sequences may also be used as DNA probes in diagnostic assays
XX CC (e.g. polymerase chain reactions (PCR)) to detect and quantify the
XX CC presence of similar nucleic acid sequences in samples. They may also be
XX CC used to study the expression and function of secretory proteins/membrane
XX CC polypeptides and their role in metabolism. The polypeptides may be used
XX CC as antigens in the production of antibodies against them and in assays to
XX CC identify modulators (agonists and antagonists) of expression and
XX CC activity. The antibodies and antagonists may also be used as therapeutic
XX CC agents to down regulate expression and activity. The antibodies may also
XX CC be used as diagnostic agents for detecting the presence of the
XX CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay
XX CC (ELISA). Examples of diseases which may be treated include rheumatoid
XX CC arthritis and diabetes.
SQ Sequence 1722 BP; 449 A; 414 C; 412 G; 447 T; 0 other;
Query Match 99.5%; Score 1713; DB 22; Length 1722;
Best Local Similarity 99.7%; Pred. No. 0;
Matches 1716; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Qy 1 CTAAGCTTTCGACTTCCTGCGGCAAGCTGGCGGGGAGACACCAAGTGAAGCCA 60

```

Db	2	CTAGAGCTCTGGA	CTTCGCGTGC	CGGACAGCTGGCCGGGGGAGACAGCCAGGTGAGCCCA	61
Qy	61	AGATGCTGCTGGCT	CGAAGCTGGGCGGCGCGCCGCTGATGCTGCTCTCGGGGC	120	
Db	62	AGATGCTGCTCGCT	CGAAGCTGGGCGGCGCGCCGCTGATGCTGCTCTCGGGGC	121	
Qy	121	CGCTGGGCTCCCT	CTCCCTCGGCGGCGGCGCCGCTGAGGAGACAGGACCTGCTGG	180	
Db	122	CGCTGGGCTCCCT	CTCCCTCGGCGGCGGCGGCGGAGCTGCGAGCAGGACGTCG	181	
Qy	181	ACCTGGA	CTTCTCA	CCGAGAGCCGCTGCACTGCTGAGCCCTCGTTCCTGTCCTCA	240
Db	182	ACCTGGA	CTTCTCA	CCGAGAGCCGCTGCACTGCTGAGCCCTCGTTCCTGTCCTCA	241
Qy	241	CCATTGAG	CGCAACCTGGCCACCGGCGGTTCTCATCTCTCTGGGTTCTCCAAAGC	300	
Db	242	CCATTGAG	CGCAACCTGGCCACCGGCGGTTCTCATCTCTCTGGGTTCTCCAAAGC	301	
Qy	301	TTTCGAT	CTTGAGCGGAGGAGGCTTGTCTCGGCGTACCTGAGGTTTGGTGGACCAAGACAG	360	
Db	302	TTTCGAT	CTTGAGCGGAGGAGGCTTGTCTCGGCGTACCTGAGGTTTGGTGGACCAAGACAG	361	
Qy	361	ACTTCCTAA	TTTTCGATCCCAAGAGGATCAACCTTTGAAGAGAGATTACTGGCAAT	420	
Db	362	ACTTCCTAA	TTTTCGATCCCAAGAGGATCAACCTTTGAAGAGAGATTACTGGCAAT	421	
Qy	421	CTCAAGTCA	CCAGGATATTTGGCAATATGATTCATCCCTCTGATGTGAGGAGAGT	480	
Db	422	CTCAAGTCA	CCAGGATATTTGGCAATATGATTCATCCCTCTGATGTGAGGAGAGT	481	
Qy	481	TAGGGTTGGA	TGAGGCGCTTACCAAGAGGAAATGCTATCCGAGAACACTACCAAGAAAGT	540	
Db	482	TAGGGTTGGA	TGAGGCGCTTACCAAGAGGAAATGCTATCCGAGAACACTACCAAGAAAGT	541	
Qy	541	TCAAGAA	CAGCACCTACTCAAGAAGCTCTGATGCTATACCTTTTGCAAACTGCT	600	
Db	542	TCAAGAA	CAGCACCTACTCAAGAAGCTCTGATGCTATACCTTTTGCAAACTGCT	601	
Qy	601	CAGGACTGGA	CTTGATCTTTGGCCTTAAATGCGTTATTAAGACAGCAGATTTGCAGTGA	660	
Db	602	CAGGACTGGA	CTTGATCTTTGGCCTTAAATGCGTTATTAAGACAGCAGATTTGCAGTGA	661	
Qy	661	ACAATTCTAA	TGCTCAAGTTCCTCGTGA	CTACTGCTTTTCCAGGGGATTAACATTTCTT	720
Db	662	ACAATTCTAA	TGCTCAAGTTCCTCGTGA	CTACTGCTTTTCCAGGGGATTAACATTTCTT	721
Qy	721	GGGAACTA	GGAATGAACCTTAAAGTTTCCCTTAAAGAGGCTGATTTTCAATCAATGGGT	780	
Db	722	GGGAACTA	GGAATGAACCTTAAAGTTTCCCTTAAAGAGGCTGATTTTCAATCAATGGGT	781	
Qy	781	CGCAGTTA	GAGAGAGATTATATTCATTTGCAATAA	CTTCAAGAAAGTCAACTTCAAAA	840
Db	782	CGCAGTTA	GAGAGAGATTATATTCATTTGCAATAA	CTTCAAGAAAGTCAACTTCAAAA	841
Qy	841	ATGCAAAA	CTTATGCTCTGATGTTGGTCA	GCTCGAAGAAAGCGGCTAAGATGCTGA	900
Db	842	ATGCAAAA	CTTATGCTCTGATGTTGGTCA	GCTCGAAGAAAGCGGCTAAGATGCTGA	901
Qy	901	AGAGCTTC	CTGAAGGCTGAGAGAGATTTGATTCAGTTACATGGGATCACTATATT	960	
Db	902	AGAGCTTC	CTGAAGGCTGAGAGAGATTTGATTCAGTTACATGGGATCACTATATT	961	
Qy	961	TGAATGGA	CGGACTGCTACCAAGGAGATTTTCTTAA	CCCTGATGATTTGACATTTTAA	1020
Db	962	TGAATGGA	CGGACTGCTACCAAGGAGATTTTCTTAA	CCCTGATGATTTGACATTTTAA	1021
Qy	1021	TTTCATCTG	TCGAAAAGTTTTCAGAGTGTGAGAGACA	CCAGGCTTGGCAAGAGGCT	1080
Db	1022	TTTCATCTG	TCGAAAAGTTTTCAGAGTGTGAGAGACA	CCAGGCTTGGCAAGAGGCT	1081
Qy	1081	GGTTAAGGA	AAACAAGCTGCTCATATGAGAGCGAGCGCCCTTGTAATCCGACACTTTCG	1140	

Db	1082	GGTTAGGAGAAACAAAGCTCTGCACATGAGGCGGAGGCCCTTGCTATCCGACACCTTTG	1141
Qy	1141	CAGCTGCTTTATGTGCTGTGGATTAATTGGGCGCTGTACGCGGAAATGGGAATTAAGCTGG	1200
Db	1142	CAGCTGCTTTATGTGCTGTGATTAATTGGGCGCTGTACGCGGAAATGGGAATTAAGCTGG	1201
Qy	1201	TGATGAGGCAAGTATCTTTTGSAGCAGAACTACATTATAGTGATGATAAACTTCGATC	1260
Db	1202	TGATGAGGCAAGTATCTTTTGSAGCAGAACTACATTATAGTGATGATAAACTTCGATC	1261
Qy	1261	CTTTACCTGATTAATTTGGCTATCTCTCTGTTCAGAAATTGGTGGGACCAAGGTGTAA	1320
Db	1262	CTTTACCTGATTAATTTGGCTATCTCTCTGTTCAGAAATTGGTGGGACCAAGGTGTAA	1321
Qy	1321	TGGCAACCGTGCAGAGTTCCAAAGGAAAGAAAGCTTCAAGTATACCTTCATTCACAAACA	1380
Db	1322	TGGCAACCGTGCAGAGTTCCAAAGGAAAGAAAGCTTCAAGTATACCTTCATTCACAAACA	1381
Qy	1381	CTGCAATCCAAAGGTATTAAGAGAGAGATTAACTCTGTATGCGCATTAACCTCATAGC	1440
Db	1382	CTGCAATCCAAAGGTATTAAGAGAGAGATTAACTCTGTATGCGCATTAACCTCATATAG	1441
Qy	1441	TCACCAAGTACTTGGCGTTACCTCTATCCTTTTCTTAAACAAGCAATGATTAATACCTTC	1500
Db	1442	TCACCAAGTACTTGGCGTTACCTCTATCCTTTTCTTAAACAAGCAATGATTAATACCTTC	1501
Qy	1501	TAAAGACCTTTGGGACCTTCATGATTAATCTTTCCAAATCTGTCCACACTAATGCTTAAC	1560
Db	1502	TAAAGACCTTTGGGACCTTCATGATTAATCTTTCCAAATCTGTCCACACTAATGCTTAAC	1561
Qy	1561	TAAAGATGATGATGATCAACAACCTTGGCACCTTTAATGAAAAACCTTCGGGACAGAA	1620
Db	1562	TAAAGATGATGATGATCAACAACCTTGGCACCTTTAATGAAAAACCTTCGGGACAGAA	1621
Qy	1621	GTTCACTGCGGCTTGGCAGCTTTCTCATATAGTTTTTTTGTGATTAAGAAATGCCAAAGTTG	1680
Db	1622	GTTCACTGCGGCTTGGCAGCTTTCTCATATAGTTTTTTTGTGATTAAGAAATGCCAAAGTTG	1681
Qy	1681	CTGCTTCATCTGAAAAATTAATATATAGTACTGCTGCACACTG	1721
Db	1682	CTGCTTCATCTGAAAAATTAATATATAGTACTGCTGCACACTG	1722
RESULT 9			
AAAX37259 standard; DNA; 1713 BP.			
XX	AAAX37259;		
AC	AAAX37259;		
XX			
DT	21-JUL-1999 (first entry)		
XX			
DE	Human heparanase enzyme encoding DNA.		
XX			
KW	Heparanase; endoglycuronidase; heparan sulfate proteoglycan; enzyme;		
KW	metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;		
KW	arteriosclerosis; atherosclerosis; inflammation; tissue development;		
KW	human; HSPG; ss.		
XX			
OS	Homo sapiens.		
XX			
FN	W09921975-A1.		
XX			
PD	06-MAY-1999.		
XX			
PF	28-OCT-1998; 98WO-AU00898.		
XX			
PR	09-DEC-1997; 97AU-0000812.		
XX			
PR	28-OCT-1997; 97AU-0000062.		
XX			
PA	(AUSU) UNIV AUSTRALIAN NAT.		
XX			
PI	Freeman CG, Handorf BJ, Hulett MD, Parish CR;		
XX			

DR WPI: 1999-312956/26.
DR P-PSDB; AAY17082.

PT Polynucleotides encoding mammalian endoglucuronidases, especially
heparanases, useful to promote wound healing

PS Claim 3; Page 69-73; 112pp; English.

XX The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulfonates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG. The
CC present sequence represents a DNA encoding human heparanase.

XX Sequence 1713 BP; 460 A; 404 C; 406 G; 443 T; 0 other;

Query Match 98.5%; Score 1694.6; DB 20; Length 1713;

Best Local Similarity 99.8%; Pred. No. 0; Mismatches 4; Indels 0; Gaps 0;

Matches 1697; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 18 CCGCTGCGCGGAGCTGGCGGGGAGAGCAGCCAGGTGAGCCCAAGATGTGCTGGCTCG 77
DB 1 CCGCTGCGCGGAGCTGGCGGGGAGAGCAGCCAGGTGAGCCCAAGATGTGCTGGCTCG 60
QY 78 AAGCTTGGCTGCGCGCGCGCTGATGCTGCTCTGCGGCGCGCTGGCTGCTCTCC 137
DB 61 AAGCTTGGCTGCGCGCGCGCTGATGCTGCTCTGCGGCGCGCTGGCTGCTCTCC 120
QY 138 CCGTGGCGCGCTGCGCGCGAGCTGGCGAGCAGAGCGTGTGAGCTGTGACTTCTTACC 197
DB 121 CCGTGGCGCGCTGCGCGCGAGCTGGCGAGCAGAGCGTGTGAGCTGTGACTTCTTACC 180
QY 198 CAGGAGCGCGCTGAGCTGGTGAAGCCCTGCTGCTGCTCCGTCACCATGAGCCCAACCTG 257
DB 181 CAGGAGCGCGCTGAGCTGGTGAAGCCCTGCTGCTGCTCCGTCACCATGAGCCCAACCTG 240
QY 258 GCCACGAGCGCGCGCTGCTGATCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 317
DB 241 GCCACGAGCGCGCGCTGCTGATCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 300
QY 318 GCGTGTGCTGCTGCGCGAGCTGGTGAAGCCCTGCTGCTGCTGCTGCTGCTGCTGCTG 377
DB 301 GCGTGTGCTGCTGCGCGAGCTGGTGAAGCCCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
QY 378 CCAAGAGAGGATCAACCTTTGAAGAGAGATTAAGTGAAGTCAATCAATCAAGAGAT 437
DB 361 CCAAGAGAGGATCAACCTTTGAAGAGAGATTAAGTGAAGTCAATCAATCAAGAGAT 420
QY 438 ATTTCGAATATGATGATCAATCCCTCTGATGTGAGAGAGAGATTAAGTGAAGTGAAG 497
DB 421 ATTTCGAATATGATGATCAATCCCTCTGATGTGAGAGAGAGATTAAGTGAAGTGAAG 480
QY 498 TACCGAGAGAGATTTGCTACTCCGAGAACCTACCAAGAAAAGTTCAAGAACGACCTAC 557
DB 481 TACCGAGAGAGATTTGCTACTCCGAGAACCTACCAAGAAAAGTTCAAGAACGACCTAC 540
QY 558 TCAAGAGAGCTGTAGATGTGCTATCACTTTGCAAACTGCTCAGAGACTGAGCTGATC 617
DB 541 TCAAGAGAGCTGTAGATGTGCTATCACTTTGCAAACTGCTCAGAGACTGAGCTGATC 600
QY 618 TTTGGCTTAATGCGTTATTAAGAACAGAGATTGCAAGTGAAGAGTTCTAATGCTCAG 677
DB 601 TTTGGCTTAATGCGTTATTAAGAACAGAGATTGCAAGTGAAGAGTTCTAATGCTCAG 660

QY 678 TTGCTCTGAGCTACTGCTCTTCCAGAGGGTATTAACATTTCTGGGAACTAGGCAATGAA 737
DB 661 TTGCTCTGAGCTACTGCTCTTCCAGAGGGTATTAACATTTCTGGGAACTAGGCAATGAA 720
QY 738 CCTAAGCTTTCTTAAGAGGCTGATATTTTCAATAGGCTGAGTGAAGAGAT 797
DB 721 CCTAAGCTTTCTTAAGAGGCTGATATTTTCAATAGGCTGAGTGAAGAGAT 780
QY 798 TATATCAATGCTAATACTCTAAGAAAGTCCACTTCAAAAATGCAAACTGATGCT 857
DB 781 TTTATTCATTTGATTAACCTCTAAGAAAGTCCACTTCAAAAATGCAAACTGATGCT 840
QY 858 CCGATGTTGCTGAGCTCTGAGAAAGAGCGCTAAGTCTGAAAGAGCTTCTGAAGCT 917
DB 841 CCGATGTTGCTGAGCTCTGAGAAAGAGCGCTAAGTCTGAAAGAGCTTCTGAAAGCT 900
QY 918 GGTGAGAGAGTATGATTTGATTCATGATGATACATGATTAATTTGAATGAGCGGAGCT 977
DB 901 GGTGAGAGAGTATGATTTGATTCATGATGATACATGATTAATTTGAATGAGCGGAGCT 960
QY 978 ACCAGGAGATTTTCTAACCCTGATGATTTGAGCAATTTTATTTCTGTCAGAAA 1037
DB 961 ACCAGGAGATTTTCTAACCCTGATGATTTGAGCAATTTTATTTCTGTCAGAAA 1020
QY 1038 GTTTTCCAGGTGTTGAGAGCAGGCTGCGAAGAGGTCTGTTAGAGAAACAGC 1097
DB 1021 GTTTTCCAGGTGTTGAGAGCAGGCTGCGAAGAGGTCTGTTAGAGAAACAGC 1080
QY 1098 TCTGATATGAGAGCGGAGCGCTTGTCTATCCGACACTTTTGAAGCTGCTGTTATGCTG 1157
DB 1081 TCTGATATGAGAGCGGAGCGCTTGTCTATCCGACACTTTTGAAGCTGCTGTTATGCTG 1140
QY 1158 CTGATTAATTTGGGCTGTCAGCCGAGTGGAGATAGAGTGTGATGAGGCAATTC 1217
DB 1141 CTGATTAATTTGGGCTGTCAGCCGAGTGGAGATAGAGTGTGATGAGGCAATTC 1200
QY 1218 TTTGAGAGAGAACTACCATTTAGTGAATGAAAAGTTCGATCTTACCTGATTTATG 1277
DB 1201 TTTGAGAGAGAACTACCATTTAGTGAATGAAAAGTTCGATCTTACCTGATTTATG 1260
QY 1278 CTATCTCTTCTGTTCAAGAAATTTGGTGGCACCAAGTGTATATGCGAAGCTCAAGCT 1337
DB 1261 CTATCTCTTCTGTTCAAGAAATTTGGTGGCACCAAGTGTATATGCGAAGCTCAAGCT 1320
QY 1338 TCAAGAGAGAGCTTGAAGTACCTGATGCAATTCGATGCAATTCGATGCAATTCGATG 1397
DB 1321 TCAAGAGAGAGCTTGAAGTACCTGATGCAATTCGATGCAATTCGATGCAATTCGATG 1380
QY 1398 AAAGAGAGATTTAAGTCTGATGCAATTCGATGCAATTCGATGCAATTCGATG 1457
DB 1381 AAAGAGAGATTTAAGTCTGATGCAATTCGATGCAATTCGATGCAATTCGATG 1440
QY 1458 TTACCTATCTTTTCTAACAAGAGTGAATTAATCTTCTAAGACTTTGGAGCT 1517
DB 1441 TTACCTATCTTTTCTAACAAGAGTGAATTAATCTTCTAAGACTTTGGAGCT 1500
QY 1518 CATGATTAATCTTCAAACTGTCGCACTCAATGCTCAATCTCAAAAGTGTGATGAT 1577
DB 1501 CATGATTAATCTTCAAACTGTCGCACTCAATGCTCAATCTCAAAAGTGTGATGAT 1560
QY 1578 CAACCTTGCACCTTTATGAGAAAACCTCTCGGCGCAGAGAGTTCACTGGGCTTGCA 1637
DB 1561 CAACCTTGCACCTTTATGAGAAAACCTCTCGGCGCAGAGAGTTCACTGGGCTTGCA 1620
QY 1638 GCTTCTCATATAGTTTGTGATTAAGAAATGCGAAAGTTGCTGCTGCTGCAATG 1697
DB 1621 GCTTCTCATATAGTTTGTGATTAAGAAATGCGAAAGTTGCTGCTGCTGCAATG 1680
QY 1698 TAAATATATAGTCTGAC 1718
DB 1681 TAAATATATAGTCTGAC 1701

RESULT 10	
AA37260	
ID	AA37260 standard; DNA; 1723 BP.
XX	
AC	AA37260;
XX	
DT	21-JUL-1999 (first entry)
XX	
DE	Seq ID No: 14 of W09921975.
XX	
KW	Heparanase; endoglyucuronidase; heparan sulfate proteoglycan; enzyme;
KW	metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KW	arteriosclerosis; atherosclerosis; inflammation; tissue development;
XX	human; HSPG; 88.
XX	
OS	Homo sapiens.
XX	
PN	W09921975-A1.
XX	
PD	06-MAY-1999.
XX	
PF	28-OCT-1998; 98WO-AU00898.
XX	
PR	09-DEC-1997; 97AU-0000812.
XX	
PR	28-OCT-1997; 97AU-0000062.
XX	
PA	(AUSU) UNIV AUSTRALIAN NAT.
PI	Freeman CG, Hamdorf BJ, Hulet MD, Parish CR;
XX	
DR	WPI; 1999-312956/26.
XX	
P-PSDB;	AA171083.
XX	
PT	Polynucleotides encoding mammalian endoglyucuronidases, especially
PT	heparanases, useful to promote wound healing
XX	
PS	Claim 11; Page 76-79; 112pp; English.
XX	
CC	The invention relates to nucleic acid sequences that encode heparanase
CC	enzymes having endoglyucuronidase activity. Recombinant heparanases are
CC	capable of removing the HS side chain from heparan sulfate proteoglycan
CC	(HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to
CC	inhibit heparanase, this is useful for treatment of a physiological or
CC	medical condition associated with elevated heparanase activity, such as
CC	metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC	arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC	rat heparanases can be used to enhance wound healing, especially
CC	associated with tissue development and repair. The conditions mentioned
CC	above can be diagnosed using specific antibodies, and also using primers
CC	and probes specific for the heparanase polynucleotides. Other uses of the
CC	heparanases include sequencing sulfated molecules such as HSPG.
XX	
XX	
SQ	Sequence 1723 BP; 461 A; 407 C; 412 G; 443 T; 0 other;
XX	
QY	
Query Match	98.1%; Score 1688.8; DB 20; Length 1723;
Best Local Similarity	99.8%; Pred. No. 0;
Matches 1701; Conservative	0; Mismatches 2; Indels 1; Gaps 1
DB	
18	CCGCTGCGCGGAGCTGGCGGGGGAGCAAGCCAGGTGAGCCAAAGATGCTGGCGCTCG 77
7	CCGCTGCGCGGAGCTGGCGGGGGAGCAAGCCAGGTGAGCCAAAGATGCTGGCGCTCG 66
OY	
78	AAGCTTGCGCTGCGCGCGCGCTGATGCTGCTCTTGGGGCGCTGGGTCCCTCTCC 137
DB	
67	AAAGCTTGCGCTGCGCGCGCGCTGATGCTGCTCTTGGGGCGCTGGGTCCCTCTCC 126
OY	
138	CTTGCGCGCTTGGCGCGCGCGCTGATGCTGCTCTTGGGGCGCTGGGTCCCTCTCC 197
DB	
127	CTTGCGCGCTTGGCGCGCGCGCTGATGCTGCTCTTGGGGCGCTGGGTCCCTCTCC 186
OY	
198	CAGAGCGCGCTGCACTGCTGATGCGCGCGCGCTGATGCGCGCGCTGATGCGCGCGCTG 257
DB	
187	CAGAGCGCGCTGCACTGCTGATGCGCGCGCGCTGATGCGCGCGCTGATGCGCGCGCTG 246


```

Qy 752 TAAGAGGCTGATATTTTCATCAATGGGTGCGAGTTAGAGAGATTATTCATTTGCA 811
Db 826 TAAGAGGCTGATATTTTCATCAATGGGTGCGAGTTAGAGAGATTATTCATTTGCA 885
Qy 812 TAACTTCTAAGAAAGTCCACCTTCAAAAATGCAGAAATCTATAGTCTCTGATGTTGCA 871
Db 886 TAACTTCTAAGAAAGTCCACCTTCAAAAATGCAGAAATCTATAGTCTCTGATGTTGCA 945
Qy 872 GCCCTGAAGAAAGACGGCTAAGATGCTGAGAGGCTTCTGAAGGCTGGTGGAGAGTAT 931
Db 946 GCTTGAAGAAAGACGGCTAAGATGCTGAGAGGCTTCTGAAGGCTGGTGGAGAGTAT 1005
Qy 932 TGATTCAGTTACATGGCATCACTACTATTTGATGAGAGAGCTGTACAGAGAGATTT 991
Db 1006 TGATTCAGTTACATGGCATCACTACTATTTGATGAGAGAGCTGTACAGAGAGATTT 1065
Qy 992 TCTAAACCTTGATGATTTGACATTTTATTTTCATCTGTGCAAAAAGTTTCCAGGTGCT 1051
Db 1066 TCTAAACCTTGATGATTTGACATTTTATTTTCATCTGTGCAAAAAGTTTCCAGGTGCT 1125
Qy 1052 TGAGAGGACCAAGGCTGGCAAGAGGTGCTGTTAGAGAAACAAGCTGTGATATGAGG 1111
Db 1126 TGAAGAGCAAGGCTGGCAAGAGGTGCTGTTAGAGAAACAAGCTGTGATATGAGG 1185
Qy 1112 CGAGAGCGGCTTGTCTATCCGACACCTTTGAGAGCTGTTTATGTTGGCTGATTAATTTGG 1171
Db 1186 CGAGAGCGGCTTGTCTATCCGACACCTTTGAGAGCTGTTTATGTTGGCTGATTAATTTGG 1245
Qy 1172 CCGTGCAGCCCGGAATGGGAATGAAAGTGTGATGAGGCAAGATTTCTTTGAGAGAGAA 1231
Db 1246 CCGTGCAGCCCGGAATGGGAATGAAAGTGTGATGAGGCAAGATTTCTTTGAGAGAGAA 1305
Qy 1232 CTACACATTTATGATGAGAACTTCGATCCTTACCTGATATTTGGGCTATCTCTCTGTT 1291
Db 1306 CTACACATTTATGATGAGAACTTCGATCCTTACCTGATATTTGGGCTATCTCTCTGTT 1365
Qy 1292 CAAGAAATTTGGTGGGACCAAGGTGTATATGGCAAGCTGCAAGGTTCAAGAGAGAGAA 1351
Db 1366 CAAGAAATTTGGTGGGACCAAGGTGTATATGGCAAGCTGCAAGGTTCAAGAGAGAGAA 1425
Qy 1352 GCTTCGAGTATACCTTTCATTTGCAAAACATGACATTCAGATTAAGAGAGAGATTT 1411
Db 1426 GCTTCGAGTATACCTTTCATTTGCAAAACATGACATTCAGATTAAGAGAGAGATTT 1485
Qy 1412 AACTCTGATATGCAATAAAGCTTCATTAAGCTCAAGTACTTGGGTTACCTTATCCTTT 1471
Db 1486 AACTCTGATATGCAATAAAGCTTCATTAAGCTCAAGTACTTGGGTTACCTTATCCTTT 1545
Qy 1472 TTCTTACAGGAGATGATTAATATCTTCTAAGACCTTTGGGACCTCAATGATTACTTTC 1531
Db 1546 TTCTTACAGGAGATGATTAATATCTTCTAAGACCTTTGGGACCTCAATGATTACTTTC 1605
Qy 1532 CAAATCTGTCCAACTCAATGCTTAATCTTAAGATGATGATTAAGATCTTTCACAC 1591
Db 1606 CAAATCTGTCCAACTCAATGCTTAATCTTAAGATGATGATTAAGATCTTTCACAC 1665
Qy 1592 TTTTAAATGAAAAAAGCTTCTCGGCGCAGAAAGTTCACTGAGGCTTTCATATATAG 1651
Db 1666 TTTTAAATGAAAAAAGCTTCTCGGCGCAGAAAGTTCACTGAGGCTTTCATATATAG 1725
Qy 1652 TTTTAAATGAAAAAAGCTTTCATGATGATGATGATGATGATGATGATGATGATGAT 1711
Db 1726 TTTTAAATGAAAAAAGCTTTCATGATGATGATGATGATGATGATGATGATGATGAT 1785
Qy 1712 CCTGACACTG 1721
Db 1786 CCTGACACTG 1795

```

RESULT 12
AAH20940
ID AAH20940 standard; cDNA; 1724 BP.
XX

```

AC AAH20940;
XX
XX 24-AUG-2001 (first entry)
XX
XX Human heparanase inhibitor cDNA.
DE
XX Heparanase; inhibitor; cardiac insufficiency; cardiatic; nephrotropic;
KW hepatocytic; veterinary medicine; congestive heart failure; dyspnoea;
KW primary cardiomyopathy; peripheral edema; pulmonary congestion;
KW hepatic congestion; hydrothorax; ascites; nocturia; human; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH 52..1683
FT CDS /*tag= a
FT /product= "heparanase"
FT
XX DE19955803-A1.
XX
XX 23-MAY-2001.
XX
XX 19-NOV-1999; 99DE-1055803.
XX
XX 19-NOV-1999; 99DE-1055803.
XX
XX (KNOL ) KNOL AG.
XX
XX Herr D, Hahn A, Laux V;
XX
XX WPI; 2001-368371/39.
XX
XX P-PSDB; AAB86206.
XX
XX Treatment or prevention of cardiac insufficiency and related
PT conditions, e.g. pulmonary congestion and dyspnoea, comprises
PT administration of heparanase inhibitor
XX
XX Disclosure; Page 8-11; 16pp; German.
XX
XX This invention describes a novel heparanase inhibitor which can be used
CC for the treatment or prevention of cardiac insufficiency and associated
CC indications, symptoms and/or malfunctions. The heparanase inhibitor of
CC the invention has cardiant, nephrotropic and hepatotropic activity. The
CC products of the invention can be used in human and veterinary medicine,
CC for the treatment or prevention of congestive heart failure e.g. primary
CC cardiomyopathy. Associated conditions treated or prevented with the
CC inhibitor are especially peripheral edemas, pulmonary and hepatic
CC congestion, dyspnoea, hydrothorax and ascites. Renal problems, e.g.
CC nocturia can also be treated. This sequence encodes the human heparanase
CC protein described in the method of the invention.
XX
XX Sequence 1724 BP; 466 A; 405 C; 410 G; 443 T; 0 other;
SQ

```

Query Match 97.8%; Score 1682.6; DB 22; Length 1724;
Best Local Similarity 99.7%; Pred. No. 0;
Matches 1696; Conservative 0; Mismatches 4; Indels 1; Gaps 1;

```

Qy 18 CCGCTGCGGCGACGTGGCGGGGAGAGCAGCGTAGAGCCCAAGATGCTGCGCTCG 77
Db 8 CCGCTGCGGCGACGTGGC -GGGGAGAGCAGCGTAGAGCCCAAGATGCTGCGCTCG 66
Qy 78 AAGCTGCGTGGCGGCGGCGGCGGCTGATGCTGCTCCCGGGGCGGCTGGGTCCTCC 137
Db 67 AAGCTGCGTGGCGGCGGCGGCGGCTGATGCTGCTCCCGGGGCGGCTGGGTCCTCC 126
Qy 138 CCGGCGGCGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 197
Db 127 CCGTGGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 186
Qy 198 CAGAGCGGCTGCACTGCTGAGCGGCTGTTCTGTCTGCTGCACTTGAAGCCCAACTG 257
Db 187 CAGAGCGGCTGCACTGCTGAGCGGCTGTTCTGTCTGCTGCACTTGAAGCCCAACTG 246

```

```

Qy 258 GCCACGACCGCGGCTTCTCATCTCTGGGTTCTCCAAAGCTTCTGACTTTGGCCAGA 317
Db 247 GCCACGACCGCGGTTCTCTATCTCTGGGTTCTCCAAAGCTTCTGACTTTGGCCAGA 306
Qy 318 GGGTTGTTCTCTGCTGACTGAGTTGGTGACCAAGACAGACTTCTTAATTTTGCAT 377
Db 307 GGGTTGTTCTCTGCTGACTGAGTTGGTGACCAAGACAGACTTCTTAATTTTGCAT 366
Qy 378 CCCAAGAGGAATCAACCTTTGAAGAGAAAGTTCTGGCAATCTCAAGTCAACAGAGAT 437
Db 367 CCCAAGAGGAATCAACCTTTGAAGAGAAAGTTCTGGCAATCTCAAGTCAACAGAGAT 426
Qy 438 ATTGCAATATATGATCCATCCCTCTGATGTGAGAGAAAGTTACGGTTGGATGGCCC 497
Db 427 ATTGCAATATATGATCCATCCCTCTGATGTGAGAGAAAGTTACGGTTGGATGGCCC 486
Qy 498 TACAGAGCAATTTGCTACTCCGAGAACATCCAGAAAAGTTCAAGAACAGCACTTAC 557
Db 487 TACAGAGCAATTTGCTACTCCGAGAACATCCAGAAAAGTTCAAGAACAGCACTTAC 546
Qy 558 TCAAGAACTCTGTATGATGTGTATACACTTTTGGCAACTGTCAGACTGATCTGATC 617
Db 547 TCAAGAACTCTGTATGATGTGTATACACTTTTGGCAACTGTCAGACTGATCTGATC 606
Qy 618 TTTGGCTTAATGCGTTATTAAGACAGACAGATTGACAGTGAACAGTTCTATGCTCAG 677
Db 607 TTTGGCTTAATGCGTTATTAAGACAGACAGATTGACAGTGAACAGTTCTATGCTCAG 666
Qy 678 TTGCTCTGACACTGCTCTTCCAAAGGGATTAACATTTCTTGGGAACTAGGCAATGAA 737
Db 667 TTGCTCTGACACTGCTCTTCCAAAGGGATTAACATTTCTTGGGAACTAGGCAATGAA 726
Qy 738 CCTAACAGTTCTTAAAGAGCTGATATTTTCAATCATAGGGTCCGACTAGAGAAAGAT 797
Db 727 CCTAACAGTTCTTAAAGAGCTGATATTTTCAATCATAGGGTCCGACTAGAGAAAGAT 786
Qy 798 TATATTTCAATTGATTAACCTTAAAGAGTCCACTTCAAAAATGCAAAAATCTATGAT 857
Db 787 TATATTTCAATTGATTAACCTTAAAGAGTCCACTTCAAAAATGCAAAAATCTATGAT 846
Qy 858 CCGTATGTTGGTCAGCTCGAAGAAAGACGGCTAAGATGCTGAAGAGCTTCTGAAGGCT 917
Db 847 CCGTATGTTGGTCAGCTCGAAGAAAGACGGCTAAGATGCTGAAGAGCTTCTGAAGGCT 906
Qy 918 GGTGAGAAAGTATGATTCAGTACATGAGCACTACTATTTGAATGAGACGACTGCT 977
Db 907 GGTGAGAAAGTATGATTCAGTACATGAGCACTACTATTTGAATGAGACGACTGCT 966
Qy 978 ACCAGGAAAGATTTTCTAAACCTGATGATGACATTTTATTTCAATCTGTGCAAAA 1037
Db 967 ACCAGGAAAGATTTTCTAAACCTGATGATGACATTTTATTTTCAATCTGTGCAAAA 1026
Qy 1038 GTTTTCCAGGTGTTGAGAGCACAGGCTGGCAAGAAAGTCTGTTAGAGAAACAAGC 1097
Db 1027 GTTTTCCAGGTGTTGAGAGCACAGGCTGGCAAGAAAGTCTGTTAGAGAAACAAGC 1086
Qy 1098 TCTGATATGAGAGGCGAGCGCCCTTCTGATTCGACACCTTTGAGCTGGCTTTATG 1157
Db 1087 TCTGATATGAGAGGCGAGCGCCCTTCTGATTCGACACCTTTGAGCTGGCTTTATG 1146
Qy 1158 CTGGATTAATTTGGGCTGTACGCGCAATGGGAATGAGATGATGAGGCAAGTATATTC 1217
Db 1147 CTGGATTAATTTGGGCTGTACGCGCAATGGGAATGAGATGATGAGGCAAGTATATTC 1206
Qy 1218 TTTGGAGCAGAAATCACTATTTAGTGAATGAAAATTGATCTTTTACCTGATTTATGG 1277
Db 1207 TTTGGAGCAGAAATCACTATTTAGTGAATGAAAATTGATCTTTTACCTGATTTATGG 1266
Qy 1278 CTATCTCTTCTGTTCAAGAAATTTGGGCAACAGTGTATATGAGCAAGCTGCAAGT 1337
Db 1267 CTATCTCTTCTGTTCAAGAAATTTGGGCAACAGTGTATATGAGCAAGCTGCAAGT 1326
Qy 1338 TCAAGAGAAAGAACTTGAATATACCTTATTCACAAACAATGCAATGCAAGTAT 1397

```

```

Db 1327 TCAAGAGAAAGAACTTGAATATACCTTATTCAGCAAAACACTGACAAATCAAGTAT 1386
Qy 1398 AAAGAGAGATTTTAACTCTGTATAGCCATAAACCTCCATAACGTCACCAAGTACTGGG 1457
Db 1387 AAAGAGAGATTTTAACTCTGTATAGCCATAAACCTCCATAACGTCACCAAGTACTGGG 1446
Qy 1458 TTACCTTATCTTTTCTTAAACAGAGTGAATTAATCTTCTTAAGACTTTGGGACT 1517
Db 1447 TTACCTTATCTTTTCTTAAACAGAGTGAATTAATCTTCTTAAGACTTTGGGACT 1506
Qy 1518 CATGATTAATCTTCCAAATCTGTCCAACTCAATGCTTAATCTTAAGATGATGATAT 1577
Db 1507 CATGATTAATCTTCCAAATCTGTCCAACTCAATGCTTAATCTTAAGATGATGATAT 1566
Qy 1578 CAACCTTCCACCTTTTAAAGAAAACCTCTCCGCGCAGAGAAATTCATCTGGCTTGGCA 1637
Db 1567 CAACCTTCCACCTTTTAAAGAAAACCTCTCCGCGCAGAGAAATTCATCTGGCTTGGCA 1626
Qy 1638 GCTTCTCATATATGTTTTTTTGTGATTAAGAAATGCAAGTTGCTGCTGATCTGAATA 1697
Db 1627 GCTTCTCATATATGTTTTTTTGTGATTAAGAAATGCAAGTTGCTGCTGATCTGAATA 1686
Qy 1698 TAAATATATATGCTCTGACA 1718
Db 1687 TAAATATATATGCTCTGAAA 1707

```

```

RESULT 13
ABZ22816
ID ABZ22816 standard; cDNA; 1669 BP.
XX
AC ABZ22816;
XX
DT 02-APR-2003 (first entry)
XX
DE Human heparanase encoding cDNA SEQ ID NO:17.
XX
KW Human; heparanase; phosphorothioate; antisense oligonucleotide;
XX cytosolic; gene therapy; tumour; enzyme; gene; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..1638
FT /tag= a
FT /product= "heparanase"
XX
MO2003004705-A1.
XX
PD 16-JAN-2003.
XX
PF 01-JUL-2002; 2002WO-US20636.
XX
PR 05-JUL-2001; 2001US-0899440.
XX
PA (UNCO ) UNIV COLUMBIA NEW YORK.
XX
PI Stein C;
XX
DR MPI; 2003-201558/19.
XX
DR P-PDB; ABP56822.
XX
PT New oligonucleotide having a sequence complementary to a sequence of
PT ribonucleic acid encoding a heparanase, useful for preparing a
PT composition for treating tumor -
XX
XX Disclousure; fig 3; 48pp; English.
XX
CC The present invention describes an oligonucleotide having a sequence
CC complementary to a sequence of ribonucleic acid encoding a heparanase.
CC The oligonucleotide hybridises with the ribonucleic acid under conditions
CC of high stringency and has a sequence comprising 10-40 bp. The

```


Db 721 GGGTCGCACTTAGGAGAAGATTTTATTCAATTGCATAAAGCTTCTAAGAAAGTCCACCTTC 780

[illegible]

KW Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;

KW inflammation; psoriasis; diabetic retinopathy; solid tumour; arthritis;
 KW heparin degradation; anticoagulant neutralisation; asthma; CNS disease;
 KW inflammatory disease; vascular stenosis; atherosclerosis; diagnosis;
 KW tumour growth; fibroproliferative disorder; neurodegenerative disease;
 KW therapy; ds.
 XX Homo sapiens.
 OS
 FH Key Location/Qualifiers
 FT CDS 1..1593
 FT /*tag= a.
 FT /product= pre-proheparanase
 XX MO9943830-A2.
 XX 02-SEP-1999.
 XX 18-FEB-1999; 99WO-US01489.
 XX 26-MAR-1998; 98US-0079401.
 XX 24-FEB-1998; 98US-0075706.
 XX (PHDA) PHARMACIA & UPJOHN CO.
 XX Fairbanks MB, Heinrichson RL, Mildner AM;
 XX MPI: 1999-540598/45.
 XX P-PSDB; AAY34173.
 XX New isolated platelet heparanase polypeptides, used to develop
 PT products for, e.g. wound healing and blocking angiogenesis
 XX
 PS Claim 2; Fig 7; 57pp; English.
 CC This sequence encodes the human pre-proheparanase of the invention. This
 CC sequence was isolated from human platelets. The heparanase can be used
 CC for identifying agents which alter heparanase activity. The heparanase
 CC can be used for wound healing or for blocking angiogenesis or
 CC inflammation. It can be used for treating e.g. psoriasis, diabetic
 CC retinopathy or solid tumours, or for the degradation of heparin and the
 CC neutralisation of heparin's anticoagulant properties during surgery.
 CC Inhibitors of heparanase activity can be used in the treatment of
 CC arthritis, asthma, and other inflammatory diseases, vascular stenosis,
 CC atherosclerosis, tumour growth and progression, fibroproliferative
 CC disorders, and central nervous system (CNS) and neurodegenerative
 CC diseases. The products can also be used for detection and diagnosis. The
 CC purified heparanase, both recombinantly produced human heparanase and
 CC heparanase isolated from human platelet activity, allows for the
 CC convenient selection of compounds having anti-heparanase activity,
 CC i.e. inhibitors of heparanase activity, by measuring inhibition of
 CC heparanase activity. Inhibition of heparanase activity can be measured by
 CC blocking heparanase-mediated release of radioactive fragments from in
 CC vivo radiolabelled (HSPG)/heparin.
 CC
 XX Sequence 1593 BP; 426 A; 370 C; 369 G; 428 T; 0 other;
 SQ
 Query Match 92.1%; Score 1585; DB 20; Length 1593;
 Basic Local Similarity 99.7%; Pred. No. 0;
 Matches 1588; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

DB 181 CTCCTGGGTTCTCCAAAGCTTGTAACCTTGCCAGAGGCTTGCTCGGTAACCTGAGG 240
 QY 342 TTTGGTGGCACCAAGACAGACTTCTGTAATTTTGCATCCCAAGAAAGTAACCTTTGAA 401
 DB 241 TTTGGTGGCACCAAGACAGACTTCTGTAATTTTGCATCCCAAGAAAGTAACCTTTGAA 300
 QY 402 GAGAGAAGTTACTGAGCAATCTCAAGTCAACAGAGATATTTGCAATATGATGATCCCT 461
 DB 301 GAGAGAAGTTACTGAGCAATCTCAAGTCAACAGAGATATTTGCAATATGATGATCCCT 360
 QY 462 CCGATGTGAGAGAGAAAGTTACGGTTGGATGAGCCCTTACAGAGCAATTGCTACCGGA 521
 DB 361 CCGATGTGAGAGAGAAAGTTACGGTTGGATGAGCCCTTACAGAGCAATTGCTACCGGA 420
 QY 522 GAACACTACCAAGAAAGTTCAAGAACAGCACTTACTAAGAAAGCTCTGTAGATGTGTA 581
 DB 421 GAACACTACCAAGAAAGTTCAAGAACAGCACTTACTAAGAAAGCTCTGTAGATGTGTA 480
 QY 582 TACACTTTTGGCAACTGCTCAGAGCTGGAATGATCTTGTGGCTTAATGCGTTATTAAGA 641
 DB 481 TACACTTTTGGCAACTGCTCAGAGCTGGAATGATCTTGTGGCTTAATGCGTTATTAAGA 540
 QY 642 ACAGAGATTTGCAAGTGAACAGTTCTAATGCTCAGTTGCTCTGGACTACTGCTTTC 701
 DB 541 ACAGAGATTTGCAAGTGAACAGTTCTAATGCTCAGTTGCTCTGGACTACTGCTTTC 600
 QY 702 AAGGGGTATTAACATTTCTGGGAACTAGGCAATGAACCTAACAGTTTCTTAAGAGGCT 761
 DB 601 AAGGGGTATTAACATTTCTGGGAACTAGGCAATGAACCTAACAGTTTCTTAAGAGGCT 660
 QY 762 GATATTTTCAATGAGGTGCGAGTTAGAGAAAGTTATTAATGATGATTAACCTTCTA 821
 DB 661 GATATTTTCAATGAGGTGCGAGTTAGAGAAAGTTATTAATGATGATTAACCTTCTA 720
 QY 822 AGAAAGTCCACCTTCAAAAATGCAAAACTCTATGCTCCTGATGTTGTCACCTGAGA 881
 DB 721 AGAAAGTCCACCTTCAAAAATGCAAAACTCTATGCTCCTGATGTTGTCACCTGAGA 780
 QY 882 AAGACGGTAAAGATGCTGAAGAGCTTCTGAAGGCTGCTGAGAAAGATGATTAACCTT 941
 DB 781 AAGACGGTAAAGATGCTGAAGAGCTTCTGAAGGCTGCTGAGAAAGATGATTAACCTT 840
 QY 942 ACATGGACATCACTATTTGAATGAGCGAGCTGTCACAGAGAAATTTCTTAACCT 1001
 DB 841 ACATGGACATCACTATTTGAATGAGCGAGCTGTCACAGAGAAATTTCTTAACCT 900
 QY 1002 GATGATTTGACATTTTATTTATTTCAATCTGTGCAAAAGTTTTCAGGTGTTGAGACACC 1061
 DB 901 GATGATTTGACATTTTATTTATTTCAATCTGTGCAAAAGTTTTCAGGTGTTGAGACACC 960
 QY 1062 AGGCTGCGCAAGAAAGTCTGTTAGAGAAACAAAGCTCTGATATGAGGCGAGCGGCC 1121
 DB 961 AGGCTGCGCAAGAAAGTCTGTTAGAGAAACAAAGCTCTGATATGAGGCGAGCGGCC 1020
 QY 1122 TTGCTATCGCACACTTTGACAGCTGGCTTTATGAGGCTGATTAATTTGGGCTGTACGCC 1181
 DB 1021 TTGCTATCGCACACTTTGACAGCTGGCTTTATGAGGCTGATTAATTTGGGCTGTACGCC 1080
 QY 1182 CGAATGGGAATAGAAGTGTGATGAGCAAGTATTTTGGAGAGCAACCTAACATTTTA 1241
 DB 1081 CGAATGGGAATAGAAGTGTGATGAGCAAGTATTTTGGAGAGCAACCTAACATTTTA 1140
 QY 1242 GTGATGAAAACCTTGATCTTTAATGATTTATTTGCTATCTCTTGTGTTCAAGAAATG 1301
 DB 1141 GTGATGAAAACCTTGATCTTTAATGATTTATTTGCTATCTCTTGTGTTCAAGAAATG 1200
 QY 1302 GTGGGACCAAGAGTGAATATGCAAGCTGGAAGTTCAAGAGAGAGAGCTTCGAGTA 1361
 DB 1201 GTGGGACCAAGAGTGAATATGCAAGCTGGAAGTTCAAGAGAGAGAGCTTCGAGTA 1260
 QY 1362 TACCTTCAATTGCAAAACATGACATTCAGGATTAAGAGAGATTTAACTCTGAT 1421

Db 782 AGATGCTGAGAGCTTCTCTGAGAGCTGTGAGAAAGTGAATTCAGTTACATGCGATC 841
 Qy 952 ACTACTATTTGAATGAGAGGACTGCTACAGAGGAAGATTTCTAAACCTGATGATTGG 1011
 Db 842 ACTACTATTTGATGAGAGGACTGCTACAGAGGAAGATTTCTAAACCTGATGATTGG 901
 Qy 1012 ACATTTTATTTTCATCTGTGCAAAAAAGTTTTCCAGGTGTTGAGAGCACAGGCTTGCA 1071
 Db 902 ACATTTTATTTTCATCTGTGCAAAAAAGTTTTCCAGGTGTTGAGAGCACAGGCTTGCA 961
 Qy 1072 AGAAGTCTGTTGAGAGAAACAAGCTCTGCATATGAGGCGAGCGCCCTTGCTATCCG 1131
 Db 962 AGAAGTCTGTTGAGAGAAACAAGCTCTGCATATGAGGCGAGCGCCCTTGCTATCCG 1021
 Qy 1132 ACACCTTTGAGCTGAGCTTTATGAGCTGGAATAATTGGGCGCTGTACGCGCGAATGGGA 1191
 Db 1022 ACACCTTTGAGCTGAGCTTTATGAGCTGGAATAATTGGGCGCTGTACGCGCGAATGGGA 1081
 Qy 1192 TAGAAGTGTGATGAGGCAAGTATCTTTGAGAGCAAGAACTACCATTTAGTGATGAAA 1251
 Db 1082 TAGAAGTGTGATGAGGCAAGTATCTTTGAGAGCAAGAACTACCATTTAGTGATGAAA 1141
 Qy 1252 ACTTGATCTTTTACCTGATTAATTGCGTATCTCTTCTGTTCAAGAAATTTGGGACCA 1311
 Db 1142 ACTTGATCTTTTACCTGATTAATTGCGTATCTCTTCTGTTCAAGAAATTTGGGACCA 1201
 Qy 1312 AGGTGTATGAGCAAGCTGCAAGGTTCAGAAAGAGAAAGCTTGAGATACCTTCATT 1371
 Db 1202 AGGTGTATGAGCAAGCTGCAAGGTTCAGAAAGAGAAAGCTTGAGATACCTTCATT 1261
 Qy 1372 GCACAAACACTGACATCCAAAGTATMAAGAGAGATTTAACTGTATGCCATMAAC 1431
 Db 1262 GCACAAACACTGACATCCAAAGTATMAAGAGAGATTTAACTGTATGCCATMAAC 1321
 Qy 1432 TCCATTAAGTCAACAAGTACTTGGGTTACCTATCTTTTCTAACAAGCAAGTGATA 1491
 Db 1322 TCCATTAAGTCAACAAGTACTTGGGTTACCTATCTTTTCTAACAAGCAAGTGATA 1381
 Qy 1492 AATACCTTCTAAGACCTTTGGGACCTCATGGAATTACTTCCAAATCTGTCCAACCTCAATG 1551
 Db 1382 AATACCTTCTAAGACCTTTGGGACCTCATGGAATTACTTCCAAATCTGTCCAACCTCAATG 1441
 Qy 1552 GTCTAACTCTAAGATGTGATGATCAAAACCTTGCAACCTTTAATGAAAAACCTCTCC 1611
 Db 1442 GTCTAACTCTAAGATGTGATGATCAAAACCTTGCAACCTTTAATGAAAAACCTCTCC 1501
 Qy 1612 GGCAGAGAGTTCACCTGGGCTTGCCAGCTTCTCATATAGTTTTTTGTGATAGAAATG 1671
 Db 1502 GGCAGAGAGTTCACCTGGGCTTGCCAGCTTCTCATATAGTTTTTTGTGATAGAAATG 1561
 Qy 1672 CCAAGTTGCTGCTGCATCTGA 1694
 Db 1562 CCAAGTTGCTGCTGCATCTGA 1584

Search completed: February 16, 2004, 09:18:09.
 Job time : 850.407 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 ; Search time 6685.2 Seconds
(without alignments)
6256.802 Million cell updates/sec

Title: US-10-676-079-1
Perfect score: 1721
Sequence: 1 ctgagcttcgactctccg.....atatactagtcctgacactg 1721

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 22781392 seqs, 12152238056 residues
Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
EST:
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hlc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hlc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrc:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rtd:*
26: em_gss_dhg:*
27: em_gss_vr1:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1093.6	63.5	2173	11	AK040471 Mus muscu
2	954.2	55.4	1156	9	AL552151 AL552151
3	933.4	54.2	1162	11	AK087283 Mus muscu
4	923.6	53.7	1185	9	AL552174 AL552174

5	902.6	52.4	1201	9	AL545270
6	866.4	50.3	1200	9	AL545232
7	844.8	49.1	1083	13	BX398409
8	804.6	46.8	914	13	BX373611
9	761.6	44.3	881	14	CB988510
10	750.2	43.6	924	13	BO691142
11	689.8	40.1	907	13	BQ438834
12	687.8	40.0	708	13	BQ775819
13	615.2	35.7	682	12	BM996417
14	614.8	35.7	682	12	BM996417
15	553.4	32.2	556	9	AI342512
16	541	31.4	549	10	BF197674
17	537.4	31.2	540	10	AI582254
18	486.8	28.3	553	14	N30824
19	486.4	28.3	495	9	AI660639
20	470.4	27.3	484	9	AI033490
21	468.2	27.2	479	9	AI824984
22	466.2	27.1	488	13	BU617228
23	465.8	27.1	587	14	N45367
24	456.6	26.5	518	14	N30845
25	426.4	24.8	629	14	CB483444
26	410.2	23.8	427	9	AI928508
27	404.8	23.5	412	9	AI027968
28	371.2	21.6	480	9	AW465382
29	369.6	21.5	386	9	AI393542
30	352	20.5	370	14	N41349
31	348.4	20.2	367	9	AW015299
32	341	19.8	445	10	BF040685
33	332	19.3	484	14	N41373
34	327.2	19.0	632	10	BB636167
35	320.4	18.6	506	10	BF419897
36	317.4	18.4	341	9	AI189657
37	314.4	18.3	327	9	AA948627
38	310.4	18.0	408	14	N32056
39	304.6	17.7	431	9	AA177901
40	304.4	17.7	453	9	AA429437
41	299	17.4	451	9	AA674378
42	271.2	15.8	447	10	BB815166
43	263.4	15.3	452	10	BG663158
44	254.4	14.8	283	9	AI207288
45	253.8	14.7	777	9	AL718139

ALIGNMENTS

RESULT 1
LOCUS AK040471
DEFINITION Mus musculus 0 day neonate thymus cDNA, RIKEN full-length enriched library, clone: A30101M04 product: hepatanase, full insert sequence.
ACCESSION AK040471
VERSION AK040471.1 GI:26333764
KEYWORDS HTC; CAP trapper.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning
Meth. Enzymol. 303, 19-44 (1999)
99279253
MEDLINE
PUBMED
10349636
2
Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Kono, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes
Genome Res. 10 (10), 1617-1630 (2000)
20499374
JOURNAL
MEDLINE
PUBMED
11042159
REFERENCE


```

Oy 683 CCTGACTACTGCTCTTCAAGGGATTAACATTTCTTGGAACTAGCAATGAACCTAA 742
Db 687 CTTGACTACTGCTCTTCAAGGGATTAACATTTCTTGGAACTAGCAATGAACCTAA 746
Oy 743 CAGTTTCTTAAGAGGCTGATATTTTCATCAATGGGTGCGAGTTAGAGAAATATAT 802
Db 747 CAGTTTCTTAAGAGGCTGATATTTTCATCAATGGGTGCGAGTTAGAGAAATATAT 806
Oy 803 TCAATTCATTAATCTTCAAGAAAGTCCATCTTCAAAATCCAAATCTTATGCTCCGA 862
Db 807 GGAATTCATTAATCTTCAAGAAAGTCCATCTTCAAAATCCAAATCTTATGCTCCGA 866
Oy 863 TGTGTGACGCTCGAAGAAAGACGCTAGATGCTGAAGAGCTTCTGAAGAGCTGTGG 922
Db 867 CATGCTACGCTCGAAGAAAGACGCTAGATGCTGAAGAGCTTCTGAAGAGCTGTGG 926
Oy 923 AGAAGTATGATTCAGTTACATGAGCATCACTATATTTGAATGAGACGAGTGTACCA 982
Db 927 AGAAGTATGATTCAGTTACATGAGCATCACTATATTTGAATGAGACGAGTGTACCA 986
Oy 983 GGAAGATTTTAAACCTGATGATTTGACATTTTATTCATCTGTGCAAAAGTTT 1042
Db 987 AGAAGATTTTCTGAGCTGTGATGCTGAGACATTTTATCTCTGTGCAAAAGTTT 1046
Oy 1043 CCAGGTGTTGAGACACAGGCTCGAAGAGGCTGTAGAGAAACAGCTGTGC 1102
Db 1047 GAAAGTCACTAAGAGATCACACCTGTGAGAAAGGCTGTGTTGAGAGACAGCTGTGC 1106
Oy 1103 ATATGAGGCGGAGCGCCTTGTATATCCAGACCTTTGACAGCTGTATATGTGCTGA 1162
Db 1107 TTACGTTGCGGTTGAGACCTTGTGTGTCCAAACCTTTGACAGCTGTATATGTGCTGA 1166
Oy 1163 TAAATTTGGGCTGTGAGCCGATGAGATGAGATGAGTGTGATGAGGCAATTTTGG 1222
Db 1167 TAAATTTGGGCTGTGAGCCGATGAGATGAGATGAGTGTGATGAGGCAATTTTGG 1226
Oy 1223 AGCAGGAACTACATTTAGTATGAGTAAACCTTGATCTTAACTGATTTATGAGCTATC 1282
Db 1227 AGCAGGAACTACATTTAGTATGAGTAAACCTTGATCTTAACTGATTTATGAGCTATC 1286
Oy 1283 TCTTCTGTTCAAGAAATGTTGGGCAACCAAGGTTTAAATGCGACAGTGTTCAA 1342
Db 1287 TCTTCTGTTCAAGAAATGTTGGGCAACCAAGGTTTAAATGCGACAGTGTTCAA 1346
Oy 1343 GAGAGGAGCTTGGATTAACCTTCAATGCAAAACCTGACAAATCCAGATTAAGA 1402
Db 1347 CAGAGGAACTCCGAGTGTATCTCACCTGCACTAAGCTTATCACCAAGATATCAGA 1406
Oy 1403 AGGAGATTTAACTCTGTATGCAATTAACCTCATTAACCTCAACCAAGTATCCGGTTAC 1462
Db 1407 AGGAGATTTAACTCTGTATGCAATTAACCTCATTAACCTCAACCAAGTATCCGGTTAC 1466
Oy 1463 CTATCTTTTCTTAACAAGCAAGATGATTAATACCTTCAAGACCTTTGGGCACTCATAG 1522
Db 1467 GCTCTCTGTTTCAAGAAACAGTGTATGATGATGATGATGATGATGATGATGATGATG 1526
Oy 1523 ATTAATTTTCAAAATCTGTCACATCAATGCTTAACTTAAAGATGATGATGATCAAC 1582
Db 1527 ATTAATTTTCAAAATCTGTCACATCAATGCTTAACTTAAAGATGATGATGATGATGATG 1586
Oy 1583 CTGTCACCTTTAAAGAAAACTCTCGGCAAGAAAGTTCACGAGCTTGGCCAGCTT 1642
Db 1587 CCTGTCACCTTTAAAGAAAACTCTCGGCAAGAAAGTTCACGAGCTTGGCCAGCTT 1646
Oy 1643 CTCATATAGTTTCTTGTATAGAAATGCCAAAGTGTGCTTGCATCTGAATTAATAA 1702
Db 1647 TTCATATGTTTCTTGTATAGAAATGCCAAAGTGTGCTTGCATCTGAATTAATAA 1706

```

RESULT 2
AL552151/c
LOCUS AL552151 1156 bp mRNA linear EST 31-MAY-2003

```

DEFINITION AL552151 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA
ACCESSION AL552151
VERSION AL552151.2 GI:1273967
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 1156)
JOURNAL Full-length cDNA libraries and normalization
COMMENT Unpublished
On Feb 15, 2001 this sequence version replaced gi:12890775.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 Evry cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 2469.r For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSOD1059CG08NP1&cluster=2469.r. Contact :
Peng Liang Email : lliang@lifetech.com URL :
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CSOD1059CG08NP1.
location/Qualifiers
1. 1156
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSOD1059YNI5"
/tissue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo (dT)
primer. Five prime end enriched, double-strand cDNA was
digested with Not I and cloned into the Not I and BclI V
sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT 305 a 251 c 233 g 323 t 44 others
ORIGIN
Query Match 55.4%; Score 954.2; DB 9; Length 1156;
Best Local Similarity 98.0%; Pred. No. 1.5e-252;
Matches 970; Conservative 5; Mismatches 14; Indels 1; Gaps 1;

```

```

Oy 698 TTCAGAGGGGTATACATTTCTTGGGAACCTGACATTAACCTTCTTAAGA 757
Db 989 YTTCCAGGGTATACATTTCTTGGGAACCTGACATTAACCTTCTTAAGA 931
Oy 758 GGCATATTTTCAATGAGGTGCGAGTGAAGAAATATATTCATATGCAATTAAC 817
Db 930 GGCATATTTTCAATGAGGTGCGAGTGAAGAAATATATTCATATGCAATTAAC 871
Oy 818 TCTAAGAAAGTCCACTTCAAAATGCAAAATCTATGCTCTGATGTTGGTCAAGCTCG 877
Db 870 TCTAAGAAAGTCCACTTCAAAATGCAAAATCTATGCTCTGATGTTGGTCAAGCTCG 811
Oy 878 AAGAAAGCGGTAAAGATGCTGAAGAGCTTCTGAAGGCTGTGGAAGAGATGATTC 937
Db 810 AAGAAAGCGGTAAAGATGCTGAAGAGCTTCTGAAGGCTGTGGAAGAGATGATTC 751
Oy 938 AGTTACATGGGATACATCTATTTGAATGAGCGGCTCTACAGGAAAGATTTCTAA 997
Db 750 AGTTACATGGGATACATCTATTTGAATGAGCGGCTCTACAGGAAAGATTTCTAA 691
Oy 998 CCTGATGATTTGACATTTTATTTATTCATCTGTGCAAAAGTTTCCAGGTGTTGAGAG 1057
Db 690 CCTGATGATTTGACATTTTATTTATTCATCTGTGCAAAAGTTTCCAGGTGTTGAGAG 631
Oy 1058 CACCAAGGCTTGGCAAGAGTGTGTTGAGAGAAACAGCTCTGATATGAGGCGGAGC 1117
Db 630 CACCAAGGCTTGGCAAGAGTGTGTTGAGAGAAACAGCTCTGATATGAGGCGGAGC 571

```

Oy 1118 GCCCTTGCTATCCGACACCTTTGACGCTGGCTTTATGTGGCTGATTAATATGGGCTGTC 1177
 Db 570 GCCCTTGCTATCCGACACCTTTGACGCTGGCTTTATGTGGCTGATTAATATGGGCTGTC 511
 Oy 1178 AGCCCGAATGGGAATGAAAGTGTGATGAGGCAAGTATCTTTGAGCAGCAATACCA 1237
 Db 510 AGCCCGAATGGGAATGAAAGTGTGATGAGGCAAGTATCTTTGAGCAGCAATACCA 451
 Oy 1238 TTTATGTGATGAAACCTTGACCTTTACCTGATTAATGGGCTATCTCTTGTGTAAGA 1297
 Db 450 TTTATGTGATGAAACCTTGACCTTTACCTGATTAATGGGCTATCTCTTGTGTAAGA 391
 Oy 1298 ATTGGTGGGCAACCAAGTGTGATGAGGCAAGTGTGCAAGGTTCAAGAGAGAGACCTTG 1357
 Db 390 ATTGGTGGGCAACCAAGTGTGATGAGGCAAGTGTGCAAGGTTCAAGAGAGAGACCTTG 331
 Oy 1358 AGTATACCTTCACTTGAACCAACAGTGAACATCAAGTATTAAGAGAGATTTACTCT 1417
 Db 330 AGTATACCTTCACTTGAACCAACAGTGAACATCAAGTATTAAGAGAGATTTACTCT 271
 Oy 1418 GTATGCCATTAACCTCCATACGACCAAGTGAACGCTTACCTTACCTTTCTTA 1477
 Db 270 GTATGCCATTAACCTCCATACGACCAAGTGAACGCTTACCTTACCTTTCTTA 211
 Oy 1478 CAAGCAAGTGAATTAATACCTTCTAAGACCTTTGGGACCTCATGATTAATCTTCCAAATC 1537
 Db 210 CAAGCAAGTGAATTAATACCTTCTAAGACCTTTGGGACCTCATGATTAATCTTCCAAATC 151
 Oy 1538 TGTCCACTCAATGCTTCACTCTTAAGATGATGATGATCAACCTTGCCACCTTTAAT 1597
 Db 150 TGTCCACTCAATGCTTCACTCTTAAGATGATGATGATCAACCTTGCCACCTTTAAT 91
 Oy 1598 GGAAGAACCTCCGCGGCGGCAAGTGAACGCTTGGGCTTCCAGCTTCTCATATAGTTT 1657
 Db 90 GGAAGAACCTCCGCGGCGGCAAGTGAACGCTTGGGCTTCCAGCTTCTCATATAGTTT 31
 Oy 1658 TGTGATTAAGAAATGCCAAAGTGTGCTGCTG 1687
 Db 30 TGTGATTAAGAAATGCCAAAGTGTGCTGCTG 1
 RESULT 3
 AK087283
 LOCUS
 DEFINITION Mus musculus 0 day neonate lung cDNA, RIKEN full-length enriched library, clone: E030042C09 product:heparanase, full insert sequence.
 ACCESSION AK087283.1 GI:26104170
 VERSION AK087283.1
 KEYWORDS HTC; CAP trapper.
 SOURCE Mus musculus (house mouse)
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE
 AUTHORS Carninci, P. and Hayashizaki, Y.
 TITLE High-efficiency full-length cDNA cloning
 JOURNAL Mech. Enzymol. 303, 19-44 (1999)
 MEDLINE 99279253
 PUBMED 10349636
 REFERENCE
 AUTHORS Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Kono, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
 TITLE Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes
 JOURNAL Genome Res. 10 (10), 1617-1630 (2000)
 MEDLINE 20499374
 PUBMED 11042159
 REFERENCE
 AUTHORS
 Shibata, K., Itoh, M., Aizawa, K., Nagaoka, S., Sasaki, N., Carninci, P., Kono, H., Akiyama, J., Nishi, K., Katsunai, T., Tashiro, H., Itoh, M., Suni, N., Ishii, Y., Nakamura, S., Hazama, M., Nishino, T., Harada, A., Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K., Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Watanabe, M.,

Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsura, S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kiz, A. and Hayashizaki, Y.
 RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multiplexillary sequencer
 Genome Res. 10 (11), 1757-1771 (2000)
 MEDLINE 20530913
 PUBMED 11076861
 REFERENCE
 AUTHORS
 Kawai, J., Shingawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Aizawa, K., Iwata, M., Fukunishi, Y., Kono, H., Adachi, J., Fukuda, S., Aizawa, K., Iwata, M., Nishi, K., Kiyosawa, H., Kondo, S., Yamane, I., Saito, T., Okazaki, Y., Goto, T., Bono, H., Kasukawa, T., Saito, R., Kadota, K., Matsuda, H., Asanuma, M., Bataillon, S., Casavant, T., Fleischmann, W., Gaasterland, T., Gissi, C., King, B., Kochiwa, H., Kuhl, P., Lewis, S., Matsumoto, Y., Nakai, I., Penz, G., Quackenbush, J., Schriml, L. M., Staudt, F., Suzuki, R., Tomita, M., Wagner, L., Washio, T., Sakai, K., Okido, T., Furuno, M., Aono, H., Baldarelli, R., Barsh, G., Blake, J., Boffelli, D., Bojunga, N., Carninci, P., de Bonaldo, M. F., Brownstein, M. J., Bull, C., Fletcher, C., Fujita, M., Gariboldi, M., Gustincich, S., Hill, D., Hofmann, M., Hume, D. A., Kamita, M., Lee, N. H., Lyons, P., Marchionni, L., Mashima, J., Mazzarelli, J., Mombauer, P., Nordone, P., Ring, B., Ringwald, M., Rodriguez, I., Sakamoto, N., Sasaki, H., Sato, K., Schonbach, C., Seta, T., Shibata, Y., Storch, K. F., Suzuki, H., Toyooka, K., Wang, K. H., Weitz, C., Whiteaker, C., Wilming, L., Wynshaw-Boris, A., Yoshida, K., Hasegawa, Y., Kawaji, H., Kohsaki, S. and Hayashizaki, Y.
 Functional annotation of a full-length mouse cDNA collection
 Nature 409 (6821), 685-690 (2001)
 MEDLINE 21085660
 PUBMED 11217851
 REFERENCE
 AUTHORS
 The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team.
 Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
 Nature 420, 563-573 (2002)
 MEDLINE 12101962
 PUBMED 12101962
 REFERENCE
 AUTHORS
 Adachi, J., Aizawa, K., Akimura, T., Arikawa, T., Bono, H., Carninci, P., Fukuda, S., Furuno, M., Hanagaki, T., Hara, A., Hashizume, W., Hayashida, K., Hayatsu, N., Hiramoto, K., Hirose, T., Hirozane, T., Hori, F., Imotani, K., Ishii, Y., Itoh, M., Kagawa, I., Kasukawa, T., Katoh, H., Kawai, J., Kojima, Y., Kondo, S., Kono, H., Kouda, M., Koya, S., Kuribara, C., Matsuyama, T., Miyazaki, A., Murata, M., Nakamura, M., Nishi, K., Nomura, K., Numata, R., Ohno, M., Ohsato, N., Okazaki, Y., Saito, R., Saitoh, H., Sakai, C., Sakai, K., Sakazume, N., Sano, H., Sasaki, D., Shibata, K., Shingawa, A., Shiraki, T., Sogabe, Y., Tagami, M., Tagawa, A., Takahashi, F., Takaku-Akahira, S., Takeda, Y., Tanaka, T., Tomaru, A., Toya, T., Yasunishi, A., Muramatsu, M. and Hayashizaki, Y.
 Direct Submission
 Submitted (16-APR-2002) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration and Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail: genome-res@gscc.riken.go.jp, URL: http://genome.gsc.riken.go.jp/, Tel: 81-45-503-9222, Fax: 81-45-503-9216)
 cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN.
 Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.
 Please visit our web site for further details.
 URL: http://genome.gsc.riken.go.jp/
 URL: http://fantom.gsc.riken.go.jp/
 location/Qualifiers
 1. 1962
 /organism="Mus musculus"
 /mol_type="mRNA"
 /strain="C57BL/6J"
 /db_xref="FANTOM DB:E030042C09"
 /db_xref="taxon:10090"


```

source
1..1185
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSOD1059Y15"
/issue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/notes="1st strand cDNA was primed with a NotI-oligo (dt) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT      280 a      293 c      293 g      280 t
ORIGIN
Query Match      53.7%; Score 923.6; DB 9; Length 1185;
Best Local Similarity 98.4%; Pred. No. 4,6e-244;
Matches 956; Conservative 7; Mismatches 6; Indels 3; Gaps 3;
1 CTAAGCTTTGACCTCTCCGCTGCGGCGAGCTGGGGGGAGCAGCCAGTGAGCCCA 60
68 CTAAGACTCTGACTCTCCGCTGCGC-GCAGCTGGCGGGGAGCAGCCAGTGAGCCCA 126
61 AGATGCTGCTGCGCTGGAAGCTTGGCTGCGCGCGCTGATGCTGCTCTGGGAGC 120
127 AGATGCTGCTGCGCTGGAAGCTTGGCTGCGCGCGCTGATGCTGCTCTGGGAGC 186
121 CGCTGGGCTCCCTCTCCGCTGCGGCGCTGCGCGCGCTGATGCTGCTCTGGGAGC 180
187 CGCTGGGCTCCCTCTCCGCTGCGGCGCTGCGCGCGCTGATGCTGCTCTGGGAGC 246
181 ACTGGAATCTCTTCAACCGAGAGCGCTGCACTGATGAGCCCTGCTTCTGCTGCA 240
247 ACTGGAATCTCTTCAACCGAGAGCGCTGCACTGATGAGCCCTGCTTCTGCTGCA 306
241 CCAATGAGCGCAACCTGCGCAACGAGCCGCTTCTCATCTCTGCGCTTCTCAAGC 300
307 CCAATGAGCGCAACCTGCGCAACGAGCCGCTTCTCATCTCTGCGCTTCTCAAGC 366
301 TTGCAATCTTGGCGGAGAGCTTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
367 TTGCAATCTTGGCGGAGAGCTTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 426
361 ACTTCTTAATTTTCATCCCAAGAGATCACTTGAAGAGAGAGATTACTGGCAAT 420
427 ACTTCTTAATTTTCATCCCAAGAGATCACTTGAAGAGAGAGATTACTGGCAAT 486
421 CTCAAGTCAACCGAGATATTTGCAATATGATTCATCTCTGATGTGAGAGAGAT 480
487 CTCAAGTCAACCGAGATATTTGCAATATGATTCATCTCTGATGTGAGAGAGAT 546
481 TACGCTTGGAGTGGCGCTTCAACGAGAGATTTGCTTCCGAGAGACATCAAGAGAG 540
547 TACGCTTGGAGTGGCGCTTCAACGAGAGATTTGCTTCCGAGAGACATCAAGAGAG 606
541 TCAAGAGCAGACCTACTCAAGAGAGCTGTGATGATGCTTCACTTTGCAAACTCT 600
607 TCAAGAGCAGACCTACTCAAGAGAGCTGTGATGATGCTTCACTTTGCAAACTCT 666
601 CAGAGCTGAGCTGATCTTTGGCTTAAATGCGTTATTAAGAACAGCAGATTTGCA 660
667 CAGAGCTGAGCTGATCTTTGGCTTAAATGCGTTATTAAGAACAGCAGATTTGCA 726
661 ACAATTTCAATGCTCAAGTTGCTCTGAGCTACTGCTTCCAAAGGGGATTAATTTCT 720
727 ACAATTTCAATGCTCAAGTTGCTCTGAGCTACTGCTTCCAAAGGGGATTAATTTCT 786
721 GGAAGCTAGGAGATTAATTAATCAATTTCAATTTCAATTTCAATTTCAATTTCT 780
787 GGAAGCTAGGAGATTAATTAATCAATTTCAATTTCAATTTCAATTTCAATTTCT 846
781 GGAAGCTAGGAGATTAATTAATCAATTTCAATTTCAATTTCAATTTCAATTTCT 840
847 GGAAGCTAGGAGATTAATTAATCAATTTCAATTTCAATTTCAATTTCAATTTCT 906

```

```

841 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTCGAAGAGAGAGCGCTAAGATGCTG- 899
907 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTCGAAGAGAGAGCGCTAAGATGCTG- 966
900 AAGAGCTTCTGAAGAGCTGTGGAGAGAGTGAATTAATTCAGTTAATGCAATCACTACTAT 959
967 AAGAGCTTCTGAAGAGCTGTGGAGAGAGTGAATTAATTCAGTTAATGCAATCACTACTAT 1025
960 TTGAATGAGCG 971
1026 TTGAATGAGCG 1037
RESULT 5
AL545270
LOCUS
DEFINITION
AL545270 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA
clone CSOD1028YF04 5-PRIME, mRNA sequence.
AL545270
VERSION
AL545270.2 GI:31267106
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 1201)
Full-length cDNA libraries and normalization
Unpublished
REFERENCE
Li, W.B., Gruber, C., Jessee, J. and Polyes, D.
Full-length cDNA libraries and normalization
JOURNAL
On Feb 15, 2001 this sequence version replaced gi:1287751.
COMMENT
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 Evry cedex - France
Email: seqref@genoscope.cns.fr, Web: www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster.2469.r For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSOD1028YF04&cluster=2469.r. Contact :
Feng Liang Email : fliang@life.com URL :
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CSOD1028YF04.
FEATURES
location/Qualifiers
1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSOD1028YF04"
/issue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/notes="1st strand cDNA was primed with a NotI-oligo (dt) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT      292 a      282 c      305 g      279 t
ORIGIN
Query Match      52.4%; Score 902.6; DB 9; Length 1201;
Best Local Similarity 99.3%; Pred. No. 3e-238;
Matches 916; Conservative 0; Mismatches 5; Indels 1; Gaps 1;
4 GAGCTTGAATCTTCCGCTGCGGCGAGCTGGCGGGGAGACAGCCAGTGAGCCCAAG 63
63 GAGATCTGACTCTTCCGCTGCGGCGAGCTGGCGGGGAGACAGCCAGTGAGCCCAAG 122
64 TGCTGCTGCTGCTGCAAGGCTGCGCGCGCGCTGATGCTGCTGCTGCTGCTGCTGCTG 123
123 TGCTGCTGCTGCTGCAAGGCTGCGCGCGCGCGCTGATGCTGCTGCTGCTGCTGCTG 182
124 TGGGCTCCCTCTCCGCTGCGCGCGCTGCGCGCGCTGCTGCGCAAGCAGAGAGCTG 183
183 TGGGCTCCCTCTCCGCTGCGCGCGCTGCGCGCGCTGCTGCGCAAGCAGAGAGCTG 242

```

184 TGACCTTCTTCAACGAGGCGGTGACATGATGAGCCCTGCTTCTGTCCTGACCA 243
 243 TGGACTTCTTCAACGAGGCGGTGACATGATGAGCCCTGCTTCTGTCCTGACCA 302
 244 TTGACGCAACCTGCGCCACGAGCCCGGTTCTTATCTCTGCGTTCTTCAAGCTTC 303
 303 TTGACGCAACCTGCGCCACGAGCCCGGTTCTTATCTCTGCGTTCTTCAAGCTTC 362
 304 GTACCTTGGCCAGAGGCTTGTCTCTGCTACCTGAGGTTTGGGACCAAGACACT 363
 363 GTACCTTGGCCAGAGGCTTGTCTCTGCTACCTGAGGTTTGGGACCAAGACACT 422
 364 TCCAAATTTTGCATCCCAAGAGGATCACTTGAAGAGGAACTGACATCTC 423
 423 TCCAAATTTTGCATCCCAAGAGGATCACTTGAAGAGGAACTGACATCTC 482
 424 AAGTCAACGAGATATTTGCAATATGATCATCTCTGATGTGAGGAGAACTTAC 483
 483 AAGTCAACGAGATATTTGCAATATGATCATCTCTGATGTGAGGAGAACTTAC 542
 484 GGTGGAAATGCGCTTACGAGGCAATGCTTCTCCGAGAACCTACCAAGAAAGTTCA 543
 543 GGTGGAAATGCGCTTACGAGGCAATGCTTCTCCGAGAACCTACCAAGAAAGTTCA 602
 544 AGAAGACGACCTACTCAAGAGCTGTAGATGTGCTATACATTTTGAAGCTGACG 603
 603 AGAAGACGACCTACTCAAGAGCTGTAGATGTGCTATACATTTTGAAGCTGACG 662
 604 GACTGACCTGATCTTTGGCTTAAATGCTTATTAAGAACAGCAATTTGCAAGTGA 663
 663 GACTGACCTGATCTTTGGCTTAAATGCTTATTAAGAACAGCAATTTGCAAGTGA 722
 664 GTTCTAATGCTCAGTTGCTCTGCACTGCTCTTCAAGGGGATTAACATTTTGGG 723
 723 GTTCTAATGCTCAGTTGCTCTGCACTGCTCTTCAAGGGGATTAACATTTTGGG 782
 724 AACTAGGCAATGAACCTTAACAGTTTCTTAAGAGGCTGATATTTTCAATGAGG 783
 783 AACTAGGCAATGAACCTTAACAGTTTCTTAAGAGGCTGATATTTTCAATGAGG 842
 784 AGTTAGAGAGATTTATTTCAATTCATTAACCTTCTTAAGAAAGTCCACTTCAAAA 843
 843 AGTTAGAGAGATTTATTTCAATTCATTAACCTTCTTAAGAAAGTCCACTTCAAAA 902
 844 CAAACCTATGCTGCTGATGTTGCTGAGCTCGAAGAAAGCGCTAAGATGCTGAAG 903
 903 CAAACCTATGCTGCTGATGTTGCTGAGCTCGAAGAAAGCGCTAAGATGCTGAAG 962
 904 GCTTCCGGAAGGCTGCTGAGAG 965
 963 GCTT-CTGAGGCTGCTGAGAG 983

RESULT 6
 AL545232/c 1200 bp mRNA linear EST 31-MAY-2003
 LOCUS AL545232 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA
 DEFINITION clone CS001028YF04 3-PRIME, mRNA sequence.
 ACCESSION AL545232
 VERSION AL545232.2 GI:31267068
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 REFERENCE 1 (bases 1 to 1200)
 AUTHORS Li, W. B., Gruber, C., Jessee, J. and Polayes, D.
 TITLE Full-length cDNA libraries and normalization
 JOURNAL Unpublished
 COMMENT On Feb 15, 2001 this sequence version replaced gi:12877713.
 Contact: Genoscope
 Genoscope - Centre National de Sequencage

BP 191 91006 EVRY cedex - France
 Email: segre@genoscope.cns.fr, Web : www.genoscope.cns.fr
 Library was constructed by Life Technologies, a division of
 Invitrogen. This sequence belongs to sequence cluster 2469.r For
 more information about this cluster, see
 http://www.genoscope.cns.fr/
 cgi-bin/cluster.cgi?seq=CS001028DC02NP1&cluster=2469.r. Contact :
 Feng Liang Email : fliang@life.techn.com URL :
 http://fulllength.invitrogen.com/Invitrogen Corporation 1600
 Faraday Avenue Genoscope sequence ID : CS001028DC02NP1.
 Location/Qualifiers
 1..1200
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="CS001028YF04"
 /cbase_type="PLACENTA COT 25-NORMALIZED"
 /clone_id="Homo sapiens PLACENTA COT 25-NORMALIZED"
 /note="1st strand cDNA was primed with a NotI-oligo (dt)
 primer. Five prime end enriched, double-strand cDNA was
 digested with Not I and cloned into the Not I and EcoR V
 sites of the pCMVSPORT 6 vector. Library was normalized."
 BASE COUNT 300 a 249 c 249 g 332 t 70 others
 ORIGIN
 Query Match 50.3%; Score 866.4; DB 9; Length 1200;
 Best Local Similarity 97.3%; Pred. No. 3.2e-228;
 Matches 870; Conservative 9; Mismatches 15; Indels 0; Gaps 0;

765 ATTTTCATCAATGGGTGCGACGTTAGAGAGATTAATTCATTAATTCATTAAGA 824
 894 ATATTTCATCAATGGGTGCGACGTTAGAGAGATTAATTCATTAATTCATTAAGA 835
 825 AAGTCCACCTTCAAAATGCAAACTATATGCTCTGATGTTGTCAGCCCTGAAAG 884
 834 AAGTCCACCTTCAAAATGCAAACTATATGCTCTGATGTTGTCAGCCCTGAAAG 775
 885 ACGGCTAAGATGCTGAAGAGCTTCTGAAAGCTGAGGAGAGATGATTCAGTTACA 944
 774 ACGGCTAAGATGCTGAAGAGCTTCTGAAAGCTGAGGAGAGATGATTCAGTTACA 715
 945 TGGCATCACTATATTTGAATGACGACCTGCTACGAGGAGATTTTCTAACCTGAT 1004
 714 TGGCATCACTATATTTGAATGACGACCTGCTACGAGGAGATTTTCTAACCTGAT 655
 1005 GTATTGCACTTTTATTTTCACTCTGTGCAAAAGTTTCCAGGTGTTGAAGACCA 1064
 654 GTATTGCACTTTTATTTTCACTCTGTGCAAAAGTTTCCAGGTGTTGAAGACCA 595
 1065 CTTGGCAAGAGGCTGCTGTTAGAGAAACAAGCTCTGATATGAGGCGGAGCCCTTG 1124
 594 CTTGGCAAGAGGCTGCTGTTAGAGAAACAAGCTCTGATATGAGGCGGAGCCCTTG 535
 1125 CTATCCGACACCTTTGACGCTGCTTATGCTGCTGATTAATTTGGGCTGACCCGA 1184
 534 CTATCCGACACCTTTGACGCTGCTTATGCTGCTGATTAATTTGGGCTGACCCGA 475
 1185 ATGGGATAGAGAGGCTGATGAGGCAAGTATTTCTTTGAGCAGGAACTTACATTAG 1244
 474 ATGGGATAGAGAGGCTGATGAGGCAAGTATTTCTTTGAGCAGGAACTTACATTAG 415
 1245 GATGAAACCTTGATCCCTTACCTGATATTTGAGGCTGCTCTGTTCAAGAAATTTGG 1304
 414 GATGAAACCTTGATCCCTTACCTGATATTTGAGGCTGCTCTGTTCAAGAAATTTGG 355
 1305 GGCAACCAAGGTTTATGAGGAGGCTGCAAGGTTCAAGAGAGAACTTCAAGATATAC 1364
 354 GGCAACCAAGGTTTATGAGGAGGCTGCAAGGTTCAAGAGAGAACTTCAAGATATAC 295
 1365 CTTCAATGCAAAACATGCAATTCGAAGGATTAAGAGAGATTTAATCTGTATGCC 1424
 294 CTTCAATGCAAAACATGCAATTCGAAGGATTAAGAGAGATTTAATCTGTATGCC 235

OY		1425	TTAAACCTCCAAAGTCACCAAGTACTGGCGGTTAACCTATCCTTTTCTTAACAAGAA	1486
Dd		234	ATAAACCCTCCAAAGTGCCACCAAGTACTGGCGGTTAACCTATCCTTTTCTTAACAAGAA	175
OY		1485	GTCATTAATAATACCTTCTAAGACCTTTGGGACCTCATGTATCTTCCAAATCTGTCCA	1544
Dd		1274	GTGGATTAAATACCTTCTAAGACCTTTGGGACCTCATGTATCTTCCAAATCTGTCCA	115
OY		1545	CTCAATGCTCTAATCTTAAAGATGGTGATGATCAAACCTTGCCACCTTTTAATGAAAAA	1604
Dd		1114	CTCAATGCTCTAATCTTAAAGATGGTGATGATCAAACCTTGCCACCTTTTAATGAAAAA	55
OY		1605	CCTCTCCGCCGCAGGAAGTCTACCTGGCGTTGCCAGCTTCTCTATTAAGTTTTTT	1658
Dd		54	CCTCTCCGCCGCAGGAAGTCTACCTGGCGTTGCCAGCTTCTCTATTAAGTTTTTT	1
RESULT 7				
BX398409/c				
LOCUS		BX398409	1083 bp	mRNA linear EST 13-MAY-2001
DEFINITION		BX398409 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone CS0DI058YI24 3-PRIME, mRNA sequence.		
ACCESSION		BX398409		
VERSION		BX398409.1 GI:30617572		
KEYWORDS		EST.		
SOURCE		Homo sapiens (human)		
ORGANISM		Homo sapiens		
		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
		Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
REFERENCE		1 (bases 1 to 1083)		
AUTHORS		Ll.W.B., Gruber,C., Jeesee,J. and Polayes,D.		
TITLE		Full-length cDNA libraries and normalization		
JOURNAL		Unpublished		
COMMENT		Contact: Genoscope Genoscope - Centre National de Sequencage BP 191 91006 EVRY cedex - France Email: seqref@genoscope.cns.fr Web : www.genoscope.cns.fr Library was constructed by life technologies, a division of invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CSODI058B12NP1&cluster=2469.r . Contact : Peng Liang Email : liang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSODI058B12NP1. Location/Qualifiers 1..1083 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CSODI058YI24" /tissue.type="PLACENTA COT 25-NORMALIZED" /clone.lib="Homo sapiens PLACENTA COT 25-NORMALIZED" /note="Right strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."		
FEATURES				
Source		273 a	264 c	206 g 258 t 82 others
BASE COUNT				
ORIGIN				
Query Match		49.1%	Score 844.8,	DB 13; Length 1083;
Best Local Similarity		89.6%;	Pid. No.2.9e-22;	
Matches 928;		Conservative 18;	Mismatches 75;	Indels 15; Gaps 6;
OY		670	ATGCTCAGTTGCTCTGACACTACGTCCTTCCAAAGGGGATPAACATTTCTTGGGAACTAG	729
Dd		1045	ATGCTCAAGTGTCTCT-GACVACTCTC-TCCMA3GGGATPAACATTTCTTGGGAACTAG	988
OY		730	GCAATGAACCTTAACAGTTTCTCTTAAGAAGGCGATATTTTCATCAATGGGTGCGAGTTAG	789
Dd		987	GCAATGAACCTTAACAGTTTCTCTTAAGAAGGCGATAT-TTATCAATATGGGTGCGAGTTAG	929
OY		790	GAGAAAGATTATATTCATATGATGAATACTTCTAAGAAAGTCACCTTCAAAAATGCAAAAC	849

Db	928	GAGAGAGATTTTATTCATTTGATGATTAACCTTCTAAGAAAGTCCACTTCAAAAATCCAAAC	869
QY	850	TCTATGGTCTCGATGTTGGTCAGCCTCGAAGAAAGACGGCTAAGATGCTGAAGAAGCTTCC	909
Db	868	TCTATGGTCTCGATGTTGGTCAGCCTCGAAGAAAGACGGCTAAGATGCTGAAGAAGCTTCC	809
QY	910	TGAAGGCTGCTGAGGAAGATGATTTGATTCAGTTACATGGCATCACTACTATTTGAATGAC	969
Db	808	TGAAGGCTGCTGAGGAAGATGATTTGATTCAGTTACATGGCATCACTACTATTTGAATGAC	749
QY	970	GGACGTCTACCAAGGAGATTTTCTAAACCCTGATGATTTGACATTTTATTCATCTG	1029
Db	748	GSACTGCTACCAAGGAGATTTTCTAAACCCTGATGATTTGACATTTTATTCATCTG	689
QY	1030	TGCAAAAAGTTTTCCAGGTGTTGAGACACACAGGCTGCGCAAGAGTCTGTTAGAG	1089
Db	688	TGCAAAAAGTTTTCCAGGTGTTGAGACACACAGGCTGCGCAAGAGTCTGTTAGAG	629
QY	1090	AAACAGCTCTGCATATGAGAGCGAGCGCCCTTGCTATCCGACACCTTTGACCTGCT	1149
Db	628	AAACAGCTCTGCATATGAGAGCGAGCGCCCTTGCTATCCGACACCTTTGACCTGCT	569
QY	1150	TTATGTGCTGGAATTAATGGGCGCTGTCAGCGCGAATGGGAATGAAGTGGTGAAGGC	1209
Db	568	TTATGTGCTGGAATTAATGGGCGCTGTCAGCGCGAATGGGAATGAAGTGGTGAAGGC	509
QY	1210	AAGTATCTTTGAGACAGAACTACATTAAGTGAATGAAMACTTGATCTTTAAGCTG	1269
Db	508	AAGTATCTTTGAGACAGAACTACATTAAGTGAATGAAMACTTGATCTTTAAGCTG	449
QY	1270	ATTATTTT-----TTGGCTATCTCTTCTGTTCAAGAAATGGTGGCACCAAGTGTAAAT	1321
Db	448	ATTATTTT-----TTGGCTATCTCTTCTGTTCAAGAAATGGTGGCACCAAGTGTAAAT	389
QY	1322	GGCAAGCGTGAAGGTTCAAGAGAGAGAGCTTGAATTAACCTTGATGCAAAACAC	1381
Db	388	GGCAAGCGTGAAGGTTCAAGAGAGAGAGCTTGAATTAACCTTGATGCAAAACAC	329
QY	1382	TGACATCTCAAGTATTAAGAAGAGATTTAATCTGTATGCTAATTAACCTCCATAAGT	1441
Db	328	TGACATCTCAAGTATTAAGAAGAGATTTAATCTGTATGCTAATTAACCTCCATAAGT	269
QY	1442	CACCAAGTACTTGGCGTTACCTTATCCTTTTCTAACAAGCAAGTGAATTAATCTTCT	1501
Db	268	CACCAAGTACTTGGCGTTACCTTATCCTTTTCTAACAAGCAAGTGAATTAATCTTCT	209
QY	1502	AAGAC---TTTGGGACCTCAATGATTAATCTTCCAAATCTGTCAACTCAATGCTCAAC	1558
Db	208	AAGAC---TTTGGGACCTCAATGATTAATCTTCCAAATCTGTCAACTCAATGCTCAAC	149
QY	1559	TCTAAGAATGCTGATGATCAAACTTGGCCACTTTAATGGAATAAACCCTCCGGCAGG	1618
Db	148	TCTAAGAATGCTGATGATCAAACTTGGCCACTTTAATGGAATAAACCCTCCGGCAGG	89
QY	1619	AAGTCACTGGGCTTCCAGCTTTCTCATATAGTTTTTTTGTGAAG-AAATGCCAAG	1677
Db	88	AAGTCACTGGGCTTCCAGCTTTCTCATATAGTTTTTTTGTGAAG-AAATGCCAAG	29
QY	1678	TTGCTGCTGATCTG	1693
Db	28	NTGNCGGCTGCMTNB	13

RESULT 8

EX373611/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

914 bp

RNA

linear

EST 08-MAY-2003

EX373611 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone CS001058Y124 3-PRIME, mRNA sequence.

EX373611

EX373611.1 GI:30446136

EST.

Homo sapiens (human)

ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrate; Euteleostomi;
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
TITLE	Li, W.B., Gruber, C., Jessee, J., and Polayes, D.
JOURNAL	Full-length cDNA libraries and normalization
COMMENT	Unpublished Contact: Genoscope Genoscope - Centre National de Sequencage BP 191 9106 EVRY cedex - France Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see http://www.genoscope.cns.fr/ cgi-bin/cluster.cgi?seq=CSDBAK060DC08NM1&cluster=2469.r . Contact : Feng liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSDBAK060DC08NM1. Location/Qualifiers 1. 914 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CSODI058Y124" /cbase_type="PLACENTA COT 25-NORMALIZED" /clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED" /note="1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT	260 a 191 c 188 g 275 t
ORIGIN	
Query Match	46.8%; Score 804.6; DB 13; Length 914; Best Local Similarity 95.3%; Pred. No.3.6e-211; Matches 872; Conservative 0; Mismatches 39; Indels 4; Gaps 4
Db	806 ATTCATTAACCTTTCTAGAAAGTCCACCCTTCAAAAATGCAAAACTCTATGTCTCGATGT 865 913 ATTGCATTAACTCTTAAAAAAGTCCCTTCAAATAATG-AACTTTATGTCTTATGT 855
Oy	866 TGGTCAGCCTCGAAGAAGACGGCTTAAGTCTGAAGACTTCTGGAAGCTGTGTGAGA 925 854 TGCTCAACCTCAAAAAGAACCGCTTAAATTTCTAAAGCTTCTTAAAGGCTGTGTGAGA 795
Dd	926 AGTG-TTGATTCAGTTCATGCGCATCTACTATTGTAATGG-ACGACGTGTCACGAG 983 794 AATGATTTAATCCATATACATGCCATCTTCTATTGATGAAACGACGTCTACCGAG 735
Oy	984 GAAGATTTCTTAAACCTCGATGTATTTGACATTTTATTCTCTGTGCAAAAAGTTTTC 1043 734 GAAGATTTCTTAAACCTCGATGTATTTGACATTTTATTCTCTGTGCAAAAAGTTTTC 675
Dd	1044 CAGGTGTTGAGAGACCAAGCGCTGCGCAAGAAGGTCTGTTAGAGAAAACAAGCTCTGCA 1103 674 CAGGTGTTGAGAGACCAAGCGCTGCGCAAGAAGGTCTGTTAGAGAAAACAAGCTCTGCA 615
Oy	1104 TATGAGGCGGAGCGCCCTTGTCTATCCGACACCTTTGCAAGCTGTGCTTATGTGGCTGGAT 1166 Db 614 TATGAGGCGGAGCGCCCTTGTCTATCCGACACCTTTGCAAGCTGTGCTTATGTGGCTGGAT 555
Oy	1164 AAATTGGGCGTGTGAGCCCGAATGGGAATAGAAGTGTGATAGGCAAGATATTCTTTGGA 1222 Db 554 AAATTGGGCGTGTGAGCCCGAATGGGAATAGAAGTGTGATAGGCAAGATATTCTTTGGA 495
Oy	1224 GCAGAAACTACATTTAGTGATGAAAATTGATCTCTTTAAGCTGATTTATGGCTATCT 1283 Db 494 GCAGAAACTACATTTAGTGATGAAAATTGATCTCTTTAAGCTGATTTATGGCTATCT 435
Oy	1284 CTTCCTGTTCAAGAAATGGTGGCACCAAGGTGTTATGTGCAAGCGTGCAGAGTTCAAG 1344 Db 434 CTTCCTGTTCAAGAAATGGTGGCACCAAGGTGTTATGTGCAAGCGTGCAGAGTTCAAG 375

QY	1344	AGAGAAGAGCTTGAGATATACCTTCATTGGACAAGAACCTGACATGCCAAGTATPAAAGAA	1403
Db	374	AGAGAAGAGCTTGAGATATACCTTCATTGGACAAGAACCTGACATGCCAAGTATPAAAGAA	315
QY	1404	GGAGATTAACTGTGTATGACCATTAACCTCCATTAACGTCAACCAAGTACTTGCGGTTAACCC	1463
Db	314	GGAGATTAACTGTGTATGACCATTAACCTCCATTAACGTCAACCAAGTACTTGCGGTTAACCC	255
QY	1464	TATCCTTTTCTTAAACAGCAAGTGGATPAAATACCTTCTTAAAGACCTTTTGGACCTTCATGGA	15233
Db	254	TATCCTTTTCTTAAACAGCAAGTGGATPAAATACCTTCTTAAAGACCTTTTGGACCTTCATGGA	195
QY	1524	TTACCTTCCCAATCGTCCCAACTCAATGCTTAACTCTTAAAGATGATGATCAAAAC	15833
Db	194	TTACCTTCCCAATCGTCCCAACTCAATGCTTAACTCTTAAAGATGATGATCAAAAC	135
QY	1584	TTGGCACTTTTAAATGAGAAAACCTCTCGGCGAGAAAGTTGACTGCGGCTTGCCAGCTTTC	16433
Db	134	TTGGCACTTTTAAATGAGAAAACCTCTCGGCGAGAAAGTTGACTGCGGCTTGCCAGCTTTC	75
QY	1644	TCATPATACTTTTGTGATTAAGAAATGCCAAAGTTGCTGCTTGATCTGAAAATTAAT	17033
Db	74	TCATPATACTTTTGTGATTAAGAAATGCCAAAGTTGCTGCTTGATCTGAAAATTAAT	16
QY	1704	ATACGATCGCTGACA 1718	
Db	15	ATACGATCGCTGAAA 1	
RESULT 9			
LOCUS	CB988510	881 bp	mRNA linear EST 01-MAY-2003
DEFINITION	AGENCOURT_13305817 NIH_MGC_147 Homo sapiens cDNA clone		
ACCESSION	CB988510		
VERSION	CB988510.1	GI:30283030	
KEYWORDS	EST.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	EMBL/GenBank/CCDS: CB988510.1		
AUTHORS	Mammalian Gene Collection (MGC)		
TITLE	Unpublished		
JOURNAL	Contact: Robert Strausberg, Ph.D.		
COMMENT	Email: cga@bbs.fda.gov		
	Tissue Procurement: Dr. Stefan Hansson		
	cDNA Library Preparation: Michael J. Brownstein (NHGRI) with help		
	and advice from Piero Carninci (RIKEN)		
	cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNLN)		
	DNA Sequencing by: Agencourt Bioscience Corporation		
	Clone distribution: MGC clone distribution information can be		
	found through the I.M.A.G.E. Consortium/LNLN at:		
	http://image.llnl.gov		
	Plate: NDAM370 row: f column: 22		
	High quality sequence spot: 664.		
FEATURES	Location/Qualifiers		
source	1..881		
	/organism="Homo sapiens"		
	/mol_type="mRNA"		
	/db_xref="taxon:9606"		
	/clone="IMAGE:30340461"		
	/isue_type="Human Placenta"		
	/lab_host="DH10B Tora"		
	/clone_id="NIH_MGC_147"		
	/note="Organ: Placenta; Vector: pBluescript; Site: 1;		
	ali-hol; Site: 2: BamH; Oligo-dT primed using primer		
	5'-TTTTTTTTTTTTTTVN-3', size-selected for average		
	insert size 2.3 kb and normalized to ROT 5. This is a		
	primary library enriched for full-length clones and		
	constructed using the Cap-trapper method (Carninci, in		

Oy	452	TTCCATCCCTCCTGATGTGGAGGAGAAAGTTACGGTTGGAAATGGCCCTACAGAACATTT	511
Db	524	ATCCATCCCTCCTGATGTGGAGGAGAAAGTTACGGTTGGAAATGGCCCTACAGAACATTT	583
Oy	512	GCTACTCCGAGAACACTACACAGAAAAAGTTCAAGAACAGCACTTACTCAAGAGCTCTGT	571
Db	584	GCTACTCCGAGAACACTACAGAAAAAGTTCAAGAACAGCACTTACTCAAGAGCTCTGT	643
Oy	572	AGATGTGCTATACACTTTTGGCAACTGCTCAGAGACTGACCTTGATCTTTGGCTTAATGC	631
Db	644	AGATGTGCTATACACTTTTGGCAACTGCTCAGAGACTGACCTTGATCTTTGGCTTAATGC	703
Oy	632	GTTATTAGAACAGAGAGATTGGCACTGGAACAGTTCTTAATGTCAGTGTCTCTGAGCTA	691
Db	704	GTTATTAGAACAGAGAGATTGGCACTGGAACAGTTCTTAATGTCAGTGTCTCTGAGCTA	763
Oy	692	CTGCTCTTCCAAAGGGGATTAACATTTCTTGGGAATTAGGCATGAACTAACAGTTTCT	751
Db	764	CTGCTCTTCCAAAGGGGATTAACATTTCTTGGGAATTAGGCATGAACTAACAGTTTCT	822
Oy	752	TAAGAGGCTGATATTTTCATCAATGGGTGGAGTTAGGAGAAGATTATATTCATTTGCA	811
Db	823	TAAGAGGCTGATATTTTCATCAATGGGTGGAGTTAGGAGAAGATTATATTCATTTGCA	882
Oy	812	TAAATCTTAAAGAAAGTCCACTTTCAAAAAATGCAAAACT	850
Db	883	TAAATCTTAAAGAAAGTCCACTTTCAAAAAATGCAAAACT	921

RESULT 11	
BQ438834	
LOCUS	BQ438834 907 bp mRNA linear EST 24-MAY-2007
DEFINITION	AGENCOURT_7761619 NIH_MGC_70 Homo sapiens cDNA clone IMAGE:6017952 5', mRNA sequence.

ACCESSION	BQ438834
VERSION	BQ438834.1
KEYWORDS	EST.
SOURCE	Homo sapiens (human)

ORGANISM	Homo sapiens
NCBI	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS	1 (bases 1 to 907)
TITLE	NIH-MGC http://mgc.nci.nih.gov/ .
JOURNAL	National Institutes of Health, Mammalian Gene Collection (MGC)
COMMENT	Unpublished Contact: Robert Strausberg, Ph.D.

```

Email: CGabbs-remail.nih.gov
Tissue Procurement: ATCC
CNA Library Preparation: life Technologies, Inc.
CNA Library Arrayed by: The I.M.A.G.E. Consortium (LINTL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LINTL at:
http://image.lnlnl.gov
Plate: L1AM13218 row: b column: 01
High quality sequence stop: 616.
Location/Qualifiers
1..907
FEATURES
source

```

Query Match	BASE COUNT	ORIGIN
40.1%; Score 689.8; DB 13; Length 907;	260 a	176 c 226 g 242 t 3 others

Best Local Similarity	94.8%	Pred. No. 2.2e-179	Matches 778	Conservative 0	Mismatches 34	Indels 9	Gaps 6
QY	385	AGGATCAACCTTTGAGAGAGAGATTACTGGCAATCTCAAGTCAACCGAGATATTGGCA	444				
Db	5	AAGGATCAACCTTTGAGAGAGAGATTACTGGCAATCTCAAGTCAACCGAGATATTGGCA	64				
QY	445	AATATGATTCATCCCTCTCTGATGTGGAGGAGAAAGTTACGGTTGGAAATGGCTTACCAAG	504				
Db	65	AATATGATTCATCCCTCTCTGATGTGGAGGAGAAAGTTACGGTTGGAAATGGCTTACCAAG	124				
QY	505	AGCAATTCCTACTCCGAGAACATCAACGAGAAAAAGTTCAAGAACAGCACTACTCAAGAA	564				
Db	125	AGCAATTCCTACTCCGAGAACATCAACGAGAAAAAGTTCAAGAACAGCACTACTCAAGAA	184				
QY	565	GCTCTGATGATGTGCTATACACTTTTGGCAACCTGCAAGCACTGACCTTGAATCTTTGGCC	624				
Db	185	GCTCTGATGATGTGCTATACACTTTTGGCAACCTGCAAGCACTGACCTTGAATCTTTGGCC	244				
QY	625	TAAATGCGTTATTAAGAACACAGACATTTGCAAGTTCATATGCTCAGTTGCTCC	684				
Db	245	TAAATGCGTTATTAAGAACACAGACATTTGCAAGTTCATATGCTCAGTTGCTCC	304				
QY	685	TGAGCTACTGCTCTCCAGAGGGGTATACATTTCTTGGGAACTTGGGCAATGAACCTACA	744				
Db	305	TGAGCTACTGCTCTCCAGAGGGGTATACATTTCTTGGGAACTTGGGCAATGAACCTACA	364				
QY	745	GTTTCCTTAAAGAGGCTGATATTTTTCATCAATGCGTGCAGTTGAGAGAAATTAATTC	804				
Db	365	GTTTCCTTAAAGAGGCTGATATTTTTCATCAATGCGTGCAGTTGAGAGAAATTAATTC	424				
QY	805	AATTGATTAACCTTCTAAGAAAGTCCACCTTCAAAAATGCAAAACCTATGCTCCTGATG	864				
Db	425	AATTGATTAACCTTCTAAGAAAGTCCACCTTCAAAAATGCAAAACCTATGCTCCTGATG	484				
QY	865	TTGTCACACCTCGAAGAAAGACGGCTAAGATGCTGAAGAGCTTCTGAAGCTGCTGGAG	924				
Db	485	TTGTCACACCTCGAAGAAAGACGGCTAAGATGCTGAAGAGCTTCTGAAGCTGCTGGAG	544				
QY	925	AAGTCAATGATTCAGTTACATGTCATGCGATCACTACTAT-TTGAATGAGACGACCTACCA-G	982				
Db	545	AAGTCAATGATTCAGTTACATGTCATCACTACTATTTGAATGAGACGACCTGCTACCAAG	604				
QY	983	GGAAGATTTTCTAACCCTGATGATTTGAGACATTTTATTTTCATCTG-TGCAAAAAGTT	1040				
Db	605	GGAAGATTTTCTAACCCTGATGATTTGAGACATTTTATTTTCATCTGATGCAAAAAGTT	664				
QY	1041	TTCCAGGTGTTGAGAGACACAGGCTTGGCAAG-AAGGTCTGTTTGAAGAAACAAGCTC	1098				
Db	665	TTCCAGGTGTTGAGAGACACAGGCTTGGCAAGAAAGTCTGTTGTTGAGAAACAAGCTC	724				
QY	1100	TGCATAT-TGAGGGGGAGGAGCGCCCTTGATCCGACACCTTGGACGCTGCTTTATGTGC	1158				
Db	725	TGCATATGGAGGGAGGAGCGCCCTTGATCCGACACCTTGGACGCTGCTTTATGTGC	784				
QY	1159	T---GATTAATTTGGGCTCTGTCAGGCCGCAATGGAATAGAA	1196				
Db	785	TTGGGATTAATTTGGGCTCTGTCAGGCCCAATGGGGGAAATA	825				
RESULT 12							
LOCUS	B0775819/c	708 bp	mRNA	linear	EST 26-JUL-2002		
DEFINITION	UI-H-FH0-bcg-a-07-0-UI-s1 NCI CGAP FH0 Homo sapiens cDNA clone						
ACCESSION	B0775819						
VERSION	B0775819.1						
KEYWORDS	EST.						
SOURCE	Homo sapiens (human)						
ORGANISM	Homo sapiens						
REFERENCE	1 (bases 1 to 708)						

RESULT	12
BQ775819/c	
LOCUS	BQ775819 708 bp mRNA linear EST 26-JUL-2002
DEFINITION	UI-H-FH0-bcg-a-07-0-UI.s1 NCI CGAP FH0 Homo sapiens CDNA clone
ACCESSION	UI-H-FH0-bcg-a-07-0-UI 3' , mRNA sequence.
VERSION	BQ775819
KEYWORDS	BQ775819.1 GI:21984295
SOURCE	EST.
ORGANISM	Homo sapiens (human)
	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE	1 (bases 1 to 708)

double-stranded cDNA was size selected, ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified p773 vector (Pharmacia). Library constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 181 a 138 c 149 g 182 t 2 others
 ORIGIN

Query Match 35.7%; Score 615.2; DB 13; Length 682;

Best Local Similarity 98.9%; Pred. No. 8.4e-159;

Matches 639; Conservative 0; Mismatches 5; Indels 2; Gaps 2;

1016 TTTTATTTCTGTCGCAAAAAGTTTCCAGGTGTTGAGACACAGGCGCTGGCAAGA 1075
 7 TTTTATTTATCTGCAAAAAGTTTCCAGGTGTTGAGACACAGGCGCTGGCAAGA 66
 1076 GGTCTGTAGAGAAACAAGCTGTCATATGAGAGCGGAGCGCCCTGCTATCCGACAC 1135
 67 GGTCTGTAGAGAAACAAGCTGTCATATGAGAGCGGAGCGCCCTGCTATCCGACAC 126
 1136 CTTTGACAGCTGCTTTATGTCGCTGATTAATTTGGCCCTGTCAGCCCGAATGGAATAGA 1195
 127 CTTTGACAGCTGCTTTATGTCGCTGATTAATTTGGCCCTGTCAGCCCGAATGGAATAGA 186
 1196 AGTGTGATGAGGCAAGTATCTTTGAGAGCAAGAACTACATTAAGTGAATAAATT 1255
 187 AGTGTGATGAGGCAAGTATCTTTGAGAGCAAGAACTACATTAAGTGAATAAATT 246
 1256 CGATCTTACTGATTTATGCTATCTCTGTTCAAGAAATTTGGGACCAAGT 1315
 247 CGATCTTACTGATTTATGCTATCTCTGTTCAAGAAATTTGGGACCAAGT 306
 1316 GTTAAAGCAAGCGGCAAGGTTCAAGAGAGAGCTTCAGATATCCTTCATTGCGAC 1375
 307 GTTAAAGCAAGCGGCAAGGTTCAAGAGAGAGCTTCAGATATCCTTCATTGCGAC 366
 1376 AAACATGACATCCAAAGTATTAAGAGAGAGATTAATCTGTATGTCATTAACCTCCA 1435
 367 AAACATGACATCCAAAGTATTAAGAGAGAGATTAATCTGTATGTCATTAACCTCCA 426
 1436 TAACTGACCAAGTATCTGCGGTACCTTATCTTTTCAACAGCAAGTGAATTAATA 1495
 427 TAACTGACCAAGTATCTGCGGTACCTTATCTTTTCAACAGCAAGTGAATTAATA 486
 1496 CTTTAAAGCAAGCTTTGAGGACCTCATGATTAATCTTCAAAATGTCACCACTCAATGCT 1555
 487 CTTTAAAGCAAGCTTTGAGGACCTCATGATTAATCTTCAAAATGTCACCACTCAATGCT 546
 1556 AACTTAAAGATGTGATGATCAAA-CCTTGCCACCTTTAATGGAAGAAA-CCTCTCCGG 1613
 547 AACTTAAAGATGTGATGATCAAA-CCTTGCCACCTTTAATGGAAGAAA-CCTCTCCGG 606
 1614 CCAAGAGTTCACCTGCGCTTGGCAGCTTTCTCATATAGTTTGTG 1659
 607 CCAAGAGTTCACCTGCGCTTGGCAGCTTTCTCATATAGTTTGTG 652

RESULT 14
 BM996417 682 bp mRNA linear EST 17-JUN-2002
 LOCUS UI-H-DT0-avl-m-03-0-UI.s1 NCI CGAP_DTO Homo sapiens cDNA clone
 DEFINITION IMAGE:5881130 3', mRNA sequence.
 ACCESSION BM996417
 VERSION BM996417.1 GI:19721318
 SOURCE EST.
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 REFERENCE 1 (bases 1 to 682)
 AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index

JOURNAL COMMENT

Unpublished
 Contact: Robert Strausberg, Ph.D.
 Email: cgapdb-remail.nih.gov
 Tissue Procurement: Dr. Jose Mercuende
 cDNA Library preparation: Dr. M. Bento Soares, University of Iowa
 DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
 Clone Distribution: Clone distribution information can be found
 through the I.M.A.G.E. Consortium/LINL at: http://image.lnl.gov
 Seq primer: M13 FORWARD
 POLYA=Yes.

FEATURES

source

Location/Qualifiers

1..682
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:5881130"
 /tissue_type="Metastatic Chondrosarcoma"
 /dev_stage="Adult"
 /lab_host="DH10B (Life Technologies)"
 /clone_id="NCI CGAP DT0"
 /note="Organ: Lung; Vector: p773-Pac (Pharmacia) with a modified polylinker; Site 1: EcoR I; Site 2: Not I; NCI CGAP DT0 is a cDNA library containing the following tissue(s): Metastatic Chondrosarcoma in lung. The library was constructed according to Bonaldo, Lennon and Soares, Genome Research, 6:791-806, 1996. First strand cDNA synthesis was primed with an oligo-dT primer containing a Not I site. Double stranded cDNA was ligated to an EcoR I adaptor, digested with Not I, and cloned directionally into p773-Pac vector. The oligonucleotide used to prime the synthesis of first-strand cDNA contains a library tag sequence that is located between the Not I site and the (dT)18 tail. The sequence tag for this library is AACTCTGCG.
 TAG_LIB=UI-H-DT0
 TAG_TISSUE=Lung metastatic chondrosarcoma
 TAG_SEQ=AACTCTGCG"

BASE COUNT 182 a 146 c 139 g 210 t 5 others
 ORIGIN

Query Match 35.7%; Score 614.8; DB 12; Length 682;

Best Local Similarity 98.8%; Pred. No. 1.1e-158;

Matches 660; Conservative 0; Mismatches 4; Indels 4; Gaps 4;

1054 AGAGCAGCAGCGCTGGCAAGAGCTGTAGAGAAACAAGCTTCATATGAGAGCG 1113
 682 AGAGCAGCAGCGCTGGCAAGAG-GTCTGTTAGAGAAACAAGCTTCATATGAGAGCG 624
 1114 GAGCGCCCTTGCTATCCGACACCTTTGAGAGCTGCTTTATGCTGATTAATTTGGGCC 1173
 623 GAGCGCCCTTGCTATCCGACACCTTTGAGAGCTGCTTTATGCTGATTAATTTGGGCC 564
 1174 TGTGAGCCCGAATGGAATAGAGTGTGATGAGCAAGTATCTTTGAGAGCAAACT 1233
 563 TGTGAGCCCGAATGGAATAGAGTGTGATGAGCAAGTATCTTTGAGAGCAAACT 504
 1234 ACCATTATGATTAATAAATTGATCCTTTAATCTGATTAATTTGGCTATCTCTGTTCA 1293
 503 ACCATTATGATTAATAAATTGATCCTTTAATCTGATTAATTTGGCTATCTCTGTTCA 444
 1294 -AGAAATGTTGGGACCAAA-GGTGTTAATGAGCAAGCTGCAAGTTCAAAGAGAGAA 1351
 443 NAGAAATGTTGGGACCAAAANGTGTTAATGAGCAAGCTGCAAGTTCAAAGAGAGAA 384
 1352 GCTTGAGTATACCTTCAATGCAACAACAGTACAATCAAGTATTAAGAGAGAGATT 1411
 383 GCTTGAGTATACCTTCAATGCAACAACAGTACAATCAAGTATTAAGAGAGAGATT 324
 1412 AACTCTGATGATTAACCTTCATTAAGTACCAAGTACTTGGGTTACCTTATCCTTT 1471
 323 AACTCTGATGATTAACCTTCATTAAGTACCAAGTACTTGGGTTACCTTATCCTTT 264

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 8216.88 Seconds
(without alignments)
8568.399 Million cell updates/sec

Title: US-10-676-079-1

Perfect score: 1721

Sequence: 1 ctgagcttcgactctccg.....atatactagctctgacactg 1721

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:
1: gb_ba:*
2: gb_hcg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_ov:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vl:*
30: em_hcg_hum:*
31: em_hcg_inv:*
32: em_hcg_other:*
33: em_hcg_mus:*
34: em_hcg_pln:*
35: em_hcg_rod:*
36: em_hcg_mam:*
37: em_hcg_vrt:*
38: em_by:*
39: em_hcgo_hum:*
40: em_hcgo_mus:*
41: em_hcgo_other:*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1721	100.0	1721 6	AR080679 Sequence
2	1721	100.0	1721 6	AR080680 Sequence
3	1721	100.0	1721 6	AR125603 Sequence
4	1721	100.0	1721 6	AR125604 Sequence
5	1721	100.0	1721 6	AR194189 Sequence
6	1721	100.0	1721 6	AR194190 Sequence
7	1721	100.0	1721 6	AR221285 Sequence
8	1721	100.0	1721 6	AR221286 Sequence
9	1721	100.0	1721 6	AR243203 Sequence
10	1721	100.0	1721 6	AR243204 Sequence
11	1721	100.0	1721 6	AR287435 Sequence
12	1721	100.0	1721 6	AR287436 Sequence
13	1721	100.0	1721 6	BD074427 Polynucle
14	1721	100.0	1721 6	BD074428 Polynucle
15	1719.4	99.9	1899 6	BD074430 Polynucle
16	1719.4	99.9	1899 6	BD074431 Polynucle
17	1717.8	99.8	1758 9	AR144325 Homo sapi
18	1713	99.5	1722 6	AR136167 Sequence
19	1713	99.5	1722 6	BD123536 Secretory
20	1713	99.5	1722 9	AK075400 Homo sapi
21	1694.6	98.5	1713 6	AR156691 Sequence
22	1694.6	98.5	1713 6	AR034643 Sequence
23	1688.8	98.1	1723 6	AR156692 Sequence
24	1688.8	98.1	1723 6	AR034645 Sequence
25	1686.8	98.0	3726 6	AR235866 Sequence
26	1686.8	98.0	3726 6	AR019348 Sequence
27	1686.8	98.0	3726 6	BD131218 Human hep
28	1686.8	98.0	3726 6	AR155510 Homo sapi
29	1683.8	97.8	1810 9	BC051321 Homo sapi
30	1682.6	97.8	1724 6	AX147946 Sequence
31	1682.6	97.8	1724 9	AF165154 Homo sapi
32	1660.8	96.5	1694 9	AF152376 Homo sapi
33	1631.4	94.8	1669 9	AF084467 Homo sapi
34	1585	92.1	1593 6	AR210040 Sequence
35	1585	92.1	1593 6	BD136761 Human pla
36	1254.4	72.9	1662 4	AF281160 Bos tauru
37	1099.2	63.9	1736 10	AY077467 Mus muscu
38	1081.6	62.8	3177 10	AF184967 Rattus no
39	802.2	46.6	1380 6	AR156693 Sequence
40	802.2	46.6	1380 6	AX034647 Sequence
41	786.2	45.7	1191 6	AR156694 Sequence
42	786.2	45.7	1191 6	AX034649 Sequence
43	595	34.6	1605 5	AY037007 Gallus ga
44	486.8	28.3	553 6	AX336600 Sequence
45	453	26.3	824 6	AR080681 Sequence

ALIGNMENTS

RESULT 1
AR080679
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

AR080679
Sequence 9 from patent US 5968822.
AR080679.1 GI:10007409
Unknown.
Unclassified.
1 (bases 1 to 1721)
Pecker,I., Vlodavsky,I. and Feinstein,E.
Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
Patent: US 5968822-A 9 19-OCT-1999;

1721 bp
DNA
linear
PAT 31-AUG-2000

Pred. No. is the number of results predicted by chance to have a

ORIGIN

Query Match 100.0%; Score 1721; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 CTAGAGCTTTGACTCTCTCCGCGGAGCTGGGGGGAGAGACCCAGGTAGCCCA 60
 1 CTAGAGCTTTGACTCTCTCCGCGGAGCTGGGGGGAGAGACCCAGGTAGCCCA 60
 61 AGATCTGCTGGCGCTGAGAGCTGGCGCGCGCGCGTGTATGCTGCTCTCCGCGG 120
 61 AGATCTGCTGGCGCTGAGAGCTGGCGCGCGCGCGTGTATGCTGCTCTCCGCGG 120
 121 CGCTGGGTCCTCTCTCCGCGCGCGCGCGCGCTGCGAGCTGGCGAGCAGACGTCG 180
 121 CGCTGGGTCCTCTCTCCGCGCGCGCGCGCGCTGCGAGCTGGCGAGCAGACGTCG 180
 181 ACCTGGAATTCTTCAACCCAGAGAGCGCTGCACTGGTGAAGCCCTGCTGCTGCTCA 240
 181 ACCTGGAATTCTTCAACCCAGAGAGCGCTGCACTGGTGAAGCCCTGCTGCTGCTCA 240
 241 CCATGAGAGCCCAACCTGGCGAGAGACCGCGGCTTCTCATCTCTGCGGTTCTCCAAAGC 300
 241 CCATGAGAGCCCAACCTGGCGAGAGACCGCGGCTTCTCATCTCTGCGGTTCTCCAAAGC 300
 301 TTCCGACCTGGCGAGAGGCTTGTCTCTGCGTACCTGAGGTTTGGTGACCAAGAGAGC 360
 301 TTCCGACCTGGCGAGAGGCTTGTCTCTGCGTACCTGAGGTTTGGTGACCAAGAGAGC 360
 361 ACTTCTTAATTTTGCATCTCCAGAGAGATCAACCTTTGAGAGAGAGATTACTGGCAAT 420
 361 ACTTCTTAATTTTGCATCTCCAGAGAGATCAACCTTTGAGAGAGAGATTACTGGCAAT 420
 421 CTCAAGTCAACAGAGATATTTGCAATATGATTCATCTCTCTGATGAGAGAGAGT 480
 421 CTCAAGTCAACAGAGATATTTGCAATATGATTCATCTCTCTGATGAGAGAGAGT 480
 481 TACGGTGAATGGCGCTACAGAGAGCAATGCTCTCCGAGAGACACTACAGAGAGAGT 540
 481 TACGGTGAATGGCGCTACAGAGAGCAATGCTCTCCGAGAGACACTACAGAGAGAGT 540
 541 TCAAGT 600
 541 TCAAGT 600
 601 CAGGACTGGAATGATCTTTGGCTTAATGCGTTATTAAGAGAGAGAGAGAGAGT 660
 601 CAGGACTGGAATGATCTTTGGCTTAATGCGTTATTAAGAGAGAGAGAGAGAGT 660
 661 ACAGTTTAATGCTGAGTGTCTCCGAGAGCAATGCTCTCCGAGAGAGAGAGAGT 720
 661 ACAGTTTAATGCTGAGTGTCTCCGAGAGCAATGCTCTCCGAGAGAGAGAGAGT 720
 721 GGGAGCTAGT 780
 721 GGGAGCTAGT 780
 781 GCGAGTGAAGAGAGATTAATTAATGATGATTAATTAATTAATTAATTAATTAATTA 840
 781 GCGAGTGAAGAGAGATTAATTAATGATGATTAATTAATTAATTAATTAATTAATTA 840
 841 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTCTGAGAGAGAGAGAGAGAGT 900
 841 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTCTGAGAGAGAGAGAGAGAGT 900
 901 AGAGCTTCTGAGT 960
 901 AGAGCTTCTGAGT 960
 961 TGAATGAGT 1020
 961 TGAATGAGT 1020

1021 TTTCACTGTGCAAAAGTTTCCAGTGTGAGAGACAGAGGCTGGCAAGAGTCT 1080
 1021 TTTCACTGTGCAAAAGTTTCCAGTGTGAGAGAGAGAGGCTGGCAAGAGTCT 1080
 1081 GGTGAGT 1140
 1081 GGTGAGT 1140
 1141 CAGTGGCTTATATGAGTGGTGAATTAATGGGCTGTGAGAGAGAGAGAGAGT 1200
 1141 CAGTGGCTTATATGAGTGGTGAATTAATGGGCTGTGAGAGAGAGAGAGAGT 1200
 1201 TGATGAGAGAGAGATTTCTTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1260
 1201 TGATGAGAGAGAGATTTCTTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1260
 1261 CTTTACCTGATTAATGAGTGTCTCTGCTGCTGAGAGAGAGAGAGAGAGT 1320
 1261 CTTTACCTGATTAATGAGTGTCTCTGCTGCTGAGAGAGAGAGAGAGAGT 1320
 1321 TGGCAAGGTCAGAGAGTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1380
 1321 TGGCAAGGTCAGAGAGTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1380
 1381 CTGACATTCAGAGATTAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1440
 1381 CTGACATTCAGAGATTAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1440
 1441 TCACCAAGTCTTGGGTTACCTTATCTCTTTTCTTCAACAGAGAGAGAGT 1500
 1441 TCACCAAGTCTTGGGTTACCTTATCTCTTTTCTTCAACAGAGAGAGAGT 1500
 1501 TAAAGCTTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1560
 1501 TAAAGCTTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1560
 1561 TAAAGAGTGTGATGATCAACCTTGGAGAGAGAGAGAGAGAGAGAGAGT 1620
 1561 TAAAGAGTGTGATGATCAACCTTGGAGAGAGAGAGAGAGAGAGAGAGT 1620
 1621 GTTCACTGGGCTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1680
 1621 GTTCACTGGGCTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGT 1680
 1681 CTGCTTGCATCTGAAGATTAATTAATTAATTAATTAATTAATTAATTAATTA 1740
 1681 CTGCTTGCATCTGAAGATTAATTAATTAATTAATTAATTAATTAATTAATTA 1740

RESULT 3
 AR125603 1721 bp DNA linear PAT 16-MAY-2001
 LOCUS AR125603 Sequence 1 from patent US 6177545.
 DEFINITION AR125603
 ACCESSION AR125603.1 GI:14111665
 VERSION AR125603.1 GI:14111665
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 1721)
 Pecker, I., Vlodavsky, I., Friedman, Y. and Peretz, T.
 Hepatitis specific molecular probes and their use in research and
 medical applications
 Patent: US 6177545-A 1 23-JAN-2001;
 JOURNAL location/Qualifiers
 FEATURES 1..1721
 source /organism="unknown"
 BASE COUNT 451 a 413 c 410 g 447 t
 ORIGIN
 Query Match 100.0%; Score 1721; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;

Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	1	CTAGAGCTTTGACCTCCGCTGCGGAGCTGGGCGGGGAGAGCAGGCTGAGCCCA	60
Db	1	CTAGAGCTTTGACCTCCGCTGCGGAGCTGGGCGGGGAGAGCAGGCTGAGCCCA	60
Qy	61	AGATCTGCTGCGCTGGAAGCTGCGCTGCGCGCGCTGATGCTGCTCTGAGGCG	120
Db	61	AGATCTGCTGCGCTGGAAGCTGCGCTGCGCGCGCTGATGCTGCTCTGAGGCG	120
Qy	121	CGCTGGGTCCTCTCTCCCTGCGCGCTGCGCGCGCTGATGCTGCTCTGAGGCG	180
Db	121	CGCTGGGTCCTCTCTCCCTGCGCGCTGCGCGCGCTGATGCTGCTCTGAGGCG	180
Qy	181	ACCTGGAAGCTTCTTCAACCAAGAGCGCTGACCTGGTGAAGCCCTGCTCTGCTGCA	240
Db	181	ACCTGGAAGCTTCTTCAACCAAGAGCGCTGACCTGGTGAAGCCCTGCTCTGCTGCA	240
Qy	241	CCATTGAGCGCAACCTGCGCAGGAGCCCGGCTCTCATCTCTGCTGCTCTGCAAAAG	300
Db	241	CCATTGAGCGCAACCTGCGCAGGAGCCCGGCTCTCATCTCTGCTGCTCTGCAAAAG	300
Qy	301	TTGCTGACCTTGGCGCAGAGGCTTGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTG	360
Db	301	TTGCTGACCTTGGCGCAGAGGCTTGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTG	360
Qy	361	ACTTCTTAATTTTCCATCCCAAGAGGATTCACCTTTGAAGAGAGATTTCTGGCAAT	420
Db	361	ACTTCTTAATTTTCCATCCCAAGAGGATTCACCTTTGAAGAGAGATTTCTGGCAAT	420
Qy	421	CTCAAGTCAACAGGATTTTGCATATGATGATCCATCCCTGCTGCTGCTGCTGCTG	480
Db	421	CTCAAGTCAACAGGATTTTGCATATGATGATCCATCCCTGCTGCTGCTGCTGCTG	480
Qy	481	TACGGTGGAAATGCGCCCTTACAGAGCAATGCTACTCCGAGAAACATCCAGAAAGT	540
Db	481	TACGGTGGAAATGCGCCCTTACAGAGCAATGCTACTCCGAGAAACATCCAGAAAGT	540
Qy	541	TCAAGAACAGCACTTACTAAGAGCTCTGTAGATGCTATACCTTTTGAAGCTGCT	600
Db	541	TCAAGAACAGCACTTACTAAGAGCTCTGTAGATGCTATACCTTTTGAAGCTGCT	600
Qy	601	CAGGACTGAGCTTGAATCTTTGGCTTAATGCTTATTAAGAACAGAGATTTGACGTGA	660
Db	601	CAGGACTGAGCTTGAATCTTTGGCTTAATGCTTATTAAGAACAGAGATTTGACGTGA	660
Qy	661	ACAGTTCTATGCTCAGTGTCTCTGCTGCTGCTCTTCAAGGGGATTAACATTTCTT	720
Db	661	ACAGTTCTATGCTCAGTGTCTCTGCTGCTGCTCTTCAAGGGGATTAACATTTCTT	720
Qy	721	GGGAACTAGGCAATGAACCTAAGCTTCTTAAGAAAGCTGATATTTTCAATGAGGT	780
Db	721	GGGAACTAGGCAATGAACCTAAGCTTCTTAAGAAAGCTGATATTTTCAATGAGGT	780
Qy	781	CGCAGTTAGAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA	840
Db	781	CGCAGTTAGAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA	840
Qy	841	ATGCAAACTATATGCTGCTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	900
Db	841	ATGCAAACTATATGCTGCTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	900
Qy	901	AAGGCTTCTGAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	960
Db	901	AAGGCTTCTGAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	960
Qy	961	TGAATGAGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1020
Db	961	TGAATGAGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1020
Qy	1021	TTTCACTCTGCAAAAGTTTTCAGAGTGTGAGAGCAACAGGCTGCTGCAAGAGTCT	1080
Db	1021	TTTCACTCTGCAAAAGTTTTCAGAGTGTGAGAGCAACAGGCTGCTGCAAGAGTCT	1080

Qy	1081	GGTAGAGAGAAACAAGCTCTGCTATATGAGGCGGAGCGCCCTTCTATCCGACCTTTG	1140
Db	1081	GGTAGAGAGAAACAAGCTCTGCTATATGAGGCGGAGCGCCCTTCTATCCGACCTTTG	1140
Qy	1141	CAGCTGCTTTATGCTGCTGATTAATTTGGCCCTGCTGAGCCCGGAAATGAGAACTG	1200
Db	1141	CAGCTGCTTTATGCTGCTGATTAATTTGGCCCTGCTGAGCCCGGAAATGAGAACTG	1200
Qy	1201	TGATGAGCAGATATTTCTTTGAGAGAGAACTACATTTATGATGATGAAATCTTCATC	1260
Db	1201	TGATGAGCAGATATTTCTTTGAGAGAGAACTACATTTATGATGATGAAATCTTCATC	1260
Qy	1261	CTTACCTGATATTTGCTATCTCTTCTGTTCAAGAAATGCTGAGCAACAGGCTTTAA	1320
Db	1261	CTTACCTGATATTTGCTATCTCTTCTGTTCAAGAAATGCTGAGCAACAGGCTTTAA	1320
Qy	1321	TGGCAGGCTGCAAGCTTCAAGAGAGAGAGCTTCCAGATATCTTATCTTATGCAAAACA	1380
Db	1321	TGGCAGGCTGCAAGCTTCAAGAGAGAGAGCTTCCAGATATCTTATCTTATGCAAAACA	1380
Qy	1381	CTGACATCCAAAGATTAAGAGAGATTAATCTGATGCTGATGCTGATGCTGATGCTG	1440
Db	1381	CTGACATCCAAAGATTAAGAGAGATTAATCTGATGCTGATGCTGATGCTGATGCTG	1440
Qy	1441	TCACCAATCTATGCGGTTACCTTATCTTTTCTTAACAAAGAGTGAATTAATCTTC	1500
Db	1441	TCACCAATCTATGCGGTTACCTTATCTTTTCTTAACAAAGAGTGAATTAATCTTC	1500
Qy	1501	TAAAGCTTTGGGACCTCATGATTAATCTTCAAACTGCTGCTGCTGCTGCTGCTGCTG	1560
Db	1501	TAAAGCTTTGGGACCTCATGATTAATCTTCAAACTGCTGCTGCTGCTGCTGCTGCTG	1560
Qy	1561	TAAAGATGATGATGATTAACCTTGGCACTTTAATGAGAAACCTTCGCGCAGGAA	1620
Db	1561	TAAAGATGATGATGATTAACCTTGGCACTTTAATGAGAAACCTTCGCGCAGGAA	1620
Qy	1621	GTTCACTGGGCTTGGCAGCTTCTCATATGATTTTGTGATTAAGAAATGCAAAAGTTG	1680
Db	1621	GTTCACTGGGCTTGGCAGCTTCTCATATGATTTTGTGATTAAGAAATGCAAAAGTTG	1680
Qy	1681	CTGCTTGCATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT	1740
Db	1681	CTGCTTGCATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT	1740
RESULT 4			
AR125604			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
BASE COUNT			
ORIGIN			
Query Match			
Best Local Similarity			
Matches 1721; Conservative			
Qy	1	CTAGAGCTTTGACCTCCGCTGCGGAGCTGGGCGGGGAGAGCAGGCTGAGCCCA	60
Db	1	CTAGAGCTTTGACCTCCGCTGCGGAGCTGGGCGGGGAGAGCAGGCTGAGCCCA	60

Db	1	TTAAGAGCTTTGGA	CTCTCCGCTGCGCGGAGCTGGCGGGAGGAGCAGCAGGCTGAGCCCA	60	
Qy	61	AGATGCTGCTGCGCT	CGAAGCCTGCGCTGCGCGCGCGCGCTGATGCTGCTGCTGCGGCG	120	
Db	61	AGATGCTGCTGCTGCG	CTCGAAGCCTGCGCTGCGCGCGCGCGCTGATGCTGCTGCTGCGGCG	120	
Qy	121	CGCTGGGCGCCCTG	CCCCCTGGCGCGCGCGCGCGCGCTGCGCGAACAAGAGCGTGTGG	180	
Db	121	CGTGGGTCCTCTTC	CCCCCTGGCGCGCGCGCGCGCGCTGCGCGAACAAGAGCGTGTGG	180	
Qy	181	ACCTGGA	CTTCTTCACCCAGAGCGCGCTGCACTTGATGAGCCCTGCTTCGTCCGTCA	240	
Db	181	ACCTGGA	CTTCTTCACCCAGAGCGCGCTGCACTTGATGAGCCCTGCTTCGTCCGTCA	240	
Qy	241	CCATTGA	CGCCAACTTGCGCAACCGCGGTTCTCTACTCTCTGGGTTCTCCAAAGC	300	
Db	241	CCATTGA	CGCCAACTTGCGCAACCGCGGTTCTCTACTCTCTGGGTTCTCCAAAGC	300	
Qy	301	TTTGGTACCTTG	GGCCAGAGGCTTGTCTCCGGGTACTGAGTTTGCTGGCCACAGACAG	360	
Db	301	TTTGGTACCTTG	GGCCAGAGGCTTGTCTCCGGGTACTGAGTTTGCTGGCCACAGACAG	360	
Qy	361	ACTTCCTA	TTTTGCGATCCCAAGAAAGATCACTTTGAAGAGAAATTACTGGCAAT	420	
Db	361	ACTTCCTA	TTTTGCGATCCCAAGAAAGATCACTTTGAAGAGAAATTACTGGCAAT	420	
Qy	421	CTCAAGTCA	MACAGATATTTGCCAAATATGAAATCCATCCCTCTGATGTGAGAGAAAT	480	
Db	421	CTCAAGTCA	MACAGATATTTGCCAAATATGAAATCCATCCCTCTGATGTGAGAGAAAT	480	
Qy	481	TACGGTTGGA	TATGGCCCTTACCAAGGAGCAATTTGCTCTCGAGAACATACCGAATAAAT	540	
Db	481	TACGGTTGGA	TATGGCCCTTACCAAGGAGCAATTTGCTCTCGAGAACATACCGAATAAAT	540	
Qy	541	TCAAGAA	CAGACCTACTCAAGAAAGCTGATGATGTGCTATACCTTTTGCAACCTG	600	
Db	541	TCAAGAA	CAGACCTACTCAAGAAAGCTGATGATGTGCTATACCTTTTGCAACCTG	600	
Qy	601	CAGAC	CTGGA	CTTGTGCTTAAATGCGTTATTAAGAACAGACAGATTTGCACTGGA	660
Db	601	CAGAC	CTGGA	CTTGTGCTTAAATGCGTTATTAAGAACAGACAGATTTGCACTGGA	660
Qy	661	ACAGTTCTA	TATGCTCAGTTGCTCCTCGAGACTGCTCTTCCAAAGGGATTAACATTTCT	720	
Db	661	ACAGTTCTA	TATGCTCAGTTGCTCCTCGAGACTGCTCTTCCAAAGGGATTAACATTTCT	720	
Qy	721	GGGA	ACTGGAATGAACCTAACAGTTTCTTAAAGGCTGATATTTTCAATAGGCT	780	
Db	721	GGGA	ACTGGAATGAACCTAACAGTTTCTTAAAGGCTGATATTTTCAATAGGCT	780	
Qy	781	CGCAGTTA	GAGAGATATATTTCAATTTGCAATAA	CTTCTTAAGAAGTCACTTCAAAA	840
Db	781	CGCAGTTA	GAGAGATATATTTCAATTTGCAATAA	CTTCTTAAGAAGTCACTTCAAAA	840
Qy	841	ATGCAAAA	CTCTATGCTCTGATGTTGGTCA	GCTCGAAGAAAGCGCTAAGATGCTGA	900
Db	841	ATGCAAAA	CTCTATGCTCTGATGTTGGTCA	GCTCGAAGAAAGCGCTAAGATGCTGA	900
Qy	901	AGAGCTTC	TCTTAAGGCTGTGGAAGATGATTTCAAGTTACATGCAATCACTATAT	960	
Db	901	AGAGCTTC	TCTTAAGGCTGTGGAAGATGATTTCAAGTTACATGCAATCACTATAT	960	
Qy	961	TGAATGGA	CGACCTGCTACAGAGGAAGATTTTCTAAACCTGATATTTGACATTTT	1020	
Db	961	TGAATGGA	CGACCTGCTACAGAGGAAGATTTTCTAAACCTGATATTTGACATTTT	1020	
Qy	1021	TTTCA	TCTGTGCAAAAAGTTTTTCCAGTGTGTTGAGAGCACAGGCTGCAAGAGTCT	1080	
Db	1021	TTTCA	TCTGTGCAAAAAGTTTTTCCAGTGTGTTGAGAGCACAGGCTGCAAGAGTCT	1080	
Qy	1081	GGTTA	GGAAGAAACAGCTCTGATATGAGGCGGAGCGCTTGTCTATCCGACACTTTG	1144	
Db	1081	GGTTA	GGAAGAAACAGCTCTGATATGAGGCGGAGCGCTTGTCTATCCGACACTTTG	1144	

Qy	1141	CAGCTGGCTTTAATGGCTGTAATTAATGGGCGCTGACGCCGAATGGAAATACAATG	1200			
Db	1141	CAGCTGGCTTTAATGGCTGTAATTAATGGGCGCTGACGCCGAATGGAAATACAATG	1200			
Qy	1201	TGATGAGCAAGTATTTCTTTGGAGCAGAAACTACATTTAGTGGATGAAAACTTCGATC	1260			
Db	1201	TGATGAGCAAGTATTTCTTTGGAGCAGAAACTACATTTAGTGGATGAAAACTTCGATC	1260			
Qy	1261	CTTTACTGATTTATTTGGCTATCTTCTTGTTCAAGAAATTGGTGGCAACCAAGTGTAA	1320			
Db	1261	CTTTACTGATTTATTTGGCTATCTTCTTGTTCAAGAAATTGGTGGCAACCAAGTGTAA	1320			
Qy	1321	TGGCAAGCTGCAAGGTTCAAGAGAGAAAGCTCGAGTATACCTTCATTGCAACAACA	1380			
Db	1321	TGGCAAGCTGCAAGGTTCAAGAGAGAAAGCTCGAGTATACCTTCATTGCAACAACA	1380			
Qy	1381	CTGACAAATCCAAAGGTATTAAGAAAGAGATTTAACTCTGTATGCCATAAACCTCCATACG	1440			
Db	1381	CTGACAAATCCAAAGGTATTAAGAAAGAGATTTAACTCTGTATGCCATAAACCTCCATACG	1440			
Qy	1441	TCACCAAGTACTTGGCGTTACCCCTATCTCTTTTCTACAAAGCAAGTGGATTTAAATCCTTC	1500			
Db	1441	TCACCAAGTACTTGGCGTTACCCCTATCTCTTTTCTACAAAGCAAGTGGATTTAAATCCTTC	1500			
Qy	1501	TAAGACCTTTGGGACCTCATAGATTAATCTTTCCAAATCTGTCCAACTGAATGTTAACTC	1560			
Db	1501	TAAGACCTTTGGGACCTCATAGATTAATCTTTCCAAATCTGTCCAACTGAATGTTAACTC	1560			
Qy	1561	TAAAGATGGTGGATGATCAAACTCTTGGCACCTTTAATGAGAAAACTTCTCGGCGCAGGAA	1620			
Db	1561	TAAAGATGGTGGATGATCAAACTCTTGGCACCTTTAATGAGAAAACTTCTCGGCGCAGGAA	1620			
Qy	1621	GTTTACATGGGCTTGGCCAGCTTTCTCATATAGTTTTTTTGATTAAGAAATGCCAAAGTTG	1680			
Db	1621	GTTTACATGGGCTTGGCCAGCTTTCTCATATAGTTTTTTTGATTAAGAAATGCCAAAGTTG	1680			
Qy	1681	CTGCTTCATCTGAAATTAATAATTTACTAGTCTGACACTG	1721			
Db	1681	CTGCTTCATCTGAAATTAATAATTTACTAGTCTGACACTG	1721			
RESULT 5						
AR194189						
LOCUS	AR194189	1721 bp	DNA linear PAT 20-APR-2002			
DEFINITION	Sequence 1 from patent US 6348344.					
ACCESSION	AR194189					
VERSION	AR194189.1 GI:20240781					
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	Unclassified.					
AUTHORS	1 (bases 1 to 1721)					
TITLE	Ayal-Hershkovitz,M., Moskowitz,H., Miron,D., Gilboa,A., Mimou,M., Ben-Atzi,H., Yacoby-Zeevi,O., Becker,I., Peleg,Y. and Schloim,Y. Genetically modified cells and methods for expressing recombinant heparinase and methods of purifying same					
JOURNAL	Patent: US 6348344-A 1 19-FEB-2002;					
FEATURES	Location/Qualifiers					
source	1..1721 /organism="unknown"					
BASE COUNT	451 a	413 c	410 g 447 t			
ORIGIN						
Query Match 100.0%; Score 1721; DB 6; Length 1721;						
Best Local Similarity 100.0%; Prid. No. 0;						
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;						
Qy	1	CTAAGAGCTTTGCACTCTCGCTGCGCGGCAAGCTGGCGGGGAGACCAAGTGAAGCCCA	60			
Db	1	CTAAGAGCTTTGCACTCTCGCTGCGCGGCAAGCTGGCGGGGAGACCAAGTGAAGCCCA	60			
Qy	61	AGATGCTGCTGCGCTGCAAGCTGCGCTGCGCGCGCGCTGAATGCTGCTCTCGGAGC	120			

```

Db      ||| 120
61 AGATCTGCTGCTGAAAGCTGCGCTGCGCGCGCTGATGCTGCTGCTGCGGCG 120
Qy      ||| 180
121 CGCTGGGTCCTCTCTCCCTGGCGCCCTGCGCCGCACTGCGCAACAGACAGACCTGCG 180
Db      ||| 180
121 CGCTGGGTCCTCTCTCCCTGGCGCCCTGCGCCGCACTGCGCAACAGACAGACCTGCG 180
Qy      ||| 240
181 ACCTGGAATCTTCAACCGAGAGCGCTGCACTGAGAGCCCTGCTGCTGCTGCTGCA 240
Db      ||| 240
181 ACCTGGAATCTTCAACCGAGAGCGCTGCACTGAGAGCCCTGCTGCTGCTGCTGCA 240
Qy      ||| 300
241 CCATTGAGCGCAACCTGCGCAAGACCCGCGGCTCTCATCTCTGCTGCTGCTGCA 300
Db      ||| 300
241 CCATTGAGCGCAACCTGCGCAAGACCCGCGGCTCTCATCTCTGCTGCTGCTGCA 300
Qy      ||| 360
301 TTGCGTACCTGGCGAGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCA 360
Db      ||| 360
301 TTGCGTACCTGGCGAGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCA 360
Qy      ||| 420
361 ACTTCTAATTTTGGATCCCAAGAGAAATCAACCTTTGAGAGAGAGTTACTGCAAT 420
Db      ||| 420
361 ACTTCTAATTTTGGATCCCAAGAGAAATCAACCTTTGAGAGAGAGTTACTGCAAT 420
Qy      ||| 480
421 CTCAAGTCAACCCAGAGATATTTGCAATATGATGATCCATCCCTGCTGATGAGAGAG 480
Db      ||| 480
421 CTCAAGTCAACCCAGAGATATTTGCAATATGATGATCCATCCCTGCTGATGAGAGAG 480
Qy      ||| 540
481 TACGCTTGAATGCGCCCTTACAGAGAGCAATGCTACTCCGAGAAACATCCAGAAAAGT 540
Db      ||| 540
481 TACGCTTGAATGCGCCCTTACAGAGAGCAATGCTACTCCGAGAAACATCCAGAAAAGT 540
Qy      ||| 600
541 TCAAGAACAGCACTACTCAAGAGCTCTGTAGATGCTGATATGCTTGTGCAAACTGCT 600
Db      ||| 600
541 TCAAGAACAGCACTACTCAAGAGCTCTGTAGATGCTGATATGCTTGTGCAAACTGCT 600
Qy      ||| 660
601 CAGGACTGGAATCTTGTGCTTGTGCTTGTGCTTGTGCTTGTGCTTGTGCTTGTG 660
Db      ||| 660
601 CAGGACTGGAATCTTGTGCTTGTGCTTGTGCTTGTGCTTGTGCTTGTGCTTGTG 660
Qy      ||| 720
661 ACAGTTCTAATGCTCAAGTTGCTCTGAGACTACTGCTCTTCCAGAGGGCTTAACTTTCT 720
Db      ||| 720
661 ACAGTTCTAATGCTCAAGTTGCTCTGAGACTACTGCTCTTCCAGAGGGCTTAACTTTCT 720
Qy      ||| 780
721 GGGAACTGAGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCAATGAGGT 780
Db      ||| 780
721 GGGAACTGAGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCAATGAGGT 780
Qy      ||| 840
781 CGCAGTTAGAGAGATTAATTAATTAATGATGATTAATTAATTAATTAATTAATTAAT 840
Db      ||| 840
781 CGCAGTTAGAGAGATTAATTAATTAATGATGATTAATTAATTAATTAATTAATTAAT 840
Qy      ||| 900
841 ATGCAAAATCTATGCTGCTGATGTTGCTGAGCTTGAAGAGAGAGAGAGAGAGAGAG 900
Db      ||| 900
841 ATGCAAAATCTATGCTGCTGATGTTGCTGAGCTTGAAGAGAGAGAGAGAGAGAGAG 900
Qy      ||| 960
901 AGAGCTTCTGTAAGGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
Db      ||| 960
901 AGAGCTTCTGTAAGGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
Qy      ||| 1020
961 TGAATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020
Db      ||| 1020
961 TGAATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020
Qy      ||| 1080
1021 TTTTCTGCTGCAAAAGTTTCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1080
Db      ||| 1080
1021 TTTTCTGCTGCAAAAGTTTCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1080
Qy      ||| 1140
1081 GGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1140
Db      ||| 1140
1081 GGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1140
Qy      ||| 1200
1141 CAGCTGCTTATGCTGAGATTAATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1200

```

```

Db      ||| 1200
1141 CAGCTGCTTATGCTGAGATTAATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1200
Qy      ||| 1260
1201 TGATAGGCAAGATATTTTGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1260
Db      ||| 1260
1201 TGATAGGCAAGATATTTTGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1260
Qy      ||| 1320
1261 CTTTACCTGATATTTGCTATCTCTTCTGTTCAAGAAATGCTGAGAGAGAGAGAGAG 1320
Db      ||| 1320
1261 CTTTACCTGATATTTGCTATCTCTTCTGTTCAAGAAATGCTGAGAGAGAGAGAGAG 1320
Qy      ||| 1380
1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
Db      ||| 1380
1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
Qy      ||| 1440
1381 CTGACATCCAGAGATTAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1440
Db      ||| 1440
1381 CTGACATCCAGAGATTAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1440
Qy      ||| 1500
1441 TCACCAAGTACCTGCGTTACCTATCTCTTCTTCAACAGAGAGAGAGAGAGAGAGAG 1500
Db      ||| 1500
1441 TCACCAAGTACCTGCGTTACCTATCTCTTCTTCAACAGAGAGAGAGAGAGAGAGAG 1500
Qy      ||| 1560
1501 TAAAGCTTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1560
Db      ||| 1560
1501 TAAAGCTTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1560
Qy      ||| 1620
1561 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1620
Db      ||| 1620
1561 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1620
Qy      ||| 1680
1621 GTTCACTGCGGCTGCGAGCTTCTCATATGATTTTGTGATTAAGAGAGAGAGAGAG 1680
Db      ||| 1680
1621 GTTCACTGCGGCTGCGAGCTTCTCATATGATTTTGTGATTAAGAGAGAGAGAGAG 1680
Qy      ||| 1720
1681 CTGCTTGCATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1720
Db      ||| 1720
1681 CTGCTTGCATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1720

RESULT 6
ARI94190 1721 bp DNA linear PAT 20-APR-2002
LOCUS ARI94190
DEFINITION Sequence 3 from patent US 6348344.
ACCESSION ARI94190
VERSION ARI94190.1 GI:20240782
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 1721)
AUTHORS Ayal-Hersbkovitz, M., Moskowicz, H., Miron, D., Gilboa, A., Miron, M., Ben-Artzi, H., Yacoby-Zeevi, O., Pecker, I., Peleg, Y. and Schloimi, Y.
TITLE Genetically modified cells and methods for expressing recombinant
hepatanase and methods of purifying same
JOURNAL Patent: US 6348344-A 3 19-FEB-2002;
FEATURES
source location/Qualifiers
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN
Query Match 100.0%; Score 1721; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      ||| 60
1 CTAGAGCTTTGACCTCTCCGCTGCGGCACTGCGGAGAGAGAGAGAGAGAGAGAGAGAGAG 60
Db      ||| 60
1 CTAGAGCTTTGACCTCTCCGCTGCGGCACTGCGGAGAGAGAGAGAGAGAGAGAGAGAGAG 60
Qy      ||| 120
61 AGATCTGCTGCTGCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
Db      ||| 120
61 AGATCTGCTGCTGCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120

```


QY 121 CGCTGGGTCCTCTCCCTGGGCGCCCTGCGCACTGCGCAGCAAGAGCTGCTGG 180
 DB 121 CGCTGGGTCCTCTCCCTGGGCGCCCTGCGCACTGCGCAGCAAGAGCTGCTGG 180
 QY 181 ACCCTGACCTTCTTCAACCAAGAGCGGCTGCACTGCTGAGAGCCCTGCTTCCCTGCTCA 240
 DB 181 ACCCTGACCTTCTTCAACCAAGAGCGGCTGCACTGCTGAGAGCCCTGCTTCCCTGCTCA 240
 QY 241 CCATTGAGCGCAACCTGGCAGGACCGCGGTTCTCTCATCTCTGGGTTCTCCAAAGC 300
 DB 241 CCATTGAGCGCAACCTGGCAGGACCGCGGTTCTCTCATCTCTGGGTTCTCCAAAGC 300
 QY 301 TTCTGATCTTGGCCAGAGGCTGTCTCTCTGCTACCTGAGGTTGGTGGCAGCAAGACG 360
 DB 301 TTCTGATCTTGGCCAGAGGCTGTCTCTCTGCTACCTGAGGTTGGTGGCAGCAAGACG 360
 QY 361 ACTTCTTAATTTTGCATCCCAAGAGGATCACTTTGAGAGAGAGTTACTGGCAAT 420
 DB 361 ACTTCTTAATTTTGCATCCCAAGAGGATCACTTTGAGAGAGAGTTACTGGCAAT 420
 QY 421 CTCAGTCAACCAAGGATATTTGCAATATGATTCATCCCTCTGATGTGAGAGAGAGT 480
 DB 421 CTCAGTCAACCAAGGATATTTGCAATATGATTCATCCCTCTGATGTGAGAGAGAGT 480
 QY 481 TACGGTTGGAATGCGCTTACCAAGAGCAATGCTACTCCGAGAGCACTACCAAGAAAAGT 540
 DB 481 TACGGTTGGAATGCGCTTACCAAGAGCAATGCTACTCCGAGAGCACTACCAAGAAAAGT 540
 QY 541 TCAAGAACAGCACCTACTCAAGAGAGCTGTGATGATGTGCTATACCTTTGCAAACTGCT 600
 DB 541 TCAAGAACAGCACCTACTCAAGAGAGCTGTGATGATGTGCTATACCTTTGCAAACTGCT 600
 QY 601 CAGGACTGGAATCTTGTGCTTGGCTTAAATGCGTTATTAAGAACAGCAGATTGGAGTGA 660
 DB 601 CAGGACTGGAATCTTGTGCTTGGCTTAAATGCGTTATTAAGAACAGCAGATTGGAGTGA 660
 QY 661 ACAGTTCTAATGCTCAGTTGCTCTGAGACTACCTGCTCTTCCAAAGGATTAACATTTCTT 720
 DB 661 ACAGTTCTAATGCTCAGTTGCTCTGAGACTACCTGCTCTTCCAAAGGATTAACATTTCTT 720
 QY 721 GGGAACTGAGCAATGAACTTAAAGAGCTTCTTAAGAGAGCTGATATTTTCAATATGGGT 780
 DB 721 GGGAACTGAGCAATGAACTTAAAGAGCTTCTTAAGAGAGCTGATATTTTCAATATGGGT 780
 QY 781 CGCAGTTGGAAGATTAATATTAATGCAATTAACCTTCTAAGAGAGCTCAACTCAAA 840
 DB 781 CGCAGTTGGAAGATTAATATTAATGCAATTAACCTTCTAAGAGAGCTCAACTCAAA 840
 QY 841 ATGCAAACTATGATGCTGATGTTGGTCAAGCTGCAAGAAAGACGGCTAAGATGCTGA 900
 DB 841 ATGCAAACTATGATGCTGATGTTGGTCAAGCTGCAAGAAAGACGGCTAAGATGCTGA 900
 QY 901 AGAGCTTCTGAGAGCTGCTGAGAGAGTGAATTCAGTTAATGATGCAATCACTAAT 960
 DB 901 AGAGCTTCTGAGAGCTGCTGAGAGAGTGAATTCAGTTAATGATGCAATCACTAAT 960
 QY 961 TGAATGAGAGAGCTGCTACCAAGGAGAGATTTCTAAACCTGATATTTTGAATTTTGA 1020
 DB 961 TGAATGAGAGAGCTGCTACCAAGGAGAGATTTCTAAACCTGATATTTTGAATTTTGA 1020
 QY 1021 TTTTCACTGTGCAAAAAGTTTCCAGTGTGTTGAGAGCAGGAGCTGGCAAGAGCT 1080
 DB 1021 TTTTCACTGTGCAAAAAGTTTCCAGTGTGTTGAGAGCAGGAGCTGGCAAGAGAGCT 1080
 QY 1081 GGTGAGAGAGAGAGCTGCTGATATGAGAGCGAGCGCTTGTCTATCCAGACCTTTG 1140
 DB 1081 GGTGAGAGAGAGAGCTGCTGATATGAGAGCGAGCGCTTGTCTATCCAGACCTTTG 1140
 QY 1141 CAGCTGGCTTATATGAGCTGATTAATGGGCTGCTGAGCGAGAGAGAGAGAGTGG 1200
 DB 1141 CAGCTGGCTTATATGAGCTGATTAATGGGCTGCTGAGCGAGAGAGAGAGAGTGG 1200
 QY 1201 TGATGAGGCAAGTATTTCTTGGAGCAGAACTACCATTTATGATGATGAAAATCTGATC 1260

DB 1201 TGATGAGGCAAGTATTTCTTGGAGAGAGAACTACATTTATGATGATGAAAATCTGATC 1260
 QY 1261 CTTTACCGATATTTATGCTATCTCTCTGTTCAAGAAATGATGGGAGCAAGAGTTAA 1320
 DB 1261 CTTTACCGATATTTATGCTATCTCTCTGTTCAAGAAATGATGGGAGCAAGAGTTAA 1320
 QY 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGTTCAGATATACCTTCTTTCACAAACA 1380
 DB 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGTTCAGATATACCTTCTTTCACAAACA 1380
 QY 1381 CTGACATCCAAAGGATTAAGAGAGAGATTTAATCTGTATGCTCAATTAACCTCAACG 1440
 DB 1381 CTGACATCCAAAGGATTAAGAGAGAGATTTAATCTGTATGCTCAATTAACCTCAACG 1440
 QY 1441 TCACCAATCTGCGGTTACCTTACCTCTTTTCAACAAGAGTGAATTAATCTTC 1500
 DB 1441 TCACCAATCTGCGGTTACCTTACCTCTTTTCAACAAGAGTGAATTAATCTTC 1500
 QY 1501 TAAAGCTTTGGGAGCTCATGGAATTAATCTTCCAAATCTGCAATGATGCTAATCTC 1560
 DB 1501 TAAAGCTTTGGGAGCTCATGGAATTAATCTTCCAAATCTGCAATGATGCTAATCTC 1560
 QY 1561 TAAAGATGATGATGATCAAACTTTGCCAATTAATGAGAAACCTTCCGCGCAGGAA 1620
 DB 1561 TAAAGATGATGATGATCAAACTTTGCCAATTAATGAGAAACCTTCCGCGCAGGAA 1620
 QY 1621 GTTACCTGGGCTGCGCACTTTCATATATGTTTTTGTGATTAAGAAATGCCAAGTTG 1680
 DB 1621 GTTACCTGGGCTGCGCACTTTCATATATGTTTTTGTGATTAAGAAATGCCAAGTTG 1680
 QY 1681 CTGCTTGATCTGAATAATAATAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
 DB 1681 CTGCTTGATCTGAATAATAATAATAATTAATTAATTAATTAATTAATTAATTAAT 1721

RESULT 7
 AR221285
 LOCUS AR221285 1721 bp DNA linear PAT 26-SEP-2002
 DEFINITION Sequence 1 from patent US 6426209.
 ACCESSION AR221285
 VERSION AR221285.1 GI:23328256
 KEYWORDS
 SOURCE
 ORGANISM
 Unclassified.
 REFERENCES
 1 (bases 1 to 1721)
 Ayal-HersHKovitz,M., Pecker,I. and Yacoby-Zeev1,O.
 Genetically modified cells and methods for expressing recombinant
 heparanase and methods of purifying same
 JOURNAL Patent: US 6426209-A 1 30-JUL-2002;
 FEATURES
 source
 1. .1721
 /organism="unknown"
 ORIGIN
 BASE COUNT 451 a 413 c 410 g 447 t
 Query Match 100.0%; Score 1721; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTAGAGCTTTGAGACTCCGCTGCGCGGACCTGCGGAGGAGAGAGCAGGAGAGCCCA 60
 DB 1 CTAGAGCTTTGAGACTCCGCTGCGCGGACCTGCGGAGGAGAGAGCAGGAGAGCCCA 60
 QY 61 AGATGCTGCTGCTGCTGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 120
 DB 61 AGATGCTGCTGCTGCTGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 120
 QY 121 CGCTGGGTCCTCTCTCCCTGGGCGCCCTGCGCACTGCGCAAGCAGAGAGCTGCTGG 180
 DB 121 CGCTGGGTCCTCTCTCCCTGGGCGCCCTGCGCACTGCGCAAGCAGAGAGCTGCTGG 180

QY 181 ACTGGAATTCTTCAACCGAGAGCGGCTGCACTGTGTAGAGCCCTGTTCTGTCTGCTCA 240
 Db 181 ACTGGAATTCTTCAACCGAGAGCGGCTGCACTGTGTAGAGCCCTGTTCTGTCTGCTCA 240
 QY 241 CCATTGACGCGCAACCTGGCCAGGACCCGCGGTTCTCTATCTCTGTGGTTCTCCAAAGC 300
 Db 241 CCATTGACGCGCAACCTGGCCAGGACCCGCGGTTCTCTATCTCTGTGGTTCTCCAAAGC 300
 QY 301 TTCGTAACCTTGGCCAGAGGCTGTCTCTGCGCTACCTGAGGTTGTGTGCAACAGACAG 360
 Db 301 TTCGTAACCTTGGCCAGAGGCTGTCTCTGCGCTACCTGAGGTTGTGTGCAACAGACAG 360
 QY 361 ACTTCCTAATTTTCGATCCCAAGAGAAATCAACTTTGAGAGAGAAATTACTGCAAT 420
 Db 361 ACTTCCTAATTTTCGATCCCAAGAGAAATCAACTTTGAGAGAGAAATTACTGCAAT 420
 QY 421 CTCAAGTCAACCGAGATATTTGCAAAATATGATCCATCCCTCTGATGTGAGAGAAAGT 480
 Db 421 CTCAAGTCAACCGAGATATTTGCAAAATATGATCCATCCCTCTGATGTGAGAGAAAGT 480
 QY 481 TACGGTTGGAATGGCCCTTACCGAGAGCAATGCTACTCCGAGAACATCAACGAGAAAGT 540
 Db 481 TACGGTTGGAATGGCCCTTACCGAGAGCAATGCTACTCCGAGAACATCAACGAGAAAGT 540
 QY 541 TCAAGAACAGCACTACTCAAGAGCTGTGATGTGTCTATACATTTTGGCAACTGCT 600
 Db 541 TCAAGAACAGCACTACTCAAGAGCTGTGATGTGTCTATACATTTTGGCAACTGCT 600
 QY 601 CAGGACTGGAATCTTGTGGCTTAAATGCGTTATTAAGAACAGCAATTTGCAAGTGA 660
 Db 601 CAGGACTGGAATCTTGTGGCTTAAATGCGTTATTAAGAACAGCAATTTGCAAGTGA 660
 QY 661 ACACTTCTAATCTCAATGTTGCTCTGAGACTACTGCTCTTCCAAAGGGGTATCAATTTCT 720
 Db 661 ACACTTCTAATCTCAATGTTGCTCTGAGACTACTGCTCTTCCAAAGGGGTATCAATTTCT 720
 QY 721 GGGAACTAGGCAATGAACCTAACAGTTTCTTAAAGAGGCTATATTTTTCATCAATGGGT 780
 Db 721 GGGAACTAGGCAATGAACCTAACAGTTTCTTAAAGAGGCTATATTTTTCATCAATGGGT 780
 QY 781 CGCAGTTAGAGAGATTAATATTCATATGATCAATTAACCTTAAAGAAAGTCCACTTCAAA 840
 Db 781 CGCAGTTAGAGAGATTAATATTCATATGATCAATTAACCTTAAAGAAAGTCCACTTCAAA 840
 QY 841 ATGCAAACTCTATGTCTCTGATGTGTGCTACAGCTTCAAGAAAGAGCGCTAAGATGCTGA 900
 Db 841 ATGCAAACTCTATGTCTCTGATGTGTGCTACAGCTTCAAGAAAGAGCGCTAAGATGCTGA 900
 QY 901 AGAGCTTCTGAAAGGCTGGTGAAGAGATGATTCAGTTACATGSCATCACTACTAT 960
 Db 901 AGAGCTTCTGAAAGGCTGGTGAAGAGATGATTCAGTTACATGSCATCACTACTAT 960
 QY 961 TGAATGACGCACTGCTACAGAGAAAGATTTTCTAAACCTGATGATTTGACATTTTAA 1020
 Db 961 TGAATGACGCACTGCTACAGAGAAAGATTTTCTAAACCTGATGATTTGACATTTTAA 1020
 QY 1021 TTTTCTCTGTGCAAAAGTTTTCAGGTGTGAGAGCAACGAGCTTGCAGAAAGAGTCT 1080
 Db 1021 TTTTCTCTGTGCAAAAGTTTTCAGGTGTGAGAGCAACGAGCTTGCAGAAAGAGTCT 1080
 QY 1081 GATTAGAGAAACAGCTCTGATATGAGAGGAGGAGCGGCTTGTGTAATCCGACACCTTGG 1140
 Db 1081 GATTAGAGAAACAGCTCTGATATGAGAGGAGGAGCGGCTTGTGTAATCCGACACCTTGG 1140
 QY 1141 CAGCTGGCTTATATGTGCTGATTAATTTGGGCTGTCAAGCCCGAAATGGGAAATGAAAGTGG 1200
 Db 1141 CAGCTGGCTTATATGTGCTGATTAATTTGGGCTGTCAAGCCCGAAATGGGAAATGAAAGTGG 1200
 QY 1201 TGATGAGGCAAGTATTTCTTGGAGCAGAACTACATTTAGTGTGTAAGAACTTCTGATC 1260
 Db 1201 TGATGAGGCAAGTATTTCTTGGAGCAGAACTACATTTAGTGTGTAAGAACTTCTGATC 1260
 QY 1261 CTTTACCTGATTAATTTGGCTATCTCTTCTGTCAAGAAATTTGGTGGCAACAGAGTGTAA 1320

Db 1261 CTTTACCTGATTAATTTGGCTATCTCTTCTGTCAAGAAATTTGGTGGCAACAGAGTGTAA 1320
 QY 1321 TGGCAAGGCTGCAAGCTTCAAGAGAGAGAGCTTGGATTAACCTTATATGCAACAA 1380
 Db 1321 TGGCAAGGCTGCAAGCTTCAAGAGAGAGAGCTTGGATTAACCTTATATGCAACAA 1380
 QY 1381 CTGACATTCGAAGTATTAAGAGAGATTAATCTGTATGCCATAAACCCTCCATAACG 1440
 Db 1381 CTGACATTCGAAGTATTAAGAGAGATTAATCTGTATGCCATAAACCCTCCATAACG 1440
 QY 1441 TCACCAAGTACTGGGTTACCTTACCTTTTCTTCAACAGCAAGTGAATTAATCTTC 1500
 Db 1441 TCACCAAGTACTGGGTTACCTTACCTTTTCTTCAACAGCAAGTGAATTAATCTTC 1500
 QY 1501 TAAAGCTTTGGGACCTGATGATTAATCTTCCAAATCTGTCCAACTCAATGCTCACTC 1560
 Db 1501 TAAAGCTTTGGGACCTGATGATTAATCTTCCAAATCTGTCCAACTCAATGCTCACTC 1560
 QY 1561 TAAAGATGATGATTAATCAACCTTGCACCTTATATGAGAAACCTCTCCGCGCAGGA 1620
 Db 1561 TAAAGATGATGATTAATCAACCTTGCACCTTATATGAGAAACCTCTCCGCGCAGGA 1620
 QY 1621 GTTCACTGGGCTTGCACCTTCTCATATATGATTTTGTGATTAAGAAATGCCAAGTTG 1680
 Db 1621 GTTCACTGGGCTTGCACCTTCTCATATATGATTTTGTGATTAAGAAATGCCAAGTTG 1680
 QY 1681 CTGCTTGCATCTGAAATTAATATATCTAGTCTGACACTG 1721
 Db 1681 CTGCTTGCATCTGAAATTAATATATATCTAGTCTGACACTG 1721

RESULT 8
 AR221286 1721 bp DNA linear PAT 26-SEP-2002
 LOCUS AR221286 Sequence 3 from patent US 6426209.
 DEFINITION AR221286
 ACCESSION AR221286
 VERSION AR221286.1 GI:2328257
 KEYWORDS

SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 1721)
 AUTHORS Ayal-Hershkovitz, M., Pecker, I., and Yacoby-Zeevi, O.
 TITLE Genetically modified cells and methods for expressing recombinant
 JOURNAL heparanase and methods of purifying same
 FEATURES Patent: US 6426209-A 3 30-0UL-2002;
 location/Qualifiers
 source 1..1721

BASE COUNT 451 a 413 c 410 g 447 t
 ORIGIN

Query Match 100.0%; Score 1721; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTAGAGCTTTGACATCTCTCCGCTGCGGCAAGTGTGCGGGGAGACAGCAAGTGAAGCCCA 60
 Db 1 CTAGAGCTTTGACATCTCTCCGCTGCGGCAAGTGTGCGGGGAGACAGCAAGTGAAGCCCA 60
 QY 61 AGATGCTGCTGCGTGAAGGCTGCGGCGCGCGCGCTGATGCTGTGCTCTGCGGAGC 120
 Db 61 AGATGCTGCTGCGTGAAGGCTGCGGCGCGCGCGCGCTGATGCTGTGCTCTGCGGAGC 120
 QY 121 CGCTGGGTCCCTCTCTCCCTGCGGCTGCGGCGGCACTGCGCAAGCAAGAGCGTGTGG 180
 Db 121 CGCTGGGTCCCTCTCTCCCTGCGGCTGCGGCGGCACTGCGCAAGCAAGAGCGTGTGG 180
 QY 181 ACTGGAATTTCTTCAACCGAGAGCGGCTGCACTGTGTAGAGCCCTGTTCTGTCTGCTCA 240
 Db 181 ACTGGAATTTCTTCAACCGAGAGCGGCTGCACTGTGTAGAGCCCTGTTCTGTCTGCTCA 240

Oy	241	CCATTGAAGCAA	CCTGGCCCA	CGGACCGGCGGTTCTCATCTCCTGGGTTCTCCAAAGC	300
Db	241	CCATTGAGCCAA	CCTGGCCCA	CGGACCGGCGGTTCTCATCTCCTGGGTTCTCCAAAGC	300
Oy	301	TTTCGTA	CTTGAGCCAGAGGCTTGCTCTCGGCTACCTGAGGTTTGTTGTTGGCACAAGACAG	360	
Db	301	TTTCGTA	CTTGAGCCAGAGGCTTGCTCTCGGCTACCTGAGGTTTGTTGTTGGCACAAGACAG	360	
Oy	361	ACTTCCTAATTTTGCAT	CCCAAGAGAAATCAACCTTTGAAGAGAAAGTTACTGGCAAT	420	
Db	361	ACTTCCTAATTTTGCAT	CCCAAGAGAAATCAACCTTTGAAGAGAAAGTTACTGGCAAT	420	
Oy	421	CTCAAGTCAACCAAGATATTTTGCAAAATATGAAATCCATCCCTCGATGTGAGAGAAAGT	480		
Db	421	CTCAAGTCAACCAAGATATTTTGCAAAATATGAAATCCATCCCTCGATGTGAGAGAAAGT	480		
Oy	481	TACGGTTGGAATGCGCCCTACCAAGAGCAATTTGCTACTCCGAGAA	CATCAACCAAGAAAGT	540	
Db	481	TACGGTTGGAATGCGCCCTACCAAGAGCAATTTGCTACTCCGAGAA	CATCAACCAAGAAAGT	540	
Oy	541	TCGAAGACAGCA	CCTACTCAAGAGCTCTGTAGATGTGCTATAC	CTTTGCAAACTGCT	600
Db	541	TCGAAGACAGCA	CCTACTCAAGAGCTCTGTAGATGTGCTATAC	CTTTGCAAACTGCT	600
Oy	601	CAGACCTGAGACTTGA	TCCTTTGGCCCTAAATGGCTATTTAAGAACAGCAATTTTGACAGTGA	660	
Db	601	CAGACCTGAGACTTGA	TCCTTTGGCCCTAAATGGCTATTTAAGAACAGCAATTTTGACAGTGA	660	
Oy	661	ACAGTTCTAATAGCTCAGTTGCTCCCTGACCTACCTGCTCTTCCAAAGGGATATAACATTTCTT	720		
Db	661	ACAGTTCTAATAGCTCAGTTGCTCCCTGACCTACCTGCTCTTCCAAAGGGATATAACATTTCTT	720		
Oy	721	GGGAACTAGGCAATGAACTTAACAGTTTCTTTAAGAGGCTGATATTTTCAATCAATGGGT	780		
Db	721	GGGAACTAGGCAATGAACTTAACAGTTTCTTTAAGAGGCTGATATTTTCAATCAATGGGT	780		
Oy	781	CGCAGTTAGGAGAAATTAATATTCAAATTTGCAATAA	CTTCTAAGAAAGTCCACCTTCAAA	840	
Db	781	CGCAGTTAGGAGAAATTAATATTCAAATTTGCAATAA	CTTCTAAGAAAGTCCACCTTCAAA	840	
Oy	841	ATGCAAAA	CTCTATGATGTCCTGATGTTTGGTCAGCTCCGAAAGAAAGACGGCTAAGATGCTGA	900	
Db	841	ATGCAAAA	CTCTATGATGTCCTGATGTTTGGTCAGCTCCGAAAGAAAGACGGCTAAGATGCTGA	900	
Oy	901	AGAGCTTCTGAAAGGCTGGTGGAGAAAGTATGATTTCAAGTTACATGAGCATCACTACTAT	960		
Db	901	AGAGCTTCTGAAAGGCTGGTGGAGAAAGTATGATTTCAAGTTACATGAGCATCACTACTAT	960		
Oy	961	TGAATGACAGGACTCTCTACACAGGGAAGATTTTCTAAACCCCTGATGTATTTGACATTTT	1020		
Db	961	TGAATGACAGGACTCTCTACACAGGGAAGATTTTCTAAACCCCTGATGTATTTGACATTTT	1020		
Oy	1021	TTTCAATCTGTGCAAAAAGTTTTCAAGGATGTTGAAGACACAGGCTGGCAAGAGGCT	1080		
Db	1021	TTTCAATCTGTGCAAAAAGTTTTCAAGGATGTTGAAGACACAGGCTGGCAAGAGGCT	1080		
Oy	1081	GGTTAGAGAAA	CAAGACTCTGCAATATGAGAGCGGACGCGCTTGCTATCCGACACCTTTG	1140	
Db	1081	GGTTAGAGAAA	CAAGACTCTGCAATATGAGAGCGGACGCGCTTGCTATCCGACACCTTTG	1140	
Oy	1141	CAGCTGGCTTTATGTGGCTGATTAATTTGGCGCTCTCAGCCCGAATGGGAATAGAAATGG	1200		
Db	1141	CAGCTGGCTTTATGTGGCTGATTAATTTGGCGCTCTCAGCCCGAATGGGAATAGAAATGG	1200		
Oy	1201	TGATAGAGCAAGTATTTCTTTGAGAGAGAAATCACTAATTTAGTGATGAAAACCTTGCAATC	1260		
Db	1201	TGATAGAGCAAGTATTTCTTTGAGAGAGAAATCACTAATTTAGTGATGAAAACCTTGCAATC	1260		
Oy	1261	CTTTA	CTGATTAATTTGGCTATCTCTTCTGTTCAAGAAAATTTGGTGGGCAACAAGTGTATA	1320	
Db	1261	CTTTA	CTGATTAATTTGGCTATCTCTTCTGTTCAAGAAAATTTGGTGGGCAACAAGTGTATA	1320	
Oy	1321	TGGCAAGCGTGCAGGTTCAAAAGAGAAAGCTTCGAGTATACCTTCAATTTGCACAAACA	1380		

Db	1321	TGGCAGGCTGCCAAGTTCAAGAGAGAGAGCTTCGAGTATACCTTATTCAGCAACAA	1380
Qy	1381	CTGACAACTCCAAAGGTATTAAGAGAGATTTAACTCTGTATGCCATTAACCTCCATAACG	1440
Db	1381	CTGACAACTCCAAAGGTATTAAGAGAGATTTAACTCTGTATGCCATTAACCTCCATAACG	1440
Qy	1441	TCACCAACTACTTCGGCTTACCCCTATCTCTTTTCTTACCAAGCAGTGGATTAATACCTTC	1500
Db	1441	TCACCAACTACTTCGGCTTACCCCTATCTCTTTTCTTACCAAGCAGTGGATTAATACCTTC	1500
Qy	1501	TAAAGACTTTGGAGCCTCATGAGATTAATCTTCCAAATCTGTCCAACTCAATGCTTAATC	1560
Db	1501	TAAAGACTTTGGAGCCTCATGAGATTAATCTTCCAAATCTGTCCAACTCAATGCTTAATC	1560
Qy	1561	TAAAGATGTGGATGATCAAACTTTGCCACCTTTAATGAGAAAACCTTCCTGGCCAGGAA	1620
Db	1561	TAAAGATGTGGATGATCAAACTTTGCCACCTTTAATGAGAAAACCTTCCTGGCCAGGAA	1620
Qy	1621	GTTCACCTGGGCTGGCAGCTTCTCATATATTTTTTTTGTATGAATGAATGCCAAAGTTG	1680
Db	1621	GTTCACCTGGGCTGGCAGCTTCTCATATATTTTTTTTGTATGAATGAATGCCAAAGTTG	1680
Qy	1681	CTGCTTGATCTGAAAAATAAATATATAGTCTGACACTG 1721	
Db	1681	CTGCTTGATCTGAAAAATAAATATATAGTCTGACACTG 1721	
RESULT 9			
AR243203			
LOCUS	AR243203	1721 bp	DNA linear PAT 20-DEC-2002
DEFINITION	Sequence 1 from patent US 6475763.		
ACCESSION	AR243203		
VERSION	AR243203.1 GI:2729018		
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 1721)		
TITLE	Ayal-Hershkovitz, M., Moskowitz, H., Miron, D., Galboa, A., Mimon, M., Ben-Artzi, H., Yacoby-Zeevi, O., Pecker, I., Peleg, Y. and Shlom, Y. Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same		
JOURNAL FEATURES	Patent: US 6475763-A 1 05-NOV-2002;		
source	Location/Qualifiers		
BASE COUNT	/organism="unknown"		
ORIGIN	451 a	413 c	410 g 447 t
Query Match 100.0%; Score 1721; DB 6; Length 1721;			
Best Local Similarity 100.0%; Pred. No. 0;			
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	1	CTAGAGCTTTGACATCTCTCCGCTGCCGCGCAGCTGCGGGGGAGACGACAGTGAAGCCCA	60
Db	1	CTAGAGCTTTGACATCTCTCCGCTGCCGCGCAGCTGCGGGGGAGACGACAGTGAAGCCCA	60
Qy	61	AGATGCTGTGGGCTGCGAGAGCTGCGGCTGCCGCGCGCTGATGTGCTGCTCTGCGGAC	120
Db	61	AGATGCTGTGGGCTGCGAGAGCTGCGGCTGCCGCGCGCTGATGTGCTGCTCTGCGGAC	120
Qy	121	CGCTGGTCCCTCTCCCTCGCGCGCTGCCCGCACTTGCAGAACAGACGATCGTGG	180
Db	121	CGCTGGTCCCTCTCCCTCGCGCGCTGCCCGCACTTGCAGAACAGACGATCGTGG	180
Qy	181	ACCTGAGCTTCTTACCCAGAGACCGCTGACCTGTGTAGGCCCTCTGTTCTCTGTCCTCA	240
Db	181	ACCTGAGCTTCTTACCCAGAGACCGCTGACCTGTGTAGGCCCTCTGTTCTCTGTCCTCA	240
Qy	241	CGATTGAGCGCAACCTGGCGACAGACCGCGGCTCTCATCTCTCGAGTTCTCCAAAGC	300
Db	241	CGATTGAGCGCAACCTGGCGACAGACCGCGGCTCTCATCTCTCGAGTTCTCCAAAGC	300

Db	301	TTGCGACTTG6GCGAGAGGCTTGTCCTGCGTACCTGAGGTTTG7GCGACCAAGACAG	360
Oy	361	ACTTCCTAATTTTGCATCCCAAGAAATCAACTTTGAAGAGAAAGTTACTGGCAAT	420
Db	361	ACTTCCTAATTTTGCATCCCAAGAAATCAACTTTGAAGAGAAAGTTACTGGCAAT	420
Oy	421	CTCAAGTCAACCAAGATATTTTGGCAATATATGATCCATCCCTCATGTGGAGAGAAAGT	480
Db	421	CTCANGTCAACCAAGATATTTTGGCAATATATGATCCATCCCTCATGTGGAGAGAAAGT	480
Oy	481	TACGGTTGAAATGGCCCTTACCAAGAGCAATGCTACTCCGAGAACACTTACCGAAAAAGT	540
Db	481	TACGGTTGAAATGGCCCTTACCAAGAGCAATGCTACTCCGAGAACACTTACCGAAAAAGT	540
Oy	541	TCAGAAACAGCACTTACTCAAGAGCTCTGTAGATGTGCTATACCTTTTGCAACTGCT	600
Db	541	TCAGAAACAGCACTTACTCAAGAGCTCTGTAGATGTGCTATACCTTTTGCAAACTGCT	600
Oy	601	CAGAGCTGGAATCTGATCTTTTGGCCCTAAATATGCTATATTAAGAACACACAGATTTGAGTGA	660
Db	601	CAGAGCTGGAATCTGATCTTTTGGCCCTAAATATGCTATATTAAGAACACACAGATTTGAGTGA	660
Oy	661	ACAGTTCTAAATGCTCAGTTGCTCTCTGAGCTACTGCTCTTCCAGGGGTATTAACATTTCTT	720
Db	661	ACAGTTCTAAATGCTCAGTTGCTCTCTGAGCTACTGCTCTTCCAGGGGTATTAACATTTCTT	720
Oy	721	GCGAACTTAGCGAATGCACTTAAACAGTTTCTTTAAGAGGCTGATATTTTCAATGAGGT	780
Db	721	GCGAACTTAGCGAATGCACTTAAACAGTTTCTTTAAGAGGCTGATATTTTCAATGAGGT	780
Oy	781	CGCAGTTAGGGAATATATATATATGCAATTCCTTAAAGAAATGCCACTTCAAA	840
Db	781	CGCAGTTAGGGAATATATATATATGCAATTCCTTAAAGAAATGCCACTTCAAA	840
Oy	841	ATGCAAAACTCTAATGCTCTGATGTTTGGTCAGCCTCGAAGAAAAGAGGCTAAGATGCTGA	900
Db	841	ATGCAAAACTCTAATGCTCTGATGTTTGGTCAGCCTCGAAGAAAAGAGGCTAAGATGCTGA	900
Oy	901	AGAGCTTCTGAAAGGCTGGTGGAGAAATGATTTGATTCAGTTACATGAGCATCTACTAT	960
Db	901	AGAGCTTCTGAAAGGCTGGTGGAGAAATGATTTGATTCAGTTACATGAGCATCTACTAT	960
Oy	961	TGAATGAGACGACCTGCTACCAAGGAAAGATTTTCTAAACCTCTGATGTATTTGACATTTT	1020
Db	961	TGAATGAGACGACCTGCTACCAAGGAAAGATTTTCTAAACCTCTGATGTATTTGACATTTT	1020
Oy	1021	TTTCACTCGTCAAAAAGTTTTCAGAGGTGTGAAGACACAGGCTGGCAAGAAAGTCT	1080
Db	1021	TTTCACTCGTCAAAAAGTTTTCAGAGGTGTGAAGACACAGGCTGGCAAGAAAGTCT	1080
Oy	1081	GATTAGAGAAACAGACTCTGCAATATGAGAGCGAGCGCCCTTGCTATCCGACACTTTG	1140
Db	1081	GATTAGAGAAACAGACTCTGCAATATGAGAGCGAGCGCCCTTGCTATCCGACACTTTG	1140
Oy	1141	CAGCTGGCTTATGTGCTGCTGATAATTTGGGCTCTCAGCCCGAATGGGAATGAAGTGG	1200
Db	1141	CAGCTGGCTTATGTGCTGCTGATAATTTGGGCTCTCAGCCCGAATGGGAATGAAGTGG	1200
Oy	1201	TGATNAGGCAAGTATTTCTTTTGGAGAGAAATCACCATTTATGTGATGAAAACTTCGATC	1260
Db	1201	TGATNAGGCAAGTATTTCTTTTGGAGAGAAATCACCATTTATGTGATGAAAACTTCGATC	1260
Oy	1261	CTTATCTGATATATGGCTATCTCTCTCTGTCAAGAAAATGGTGGGCAACAGAGTGTAA	1320
Db	1261	CTTATCTGATATATGGCTATCTCTCTCTGTCAAGAAAATGGTGGGCAACAGAGTGTAA	1320
Oy	1321	TGGCAAGCGTGCAGAGTTCAAGAGAAAGAGCCTTGAATATACCTTCAATTCACAAACA	1380
Db	1321	TGGCAAGCGTGCAGAGTTCAAGAGAAAGAGCCTTGAATATACCTTCAATTCACAAACA	1380
Oy	1381	CTGAACAATCCAAAGTATTAAGAAAGATTTAACTCTGATGCCATTAACCTCCCTAAACG	1440
Db	1381	CTGAACAATCCAAAGTATTAAGAAAGATTTAACTCTGATGCCATTAACCTCCCTCAATACG	1440

Qy	1441	TCACCAAGTACTTTCGGGTAAACCCATATCTTTTCTTAACAAGCAGTGGATTAATACCTC	1500
Db	1441	TCACCAAGTACTTTCGGGTAAACCCATATCTTTTCTTAACAAGCAGTGGATTAATACCTTC	1500
Qy	1501	TAAAGACCTTTGGAGCCTCATGATGATTTACTTTCCAAATCTGTCCAACTCAATGTCCTAACTC	1560
Db	1501	TAAAGACCTTTGGAGCCTCATGATGATTTACTTTCCAAATCTGTCCAACTCAATGTCCTAACTC	1560
Qy	1561	TAAAGATGTTGGATGATCAAACTTTGCCACTTTTAATGGA AAAACCTCTCGGCGACAGGA	1620
Db	1561	TAAAGATGTTGGATGATCAAACTTTGCCACTTTTAATGGA AAAACCTCTCGGCGACAGGA	1620
Qy	1621	GTTCACTGGGGCTTGGCAAGCTTCTCATATAGTTTTTTTGTGATAGAAATGCCAAAGTTG	1680
Db	1621	GTTCACTGGGGCTTGGCAAGCTTCTCATATAGTTTTTTTGTGATAGAAATGCCAAAGTTG	1680
Qy	1681	CTGCTTGATCTGAAAATTAATAATACTAGTCTGACACTG	1721
Db	1681	CTGCTTGATCTGAAAATTAATAATACTAGTCTGACACTG	1721
RESULT 11			
LOCUS	AR287435	1721 bp	DNA
DEFINITION	Sequence 1 from patent US 6531129.		PAT 10-APR-2003
ACCESSION	AR287435		
VERSION	AR287435.1	GI:29725129	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1. (bases 1 to 1721)		
AUTHORS	Pecker,I., Viodevsky,I., Friedman,Y. and Perets,T.		
TITLE	Heparamase specific molecular probes and their use in research and medical applications		
JOURNAL	Patent: US 6531129-A 1 11-MAR-2003;		
FEATURES	Location/Qualifiers		
source	1..1721		
BASE COUNT	451 a 413 c 410 g 447 t		
ORIGIN			
Query Match	100.0%; Score 1721; DB 6; Length 1721;		
Best Local Similarity	100.0%; Pred. No. 0;		
Matches 1721; Conservative	0; Mismatches 0; Indels 0; Gaps 0;		
Qy	1	CTAGAGCTTTGACTCTCGCTGCGCGGACGCTGCGGGGGAGCAGCAGCTGAGCCCA	60
Db	1	CTAGAGCTTTGACTCTCGCTGCGCGGACGCTGCGGGGGAGCAGCAGCTGAGCCCA	60
Qy	61	AGATGCTGCTGCGCTCGAAGCTGCGTGGCGCGCGCGCTGATGCTGTCTCGGGGC	120
Db	61	AGATGCTGCTGCGCTCGAAGCTGCGTGGCGCGCGCGCTGATGCTGTCTCGGGGC	120
Qy	121	CGCTGGGTGCCCTCTCCCTGGGCGCTGCCCGACCTGCGCAAGACAGAGCTGCTGG	180
Db	121	CGCTGGGTGCCCTCTCCCTGGGCGCTGCCCGACCTGCGCAAGACAGAGCTGCTGG	180
Qy	181	ACCTGACTTCTTCAACCCAGAGAGCGCTGCACTGTGTAGGCCCTCGTCTGTCGCTGA	240
Db	181	ACCTGACTTCTTCAACCCAGAGAGCGCTGCACTGTGTAGGCCCTCGTCTGTCGCTGA	240
Qy	241	CCATTGAGCCCACTGGCGCAACGAGACCGGCGGTTCCTCATCTCTGGGTTCTCCAAAGC	300
Db	241	CCATTGAGCCCACTGGCGCAACGAGACCGGCGGTTCCTCATCTCTGGGTTCTCCAAAGC	300
Qy	301	TTTCGTAACCTTGAGAGAGAGCTTGTCTCTCTGCGTACCTGAGGTTTGTGGCAACAAGCAG	360
Db	301	TTTCGTAACCTTGAGAGAGAGCTTGTCTCTCTGCGTACCTGAGGTTTGTGGCAACAAGCAG	360
Qy	361	ACTTCTTAATTTTGATCCCAAGAGATCAACTTTGAAGAGAGAGATTACTGGCAAT	420

Db	361	ACTTCCTAATTTTCCATCCCAAGAAAGAAATCAACCTTTGAAGAGAAATTAATGCGCAT	420
QY	421	CTCAAGTCAACCAAGATATTTGGCAATATATGATCCATCCCTCTGTGTGAGAGAAAGT	480
Db	421	CTCAAGTCAACCAAGATATTTGGCAATATATGATCCATCCCTCTGTGTGAGAGAAAGT	480
QY	481	TACGGTTGAATAGGCCCTACCAAGAGCAATGCTACTCCGAGAAACAATAACGAAGAAAGT	540
Db	481	TACGGTTGAATAGGCCCTACCAAGAGCAATGCTACTCCGAGAAACAATAACGAAGAAAGT	540
QY	541	TCAGAAGACAGCACTTACTCAAGAAAGCTCTGTAGATGTGCTATACATTTTGGCAAACTGCT	600
Db	541	TCAGAAGACAGCACTTACTCAAGAAAGCTCTGTAGATGTGCTATACATTTTGGCAAACTGCT	600
QY	601	CAGACTGGAAGCTTGAATCTTTGGCTTAAATGCGTTATTAAGAAACAGCAATTTGCAATGGA	660
Db	601	CAGACTGGAAGCTTGAATCTTTGGCTTAAATGCGTTATTAAGAAACAGCAATTTGCAATGGA	660
QY	661	AAGATTCTAATGCTCAGTTGCTCTCTGAGACTACAGCTCTTCCAAAGGGGTATACATTTCTT	720
Db	661	AAGATTCTAATGCTCAGTTGCTCTCTGAGACTACAGCTCTTCCAAAGGGGTATACATTTCTT	720
QY	721	GGGAAGTACGCAATGAACCTTAACAGTTTCTTAAAGAAAGCTGATATTTTCAATCAATGGGT	780
Db	721	GGGAAGTACGCAATGAACCTTAACAGTTTCTTAAAGAAAGCTGATATTTTCAATCAATGGGT	780
QY	781	CGCAGTTAGAGAGAGATTAATATTCATTAATTCATTAACCTTGAAGAAAGTCAACTTCAAAA	840
Db	781	CGCAGTTAGAGAGAGATTAATATTCATTAATTCATTAACCTTGAAGAAAGTCAACTTCAAAA	840
QY	841	ATGCAAAATCTTAATGCTCTGATGTTGTGACGCTCGAAGAAAGAGCGCTAAGATGCTGA	900
Db	841	ATGCAAAATCTTAATGCTCTGATGTTGTGACGCTCGAAGAAAGAGCGCTAAGATGCTGA	900
QY	901	AAGAGCTTCTGAAAGCTGTGAGAGAGATTAATGATTCAATTAATGAGCATCACTATAT	960
Db	901	AAGAGCTTCTGAAAGCTGTGAGAGAGATTAATGATTCAATTAATGAGCATCACTATAT	960
QY	961	TGAATGAGCGAGCTGCTACCAAGGAGATTTTCTAAACCTGATGATATGGAATTTTGA	1020
Db	961	TGAATGAGCGAGCTGCTACCAAGGAGATTTTCTAAACCTGATGATATGGAATTTTGA	1020
QY	1021	TTTTCATCTGTGCAAAAAGTTTTCAGGTGCTTGAGAGCACAGGCTCGCAAGAAAGTCT	1080
Db	1021	TTTTCATCTGTGCAAAAAGTTTTCAGGTGCTTGAGAGCACAGGCTCGCAAGAAAGTCT	1080
QY	1081	GGTTAGGAGAAACAAGCTCTGCATATGAGAGGGGAGCGGCTTGATATCCGACACTTTG	1140
Db	1081	GGTTAGGAGAAACAAGCTCTGCATATGAGAGGGGAGCGGCTTGATATCCGACACTTTG	1140
QY	1141	CAGCTGGCTTTATATGTGGCTGATAAATTTGGGCTCTGCAAGCCGAAATGGAGATAGAAGTGG	1200
Db	1141	CAGCTGGCTTTATATGTGGCTGATAAATTTGGGCTCTGCAAGCCGAAATGGAGATAGAAGTGG	1200
QY	1201	TGATGAGCGCAAGTATCTTTGAGACAGAAACTACATTTAGTGATGAAAACCTTGATC	1260
Db	1201	TGATGAGCGCAAGTATCTTTGAGACAGAAACTACATTTAGTGATGAAAACCTTGATC	1260
QY	1261	CTTTACCTGATTAATGTGGCTATCTCTCTTCAAGAAATTTGGTGGGACCAAGAGGTATTA	1320
Db	1261	CTTTACCTGATTAATGTGGCTATCTCTCTTCAAGAAATTTGGTGGGACCAAGAGGTATTA	1320
QY	1321	TGGCAAGCGTGAAGGTTCAAAAGAGAGAGCTTGAGATATACCTTCAACAAAACA	1380
Db	1321	TGGCAAGCGTGAAGGTTCAAAAGAGAGAGCTTGAGATATACCTTCAACAAAACA	1380
QY	1381	CTGACATTCGAAGTATTAAGAGAGATTTAACTCTGTATGCAATAACCTTCAATAACG	1440
Db	1381	CTGACATTCGAAGTATTAAGAGAGATTTAACTCTGTATGCAATAACCTTCAATAACG	1440
QY	1441	TCAACAAGTACTTGGCGTTACCTATCCCTTTTCTTAAACAAGCAAGTGAATAATACCTTC	1500
Db	1441	TCAACAAGTACTTGGCGTTACCTATCCCTTTTCTTAAACAAGCAAGTGAATAATACCTTC	1500

QY	1501	TAAGACCTTTGGGACCTCATGGATTACTTTCCAAATCTGTCCAACTCAATAGGTCTAACTC	1560
Db	1501	TAAGACCTTTGGGACCTCATGGATTACTTTCCAAATCTGTCCAACTCAATAGGTCTAACTC	1560
QY	1561	TAAAGATGGTGGATGATCAAACTTGTCCACCTTTAATGGAAGAAACCTCTCCGCCAGGAA	1620
Db	1561	TAAAGATGGTGGATGATCAAACTTGTCCACCTTTAATGGAAGAAACCTCTCCGCCAGGAA	1620
QY	1621	GTTCACTGGGCTTGCAGCTTTCCTCAATVAGTTTTTTTGTGATAGAAATGCCAAAGTTG	1680
Db	1621	GTTCACTGGGCTTGCAGCTTTCCTCAATVAGTTTTTTTGTGATAGAAATGCCAAAGTTG	1680
QY	1661	CTGCTTGACATCTGAAAATAATAAATATACAGTCCGACACTG	1721
Db	1661	CTGCTTGACATCTGAAAATAATAAATATACAGTCCGACACTG	1721
RESULT 12			
LOCUS	AR287436	1721 bp	DNA
DEFINITION	Sequence 3 from patent US 6531129.	linear	PAT 10-APR-2003
ACCESSION	AR287436		
VERSION	AR287436.1	GI:29725130	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unclassified.		
REFERENCE	1 (bases 1 to 1721)		
AUTHORS	Pecker,I., Vlodavsky,I., Friedman,Y. and Perets,T.		
TITLE	Heparanase specific molecular probes and their use in research and medical applications		
JOURNAL	Patent: US 6531129-A 3 11-MAR-2003;		
FEATURES	Location/Qualifiers		
source	1..1721		
BASE COUNT	451 a 413 c 410 g 447 t		
ORIGIN	/organism="unknown"		
Query Match 100.0%; Score 1721; DB 6; Length 1721;			
Beet Local Similarity 100.0%; Pred. No. 0;			
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	CTAAGAGCTTTGCACTCTCCGCTGCGCGGACACTGGCGGGGAGAGCAGAGTGAAGCCCA	60
Db	1	CTAAGAGCTTTGCACTCTCCGCTGCGCGGACACTGGCGGGGAGAGCAGAGTGAAGCCCA	60
QY	61	AGATGCTGCTCGCTCGAAGCCTTGCGCTGCCGCGCGCTGATGCTGTGCTCTTGAGGC	120
Db	61	AGATGCTGCTCGCTCGAAGCCTTGCGCTGCCGCGCGCTGATGCTGTGCTCTTGAGGC	120
QY	121	CGCTGGGCTCCCTCTCCCTCTGCGCGCCCTGCCGACCTTGCGGCAAGCAGACGTCCTGG	180
Db	121	CGCTGGGCTCCCTCTCCCTCTGCGCGCCCTGCCGACCTTGCGGCAAGCAGACGTCCTGG	180
QY	181	ACCTGGAATTTCTTACCCAGAGAGCGGCTGACCTGTGAGGCGCCTGTTCTCTGTCCTCA	240
Db	181	ACCTGGAATTTCTTACCCAGAGAGCGGCTGACCTGTGAGGCGCCTGTTCTCTGTCCTCA	240
QY	241	CGATTGACGCAACCTTGCGCAAGCACCAGGCTTCTCATCTCTCTGGGTTCTCCAAAGC	300
Db	241	CGATTGACGCAACCTTGCGCAAGCACCAGGCTTCTCATCTCTCTGGGTTCTCCAAAGC	300
QY	301	TTTCGACCTTGGCCAGAGGCTTGTCTCCTGCTGACCTGAGGTTTGGTGGCCAAAGACAG	360
Db	301	TTTCGACCTTGGCCAGAGGCTTGTCTCCTGCTGACCTGAGGTTTGGTGGCCAAAGACAG	360
QY	361	ACTTCTTAATTTTGATCTCCAAAGAGATCAACTTTGAAGAGAGAGTTACTGGCAAT	420
Db	361	ACTTCTTAATTTTGATCTCCAAAGAGATCAACTTTGAAGAGAGAGTTACTGGCAAT	420
QY	421	CTCAAGTCAACCAAGATATTTTGCAATATGATCATCTCTCTGATGTGAGAGAAAGT	480
Db	421	CTCAAGTCAACCAAGATATTTTGCAATATGATCATCTCTCTGATGTGAGAGAAAGT	480

```

Db      421 CTCACGTCAACGAGATATTTGCAAAATATGATCCATCCCTCTGATGCGAGAAAGT 480
Qy      481 TACGGTGGAAATGGCCCTACACGAGCAATTTGCTACTCCGAGAGACCTACAGAAAAGT 540
Db      481 TACGGTGGAAATGGCCCTACACGAGCAATTTGCTACTCCGAGAGACCTACAGAAAAGT 540
Qy      541 TCAGAACAGACGACCTACTCAAGAGCTCTGATGCTATACATTTTGGCAACCTGCT 600
Db      541 TCAGAACAGACGACCTACTCAAGAGCTCTGATGCTATACATTTTGGCAACCTGCT 600
Qy      601 CAGAGCTGAGCTTGAATCTTTGGCCCTTAATGCTTATTAAGAACAGCAATTTGCACTGA 660
Db      601 CAGAGCTGAGCTTGAATCTTTGGCCCTTAATGCTTATTAAGAACAGCAATTTGCACTGA 660
Qy      661 ACAGTTCTAATGCTAGTTGCTCTGAGACTAGCTCTCAAGGGGATTAACATTTCTT 720
Db      661 ACAGTTCTAATGCTAGTTGCTCTGAGACTAGCTCTCTCAAGGGGATTAACATTTCTT 720
Qy      721 GGGAACTAGGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCATCAATGGGT 780
Db      721 GGGAACTAGGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCATCAATGGGT 780
Qy      781 CGCAGTTGAGAGAAATTAATTAATTAATGCAATTAACCTTCAAGAAAGTCACTTCAAAA 840
Db      781 CGCAGTTGAGAGAAATTAATTAATTAATGCAATTAACCTTCAAGAAAGTCACTTCAAAA 840
Qy      841 ATGCAAACTCTATGCTCTGATGCTGCTGAGCTCTGAGAAAGACGCTAGATAGCTGA 900
Db      841 ATGCAAACTCTATGCTCTGATGCTGCTGAGCTCTGAGAAAGACGCTAGATAGCTGA 900
Qy      901 AGAGCTTCTGAGAGCTGCTGAGAGAGATTAATTAATTAATGCAATTAACCTTCAAT 960
Db      901 AGAGCTTCTGAGAGCTGCTGAGAGAGATTAATTAATTAATGCAATTAACCTTCAAT 960
Qy      961 TGAATGAGACGAGCTGCTACAGGAGAAATTTCTTAACCTGATGATTTGAACATTTTGA 1020
Db      961 TGAATGAGACGAGCTGCTACAGGAGAAATTTCTTAACCTGATGATTTGAACATTTTGA 1020
Qy      1021 TTTCACTGCTGCAAAAAGTTTCCAGGCTGCTGAGAGACGAGGCTGCGCAAGAAAGTCT 1080
Db      1021 TTTCACTGCTGCAAAAAGTTTCCAGGCTGCTGAGAGACGAGGCTGCGCAAGAAAGTCT 1080
Qy      1081 GGTTAAGAGAAACAAGCTCTGATATGAGAGGAGAGGCTTGTGATTCGACACCTTTG 1140
Db      1081 GGTTAAGAGAAACAAGCTCTGATATGAGAGGAGAGGCTTGTGATTCGACACCTTTG 1140
Qy      1141 CAGCTGCTTATATGCTGATTAATGAGGCTGCTGAGGCTGCAAGTGGAAATGAAGTGG 1200
Db      1141 CAGCTGCTTATATGCTGATTAATGAGGCTGCTGAGGCTGCAAGTGGAAATGAAGTGG 1200
Qy      1201 TGATAGGCAAGATATTTCTTTGAGAGCAAGAACTACATTTAGTGATGAAAACTTCGATC 1260
Db      1201 TGATAGGCAAGATATTTCTTTGAGAGCAAGAACTACATTTAGTGATGAAAACTTCGATC 1260
Qy      1261 CTTTACCTGATTAATGCTATCTCTTCTGTTCAAGAAATTTGGTGGACCAAGAGTGTGA 1320
Db      1261 CTTTACCTGATTAATGCTATCTCTTCTGTTCAAGAAATTTGGTGGACCAAGAGTGTGA 1320
Qy      1321 TGGCAAGCGTGCAGAGTTCAAGAGAGAGAACTTGAATATACCTTCAATTCACAAACA 1380
Db      1321 TGGCAAGCGTGCAGAGTTCAAGAGAGAGAACTTGAATATACCTTCAATTCACAAACA 1380
Qy      1381 CTGACAAATTCAGAGATTAAGAGAGAGATTAATCTGATGCTCAATTAACCTTCATACG 1440
Db      1381 CTGACAAATTCAGAGATTAAGAGAGAGATTAATCTGATGCTCAATTAACCTTCATACG 1440
Qy      1441 TCACCAAGACTCTGGGTTACCTTATCTTTTCTAACAAGCAAGTGATTAATACCTTC 1500
Db      1441 TCACCAAGACTCTGGGTTACCTTATCTTTTCTAACAAGCAAGTGATTAATACCTTC 1500
Qy      1501 TAAAGACTTTGGGAGCTCATGATTAATCTTCCAAATCTGTCCAACTCAATGGTCTAATCTC 1560
Db      1501 TAAAGACTTTGGGAGCTCATGATTAATCTTCCAAATCTGTCCAACTCAATGGTCTAATCTC 1560

```

```

Qy      1561 TAAAGATGATGATGATCAAACTTTGCCACCTTTAATGAAAAAATCTCTCCGCGCAGGAA 1620
Db      1561 TAAAGATGATGATGATCAAACTTTGCCACCTTTAATGAAAAAATCTCTCCGCGCAGGAA 1620
Qy      1621 GTTCACTGGGCTTGGCAGCTTTCATATAGTTTGTGTATGAAGAAATGCAAAAGTTG 1680
Db      1621 GTTCACTGGGCTTGGCAGCTTTCATATAGTTTGTGTATGAAGAAATGCAAAAGTTG 1680
Qy      1681 CTGCTTGATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1721
Db      1681 CTGCTTGATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1721

RESULT 13
BD074427
LOCUS      BD074427          1721 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION Polynucleotide encoding polypeptide having heparanase activity and
expression of the polypeptide in induced cell.
ACCESSION  BD074427
VERSION    BD074427.1 GI:22620030
KEYWORDS   unclassified
SOURCE     unidentified
ORGANISM   unidentified.
REFERENCE  1 (bases 1 to 1721)
AUTHORS    Becker,I., Vlodavsky,I. and Eliens,F.
TITLE      Polynucleotide encoding polypeptide having heparanase activity and
expression of the polypeptide in induced cell
JOURNAL    Patent: JP 2001514855-A 8 18-SEP-2001;
INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES
& DEVELOPMENT LTD
OS         Nucleic acid
PN         JP 2001514855-A/8
PD         18-SEP-2001
PF         31-AUG-1998 JP 2000508806
PR         02-SEP-1997 US 08/922170, 02-JUL-1998 US 09/109386 PI
IRIS       PECKER, ISRAEL VLODAVSKY, PEINSTEIN ELENA
PC         C12N15/09,A61K38/00,A61P9/10,A61P17/00,A61P29/00,A61P35/00, PC
A61P37/00,
PC         A61P43/00,C12N5/10,C12N9/24,C12Q1/68,G01N33/15,G01N33/50// PC
A61K39/395,
PC         A61K39/395,C12N15/00,A61K37/02,C12N5/00
CC         Polynucleotide encoding polypeptide having
heparanase activity
CC         and
CC         expression of the polypeptide in induced cell FH Key
Location/Qualifiers 1..1721
FT source
FEATURES
source
1..1721 Location/Qualifiers
1..1721 /organism="Nucleic acid".
1..1721 /organism="unidentified"
/mol type="genomic DNA"
/db xref="taxon:32644"
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN
Query Match 100.0%; Score 1721; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 181 ACTGAGCTTCTTCAACCGAGAGCCGCTGCACTGCTGAGCCCTCGTTCCTGTCCTCA 240
 Db 181 ACTGAGCTTCTTCAACCGAGAGCCGCTGCACTGCTGAGCCCTCGTTCCTGTCCTCA 240
 QY 241 CCATTGAGGCCAAGCTGGCCAGAGACCGCGGCTTCTCATCTCTGGGTTCTCCAAAGC 300
 Db 241 CCATTGAGGCCAAGCTGGCCAGAGACCGCGGCTTCTCATCTCTGGGTTCTCCAAAGC 300
 QY 301 TTCCGACCTTGGCCAGAGGCTTGTCTCCGCTACCTGAGGTTGGTGGCAACAGACAG 360
 Db 301 TTCCGACCTTGGCCAGAGGCTTGTCTCCGCTACCTGAGGTTGGTGGCAACAGACAG 360
 QY 361 ACTTCCTAATTTTCATCCCAAGAGATCAACTTTGAGAGAGAAATTACTGGCAAT 420
 Db 361 ACTTCCTAATTTTCATCCCAAGAGATCAACTTTGAGAGAGAAATTACTGGCAAT 420
 QY 421 CTCAGATCAACGAGATATTTGCAAAATATGATCCATCTCTGATGTGGAGAGAAAGT 480
 Db 421 CTCAGATCAACGAGATATTTGCAAAATATGATCCATCTCTGATGTGGAGAGAAAGT 480
 QY 481 TACGGTGGAAATGGCCCTACAGAGCAATGGCTACTCCGAGAGACTACCGAGAAAGT 540
 Db 481 TACGGTGGAAATGGCCCTACAGAGCAATGGCTACTCCGAGAGACTACCGAGAAAGT 540
 QY 541 TCAAGAACAGCACTACTCAAGAGACTCTGTAGATGTGCTATACCTTTTGGCAACTGCT 600
 Db 541 TCAAGAACAGCACTACTCAAGAGACTCTGTAGATGTGCTATACCTTTTGGCAACTGCT 600
 QY 601 CAGGACTGAGCTTGTATCTTTGGCCTTAATGCGTTATTAAGAACAGCAATTTGCAAGTGA 660
 Db 601 CAGGACTGAGCTTGTATCTTTGGCCTTAATGCGTTATTAAGAACAGCAATTTGCAAGTGA 660
 QY 661 ACAGTCTAATGCTAGTTCCTGCTGCTGCTACTGCTCTTCCAGAGGCTAATACATTTCT 720
 Db 661 ACAGTCTAATGCTAGTTCCTGCTGCTGCTACTGCTCTTCCAGAGGCTAATACATTTCT 720
 QY 721 GGGAACTAGGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCAATCAATGGGT 780
 Db 721 GGGAACTAGGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCAATCAATGGGT 780
 QY 781 CGCAGTTAGAGAGATTAATTAATTCATATTCATTAATCTTGAAGAAAGTCCACTTCAAAA 840
 Db 781 CGCAGTTAGAGAGATTAATTAATTCATATTCATTAATCTTGAAGAAAGTCCACTTCAAAA 840
 QY 841 ATGCAAACTCTATGCTCTGATGTGCTGCTGAGCTCGAAGAAAGCGCTAAGATGCTGA 900
 Db 841 ATGCAAACTCTATGCTCTGATGTGCTGCTGAGCTCGAAGAAAGCGCTAAGATGCTGA 900
 QY 901 AGAGCTTCTGAGAGGCTGGTGGAGAGATGATGATTCAGTTACATGGCATCACTACTAT 960
 Db 901 AGAGCTTCTGAGAGGCTGGTGGAGAGATGATGATTCAGTTACATGGCATCACTACTAT 960
 QY 961 AGAGCTTCTGAGAGGCTGGTGGAGAGATGATGATTCAGTTACATGGCATCACTACTAT 960
 Db 961 AGAGCTTCTGAGAGGCTGGTGGAGAGATGATGATTCAGTTACATGGCATCACTACTAT 960
 QY 961 TGAATGAGCGAGCTGCTACAGAGAGATTTCTAAACCTGATGATTTGACATTTTGA 1020
 Db 961 TGAATGAGCGAGCTGCTACAGAGAGATTTCTAAACCTGATGATTTGACATTTTGA 1020
 QY 1021 TTTGATCTGTGCAAAAAGTTTCCAGGCTGTTGAGAGACCGAGGCTGCAAGAGGCT 1080
 Db 1021 TTTGATCTGTGCAAAAAGTTTCCAGGCTGTTGAGAGACCGAGGCTGCAAGAGGCT 1080
 QY 1081 GGTATGAGAGAAACAAGCTCTGATATGAGAGGCGAGGCGCTTGTCTATCCGACACTTTG 1140
 Db 1081 GGTATGAGAGAAACAAGCTCTGATATGAGAGGCGAGGCGCTTGTCTATCCGACACTTTG 1140
 QY 1141 CAGCTGCTTTATGTGGCTGATTAATTTGGGCTGTCAAGCCGAGATGGGAATAGAAGTGG 1200
 Db 1141 CAGCTGCTTTATGTGGCTGATTAATTTGGGCTGTCAAGCCGAGATGGGAATAGAAGTGG 1200
 QY 1201 TGATGAGGCAAGATATTTCTTTGAGAGCAAGAACTACCATTTAGTGATGAAAACTTCGATC 1260
 Db 1201 TGATGAGGCAAGATATTTCTTTGAGAGCAAGAACTACCATTTAGTGATGAAAACTTCGATC 1260

QY 1261 CTTTACTGATTAATTTGGCTATCTCTTCTGTTCAAGAAATGGTGGCCACCAAGTGTAA 1320
 Db 1261 CTTTACTGATTAATTTGGCTATCTCTTCTGTTCAAGAAATGGTGGCCACCAAGTGTAA 1320
 QY 1321 TGGCAAGGCTCAAGGTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
 Db 1321 TGGCAAGGCTCAAGGTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
 QY 1381 CTGACATCCAAAGGATTAAGAGAGAGATTAATCTGATGATGATTAACCTCCATAACG 1440
 Db 1381 CTGACATCCAAAGGATTAAGAGAGAGATTAATCTGATGATGATTAACCTCCATAACG 1440
 QY 1441 TCACCAAGTCTTGGGCTTACCTATCTCTTTTCTTCAACAGCAAGTGATTAATCTTC 1500
 Db 1441 TCACCAAGTCTTGGGCTTACCTATCTCTTTTCTTCAACAGCAAGTGATTAATCTTC 1500
 QY 1501 TAAAGCTTTGGGAGCTTCATGATTAATCTTCAATCTGATGATGATGATGATGATGATG 1560
 Db 1501 TAAAGCTTTGGGAGCTTCATGATTAATCTTCAATCTGATGATGATGATGATGATGATG 1560
 QY 1561 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1620
 Db 1561 TAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1620
 QY 1621 GTTCACTGGGCTTGGCAGCTTCTCATATATGATTTTGTGATTAAGAAATGCCAAAGTTG 1680
 Db 1621 GTTCACTGGGCTTGGCAGCTTCTCATATATGATTTTGTGATTAAGAAATGCCAAAGTTG 1680
 QY 1681 CTGCTTGATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
 Db 1681 CTGCTTGATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721

RESULT 14

LOCUS BD074428 1721 bp DNA linear PAT 27-AUG-2002
 DEFINITION Polynucleotide encoding polypeptide having heparanase activity and
 expression of the polypeptide in induced cell.

ACCESSION BD074428
 VERSION BD074428.1 GI:22620031

KEYWORDS JP 2001514855-A/9.
 SOURCE unclassified
 ORGANISM unclassified.

REFERENCE 1 (bases 1 to 1721)
 Pecker, I., Vlodavsky, I. and Elena, F.

AUTHORS Polynucleotide encoding polypeptide having heparanase activity and
 expression of the polypeptide in induced cell

TITLE Patent: JP 2001514855-A 9 18-SEP-2001;
 INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES

JOURNAL & DEVELOPMENT LTD

COMMENT OS Nucleic acid
 PN JP 2001514855-A/9
 PD 18-SEP-2001
 PF 31-AUG-1998 JP 2000508806
 PR 02-SEP-1997 US 08/922170, 02-JUL-1998 US 09/109386 PI
 IRIS PECKER, ISRAEL, VLODAVSKY, FEINSTEIN ELENA
 PC C12N15/09, A61K38/00, A61P9/10, A61P17/00, A61P29/00, A61P35/00, PC

A61P37/00, A61P43/00, C12N5/10, C12N9/24, C12Q1/68, G01N33/15, G01N33/50// PC

A61K39/395, PC A61K39/395, C12N15/00, A61K37/02, C12N5/00
 CC Polynucleotide encoding polypeptide having heparanase activity

CC expression of the polypeptide in induced cell FH Key
 Location/Qualifiers (63).. (1691).

FT CDS location/qualifiers

FEATURES location/qualifiers

source 1..1721
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

BASE COUNT	451 a	413 c	410 g	447 t	ORIGIN
Query Match	100.0%; Score 1721; DB 6; Length 1721;				
Best Local Similarity	100.0%; Pred. No. 0;				
Matches 1721; Conservative	0; Mismatches 0; Indels 0; Gaps 0;				
Oy	1 CTAGAGCTTTGACTCTCCGCTGCGGAGCTGGCGGGGAGAGCAGGCTGAGCCCA 60				
Db	1 CTAGAGCTTTGACTCTCCGCTGCGGAGCTGGCGGGGAGAGCAGGCTGAGCCCA 60				
Oy	61 AGATGCTGCTGCTGCGGAGCTGGCTGGCGGGGAGAGCAGGCTGAGCCCA 120				
Db	61 AGATGCTGCTGCTGCGGAGCTGGCTGGCGGGGAGAGCAGGCTGAGCCCA 120				
Oy	121 CGCTGGGCTGCTGCTGCGGAGCTGGCTGGCGGGGAGAGCAGGCTGAGCCCA 180				
Db	121 CGCTGGGCTGCTGCTGCGGAGCTGGCTGGCGGGGAGAGCAGGCTGAGCCCA 180				
Oy	181 ACTGGAAGCTTCTTCAACCGAGAGCGCTGCACTGGTGAAGCCCTGTTCCCTGCTCA 240				
Db	181 ACTGGAAGCTTCTTCAACCGAGAGCGCTGCACTGGTGAAGCCCTGTTCCCTGCTCA 240				
Oy	241 CCATTGAGCCCACTGGGCAAGGAGCCGCGGCTTCTCATCTCTGCGGTTCTCCAAAGC 300				
Db	241 CCATTGAGCCCACTGGGCAAGGAGCCGCGGCTTCTCATCTCTGCGGTTCTCCAAAGC 300				
Oy	301 TTTCGACCTTGGCCGAGAGCTTGTCTCTGCTGCTAAGGTTGGTGGCAACAGAGAG 360				
Db	301 TTTCGACCTTGGCCGAGAGCTTGTCTCTGCTGCTAAGGTTGGTGGCAACAGAGAG 360				
Oy	361 ACTTCTTAATTTTGCATCCCAAGAGATCAACCTTTGAAGAGAGATTACTGGCAAT 420				
Db	361 ACTTCTTAATTTTGCATCCCAAGAGATCAACCTTTGAAGAGAGATTACTGGCAAT 420				
Oy	421 CTCAAGTCAACCGAGATTTTGGCAATATGATTCATCCCTCTGATGGAGAGAGT 480				
Db	421 CTCAAGTCAACCGAGATTTTGGCAATATGATTCATCCCTCTGATGGAGAGAGT 480				
Oy	481 TACGGTTGGAATGGCCCTTACCGAGAGCAATGCTACTCCGAGAACCACTACGAAAGT 540				
Db	481 TACGGTTGGAATGGCCCTTACCGAGAGCAATGCTACTCCGAGAACCACTACGAAAGT 540				
Oy	541 TCAAGAACGAGCACTACTCAAGAGCTCTGTAGATGTGTATACCTTTTGGCAACTGCT 600				
Db	541 TCAAGAACGAGCACTACTCAAGAGCTCTGTAGATGTGTATACCTTTTGGCAACTGCT 600				
Oy	601 CAGGACTGGAATTTGCTTTGGCTTAAATGCGTTATTAAGAACACAGATTGGAGTGA 660				
Db	601 CAGGACTGGAATTTGCTTTGGCTTAAATGCGTTATTAAGAACACAGATTGGAGTGA 660				
Oy	661 ACAATTTCTAATGCTCAATTTGCTTCTGCACTACTGCTCTTCCAGGGGATTAACATTTCTT 720				
Db	661 ACAATTTCTAATGCTCAATTTGCTTCTGCACTACTGCTCTTCCAGGGGATTAACATTTCTT 720				
Oy	721 GGGAACTGGAAGTAACTTAACATTTTCTTAAAGAGCTGATATTTTCACTCAATGGGT 780				
Db	721 GGGAACTGGAAGTAACTTAACATTTTCTTAAAGAGCTGATATTTTCACTCAATGGGT 780				
Oy	781 CGGAGTTGAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 840				
Db	781 CGGAGTTGAGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 840				
Oy	841 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTTGAAGAAAGCGCTTAAGATGCTGA 900				
Db	841 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTTGAAGAAAGCGCTTAAGATGCTGA 900				
Oy	901 AGAGCTTCTTAAGGCTGTGAGAGATGATTTGATTCATGATGATGATGATGATGATGAT 960				
Db	901 AGAGCTTCTTAAGGCTGTGAGAGATGATTTGATTCATGATGATGATGATGATGATGAT 960				
Oy	961 TGAATGAGCGGACTCTACAGGAGAAATTTCTAAACCTGATGATGATGATGATGATGAT 1020				

Db	961 TGAATGAGCGGACTCTACAGGAGAAATTTCTAAACCTGATGATGATGATGATGATGAT 1020
Oy	1021 TTTGATCTGTGCAAAAATTTTCCAGGTGTTGAGAGCAGGCTGGCAAGAGGTCT 1080
Db	1021 TTTGATCTGTGCAAAAATTTTCCAGGTGTTGAGAGCAGGCTGGCAAGAGGTCT 1080
Oy	1081 GGTAGAGAAACAAGCTCTGATATGAGAGGCGGCGCTTGTCTATCCGACACTTTTG 1140
Db	1081 GGTAGAGAAACAAGCTCTGATATGAGAGGCGGCGCTTGTCTATCCGACACTTTTG 1140
Oy	1141 CAGCTGCTTATATGCTGATTAATTTGGGCTGTACGCCGGAATGGGATTAAGTGG 1200
Db	1141 CAGCTGCTTATATGCTGATTAATTTGGGCTGTACGCCGGAATGGGATTAAGTGG 1200
Oy	1201 TGATGAGGCAAGTATTTCTTGGAGAGGAACTACATTTAGTGAATGAATTTGATC 1260
Db	1201 TGATGAGGCAAGTATTTCTTGGAGAGGAACTACATTTAGTGAATGAATTTGATC 1260
Oy	1261 CTTTACCTGATTAATTTGCTATCTCTTCTGTTCAAGAAATTTGGTGGCAAGGTTTAA 1320
Db	1261 CTTTACCTGATTAATTTGCTATCTCTTCTGTTCAAGAAATTTGGTGGCAAGGTTTAA 1320
Oy	1321 TGGCAAGGCTGCAAGTTTCAAGAGAGAGAGCTTCCAGTATACCTTCACTTGCACAA 1380
Db	1321 TGGCAAGGCTGCAAGTTTCAAGAGAGAGAGCTTCCAGTATACCTTCACTTGCACAA 1380
Oy	1381 CTGACCAATCCAAAGGATTAAGAGAGATTAATTAATTAATTAATTAATTAATTAATTA 1440
Db	1381 CTGACCAATCCAAAGGATTAAGAGAGATTAATTAATTAATTAATTAATTAATTAATTA 1440
Oy	1441 TCACCAAGTACTTGGCTTACCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1500
Db	1441 TCACCAAGTACTTGGCTTACCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1500
Oy	1501 TAAAGCTTTGGGAGCTTCAATGATTAATTAATTAATTAATTAATTAATTAATTAATTA 1560
Db	1501 TAAAGCTTTGGGAGCTTCAATGATTAATTAATTAATTAATTAATTAATTAATTAATTA 1560
Oy	1561 TAAAGTGTGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1620
Db	1561 TAAAGTGTGATGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1620
Oy	1621 GTTCACTGGGCTTCCAGGCTTCTCATATGATTTTGTGATTAAGAAATCCCAAGTTG 1680
Db	1621 GTTCACTGGGCTTCCAGGCTTCTCATATGATTTTGTGATTAAGAAATCCCAAGTTG 1680
Oy	1681 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1740
Db	1681 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1740
RESULT 15	
BD074430 1899 bp DNA linear PAT 27-AUG-2002	
LOCUS	
DEFINITION Polynucleotide encoding polypeptide having heparanase activity and	
expression of the polypeptide in induced cell.	
ACCESSION BD074430.1 GI:22620033	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
COMMENT	
OS Nucleic acid	
PN JP 2001514855-A/11	
PD 18-SEP-2001	
PF 31-AUG-1998 JP 200050806	

```

PR 02-SEP-1997 US 08/922170, 02-JUL-1998 US 09/109386 PI
IRIS PICKER, ISRAEL, VIODAVSKY, FEINSTEIN ELENA
PC C12N5/00, A61K38/00, A61P9/10, A61P17/00, A61P29/00, A61P35/00, PC
A61P37/00
PC A61P3/00, C12N5/10, C12N9/24, C12Q1/68, G01N33/15, G01N33/50// PC
A61K39/395,
PC A61K39/395, C12N15/00, A61K37/02, C12N5/00
CC Polynucleotide encoding polypeptide having
heparanase activity
CC and
CC expression of the polypeptide in induced cell FH Key
Location/Qualifiers
FT source 1. 1899
/organism='Nucleic acid'.
FEATURES
1. 1899
Location/Qualifiers
/source='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'
BASE COUNT 495 a 433 c 510 g 461 t
ORIGIN
Query Match 99.9%; Score 1719.4; DB 6; Length 1899;
Best Local Similarity: 99.9%; Pred. No. 0;
Matches 1720; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 CTAGAGCTTTGACCTCCGCTGCGGAGCTGGCGGGGGAGAGCCAGGTGAGCCCA 60
DB 179 CTAGAGCTTTGACCTCCGCTGCGGAGCTGGCGGGGGAGAGCCAGGTGAGCCCA 238
QY 61 AGATCTCTGCTGCTGGAAGCTGCGCTGCGCGCGCGCTGATGCTGCTGCTGCGGAC 120
DB 239 AGATCTCTGCTGCTGGAAGCTGCGCTGCGCGCGCGCTGATGCTGCTGCTGCGGAC 298
QY 121 CGCTGGTCCCTCTCCCTGCGCGCTGCGCGCGCTGATGCTGCTGCTGCGGAC 180
DB 299 CGCTGGTCCCTCTCCCTGCGCGCTGCGCGCGCTGATGCTGCTGCTGCGGAC 358
QY 181 ACCTGGACTCTTCCACCAAGAGCGCGCTGCACTGATGAGCCCTGTTCCCTGCTGCA 240
DB 359 ACCTGGACTCTTCCACCAAGAGCGCGCTGCACTGATGAGCCCTGTTCCCTGCTGCA 418
QY 241 CCATTGAGCGCAACCTGGCGCAAGAGCCGCGCTTCTCATCTCTGCGGTTCTCCAAAGC 300
DB 419 CCATTGAGCGCAACCTGGCGCAAGAGCCGCGCTTCTCATCTCTGCGGTTCTCCAAAGC 478
QY 301 TTCTGATCTTGGCGCAAGAGCTTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
DB 479 TTCTGATCTTGGCGCAAGAGCTTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 538
QY 361 ACTTCTTAATTTTGCATCCCAAGAGGATCAACCTTTGAGAGAGAGTTACTGCGCAAT 420
DB 539 ACTTCTTAATTTTGCATCCCAAGAGGATCAACCTTTGAGAGAGAGTTACTGCGCAAT 598
QY 421 CTCAAGTCAACCAAGAGATATTTGCAATATGATTCATCTCTGATGCTGAGAGAGAGT 480
DB 599 CTCAAGTCAACCAAGAGATATTTGCAATATGATTCATCTCTGATGCTGAGAGAGT 658
QY 481 TACGGTGGATGCGCTTACCAAGAGCAATTTCTACTCTCCAGAGACACTACCAAGAAAAGT 540
DB 659 TACGGTGGATGCGCTTACCAAGAGCAATTTCTACTCTCCAGAGACACTACCAAGAAAAGT 718
QY 541 TCAAAACAGCACTTACCAAGAGCAATTTCTACTCTCCAGAGACACTACCAAGAAAAGT 600
DB 719 TCAAAACAGCACTTACCAAGAGCAATTTCTACTCTCCAGAGACACTACCAAGAAAAGT 778
QY 601 CAGAGCTGAGCTTGAATCTTTGCGCTAAATGCGTATTAAGAACACAGATTTGCGAGTGA 660
DB 779 CAGAGCTGAGCTTGAATCTTTGCGCTAAATGCGTATTAAGAACACAGATTTGCGAGTGA 838
QY 661 ACAAGTTCTAATGCTGAGTGTCTCTGAGACTACTGCTTCCAAAGGGGATTAACATTTCTT 720
DB 839 ACAAGTTCTAATGCTGAGTGTCTCTGAGACTACTGCTTCCAAAGGGGATTAACATTTCTT 898

```

```

QY 721 GGAAGACTAGCAATGAACCTTAACAGTTTCTTAAGAGGCTGATATTTTCATCATGGGT 780
DB 899 GGAAGACTAGCAATGAACCTTAACAGTTTCTTAAGAGGCTGATATTTTCATCATGGGT 958
QY 781 CGCAGTTAGAGAGATTAATTTCAATTTGCTAATACTTCAAGAAAGTCCACTTCAAAA 840
DB 959 CGCAGTTAGAGAGATTAATTTCAATTTGCTAATACTTCAAGAAAGTCCACTTCAAAA 1018
QY 841 ATGCAAACTCTAATGCTGATGTTGCTGAGCTCCGAGAGAAAGCGGCTAAGATGCTGA 900
DB 1019 ATGCAAACTCTAATGCTGATGTTGCTGAGCTCCGAGAGAAAGCGGCTAAGATGCTGA 1078
QY 901 AGAGCTTCTGAGAGGCTGCTGAGAGAGATGATGATGATGATGATGATGATGATGATGAT 960
DB 1079 AGAGCTTCTGAGAGGCTGCTGAGAGAGATGATGATGATGATGATGATGATGATGATGAT 1138
QY 961 TGAATGAGCGGACTGCTACCAAGGAGATTTTCTAACCCTGATGATGATGATGATGATGAT 1020
DB 1139 TGAATGAGCGGACTGCTACCAAGGAGATTTTCTAACCCTGATGATGATGATGATGATGAT 1198
QY 1021 TTTCATCTGTCGCAAAAAGTTTCCAGGCTGTCAGAGACCAAGGCTGCGCAAGGCTCT 1080
DB 1199 TTTCATCTGTCGCAAAAAGTTTCCAGGCTGTCAGAGACCAAGGCTGCGCAAGGCTCT 1258
QY 1081 GGTAGAGAGAAACAAGCTCTGCTATGAGAGCGGAGCGCCCTTCTATCCGACACTTTTG 1140
DB 1259 GGTAGAGAGAAACAAGCTCTGCTATGAGAGCGGAGCGCCCTTCTATCCGACACTTTTG 1318
QY 1141 CAGCTGCTTATGCTGCTGATTAATTTGGGCTGTCAGCCGAGTGGAGATAGAGTGG 1200
DB 1319 CAGCTGCTTATGCTGCTGATTAATTTGGGCTGTCAGCCGAGTGGAGATAGAGTGG 1378
QY 1201 TGATGAGCAAGATATTTCTTGGAGACAGAGAACTACATTTAGTGGATGAAAACCTTCATC 1260
DB 1379 TGATGAGCAAGATATTTCTTGGAGACAGAGAACTACATTTAGTGGATGAAAACCTTCATC 1438
QY 1261 CTTTACCTGATTTATTTGGCTATCTCTTCTGTTCAAGAAATTTGGGACCAAGGTGTTAA 1320
DB 1439 CTTTACCTGATTTATTTGGCTATCTCTTCTGTTCAAGAAATTTGGGACCAAGGTGTTAA 1498
QY 1321 TGGCAAGCTGCAAGGTTCAAGAGAGAGAGCTTGAAGTATCTTCAATTTGCAACAA 1380
DB 1499 TGGCAAGCTGCAAGGTTCAAGAGAGAGAGCTTGAAGTATCTTCAATTTGCAACAA 1558
QY 1381 CTGCAATCCAAAGGTTATTAAGAGATTTAATCTGCTGATGCTGATTAACCTCCATACG 1440
DB 1559 CTGCAATCCAAAGGTTATTAAGAGATTTAATCTGCTGATGCTGATTAACCTCCATACG 1618
QY 1441 TCACCAAGTACTTGGCTGATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1500
DB 1619 TCACCAAGTACTTGGCTGATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1678
QY 1501 TAAAGCTTTGGAGCTTCATGATGATTTCTTCAATCTGTCCTCAATCTCATAGTCTTAACTC 1560
DB 1679 TAAAGCTTTGGAGCTTCATGATGATTTCTTCAATCTGTCCTCAATCTCATAGTCTTAACTC 1738
QY 1561 TAAAGTGTGTGATGATTAACCTTGGCACTTTTAAGAGAAACCTCTCCGGGACAGAA 1620
DB 1739 TAAAGTGTGTGATGATTAACCTTGGCACTTTTAAGAGAAACCTCTCTCCGGGACAGAA 1798
QY 1621 GTTCACTGGGCTTGGCACTTCTCATTAATTTTGTGATTAAGAAATCCCAAGTTG 1680
DB 1799 GTTCACTGGGCTTGGCACTTCTCATTAATTTTGTGATTAAGAAATCCCAAGTTG 1858
QY 1681 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
DB 1859 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1899

```

Search completed: February 16, 2004, 11:42:58
Job time : 822.88 secs